# Predictive correlates of response to the anti-PD-L1 anti[

Citation Report

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 1 | Calcium-Induced Contraction of the Rhizoplast of a Quadriflagellate Green Alga. Science, 1978, 202, 975-977. | 6.0 | 185 |
| 2 | Current state of immunotherapy for non-small cell lung cancer. Translational Lung Cancer Research, 2007, 6, 196-211. | 1.3 | 150 |
| 3 | Immune system offers clues to cancer treatment. Nature, 2014, , . | 13.7 | 0 |
| 4 | MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature, 2014, 515, 558-562. | 13.7 | 2,109 |
| 5 | Cosmic triangles and black-hole masses. Nature, 2014, 515, 498-499. | 13.7 | 0 |
| 6 | Antitumour immunity gets a boost. Nature, 2014, 515, 496-498. | 13.7 | 90 |
| 7 | Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?. Journal of Thoracic Oncology, 2015, 10, 985-989. | 0.5 | 241 |
| 9 | Targeting immune checkpoints in melanoma: an update. Melanoma Management, 2015, 2, 339-352. | 0.1 | 2 |
| 11 | Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 1726-1735. | 0.5 | 208 |
| 12 | Associations among pretreatment tumor necrosis and the expression of HIF-1α and PD-L1 in advanced oral squamous cell carcinoma and the prognostic impact thereof. Oral Oncology, 2015, 51, 1004-1010. | 0.8 | 61 |
| 13 | New clinical advances in immunotherapy for the treatment of solid tumours. Immunology, 2015, 145, 182-201. | 2.0 | 35 |
| 14 | Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. Cancer Science, 2015, 106, 945-950. | 1.7 | 78 |
| 15 | Non–Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. Journal of Thoracic Oncology, 2015, 10, 974-984. | 0.5 | 127 |
| 16 | <scp>ADAP</scp> and <scp>SKAP</scp> 55 deficiency suppresses <scp>PD</scp> €1 expression in <scp>CD</scp> 8 <sup>+</sup> cytotoxic T lymphocytes for enhanced anti€tumor immunotherapy. EMBO Molecular Medicine, 2015, 7, 754-769. | 3.3 | 41 |
| 17 | Immune Checkpoint Blockade in Hepatocellular Carcinoma. Liver Cancer, 2015, 4, 201-207. | 4.2 | 40 |
| 18 | MAP3K3 expression in tumor cells and tumor-infiltrating lymphocytes is correlated with favorable patient survival in lung cancer. Scientific Reports, 2015, 5, 11471. | 1.6 | 19 |
| 19 | The 2014 San Antonio Breast Cancer Symposium: A successful lift-off for breast immunotherapy?. Npj Breast Cancer, 2015, 1, . | 2.3 | 0 |
| 20 | è§£æ˜ŽãŒé€²ã‚€ãŒã‚"å…¬ç—«ç™‚æ³•. Nature Digest, 2015, 12, 30-32. | 0.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 21 | Emerging immunotherapies for bladder cancer. Current Opinion in Oncology, 2015, 27, 191-200. | 1.1 | 24 |
| 22 | Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma. , 2015, 3, 47. | | 119 |
| 23 | The Ruesch Center Symposium 2014: Fighting a Smarter War against Cancer Using Immunotherapy. Colorectal Cancer, 2015, 4, 63-68. | 0.8 | 0 |
| 24 | DNA methylation subgroups in melanoma are associated with proliferative and immunological processes. BMC Medical Genomics, 2015, 8, 73. | 0.7 | 29 |
| 25 | Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer. Journal of Translational Medicine, 2015, 13, 247. | 1.8 | 57 |
| 26 | Gene expression meta-analysis reveals immune response convergence on the IFNÎ³-STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphoma. Genome Medicine, 2015, 7, 96. | 3.6 | 24 |
| 27 | Immunotherapy for Advanced Lung Cancer. Cancer Journal (Sudbury, Mass ), 2015, 21, 383-391. | 1.0 | 10 |
| 28 | Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma. Current Opinion in Oncology, 2015, 27, 384-391. | 1.1 | 18 |
| 29 | Tumorâ€targeted and immuneâ€targeted monoclonal antibodies: Going from passive to active immunotherapy. Pediatric Blood and Cancer, 2015, 62, 1317-1325. | 0.8 | 13 |
| 31 | Blocking of the PDâ€1/PDâ€L1 Interaction by a <scp>D</scp>â€Peptide Antagonist for Cancer Immunotherapy. Angewandte Chemie - International Edition, 2015, 54, 11760-11764. | 7.2 | 286 |
| 32 | Recent developments and future challenges in immune checkpoint inhibitory cancer treatment. Current Opinion in Oncology, 2015, 27, 482-488. | 1.1 | 31 |
| 33 | Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck. Melanoma Research, 2015, 25, 503-509. | 0.6 | 59 |
| 34 | Immunotherapies for bladder cancer. Current Opinion in Urology, 2015, 25, 586-596. | 0.9 | 17 |
| 35 | Emerging Role for Novel Immunotherapy Agents in Metastatic Renal Cell Carcinoma: From Bench to Bedside. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e291-e297. | 1.8 | 4 |
| 36 | Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget, 2015, 6, 5449-5464. | 0.8 | 424 |
| 37 | Antiâ€"PD-1/PD-L1 therapy of human cancer: past, present, and future. Journal of Clinical Investigation, 2015, 125, 3384-3391. | 3.9 | 1,112 |
| 38 | Targeting PD-1/PD-L1 in lung cancer: current perspectives. Lung Cancer: Targets and Therapy, 2015, 6, 55. | 1.3 | 10 |
| 39 | Immunotherapy and Radiation â€" A New Combined Treatment Approach for Bladder Cancer?. Bladder Cancer, 2015, 1, 15-27. | 0.2 | 19 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 40 | Biomarkers of Response to Immune Modulatory Therapies in Cancer. Journal of Clinical & Cellular Immunology, 2015, 06, . | 1.5 | 1 |
| 41 | Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy. Frontiers in Immunology, 2015, 6, 271. | 2.2 | 36 |
| 42 | Real-Time Imaging of Resident T Cells in Human Lung and Ovarian Carcinomas Reveals How Different Tumor Microenvironments Control T Lymphocyte Migration. Frontiers in Immunology, 2015, 6, 500. | 2.2 | 118 |
| 43 | Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. Frontiers in Immunology, 2015, 6, 516. | 2.2 | 79 |
| 44 | Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. Viruses, 2015, 7, 5889-5901. | 1.5 | 19 |
| 45 | Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway. Forum on Immunopathological Diseases and Therapeutics, 2015, 6, 7-17. | 0.1 | 82 |
| 46 | Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PLoS ONE, 2015, 10, e0130142. | 1.1 | 390 |
| 47 | Molecular profiling in the treatment of colorectal cancer: focus on regorafenib. OncoTargets and Therapy, 2015, 8, 2949. | 1.0 | 7 |
| 48 | Bladder cancer in the elderly patient: challenges and solutions. Clinical Interventions in Aging, 2015, 10, 939. | 1.3 | 44 |
| 49 | The Immune System in Hepatocellular Carcinoma and Potential New Immunotherapeutic Strategies. BioMed Research International, 2015, 2015, 1-12. | 0.9 | 25 |
| 50 | Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy. Journal of Immunology Research, 2015, 2015, 1-14. | 0.9 | 30 |
| 51 | Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review. BioMed Research International, 2015, 2015, 1-8. | 0.9 | 43 |
| 52 | From mice to humans: developments in cancer immunoediting. Journal of Clinical Investigation, 2015, 125, 3338-3346. | 3.9 | 271 |
| 53 | Personalized targeted therapy for esophageal squamous cell carcinoma. World Journal of Gastroenterology, 2015, 21, 7648. | 1.4 | 43 |
| 54 | *PDL1* expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget, 2015, 6, 13506-13519. | 0.8 | 105 |
| 55 | Managing Immune Checkpoint-Blocking Antibody Side Effects. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 76-83. | 1.8 | 344 |
| 56 | PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. New England Journal of Medicine, 2015, 372, 2509-2520. | 13.9 | 7,696 |
| 57 | Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 373, 123-135. | 13.9 | 7,261 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 58 | T cell exclusion, immune privilege, and the tumor microenvironment. Science, 2015, 348, 74-80. | 6.0 | 1,735 |
| 59 | PD-1/PD-L1 inhibitors. Current Opinion in Pharmacology, 2015, 23, 32-38. | 1.7 | 483 |
| 60 | Non-small-cell lung cancer. Nature Reviews Disease Primers, 2015, 1, 15009. | 18.1 | 653 |
| 61 | The path forward. Vaccine, 2015, 33, B60-B63. | 1.7 | 14 |
| 62 | New strategies to develop new medications for lung cancer and metastasis. Cancer and Metastasis Reviews, 2015, 34, 265-275. | 2.7 | 10 |
| 63 | Immune modulation in advanced radiotherapies: Targeting out-of-field effects. Cancer Letters, 2015, 368, 246-251. | 3.2 | 43 |
| 64 | The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clinical Therapeutics, 2015, 37, 764-782. | 1.1 | 469 |
| 65 | Lung Cancer in the Era of Precision Medicine. Clinical Cancer Research, 2015, 21, 2213-2220. | 3.2 | 148 |
| 66 | Immune Checkpoint Modulation for Non–Small Cell Lung Cancer. Clinical Cancer Research, 2015, 21, 2256-2262. | 3.2 | 90 |
| 67 | PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Annals of Oncology, 2015, 26, 1488-1493. | 0.6 | 234 |
| 68 | Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model. Cancer Immunology, Immunotherapy, 2015, 64, 1095-1108. | 2.0 | 19 |
| 69 | Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunology Research, 2015, 3, 1148-1157. | 1.6 | 391 |
| 70 | Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with *JAK3* Activation. Cancer Immunology Research, 2015, 3, 855-863. | 1.6 | 60 |
| 71 | Immunotherapeutic Advancements for Glioblastoma. Frontiers in Oncology, 2015, 5, 12. | 1.3 | 37 |
| 72 | Checkpoint blockade in lymphoma. Hematology American Society of Hematology Education Program, 2015, 2015, 69-73. | 0.9 | 11 |
| 73 | Pseudoprogression and Immune-Related Response in Solid Tumors. Journal of Clinical Oncology, 2015, 33, 3541-3543. | 0.8 | 720 |
| 74 | PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. Cancer Immunology Research, 2015, 3, 1308-1315. | 1.6 | 114 |
| 75 | Administration of sulfosuccinimidyl-4-[N-maleimidomethyl] cyclohexane-1-carboxylate conjugated GP10025–33 peptide-coupled spleen cells effectively mounts antigen-specific immune response against mouse melanoma. Biochemical and Biophysical Research Communications, 2015, 468, 46-52. | 1.0 | 4 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 76 | Promise of Immunotherapy in Lung Cancer. Progress in Tumor Research, 2015, 42, 95-109. | 0.1 | 2 |
| 77 | Toward the Identification of Genetic Determinants of Responsiveness to Cancer Immunotherapy. Cancer Drug Discovery and Development, 2015, , 99-127. | 0.2 | 4 |
| 78 | Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). OncoImmunology, 2015, 4, e1049804. | 2.1 | 51 |
| 79 | Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2015, 21, 4286-4293. | 3.2 | 627 |
| 80 | Immunotherapy for Head and Neck Squamous Cell Carcinoma. Hematology/Oncology Clinics of North America, 2015, 29, 1033-1043. | 0.9 | 30 |
| 81 | Prognostic and predictive immune gene signatures in breast cancer. Current Opinion in Oncology, 2015, 27, 433-444. | 1.1 | 75 |
| 82 | Therapeutic options in advanced squamous cell lung carcinoma. Lung Cancer Management, 2015, 4, 75-86. | 1.5 | 0 |
| 83 | Novel insights into the pathophysiology and treatment of malignant pleural mesothelioma. Lung Cancer Management, 2015, 4, 249-259. | 1.5 | 0 |
| 84 | PD-1–PD-L1 axis: efficient checkpoint blockade against cancer. Nature Reviews Clinical Oncology, 2015, 12, 63-63. | 12.5 | 58 |
| 85 | PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunology Research, 2015, 3, 326-332. | 1.6 | 310 |
| 86 | The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?. Current Opinion in Immunology, 2015, 33, 23-35. | 2.4 | 298 |
| 87 | Cancer Immunotherapy Scores Again. Cell, 2015, 160, 7-9. | 13.5 | 4 |
| 88 | Biomarkers in Cancer Immunotherapy. Cancer Cell, 2015, 27, 12-14. | 7.7 | 130 |
| 89 | Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity. Cell, 2015, 160, 48-61. | 13.5 | 2,948 |
| 90 | Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour. Current Topics in Microbiology and Immunology, 2015, 405, 79-97. | 0.7 | 8 |
| 91 | Multiple checkpoints on the long road towards cancer immunotherapy. Immunology and Cell Biology, 2015, 93, 323-325. | 1.0 | 9 |
| 92 | *APOBEC3B* expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2841-2846. | 3.3 | 118 |
| 93 | Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncology, The, 2015, 16, 257-265. | 5.1 | 1,269 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 94 | PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Molecular Cancer Therapeutics, 2015, 14, 847-856. | 1.9 | 1,787 |
| 95 | Tumour-Infiltrating Lymphocytes (TILs) in Breast Cancer: a Predictive or a Prognostic Marker?. Current Breast Cancer Reports, 2015, 7, 59-70. | 0.5 | 1 |
| 96 | The immune response in cancer: from immunology to pathology to immunotherapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 127-135. | 1.4 | 51 |
| 97 | A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. Cancer Research, 2015, 75, 3800-3811. | 0.4 | 201 |
| 98 | Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment. Advances in Cancer Research, 2015, 128, 263-307. | 1.9 | 123 |
| 99 | Combination cancer immunotherapy and new immunomodulatory targets. Nature Reviews Drug Discovery, 2015, 14, 561-584. | 21.5 | 1,058 |
| 100 | CD4 T Cell Depletion Substantially Augments the Rescue Potential of PD-L1 Blockade for Deeply Exhausted CD8 T Cells. Journal of Immunology, 2015, 195, 1054-1063. | 0.4 | 34 |
| 101 | A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Annals of Oncology, 2015, 26, 1824-1829. | 0.6 | 184 |
| 102 | Why do infections cause cancer?. Clinical Microbiology and Infection, 2015, 21, 967-968. | 2.8 | 1 |
| 104 | Therapeutic Advances and Treatment Options in Metastatic Melanoma. JAMA Oncology, 2015, 1, 380. | 3.4 | 66 |
| 105 | Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. Cancer Immunology Research, 2015, 3, 1017-1029. | 1.6 | 159 |
| 106 | Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2â˜'/â˜'IL2RÎ³null Immunodeficient Mice. Cancer Research, 2015, 75, 3466-3478. | 0.4 | 137 |
| 107 | New immunotherapies show promise in some patients: Physicians try to balance optimism with realistic expectations. Cancer, 2015, 121, 1155-1156. | 2.0 | 2 |
| 108 | Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade. Clinical Cancer Research, 2015, 21, 3969-3976. | 3.2 | 205 |
| 109 | Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. OncoImmunology, 2015, 4, e1008814. | 2.1 | 102 |
| 110 | Inflammation and Lung Cancer. , 2015, , . | | 2 |
| 111 | FDA approves Gardasil 9 for more types of HPV. Cancer, 2015, 121, 1156-1157. | 2.0 | 36 |
| 113 | Tryptophan-Degrading Enzymes in Tumoral Immune Resistance. Frontiers in Immunology, 2015, 6, 34. | 2.2 | 201 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 114 | Emerging antibody-based therapeutic strategies for bladder cancer: A systematic review. Journal of Controlled Release, 2015, 214, 40-61. | 4.8 | 28 |
| 115 | Association of Polymerase eâ€"Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. JAMA Oncology, 2015, 1, 1319. | 3.4 | 523 |
| 116 | Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies. Drug Discovery Today, 2015, 20, 1127-1134. | 3.2 | 27 |
| 117 | Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nature Reviews Cancer, 2015, 15, 457-472. | 12.8 | 576 |
| 118 | Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era?. Expert Review of Clinical Immunology, 2015, 11, 871-873. | 1.3 | 11 |
| 119 | Engineered materials for cancer immunotherapy. Nano Today, 2015, 10, 511-531. | 6.2 | 96 |
| 120 | Nivolumab in the treatment of advanced melanoma. Expert Opinion on Orphan Drugs, 2015, 3, 945-956. | 0.5 | 0 |
| 121 | The immunocheckpoints in modern oncology: the next 15 years. Expert Opinion on Biological Therapy, 2015, 15, 917-921. | 1.4 | 24 |
| 122 | Development of individualized anti-metastasis strategies by engineering nanomedicines. Chemical Society Reviews, 2015, 44, 6258-6286. | 18.7 | 115 |
| 123 | Cancer Immunotherapy: Past Progress and Future Directions. Seminars in Oncology, 2015, 42, 518-522. | 0.8 | 17 |
| 124 | Integrated Akt/PKB Signaling in Immunomodulation and Its Potential Role in Cancer Immunotherapy. Journal of the National Cancer Institute, 2015, 107, djv171-djv171. | 3.0 | 78 |
| 125 | Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncology, The, 2015, 16, 908-918. | 5.1 | 1,419 |
| 126 | The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist, 2015, 20, 812-822. | 1.9 | 198 |
| 127 | Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential. Immunotherapy, 2015, 7, 655-667. | 1.0 | 135 |
| 128 | Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses. Molecular Therapy, 2015, 23, 1630-1640. | 3.7 | 165 |
| 129 | Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nature Communications, 2015, 6, 7458. | 5.8 | 383 |
| 130 | Antagonists of PD-1 and PD-L1 in Cancer Treatment. Seminars in Oncology, 2015, 42, 587-600. | 0.8 | 259 |
| 131 | Best practice in the treatment of advanced squamous cell lung cancer. Therapeutic Advances in Respiratory Disease, 2015, 9, 224-235. | 1.0 | 14 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 132 | Nivolumab: another weapon in the growing immunotherapy arsenal. Lancet Oncology, The, 2015, 16, 350-351. | 5.1 | 4 |
| 133 | Immunotherapy for urothelial cancer: from BCG to checkpoint inhibitors and beyond. Expert Review of Anticancer Therapy, 2015, 15, 509-523. | 1.1 | 21 |
| 134 | Immuno-regulatory antibodies for the treatment of cancer. Expert Opinion on Biological Therapy, 2015, 15, 787-801. | 1.4 | 40 |
| 135 | PD-L1 Inhibition With MPDL3280A for Solid Tumors. Seminars in Oncology, 2015, 42, 484-487. | 0.8 | 46 |
| 136 | Toxicities of Immunotherapy for the Practitioner. Journal of Clinical Oncology, 2015, 33, 2092-2099. | 0.8 | 521 |
| 137 | Radiotherapy Complements Immune Checkpoint Blockade. Cancer Cell, 2015, 27, 437-438. | 7.7 | 58 |
| 138 | The future of immune checkpoint therapy. Science, 2015, 348, 56-61. | 6.0 | 3,735 |
| 139 | Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 372, 2018-2028. | 13.9 | 5,183 |
| 140 | Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature, 2015, 520, 692-696. | 13.7 | 1,030 |
| 141 | Immunotherapy in Upper GI Malignancies. Current Treatment Options in Oncology, 2015, 16, 20. | 1.3 | 9 |
| 143 | A combined approach of human leukocyte antigen ligandomics and immunogenicity analysis to improve peptide-based cancer immunotherapy. Cancer Immunology, Immunotherapy, 2015, 64, 1295-1303. | 2.0 | 10 |
| 144 | Immune checkpoint blockade in hematologic malignancies. Blood, 2015, 125, 3393-3400. | 0.6 | 208 |
| 145 | From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy. Experimental Biology and Medicine, 2015, 240, 1087-1098. | 1.1 | 52 |
| 146 | Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Annals of Oncology, 2015, 26, 1533-1546. | 0.6 | 1,449 |
| 147 | Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. Cancer Immunology Research, 2015, 3, 399-411. | 1.6 | 387 |
| 148 | Refining the treatment of NSCLC according to histological and molecular subtypes. Nature Reviews Clinical Oncology, 2015, 12, 511-526. | 12.5 | 247 |
| 149 | Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Research, 2015, 75, 2139-2145. | 0.4 | 1,167 |
| 150 | Targeting Heat-Shock Protein 90 (HSP90) as a Complementary Strategy to Immune Checkpoint Blockade for Cancer Therapy. Cancer Immunology Research, 2015, 3, 583-589. | 1.6 | 56 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 151 | Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. , 2015, 3, 11. | | 274 |
| 152 | Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science, 2015, 348, 124-128. | 6.0 | 6,756 |
| 153 | Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?. Clinical Cancer Research, 2015, 21, 2244-2255. | 3.2 | 179 |
| 154 | Overcoming T cell exhaustion in infection and cancer. Trends in Immunology, 2015, 36, 265-276. | 2.9 | 856 |
| 155 | On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Science Translational Medicine, 2015, 7, 280sr1. | 5.8 | 134 |
| 156 | Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites. Clinical Cancer Research, 2015, 21, 3052-3060. | 3.2 | 198 |
| 157 | PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma. Leukemia, 2015, 29, 2110-2113. | 3.3 | 170 |
| 158 | Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non–Small Cell Lung Cancer. Clinical Cancer Research, 2015, 21, 976-984. | 3.2 | 196 |
| 159 | Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Molecular Immunology, 2015, 67, 4-17. | 1.0 | 180 |
| 160 | Strategies to Target Tumor Immunosuppression. , 2015, , 73-86. | | 0 |
| 161 | Novel therapeutic targets and predictive markers for hepatocellular carcinoma. Expert Opinion on Therapeutic Targets, 2015, 19, 973-983. | 1.5 | 9 |
| 162 | Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558,) Tj ETQq1 1 0.784314 rgB Clinical Oncology, 2015, 33, 2004-2012. | 0.8 | 1,035 |
| 163 | Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma. Clinical Cancer Research, 2015, 21, 2892-2897. | 3.2 | 31 |
| 164 | The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors. , 2015, 3, 15. | | 57 |
| 165 | Translational value of mouse models in oncology drug development. Nature Medicine, 2015, 21, 431-439. | 15.2 | 242 |
| 166 | MicroRNA control of protein expression noise. Science, 2015, 348, 128-132. | 6.0 | 337 |
| 167 | A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. European Urology, 2015, 68, 267-279. | 0.9 | 204 |
| 168 | Clinical deployment of antibodies for treatment of melanoma. Molecular Immunology, 2015, 67, 18-27. | 1.0 | 11 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 169 | Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. British Journal of Cancer, 2015, 112, 1421-1427. | 2.9 | 215 |
| 170 | Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment. European Journal of Radiology, 2015, 84, 1259-1268. | 1.2 | 105 |
| 171 | Immune-mediated mechanisms influencing the efficacy of anticancer therapies. Trends in Immunology, 2015, 36, 198-216. | 2.9 | 121 |
| 172 | Immune Checkpoint Inhibitors for Urologic Cancer: The Tip of the Iceberg?. European Urology, 2015, 68, 280-282. | 0.9 | 4 |
| 173 | Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. Cancer Cell, 2015, 27, 450-461. | 7.7 | 3,266 |
| 174 | Targeting the immune system to treat lung cancer: rationale and clinical experience. Therapeutic Advances in Respiratory Disease, 2015, 9, 105-120. | 1.0 | 13 |
| 175 | Macrophages and Therapeutic Resistance in Cancer. Cancer Cell, 2015, 27, 462-472. | 7.7 | 1,130 |
| 176 | Immunotherapeutic options on the horizon in breast cancer treatment. , 2015, 156, 90-101. | | 17 |
| 177 | Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers. Modern Pathology, 2015, 28, 1594-1602. | 2.9 | 228 |
| 178 | Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. Modern Pathology, 2015, 28, 1535-1544. | 2.9 | 76 |
| 179 | PD-1 and PD-L1 blockade in gastrointestinal malignancies. Cancer Treatment Reviews, 2015, 41, 893-903. | 3.4 | 55 |
| 180 | Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Annals of Oncology, 2015, 26, 2375-2391. | 0.6 | 1,136 |
| 181 | Predictive biomarkers in precision medicine and drug development against lung cancer. Chinese Journal of Cancer, 2015, 34, 295-309. | 4.9 | 34 |
| 182 | Immunothérapie anticancer : les molécules immunomodulatrices en développement clinique. Oncologie, 2015, 17, 379-389. | 0.2 | 0 |
| 183 | Predictors of clinical response to immunotherapy with or without radiotherapy. Journal of Radiation Oncology, 2015, 4, 339-345. | 0.7 | 17 |
| 186 | Immune checkpoints and immunotherapy for colorectal cancer. Gastroenterology Report, 2015, 3, gov053. | 0.6 | 80 |
| 187 | Interferons and the Immunogenic Effects of Cancer Therapy. Trends in Immunology, 2015, 36, 725-737. | 2.9 | 107 |
| 189 | Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. Structure, 2015, 23, 2341-2348. | 1.6 | 399 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 190 | Programmed death-1 &amp; its ligands: promising targets for cancer immunotherapy. Immunotherapy, 2015, 7, 777-792. | 1.0 | 18 |
| 191 | Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma: TableÂ1.. Neuro-Oncology, 2015, 17, 1043-1045. | 0.6 | 24 |
| 192 | Why has active immunotherapy not worked in lung cancer?. Annals of Oncology, 2015, 26, 2213-2220. | 0.6 | 35 |
| 193 | Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?. Future Oncology, 2015, 11, 2299-2306. | 1.1 | 20 |
| 194 | Immunological landscape and immunotherapy of hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 681-700. | 8.2 | 478 |
| 195 | Circulating <scp>PD</scp>â€‹<scp>L</scp>1 in <scp>NSCLC</scp> patients and the correlation between the level of <scp>PD</scp>â€‹<scp>L</scp>1 expression and the clinical characteristics. Thoracic Cancer, 2015, 6, 534-538. | 0.8 | 107 |
| 196 | Immunological hallmarks of stromal cells in the tumour microenvironment. Nature Reviews Immunology, 2015, 15, 669-682. | 10.6 | 850 |
| 197 | Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer. Seminars in Oncology, 2015, 42, S11-S18. | 0.8 | 55 |
| 198 | The odds of immunotherapy success. Science, 2015, 350, 158-159. | 6.0 | 87 |
| 199 | Translating Pembrolizumab to Clinical Practice: Speak Immunology and Learn Fast!. Clinical Cancer Research, 2015, 21, 4251-4253. | 3.2 | 1 |
| 200 | Efficacy of a Cancer Vaccine against <i>ALK</i>-Rearranged Lung Tumors. Cancer Immunology Research, 2015, 3, 1333-1343. | 1.6 | 42 |
| 201 | Immune Response to Cancer Therapy: Mounting an Effective Antitumor Response and Mechanisms of Resistance. Trends in Cancer, 2015, 1, 66-75. | 3.8 | 101 |
| 203 | Stromal infiltration of CD8 T cells is associated with improved clinical outcome in HPV-positive oropharyngeal squamous carcinoma. British Journal of Cancer, 2015, 113, 886-893. | 2.9 | 136 |
| 204 | Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy, 2015, 7, 967-980. | 1.0 | 83 |
| 205 | Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer and Prostatic Diseases, 2015, 18, 325-332. | 2.0 | 149 |
| 206 | Oncolytic viruses: a new class of immunotherapy drugs. Nature Reviews Drug Discovery, 2015, 14, 642-662. | 21.5 | 1,055 |
| 207 | Immune-mediated adverse events of anticytotoxic T lymphocyteâ€“associated antigen 4Âantibody therapy in metastatic melanoma. Translational Research, 2015, 166, 412-424. | 2.2 | 65 |
| 208 | Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS. Seminars in Oncology, 2015, 42, 640-655. | 0.8 | 179 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 209 | Adaptive Immune Resistance: How Cancer Protects from Immune Attack. Cancer Discovery, 2015, 5, 915-919. | 7.7 | 495 |
| 210 | Pembrolizumab. , 2015, 3, 36. | | 171 |
| 211 | Immune Checkpoint Inhibitors. Progress in Tumor Research, 2015, 42, 55-66. | 0.1 | 151 |
| 212 | Immunopharmacogenomics. , 2015, , . | | 3 |
| 213 | Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. Cell, 2015, 162, 1242-1256. | 13.5 | 507 |
| 214 | FcÎ³Rs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis. Cancer Cell, 2015, 28, 285-295. | 7.7 | 291 |
| 215 | Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma. European Journal of Cancer, 2015, 51, 2580-2586. | 1.3 | 79 |
| 216 | Epstein-Barr Virus-Associated Gastric Carcinoma: Use of Host Cell Machineries and Somatic Gene Mutations. Pathobiology, 2015, 82, 212-223. | 1.9 | 46 |
| 217 | Cancer gene therapy with T cell receptors and chimeric antigen receptors. Current Opinion in Pharmacology, 2015, 24, 113-118. | 1.7 | 30 |
| 218 | PD-L1 expression in small cell lung cancer. European Journal of Cancer, 2015, 51, 1853-1855. | 1.3 | 32 |
| 219 | Breast cancer and immunology: biomarker and therapeutic developments. Expert Review of Anticancer Therapy, 2015, 15, 1215-1222. | 1.1 | 9 |
| 220 | PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation. Cancer Immunology Research, 2015, 3, 1303-1307. | 1.6 | 135 |
| 221 | Advancing pharmacological treatment options for advanced gastric cancer. Expert Opinion on Pharmacotherapy, 2015, 16, 2293-2305. | 0.9 | 10 |
| 223 | Current state of biomarkers in ovarian cancer prognosis. Future Oncology, 2015, 11, 3187-3195. | 1.1 | 45 |
| 224 | Landscape of Tumor Antigens in T Cell Immunotherapy. Journal of Immunology, 2015, 195, 5117-5122. | 0.4 | 124 |
| 225 | Nivolumab for treating non-small cell lung cancer. Expert Opinion on Biological Therapy, 2015, 15, 1789-1797. | 1.4 | 27 |
| 226 | Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. Therapeutic Advances in Urology, 2015, 7, 365-377. | 0.9 | 103 |
| 227 | Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Cancer Treatment Reviews, 2015, 41, 868-876. | 3.4 | 358 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 228 | Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6506-14. | 3.3 | 299 |
| 229 | Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells. Molecular Oncology, 2015, 9, 2054-2062. | 2.1 | 85 |
| 230 | Clinical blockade of PD1 and LAG3 â€" potential mechanisms of action. Nature Reviews Immunology, 2015, 15, 45-56. | 10.6 | 524 |
| 231 | Checkpoint parley. Nature Reviews Cancer, 2015, 15, 3-3. | 12.8 | 25 |
| 232 | Checkpoint parley. Nature Reviews Immunology, 2015, 15, 5-5. | 10.6 | 9 |
| 233 | Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. Oncotarget, 2016, 7, 33498-33511. | 0.8 | 85 |
| 234 | Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis. Oncotarget, 2016, 7, 10557-10567. | 0.8 | 154 |
| 235 | Mechanism of Action of Diseases and Drugsâ€"Part I. , 2016, , 569-594. | | 0 |
| 236 | Immunotherapy for Non-Small Cell Lung Cancer - Finally a Hint of Hope. Reviews on Recent Clinical Trials, 2016, 11, 87-92. | 0.4 | 3 |
| 237 | IL-15 superagonist/IL-15RÎ±Sushi-Fc fusion complex (IL-15SA/IL-15RÎ±Su-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas. Oncotarget, 2016, 7, 16130-16145. | 0.8 | 138 |
| 238 | Clinical significance of *PD-L1* and *PD-L2* copy number gains in non-small-cell lung cancer. Oncotarget, 2016, 7, 32113-32128. | 0.8 | 100 |
| 239 | Immune checkpoint inhibition in patients with brain metastases. Annals of Translational Medicine, 2016, 4, S9-S9. | 0.7 | 29 |
| 240 | PD-L1 is a diverse molecule regulating both tumor-intrinsic signaling and adaptive immunosuppression. Translational Cancer Research, 2016, 5, S1396-S1399. | 0.4 | 8 |
| 241 | Identifying candidate agents for lung adenocarcinoma by walking the human interactome. OncoTargets and Therapy, 2016, Volume 9, 5439-5450. | 1.0 | 3 |
| 242 | Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget, 2016, 7, 30323-30335. | 0.8 | 297 |
| 243 | Association of *Fusobacterium nucleatum* with immunity and molecular alterations in colorectal cancer. World Journal of Gastroenterology, 2016, 22, 557. | 1.4 | 278 |
| 244 | Tumor immune profiling predicts response to antiâ€"PD-1 therapy in human melanoma. Journal of Clinical Investigation, 2016, 126, 3447-3452. | 3.9 | 439 |
| 245 | Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?. Cancer Biology and Medicine, 2016, 13, 157-170. | 1.4 | 86 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 246 | Emerging Immunotargets in Metastatic Renal Cell Carcinoma. Current Drug Targets, 2016, 17, 771-776. | 1.0 | 20 |
| 247 | Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer. OncoTargets and Therapy, 2016, 9, 3187. | 1.0 | 11 |
| 248 | Análise da expressão de PD-L1 no microambiente do câncer de pulmão de não pequenas células e de seu papel como potencial marcador preditivo. , 2016, 95, 76. | 0.0 | 0 |
| 249 | The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1. Journal of Gastrointestinal Oncology, 2016, 7, 771-788. | 0.6 | 84 |
| 250 | Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast. Oncotarget, 2016, 7, 1707-1716. | 0.8 | 25 |
| 251 | Seeking New Approaches to Patients With Small Cell Lung Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e477-e482. | 1.8 | 2 |
| 252 | From the era of ineffective tumor vaccines to a future with effective immunotherapy. Journal of Thoracic Disease, 2016, 8, 1916-1917. | 0.6 | 0 |
| 253 | The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight, 2016, 1, e89829. | 2.3 | 569 |
| 254 | Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers. Oncotarget, 2016, 7, 32925-32932. | 0.8 | 248 |
| 255 | Biomarkers for Immunotherapy: Current Developments and Challenges. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e493-e503. | 1.8 | 85 |
| 256 | PD-L1 expression in lung cancer. Journal of Thoracic Disease, 2016, 8, 3053-3055. | 0.6 | 2 |
| 257 | Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature. Translational Lung Cancer Research, 2016, 5, 720-726. | 1.3 | 32 |
| 258 | Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. Oncotarget, 2016, 7, 32318-32328. | 0.8 | 141 |
| 259 | Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective. BioMed Research International, 2016, 2016, 1-12. | 0.9 | 19 |
| 260 | Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data. Journal of Immunology Research, 2016, 2016, 1-12. | 0.9 | 17 |
| 261 | PD-L1 Expression Is Associated with Tumor FOXP3+ Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient. Journal of Cancer, 2016, 7, 784-793. | 1.2 | 125 |
| 262 | Inflammation and Cancer. , 2016, , 406-415. | | 10 |
| 263 | Clinical utility of nivolumab in the treatment of advanced melanoma. Therapeutics and Clinical Risk Management, 2016, 12, 313. | 0.9 | 16 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 264 | The emerging role of immunotherapy in colorectal cancer. Annals of Translational Medicine, 2016, 4, 305-305. | 0.7 | 63 |
| 265 | The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Frontiers in Immunology, 2016, 7, 550. | 2.2 | 409 |
| 266 | Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells. Frontiers in Immunology, 2016, 7, 610. | 2.2 | 111 |
| 267 | Systemic Immunotherapy for the Treatment of Brain Metastases. Frontiers in Oncology, 2016, 6, 49. | 1.3 | 66 |
| 268 | Cancer Immunosurveillance: Immunoediting. , 2016, , 396-405. | | 3 |
| 269 | A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway &amp; Translational Blockade of Immune Checkpoints. International Journal of Molecular Sciences, 2016, 17, 1151. | 1.8 | 134 |
| 270 | Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?. International Journal of Molecular Sciences, 2016, 17, 1169. | 1.8 | 53 |
| 271 | Chemo-Immunotherapy Using Lentinan for the Treatment of Gastric Cancer with Liver Metastases. Medical Sciences (Basel, Switzerland), 2016, 4, 8. | 1.3 | 7 |
| 272 | Inhibition of Cellular Adhesion by Immunological Targeting of Osteopontin Neoepitopes Generated through Matrix Metalloproteinase and Thrombin Cleavage. PLoS ONE, 2016, 11, e0148333. | 1.1 | 7 |
| 273 | Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology. PLoS ONE, 2016, 11, e0161779. | 1.1 | 172 |
| 274 | The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs. Journal of Cancer, 2016, 7, 484-489. | 1.2 | 106 |
| 275 | PD-1/PD-L1 blockades in non-small-cell lung cancer therapy. OncoTargets and Therapy, 2016, 9, 489. | 1.0 | 43 |
| 276 | Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer. Bladder Cancer, 2016, 2, 15-25. | 0.2 | 29 |
| 277 | Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix. Oncotarget, 2016, 7, 75379-75393. | 0.8 | 27 |
| 278 | A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. Oncotarget, 2016, 7, 10215-10227. | 0.8 | 158 |
| 279 | Immune Checkpoint Therapy in Melanoma. Cancer Journal (Sudbury, Mass ), 2016, 22, 73-80. | 1.0 | 10 |
| 280 | MYB-fusions and other potential actionable targets in adenoid cystic carcinoma. Current Opinion in Oncology, 2016, 28, 195-200. | 1.1 | 32 |
| 281 | Pembrolizumab (Keytruda). Human Vaccines and Immunotherapeutics, 2016, 12, 2777-2789. | 1.4 | 237 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 282 | Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. Immunotherapy, 2016, 8, 821-837. | 1.0 | 139 |
| 283 | MAGE-A is More Highly Expressed Than NY-ESO-1 in a Systematic Immunohistochemical Analysis of 3668 Cases. Journal of Immunotherapy, 2016, 39, 181-187. | 1.2 | 54 |
| 284 | Immune Checkpoint Therapy in Non–Small Cell Lung Cancer. Cancer Journal (Sudbury, Mass ), 2016, 22, 81-91. | 1.0 | 11 |
| 285 | Immune Checkpoint Therapy and the Search for Predictive Biomarkers. Cancer Journal (Sudbury, Mass) Tj ETQq1 1 0.784314 rgBT /Ov | 1.0 | 31 |
| 286 | Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages. Lung Cancer, 2016, 98, 51-58. | 0.9 | 110 |
| 287 | Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. Clinical Cancer Research, 2016, 22, 4309-4321. | 3.2 | 182 |
| 288 | Multispectral Imaging of T and B Cells in Murine Spleen and Tumor. Journal of Immunology, 2016, 196, 3943-3950. | 0.4 | 63 |
| 289 | Immune Checkpoint Therapy in Renal Cell Carcinoma. Cancer Journal (Sudbury, Mass ), 2016, 22, 92-95. | 1.0 | 35 |
| 290 | Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. Investigational New Drugs, 2016, 34, 596-603. | 1.2 | 43 |
| 291 | Intratumoral expression levels of *PD-L1*, *GZMA*, and *HLA-A* along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma. OncoImmunology, 2016, 5, e1204507. | 2.1 | 107 |
| 292 | BRAFV600E mutation correlates with suppressive tumor immune microenvironment and reduced disease-free survival in Langerhans cell histiocytosis. OncoImmunology, 2016, 5, e1185582. | 2.1 | 46 |
| 293 | Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. OncoImmunology, 2016, 5, e1196310. | 2.1 | 176 |
| 294 | <scp>PD</scp>‑L1 expression in tumour buds of colorectal carcinoma. Histopathology, 2016, 69, 158-160. | 1.6 | 12 |
| 295 | Targeted therapies for treatment of non–small cell lung cancer—Recent advances and future perspectives. International Journal of Cancer, 2016, 138, 2549-2561. | 2.3 | 155 |
| 296 | Update on immune therapy in melanoma. Expert Opinion on Orphan Drugs, 2016, 4, 799-808. | 0.5 | 0 |
| 297 | Nivolumab in Combination With Platinum–Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2016, 34, 2969-2979. | 0.8 | 397 |
| 298 | Moving Programmed Death-1 Inhibitors to the Front Lines in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2016, 34, 2953-2955. | 0.8 | 13 |
| 299 | Novel Targets and Their Assessment for Cancer Treatment. , 2016, , 163-180. | | 0 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 300 | Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Modern Pathology, 2016, 29, 1165-1172. | 2.9 | 340 |
| 301 | mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma. OncoImmunology, 2016, 5, e1207842. | 2.1 | 29 |
| 302 | Functional reprogramming of human prostate cancer to promote local attraction of effector CD8$^+$ T cells. Prostate, 2016, 76, 1095-1105. | 1.2 | 48 |
| 303 | Immune Checkpoint Therapies in Prostate Cancer. Cancer Journal (Sudbury, Mass ), 2016, 22, 117-120. | 1.0 | 46 |
| 304 | A meta-analysis reveals prognostic role of programmed death ligand-1 in Asian patients with non-small cell lung cancer. Journal of Huazhong University of Science and Technology [Medical Sciences], 2016, 36, 313-320. | 1.0 | 4 |
| 305 | Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells. Cancer Letters, 2016, 380, 424-433. | 3.2 | 80 |
| 306 | Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro-Oncology, 2016, 18, 1357-1366. | 0.6 | 116 |
| 307 | Panâ€cancer analysis of copy number changes in programmed deathâ€ligand 1 (PDâ€L1, CD274) â€" associations with gene expression, mutational load, and survival. Genes Chromosomes and Cancer, 2016, 55, 626-639. | 1.5 | 80 |
| 308 | Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas. Histopathology, 2016, 68, 1079-1089. | 1.6 | 135 |
| 309 | The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches. ESMO Open, 2016, 1, e000122. | 2.0 | 55 |
| 310 | PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker. SpringerPlus, 2016, 5, 805. | 1.2 | 61 |
| 311 | Case report: impressive response to pembrolizumab in a patient with mismatch-repair deficient metastasized colorectal cancer and bulky disease. ESMO Open, 2016, 1, e000084. | 2.0 | 9 |
| 312 | Explaining the Paucity of Intratumoral T Cells: A Construction Out of Known Entities. Cold Spring Harbor Symposia on Quantitative Biology, 2016, 81, 219-226. | 2.0 | 6 |
| 313 | What does PD-L1 positive or negative mean?. Journal of Experimental Medicine, 2016, 213, 2835-2840. | 4.2 | 263 |
| 314 | Validation of biomarkers to predict response to immunotherapy in cancer: Volume I â€" pre-analytical and analytical validation. , 2016, 4, 76. |  | 155 |
| 315 | The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecologic Oncology Research and Practice, 2016, 3, 11. | 3.6 | 118 |
| 316 | Interferon-Î³ and Tumor Necrosis Factor-Î± Polarize Bone Marrow Stromal Cells Uniformly to a Th1 Phenotype. Scientific Reports, 2016, 6, 26345. | 1.6 | 69 |
| 317 | An ILâ€27/Stat3 axis induces expression of programmed cell death 1 ligands (PDâ€L1/2) on infiltrating macrophages in lymphoma. Cancer Science, 2016, 107, 1696-1704. | 1.7 | 104 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 318 | Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells. Cancer Immunology Research, 2016, 4, 1049-1060. | 1.6 | 34 |
| 319 | Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. Cell, 2016, 167, 1540-1554.e12. | 13.5 | 830 |
| 321 | PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer. Breast Care, 2016, 11, 385-390. | 0.8 | 20,872 |
| 322 | Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. Scientific Reports, 2016, 6, 20090. | 1.6 | 138 |
| 324 | Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer. Npj Breast Cancer, 2016, 2, 16002. | 2.3 | 31 |
| 325 | The Role of Nextâ€Generation Sequencing in Enabling Personalized Oncology Therapy. Clinical and Translational Science, 2016, 9, 283-292. | 1.5 | 36 |
| 326 | A Novel PD-L1-targeting Antagonistic DNA Aptamer With Antitumor Effects. Molecular Therapy - Nucleic Acids, 2016, 5, e397. | 2.3 | 114 |
| 327 | Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies. Journal of Translational Medicine, 2016, 14, 173. | 1.8 | 103 |
| 328 | PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy. Scientific Reports, 2016, 6, 25952. | 1.6 | 36 |
| 329 | Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Nonâ€"Small-cell Lung Cancer. Applied Immunohistochemistry and Molecular Morphology, 2016, 24, 392-397. | 0.6 | 261 |
| 330 | Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. BMC Cancer, 2016, 16, 434. | 1.1 | 124 |
| 331 | T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFÎ± Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma. Journal of Immunotherapy, 2016, 39, 343-354. | 1.2 | 21 |
| 332 | A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. Melanoma Research, 2016, 26, 469-480. | 0.6 | 30 |
| 333 | Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability. American Journal of Surgical Pathology, 2016, 40, 1496-1506. | 2.1 | 134 |
| 335 | Immune contexture and histological response after neoadjuvant chemotherapy predict clinical outcome of lung cancer patients. OncoImmunology, 2016, 5, e1255394. | 2.1 | 62 |
| 336 | Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk. OncoImmunology, 2016, 5, e1240857. | 2.1 | 56 |
| 337 | De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute. Cancer Immunology Research, 2016, 4, 279-288. | 1.6 | 29 |
| 338 | Disentangling the relationship between tumor genetic programs and immune responsiveness. Current Opinion in Immunology, 2016, 39, 150-158. | 2.4 | 57 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 339 | GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade. Molecular Therapy, 2016, 24, 1135-1149. | 3.7 | 281 |
| 340 | Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses. OncoImmunology, 2016, 5, e1165377. | 2.1 | 42 |
| 341 | Monitoring immune responses in the tumor microenvironment. Current Opinion in Immunology, 2016, 41, 23-31. | 2.4 | 96 |
| 342 | Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. Journal of Hematology and Oncology, 2016, 9, 47. | 6.9 | 271 |
| 343 | Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies. Annals of Medicine, 2016, 48, 428-439. | 1.5 | 32 |
| 344 | Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?. Drugs, 2016, 76, 925-945. | 4.9 | 123 |
| 345 | *EGFR* Mutations and *ALK* Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis. Clinical Cancer Research, 2016, 22, 4585-4593. | 3.2 | 977 |
| 346 | Novel immunotherapies for the treatment of melanoma. Immunotherapy, 2016, 8, 613-632. | 1.0 | 5 |
| 347 | Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches. Annals of Oncology, 2016, 27, 1706-1712. | 0.6 | 113 |
| 348 | PDL1: The Illusion of an Ideal Biomarker. European Urology Focus, 2016, 1, 269-271. | 1.6 | 11 |
| 349 | A fully human IgG1 anti-PD-L1 MAb in an *in vitro* assay enhances antigen-specific T-cell responses. Clinical and Translational Immunology, 2016, 5, e83. | 1.7 | 52 |
| 350 | Emerging molecular classifications and therapeutic implications for gastric cancer. Chinese Journal of Cancer, 2016, 35, 49. | 4.9 | 35 |
| 351 | Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma. Current Treatment Options in Oncology, 2016, 17, 31. | 1.3 | 57 |
| 352 | PD-L1 Expression in Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 964-975. | 0.5 | 329 |
| 353 | Investigational new drugs for brain cancer. Expert Opinion on Investigational Drugs, 2016, 25, 937-956. | 1.9 | 16 |
| 354 | Targeting T Cell Co-receptors for Cancer Therapy. Immunity, 2016, 44, 1069-1078. | 6.6 | 418 |
| 355 | Combinatorial Cancer Immunotherapies. Advances in Immunology, 2016, 130, 251-277. | 1.1 | 107 |
| 356 | Upregulated Glucose Metabolism Correlates Inversely with CD8+ T-cell Infiltration and Survival in Squamous Cell Carcinoma. Cancer Research, 2016, 76, 4136-4148. | 0.4 | 83 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 357 | A tribute to the life and career of Holbrook Kohrt. Annals of Oncology, 2016, 27, 1183-1184. | 0.6 | 1 |
| 358 | Molecular Pathways: Targeting DNA Repair Pathway Defects Enriched in Metastasis. Clinical Cancer Research, 2016, 22, 3132-3137. | 3.2 | 28 |
| 359 | The Role of Surgical Pathology in Guiding Cancer Immunotherapy. Annual Review of Pathology: Mechanisms of Disease, 2016, 11, 313-341. | 9.6 | 15 |
| 360 | Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors. Molecular Cancer Therapeutics, 2016, 15, 1746-1756. | 1.9 | 45 |
| 361 | PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges. Immunotherapy, 2016, 8, 733-746. | 1.0 | 28 |
| 362 | Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer. Trends in Immunology, 2016, 37, 462-476. | 2.9 | 232 |
| 363 | Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Annals of Oncology, 2016, 27, 1492-1504. | 0.6 | 460 |
| 364 | CIS is a potent checkpoint in NK cell–mediated tumor immunity. Nature Immunology, 2016, 17, 816-824. | 7.0 | 289 |
| 365 | Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications. Expert Review of Clinical Pharmacology, 2016, 9, 1091-1108. | 1.3 | 9 |
| 366 | Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling. Cell, 2016, 165, 272-275. | 13.5 | 224 |
| 367 | An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression. Vaccine, 2016, 34, 2147-2156. | 1.7 | 20 |
| 368 | Les anticorps monoclonaux dirigés contre les checkpoints immunologiques: de nouvelles approches d'immunothérapie en onco-hématologie. Revue D'Oncologie Hématologie Pédiatrique, 2016, 4, 5-12. | 0.1 | 4 |
| 369 | PD-1 Blockade Boosts Radiofrequency Ablation–Elicited Adaptive Immune Responses against Tumor. Clinical Cancer Research, 2016, 22, 1173-1184. | 3.2 | 207 |
| 370 | Next-Generation Sequencing and Immunotherapy Biomarkers: A Medical Oncology Perspective. Archives of Pathology and Laboratory Medicine, 2016, 140, 245-248. | 1.2 | 11 |
| 371 | Non–Small Cell Lung Cancer, PD-L1, and the Pathologist. Archives of Pathology and Laboratory Medicine, 2016, 140, 249-254. | 1.2 | 83 |
| 372 | Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nature Reviews Cancer, 2016, 16, 275-287. | 12.8 | 2,133 |
| 373 | The role of neoantigens in response to immune checkpoint blockade. International Immunology, 2016, 28, 411-419. | 1.8 | 148 |
| 374 | Epithelial–Mesenchymal Transition and Immune Evasion during Lung Cancer Progression: The Chicken or the Egg?. Clinical Cancer Research, 2016, 22, 3422-3424. | 3.2 | 65 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 375 | The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition. Clinical Cancer Research, 2016, 22, 1865-1874. | 3.2 | 700 |
| 376 | Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines. Clinical Cancer Research, 2016, 22, 1885-1896. | 3.2 | 128 |
| 377 | Harnessing the immune system for the treatment of melanoma: current status and future prospects. Expert Review of Clinical Immunology, 2016, 12, 879-893. | 1.3 | 8 |
| 378 | From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway. Drug Discovery Today, 2016, 21, 1027-1036. | 3.2 | 137 |
| 379 | Biomarkers for PD-1/PD-L1 Blockade Therapy in Non–Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?. Clinical Lung Cancer, 2016, 17, 350-361. | 1.1 | 100 |
| 380 | EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3. OncoImmunology, 2016, 5, e1108514. | 2.1 | 124 |
| 381 | Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. Modern Pathology, 2016, 29, 753-763. | 2.9 | 230 |
| 382 | Immune checkpoint inhibition in ovarian cancer. International Immunology, 2016, 28, 339-348. | 1.8 | 122 |
| 383 | Programmed Death Ligand-1 Immunohistochemistry— A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, 2016, 140, 341-344. | 1.2 | 107 |
| 384 | Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. Immunity, 2016, 44, 924-938. | 6.6 | 857 |
| 385 | Revving Up Dendritic Cells while Braking PD-L1 to Jump-Start the Cancer-Immunity Cycle Motor. Immunity, 2016, 44, 722-724. | 6.6 | 10 |
| 386 | Emerging targeted therapies for melanoma. Expert Opinion on Emerging Drugs, 2016, 21, 195-207. | 1.0 | 22 |
| 387 | Immune biomarkers in the spectrum of childhood noncommunicable diseases. Journal of Allergy and Clinical Immunology, 2016, 137, 1302-1316. | 1.5 | 19 |
| 388 | Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis. Breast Cancer Research, 2016, 18, 43. | 2.2 | 90 |
| 389 | High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma. European Journal of Cancer, 2016, 60, 125-135. | 1.3 | 91 |
| 390 | Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors. Immunotherapy, 2016, 8, 583-600. | 1.0 | 71 |
| 391 | Recent developments in the use of immunotherapy in non-small cell lung cancer. Expert Review of Respiratory Medicine, 2016, 10, 781-798. | 1.0 | 29 |
| 392 | HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy. OncoImmunology, 2016, 5, e1065369. | 2.1 | 18 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 393 | Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy. Cancer Discovery, 2016, 6, 703-713. | 7.7 | 92 |
| 394 | Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma. , 2016, 4, 26. | | 10 |
| 395 | Biomarkers associated with checkpoint inhibitors. Annals of Oncology, 2016, 27, 1199-1206. | 0.6 | 142 |
| 396 | Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. International Immunology, 2016, 28, 373-382. | 1.8 | 143 |
| 399 | The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials. Future Oncology, 2016, 12, 2061-2063. | 1.1 | 2 |
| 400 | Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer. Current Opinion in Oncology, 2016, 28, 122-129. | 1.1 | 41 |
| 401 | PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations. OncoImmunology, 2016, 5, e1131379. | 2.1 | 94 |
| 402 | The emerging role of immunotherapy in gastric and esophageal adenocarcinoma. Future Oncology, 2016, 12, 1833-1846. | 1.1 | 16 |
| 403 | Perspectives for immunotherapy in endocrine cancer. Endocrine-Related Cancer, 2016, 23, R469-R484. | 1.6 | 12 |
| 404 | PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?. , 2016, 4, 48. | | 178 |
| 405 | Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non–small Cell Lung Cancer. Journal of Histochemistry and Cytochemistry, 2016, 64, 587-600. | 1.3 | 30 |
| 406 | Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype. Pathology, 2016, 48, 574-580. | 0.3 | 59 |
| 407 | Demethylation of the PD-1 Promoter Is Imprinted during the Effector Phase of CD8 T Cell Exhaustion. Journal of Virology, 2016, 90, 8934-8946. | 1.5 | 69 |
| 408 | Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 581-590. | 1.4 | 71 |
| 409 | Stem-like features of cancer cells on their way to metastasis. Biology Direct, 2016, 11, 33. | 1.9 | 36 |
| 410 | Biomarkers in Melanoma: Lessons from Translational Medicine. Trends in Cancer, 2016, 2, 305-312. | 3.8 | 11 |
| 411 | Rethinking Lymphatic Vessels and Antitumor Immunity. Trends in Cancer, 2016, 2, 548-551. | 3.8 | 9 |
| 412 | Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma. Asian Journal of Urology, 2016, 3, 268-277. | 0.5 | 4 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 413 | Immunotherapy for malignant mesothelioma: reality check. Expert Review of Anticancer Therapy, 2016, 16, 1167-1176. | 1.1 | 10 |
| 414 | Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. Cancer Immunology Research, 2016, 4, 959-967. | 1.6 | 428 |
| 415 | Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. Journal of Clinical Oncology, 2016, 34, 3838-3845. | 0.8 | 715 |
| 416 | TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer. Cancer Discovery, 2016, 6, 1366-1381. | 7.7 | 196 |
| 417 | Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?. Haematologica, 2016, 101, 1144-1158. | 1.7 | 6 |
| 418 | Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients. BMC Cancer, 2016, 16, 744. | 1.1 | 94 |
| 420 | Immunotherapy for Lung Cancer: No Longer an Abstract Concept. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 771-782. | 0.8 | 12 |
| 421 | Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients. British Journal of Cancer, 2016, 115, 1186-1192. | 2.9 | 50 |
| 422 | Genomic Approaches to Understanding Response and Resistance to Immunotherapy. Clinical Cancer Research, 2016, 22, 5642-5650. | 3.2 | 134 |
| 423 | Enzyme-Instructed Self-Assembly for Spatiotemporal Profiling of the Activities of Alkaline Phosphatases on Live Cells. CheM, 2016, 1, 246-263. | 5.8 | 143 |
| 424 | Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagnostic Pathology, 2016, 11, 95. | 0.9 | 149 |
| 425 | Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma. Journal of Clinical Oncology, 2016, 34, 4102-4109. | 0.8 | 528 |
| 426 | Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology. Expert Opinion on Biological Therapy, 2016, 16, 1479-1489. | 1.4 | 10 |
| 427 | Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication. Blood, 2016, 128, 1590-1603. | 0.6 | 139 |
| 429 | Molecular Imaging of Immunotherapy Targets in Cancer. Journal of Nuclear Medicine, 2016, 57, 1487-1492. | 2.8 | 77 |
| 430 | Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non–small cell lung cancer. Lung Cancer, 2016, 99, 79-87. | 0.9 | 108 |
| 431 | Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors. JAMA Oncology, 2016, 2, 1490. | 3.4 | 68 |
| 432 | Metastatic melanoma and immunotherapy. Clinical Immunology, 2016, 172, 105-110. | 1.4 | 43 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 433 | Emerging biological therapies for the treatment of myelodysplastic syndromes. Expert Opinion on Emerging Drugs, 2016, 21, 283-300. | 1.0 | 15 |
| 434 | Immunotherapy of advanced renal cell carcinoma: Current and future therapies. Human Vaccines and Immunotherapeutics, 2016, 12, 2997-3004. | 1.4 | 12 |
| 435 | PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis. Immunotherapy, 2016, 8, 1081-1089. | 1.0 | 32 |
| 437 | Mechanisms of immune evasion and current status of checkpoint inhibitors in non–small cell lung cancer. Cancer Medicine, 2016, 5, 2567-2578. | 1.3 | 56 |
| 438 | Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers. Pediatric Blood and Cancer, 2016, 63, 1461-1464. | 0.8 | 71 |
| 439 | Concepts in glioma immunotherapy. Cancer Immunology, Immunotherapy, 2016, 65, 1269-1275. | 2.0 | 52 |
| 440 | The immune system and cancer evasion strategies: therapeutic concepts. Journal of Internal Medicine, 2016, 279, 541-562. | 2.7 | 212 |
| 441 | Immunotherapy for lung cancer. Respirology, 2016, 21, 821-833. | 1.3 | 268 |
| 442 | PD–1 Pathway Inhibitors: Immuno–Oncology Agents for Restoring Antitumor Immune Responses. Pharmacotherapy, 2016, 36, 317-334. | 1.2 | 82 |
| 443 | Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies. Cancer Science, 2016, 107, 107-115. | 1.7 | 28 |
| 444 | Evolving Immunotherapy Approaches for Renal Cell Carcinoma. Current Oncology Reports, 2016, 18, 57. | 1.8 | 24 |
| 445 | The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma. Cancer Immunology Research, 2016, 4, 726-733. | 1.6 | 133 |
| 446 | Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment. Journal of Thoracic Oncology, 2016, 11, 1869-1878. | 0.5 | 81 |
| 447 | Lymphocyte–activation gene–3, an important immune checkpoint in cancer. Cancer Science, 2016, 107, 1193-1197. | 1.7 | 168 |
| 448 | Quantification of PD-L1 and PD-1 expression on tumor and immune cells in non-small cell lung cancer (NSCLC) using non-enzymatic tissue dissociation and flow cytometry. Cancer Immunology, Immunotherapy, 2016, 65, 1317-1323. | 2.0 | 21 |
| 449 | Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy. Cancer Immunology Research, 2016, 4, 835-844. | 1.6 | 138 |
| 450 | Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Molecular Cancer, 2016, 15, 55. | 7.9 | 212 |
| 451 | Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. Lancet, The, 2016, 388, 1002-1011. | 6.3 | 132 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 452 | Malignant Mesothelioma Effusions Are Infiltrated byÂCD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Antiâ€"PD-L1 Antibody Avelumab. Journal of Thoracic Oncology, 2016, 11, 1993-2005. | 0.5 | 96 |
| 453 | Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biology, 2016, 17, 174. | 3.8 | 1,768 |
| 454 | Telltale tumor infiltrating lymphocytes (TIL) in oral, head &amp; neck cancer. Oral Oncology, 2016, 61, 159-165. | 0.8 | 60 |
| 456 | Novel Approaches to Apoptosis-Inducing Therapies. Advances in Experimental Medicine and Biology, 2016, 930, 173-204. | 0.8 | 17 |
| 457 | PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1+ and CD8+ tumor-infiltrating T cells and outcome. Modern Pathology, 2016, 29, 1552-1564. | 2.9 | 25 |
| 458 | T Cell Factor 1-Expressing Memory-like CD8+ T Cells Sustain the Immune Response to Chronic Viral Infections. Immunity, 2016, 45, 415-427. | 6.6 | 721 |
| 459 | Molecular Evaluation of Colorectal Adenocarcinoma. Surgical Pathology Clinics, 2016, 9, 427-439. | 0.7 | 16 |
| 460 | Regulatory circuits of T cell function in cancer. Nature Reviews Immunology, 2016, 16, 599-611. | 10.6 | 445 |
| 461 | The efficacy of antiâ€PDâ€1 agents in acral and mucosal melanoma. Cancer, 2016, 122, 3354-3362. | 2.0 | 236 |
| 462 | Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases. Cancer Immunology, Immunotherapy, 2016, 65, 1201-1212. | 2.0 | 36 |
| 463 | Immunotherapy in Lung Cancer. Cancer Treatment and Research, 2016, 170, 203-223. | 0.2 | 8 |
| 464 | Diagnosis and Molecular Classification of Lung Cancer. Cancer Treatment and Research, 2016, 170, 25-46. | 0.2 | 172 |
| 465 | Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade. OncoImmunology, 2016, 5, e1232222. | 2.1 | 48 |
| 466 | B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8+ T cells. Scientific Reports, 2016, 6, 36722. | 1.6 | 36 |
| 467 | High-content molecular profiling of T-cell therapy in oncology. Molecular Therapy - Oncolytics, 2016, 3, 16009. | 2.0 | 6 |
| 468 | Cancer Stem Cells. , 2016, , 341-366. | | 4 |
| 469 | Novel immunotherapy in the treatment of advanced non-small cell lung cancer. Expert Review of Clinical Pharmacology, 2016, 9, 1571-1581. | 1.3 | 21 |
| 470 | Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer. Breast Cancer Research, 2016, 18, 78. | 2.2 | 75 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 471 | Intralesional and systemic immunotherapy for metastatic melanoma. Expert Opinion on Biological Therapy, 2016, 16, 1491-1499. | 1.4 | 15 |
| 472 | Checkpoint inhibitors in lung cancer: latest developments and clinical potential. Therapeutic Advances in Medical Oncology, 2016, 8, 460-473. | 1.4 | 30 |
| 473 | Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia. Blood, 2016, 127, 1449-1458. | 0.6 | 99 |
| 474 | PD-L1 expression is associated with advanced non-small cell lung cancer. Oncology Letters, 2016, 12, 921-927. | 0.8 | 18 |
| 475 | Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer. Oncology Letters, 2016, 12, 944-950. | 0.8 | 75 |
| 476 | Advances in immunotherapy for melanoma management. Human Vaccines and Immunotherapeutics, 2016, 12, 2501-2511. | 1.4 | 15 |
| 477 | Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities. Clinical and Translational Science, 2016, 9, 89-104. | 1.5 | 144 |
| 478 | PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung. Human Pathology, 2016, 58, 7-14. | 1.1 | 135 |
| 479 | Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis. Targeted Oncology, 2016, 11, 753-761. | 1.7 | 73 |
| 480 | HDAC inhibitors with PD-1 blockade: a promising strategy for treatment of multiple cancer types?. Epigenomics, 2016, 8, 1015-1017. | 1.0 | 22 |
| 481 | Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma. Immunotherapy, 2016, 8, 775-784. | 1.0 | 24 |
| 482 | Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers. British Journal of Cancer, 2016, 115, 490-496. | 2.9 | 88 |
| 483 | Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. Modern Pathology, 2016, 29, 1433-1442. | 2.9 | 144 |
| 485 | Atezolizumab: First Global Approval. Drugs, 2016, 76, 1227-1232. | 4.9 | 91 |
| 486 | Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer. Expert Opinion on Biological Therapy, 2016, 16, 1209-1223. | 1.4 | 18 |
| 487 | PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. Scientific Reports, 2016, 6, 36956. | 1.6 | 196 |
| 488 | Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nature Communications, 2016, 7, 10582. | 5.8 | 412 |
| 489 | Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biology, 2016, 17, 231. | 3.8 | 746 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 490 | Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7769-E7777. | 3.3 | 145 |
| 491 | PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Science Translational Medicine, 2016, 8, 328rv4. | 5.8 | 1,844 |
| 492 | Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide. , 2016, 4, 68. | | 27 |
| 493 | Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nature Communications, 2016, 7, 12624. | 5.8 | 550 |
| 494 | Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Medicine, 2016, 14, 168. | 2.3 | 106 |
| 496 | Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy. Nature Communications, 2016, 7, 12335. | 5.8 | 93 |
| 497 | Diminished but not dead: chemotherapy for the treatment of NSCLC. Lancet Oncology, The, 2016, 17, 1464-1465. | 5.1 | 21 |
| 498 | Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. Protein and Cell, 2016, 7, 866-877. | 4.8 | 44 |
| 499 | A novel method for evaluating antibody-dependent cell-mediated cytotoxicity by flowcytometry using cryopreserved human peripheral blood mononuclear cells. Scientific Reports, 2016, 6, 19772. | 1.6 | 46 |
| 500 | PD-L1 testing, fit for routine evaluation? From a pathologï»¿gistâ€™s point of view. Memo - Magazine of European Medical Oncology, 2016, 9, 201-206. | 0.3 | 38 |
| 501 | Recent Trends in the Management of Hepatocellular Carcinoma with Special Emphasis on Treatment with Regorafenib and Immune Checkpoint Inhibitors. Digestive Diseases, 2016, 34, 714-730. | 0.8 | 7 |
| 502 | In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide. Science Immunology, 2016, 1, aaf6925. | 5.6 | 142 |
| 503 | Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer. Therapeutic Advances in Gastroenterology, 2016, 9, 853-860. | 1.4 | 13 |
| 504 | Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8 $^{+}$ T cells. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7240-E7249. | 3.3 | 187 |
| 505 | Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. Scientific Reports, 2016, 6, 30093. | 1.6 | 213 |
| 506 | Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. New England Journal of Medicine, 2016, 375, 1767-1778. | 13.9 | 1,025 |
| 507 | Current Status of Immunotherapy for Non-Small-Cell Lung Cancer. Tumori, 2016, 102, 337-351. | 0.6 | 6 |
| 508 | Imaging Biomarkers in Immunotherapy. Biomarkers in Cancer, 2016, 8s2, BIC.S31805. | 3.6 | 31 |

| # | Article | IF | Citations |
|---|---|---|---|
| 509 | Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer, 2016, 2, 165-202. | 0.2 | 30 |
| 510 | Programmed Death-1 Inhibition in Cancer With a Focus on Non-Small Cell Lung Cancer: Rationale, Nursing Implications, and Patient Management Strategies. Clinical Journal of Oncology Nursing, 2016, 20, 319-326. | 0.3 | 3 |
| 511 | It's TIME for a biomarker-driven approach to cancer immunotherapy. , 2016, 4, 43. | | 6 |
| 512 | Chemotherapy and radiation therapy elicits tumor specific T cell responses in a breast cancer patient. BMC Cancer, 2016, 16, 591. | 1.1 | 25 |
| 513 | Undifferentiated Carcinoma With Osteoclastic Giant Cells of the Pancreas. American Journal of Surgical Pathology, 2016, 40, 1203-1216. | 2.1 | 100 |
| 514 | Drug Monographs: Atezolizumab and Everolimus. Hospital Pharmacy, 2016, 51, 810-814. | 0.4 | 3 |
| 515 | Pools of programmed death-ligand within the oral cavity tumor microenvironment: Variable alteration by targeted therapies. Head and Neck, 2016, 38, 1176-1186. | 0.9 | 17 |
| 516 | Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1954-1961. | 3.3 | 122 |
| 517 | Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers. , 2016, 4, 17. | | 155 |
| 518 | Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma. Expert Review of Molecular Diagnostics, 2016, 16, 811-826. | 1.5 | 41 |
| 519 | Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma. OncoImmunology, 2016, 5, e1181252. | 2.1 | 52 |
| 520 | Evaluation of 29 indicators for the prognosis of advanced non-small cell lung cancer with cytokine-induced killer cell therapy combined with chemotherapy. Experimental and Therapeutic Medicine, 2016, 11, 1601-1610. | 0.8 | 7 |
| 521 | Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers. Current Treatment Options in Oncology, 2016, 17, 40. | 1.3 | 34 |
| 522 | Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. Cancer Immunology Research, 2016, 4, 679-687. | 1.6 | 81 |
| 523 | Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. Immunity, 2016, 44, 1255-1269. | 6.6 | 797 |
| 524 | NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells. Journal of Immunology, 2016, 197, 953-961. | 0.4 | 93 |
| 526 | Mouse Models of Tumor Immunotherapy. Advances in Immunology, 2016, 130, 1-24. | 1.1 | 30 |
| 527 | The development of immunotherapy in older adults: New treatments, new toxicities?. Journal of Geriatric Oncology, 2016, 7, 325-333. | 0.5 | 93 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------| 
| 528 | Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types. Journal of the National Cancer Institute, 2016, 108, djw144. | 3.0 | 271 |
| 529 | Anaplastic Thyroid Carcinoma: Treatment in the Age of Molecular Targeted Therapy. Journal of Oncology Practice, 2016, 12, 511-518. | 2.5 | 81 |
| 530 | Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC. Journal of Thoracic Oncology, 2016, 11, 1819-1836. | 0.5 | 31 |
| 531 | Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma. Journal of Thoracic Oncology, 2016, 11, 1879-1890. | 0.5 | 156 |
| 532 | Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer. Future Oncology, 2016, 12, 1805-1822. | 1.1 | 6 |
| 533 | Genomic and Epigenomic Alterations in Cancer. American Journal of Pathology, 2016, 186, 1724-1735. | 1.9 | 130 |
| 534 | Developing immunotherapeutic strategies to target brain tumors. Expert Review of Anticancer Therapy, 2016, 16, 775-788. | 1.1 | 5 |
| 535 | PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma. OncoImmunology, 2016, 5, e1176653. | 2.1 | 59 |
| 536 | Combinatorial approach to cancer immunotherapy: strength in numbers. Journal of Leukocyte Biology, 2016, 100, 275-290. | 1.5 | 90 |
| 537 | Challenges &amp; Perspectives of Immunotherapy Biomarkers &amp; The HistoOncoImmuneâ„¢ Methodology. Expert Review of Precision Medicine and Drug Development, 2016, 1, 9-24. | 0.4 | 5 |
| 538 | PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer. Human Pathology, 2016, 55, 182-189. | 1.1 | 58 |
| 539 | Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. Lung Cancer, 2016, 97, 73-80. | 0.9 | 122 |
| 540 | The PD-1:PD-L1 immune inhibitory checkpoint in Helicobacter pylori infection and gastric cancer: a comprehensive review and future perspectives. Porto Biomedical Journal, 2016, 1, 4-11. | 0.4 | 22 |
| 541 | Nivolumab and Pembrolizumab for Nonâ€"Small Cell Lung Cancer. Clinical Cancer Research, 2016, 22, 3713-3717. | 3.2 | 62 |
| 542 | Checkpoint Inhibitors and Their Application in Breast Cancer. Breast Care, 2016, 11, 108-115. | 0.8 | 45 |
| 543 | Checkpoint inhibition for colorectal cancer: progress and possibilities. Immunotherapy, 2016, 8, 693-704. | 1.0 | 5 |
| 545 | Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy. Lung Cancer, 2016, 99, 4-10. | 0.9 | 81 |
| 546 | Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers. Breast Cancer Research, 2016, 18, 50. | 2.2 | 56 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 547 | Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. , 2016, 4, 15. | | 67 |
| 548 | Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Nonâ€"Small-Cell Lung Cancer. JAMA Oncology, 2016, 2, 1217. | 3.4 | 216 |
| 549 | Biphasic function of TLR3 adjuvant on tumor and spleen dendritic cells promotes tumor T cell infiltration and regression in a vaccine therapy. OncoImmunology, 2016, 5, e1188244. | 2.1 | 41 |
| 550 | Enhancing the Efficacy of Checkpoint Blockade Through Combination Therapies. , 2016, , 1-39. | | 0 |
| 551 | CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer. Cell Reports, 2016, 15, 2719-2732. | 2.9 | 217 |
| 552 | Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma. Journal of Hematology and Oncology, 2016, 9, 48. | 6.9 | 28 |
| 553 | Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer. Breast Cancer Research, 2016, 18, 21. | 2.2 | 66 |
| 554 | SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade. OncoImmunology, 2016, 5, e1169353. | 2.1 | 33 |
| 555 | Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma. Journal of Translational Medicine, 2016, 14, 188. | 1.8 | 72 |
| 556 | Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes. JAMA Oncology, 2016, 2, 1354. | 3.4 | 426 |
| 557 | Novel technologies and emerging biomarkers for personalized cancer immunotherapy. , 2016, 4, 3. | | 183 |
| 558 | Immune-related adverse events with immune checkpoint blockade: a comprehensive review. European Journal of Cancer, 2016, 54, 139-148. | 1.3 | 1,687 |
| 559 | Doubling the blockade for melanoma immunotherapy. OncoImmunology, 2016, 5, e1106127. | 2.1 | 9 |
| 560 | Potential biomarker for checkpoint blockade immunotherapy and treatment strategy. Tumor Biology, 2016, 37, 4251-4261. | 0.8 | 78 |
| 561 | Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms. Future Oncology, 2016, 12, 551-564. | 1.1 | 8 |
| 562 | Immune-checkpoint blockade â€" durable cancer control. Nature Reviews Clinical Oncology, 2016, 13, 77-78. | 12.5 | 71 |
| 563 | Current status of immunotherapy. Japanese Journal of Clinical Oncology, 2016, 46, 191-203. | 0.6 | 52 |
| 564 | Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy. European Journal of Cancer, 2016, 55, 7-14. | 1.3 | 163 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 565 | Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach. Breast Cancer Research and Treatment, 2016, 155, 223-234. | 1.1 | 3 |
| 566 | PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunology Research, 2016, 4, 194-203. | 1.6 | 321 |
| 567 | Pembrolizumab for the treatment of non-small cell lung cancer. Expert Opinion on Biological Therapy, 2016, 16, 397-406. | 1.4 | 56 |
| 568 | Tumour-infiltrating lymphocytes in melanoma prognosis andÂcancerÂimmunotherapy. Pathology, 2016, 48, 177-187. | 0.3 | 210 |
| 569 | Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer. Clinical Cancer Research, 2016, 22, 2177-2182. | 3.2 | 119 |
| 570 | The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy. American Journal of Clinical Dermatology, 2016, 17, 1-10. | 3.3 | 8 |
| 571 | Pharmacogenomics. Urologic Clinics of North America, 2016, 43, 77-86. | 0.8 | 9 |
| 572 | Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Nonâ€"Small-Cell Lung Cancer. JAMA Oncology, 2016, 2, 46. | 3.4 | 693 |
| 573 | Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, The, 2016, 387, 1540-1550. | 6.3 | 5,456 |
| 574 | Regulatory B cells contribute to the impaired antitumor immunity in ovarian cancer patients. Tumor Biology, 2016, 37, 6581-6588. | 0.8 | 80 |
| 575 | Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nature Reviews Clinical Oncology, 2016, 13, 228-241. | 12.5 | 679 |
| 576 | New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 57-75. | 1.5 | 46 |
| 577 | Control of PD-L1 Expression by Oncogenic Activation of the AKTâ€"mTOR Pathway in Nonâ€"Small Cell Lung Cancer. Cancer Research, 2016, 76, 227-238. | 0.4 | 595 |
| 578 | PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Human Pathology, 2016, 47, 52-63. | 1.1 | 284 |
| 579 | Prognostic and predictive biomarkers in melanoma: an update. Expert Review of Molecular Diagnostics, 2016, 16, 223-237. | 1.5 | 23 |
| 580 | Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions. Future Oncology, 2016, 12, 9-23. | 1.1 | 13 |
| 581 | Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Nonâ€"Small-Cell Lung Cancer. Clinical Lung Cancer, 2016, 17, 263-270.e2. | 1.1 | 107 |
| 582 | Melanoma driver mutations and immune therapy. OncoImmunology, 2016, 5, e1051299. | 2.1 | 13 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 583 | CTLA-4 and PD-1 Pathways. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 98-106. | 0.6 | 1,644 |
| 584 | PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecologic Oncology, 2016, 141, 293-302. | 0.6 | 261 |
| 585 | Immuntherapie des Melanoms: Wirksamkeit und Wirkungsmechanismen. JDDG - Journal of the German Society of Dermatology, 2016, 14, 28-37. | 0.4 | 4 |
| 586 | Immunotherapy of melanoma: efficacy and mode of action. JDDG - Journal of the German Society of Dermatology, 2016, 14, 28-36. | 0.4 | 16 |
| 587 | Beyond CTLA-4 and PD-1: Orphan nuclear receptor NR2F6 as T cell signaling switch and emerging target in cancer immunotherapy. Immunology Letters, 2016, 178, 31-36. | 1.1 | 39 |
| 588 | TCR-engineered T cells to treat tumors: Seeing but not touching?. Seminars in Immunology, 2016, 28, 10-21. | 2.7 | 62 |
| 589 | A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage. OncoImmunology, 2016, 5, e1091146. | 2.1 | 66 |
| 590 | High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine. Familial Cancer, 2016, 15, 405-412. | 0.9 | 105 |
| 591 | PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2016, 100, 88-98. | 2.0 | 316 |
| 592 | STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Research, 2016, 76, 999-1008. | 0.4 | 451 |
| 593 | PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors. Lung Cancer, 2016, 93, 9-16. | 0.9 | 27 |
| 594 | Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?. Expert Opinion on Biological Therapy, 2016, 16, 655-674. | 1.4 | 21 |
| 595 | Immune checkpoint therapy for non-small-cell lung cancer: an update. Immunotherapy, 2016, 8, 279-298. | 1.0 | 56 |
| 596 | Plasma cells in primary melanoma. Prognostic significance and possible role of IgA. Modern Pathology, 2016, 29, 347-358. | 2.9 | 43 |
| 597 | New Strategies in Breast Cancer: Immunotherapy. Clinical Cancer Research, 2016, 22, 2105-2110. | 3.2 | 124 |
| 598 | Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer. Molecular Diagnosis and Therapy, 2016, 20, 175-181. | 1.6 | 30 |
| 599 | The Evolving Role of Nivolumab in Non–Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. Clinical Lung Cancer, 2016, 17, 161-168. | 1.1 | 13 |
| 600 | Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nature Communications, 2016, 7, 10501. | 5.8 | 1,163 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 601 | Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clinical Cancer Research, 2016, 22, 3630-3642. | 3.2 | 353 |
| 602 | Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration. Clinical Cancer Research, 2016, 22, 2261-2270. | 3.2 | 217 |
| 603 | Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. Immunity, 2016, 44, 343-354. | 6.6 | 767 |
| 605 | Rare cancers: a sea of opportunity. Lancet Oncology, The, 2016, 17, e52-e61. | 5.1 | 76 |
| 606 | The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 789-800. | 0.5 | 401 |
| 607 | Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas. Human Pathology, 2016, 52, 9-18. | 1.1 | 80 |
| 608 | Duality at the gate: Skin dendritic cells as mediators of vaccine immunity and tolerance. Human Vaccines and Immunotherapeutics, 2016, 12, 104-116. | 1.4 | 9 |
| 609 | Checkpoint Inhibitors for the Treatment of Hodgkin Lymphoma. Expert Review of Clinical Immunology, 2016, 12, 673-679. | 1.3 | 6 |
| 610 | Genetic progression of malignant melanoma. Cancer and Metastasis Reviews, 2016, 35, 93-107. | 2.7 | 60 |
| 611 | Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade. Cancer Cell, 2016, 29, 285-296. | 7.7 | 349 |
| 612 | PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. International Journal of Clinical Oncology, 2016, 21, 462-473. | 1.0 | 255 |
| 613 | Reprint of: Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies. Biology of Blood and Marrow Transplantation, 2016, 22, S9-S14. | 2.0 | 0 |
| 614 | Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma. European Journal of Cancer, 2016, 57, 91-103. | 1.3 | 120 |
| 615 | Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 511-525. | 1.4 | 212 |
| 617 | Immunotherapy of Cancer. , 2016, , . | | 3 |
| 618 | Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti–PD-1 and Anti-CD137 Monoclonal Antibodies. Journal of Thoracic Oncology, 2016, 11, 524-536. | 0.5 | 48 |
| 619 | Eavesdropping on altered cell-to-cell signaling in cancer by secretome profiling. Molecular and Cellular Oncology, 2016, 3, e1029061. | 0.3 | 6 |
| 620 | Monoclonal antibodies for treating gastric cancer: promises and pitfalls. Expert Opinion on Biological Therapy, 2016, 16, 759-769. | 1.4 | 6 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 621 | Pattern Recognition by Dendritic Cells and Its Application to Vaccine Adjuvant for Antitumor Immunotherapy. , 2016, , 235-246. | | 1 |
| 622 | Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. MAbs, 2016, 8, 593-603. | 2.6 | 156 |
| 623 | Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition. Current Oncology Reports, 2016, 18, 21. | 1.8 | 39 |
| 624 | Personalized Cancer Immunotherapy: Immune Biomarkers and Combination Immunotherapy. , 2016, , 349-358. | | 0 |
| 625 | Targeting Oral Cancer. , 2016, , . | | 0 |
| 626 | Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet, The, 2016, 387, 1909-1920. | 6.3 | 3,077 |
| 627 | MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. Immunity, 2016, 44, 609-621. | 6.6 | 566 |
| 628 | Immunotherapy in Head and Neck Cancers. , 2016, , 211-224. | | 0 |
| 629 | Predictive Markers for the Efficacy of Antiâ€"PD-1/PD-L1 Antibodies in Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 976-988. | 0.5 | 197 |
| 630 | Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. Journal of Clinical Oncology, 2016, 34, 1510-1517. | 0.8 | 627 |
| 631 | Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet, The, 2016, 387, 1837-1846. | 6.3 | 2,390 |
| 633 | Development of immuno-oncology drugs â€" from CTLA4 to PD1 to the next generations. Nature Reviews Drug Discovery, 2016, 15, 235-247. | 21.5 | 503 |
| 634 | Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research. Clinical Cancer Research, 2016, 22, 2102-2104. | 3.2 | 31 |
| 635 | Neoepitopes and CD3-Positive and CD8-Positive Cells in Polymerase eâ€"Mutated and Microsatellite-Instable Endometrial Cancersâ€"Reply. JAMA Oncology, 2016, 2, 141. | 3.4 | 1 |
| 636 | Medullary carcinoma of the colon: a distinct morphology reveals a distinctive immunoregulatory microenvironment. Modern Pathology, 2016, 29, 528-541. | 2.9 | 60 |
| 637 | HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma. Clinical Cancer Research, 2016, 22, 4119-4132. | 3.2 | 266 |
| 638 | Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Antiâ€"PD-1 Therapy. Cancer Immunology Research, 2016, 4, 474-480. | 1.6 | 17 |
| 639 | Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer. Cancer Letters, 2016, 381, 259-268. | 3.2 | 30 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 640 | Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology, 2016, 8, 4-31. | 1.4 | 40 |
| 641 | Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Annals of Oncology, 2016, 27, 409-416. | 0.6 | 597 |
| 642 | Antitumor cytotoxicity induced by bone-marrow-derived antigen-presenting cells is facilitated by the tumor suppressor protein p53 via regulation of IL-12. OncoImmunology, 2016, 5, e1112941. | 2.1 | 11 |
| 643 | New Strategies in Bladder Cancer: A Second Coming for Immunotherapy. Clinical Cancer Research, 2016, 22, 793-801. | 3.2 | 60 |
| 644 | Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. Journal of Clinical Oncology, 2016, 34, 833-842. | 0.8 | 517 |
| 645 | Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition. Current Opinion in Immunology, 2016, 39, 30-38. | 2.4 | 23 |
| 646 | Cancer immunotherapy targeting neoantigens. Seminars in Immunology, 2016, 28, 22-27. | 2.7 | 199 |
| 647 | Combining antibody–drug conjugates and immune-mediated cancer therapy: What to expect?. Biochemical Pharmacology, 2016, 102, 1-6. | 2.0 | 119 |
| 648 | Current progress in immunotherapy for pancreatic cancer. Cancer Letters, 2016, 381, 244-251. | 3.2 | 149 |
| 649 | Chemotherapy and immunotherapy: mapping the road ahead. Current Opinion in Immunology, 2016, 39, 23-29. | 2.4 | 105 |
| 650 | Mutanome directed cancer immunotherapy. Current Opinion in Immunology, 2016, 39, 14-22. | 2.4 | 55 |
| 651 | Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer. Cancer Research, 2016, 76, 472-479. | 0.4 | 140 |
| 652 | Immune suppressive mechanisms in the tumor microenvironment. Current Opinion in Immunology, 2016, 39, 1-6. | 2.4 | 407 |
| 653 | Reprogramming away from the exhausted T cell state. Seminars in Immunology, 2016, 28, 35-44. | 2.7 | 25 |
| 654 | Reprogramming the tumor microenvironment to enhance adoptive cellular therapy. Seminars in Immunology, 2016, 28, 64-72. | 2.7 | 52 |
| 655 | Combination cancer immunotherapies tailored to the tumour microenvironment. Nature Reviews Clinical Oncology, 2016, 13, 143-158. | 12.5 | 753 |
| 656 | Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. Annals of Oncology, 2016, 27, 214-224. | 0.6 | 86 |
| 657 | Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma. Clinical Cancer Research, 2016, 22, 704-713. | 3.2 | 173 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 658 | Immune checkpoint inhibitors: a new frontier in bladder cancer. World Journal of Urology, 2016, 34, 49-55. | 1.2 | 15 |
| 659 | Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies. Biology of Blood and Marrow Transplantation, 2016, 22, 17-22. | 2.0 | 16 |
| 660 | Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1865, 58-71. | 3.3 | 49 |
| 661 | Immunotherapy and tumor microenvironment. Cancer Letters, 2016, 370, 85-90. | 3.2 | 242 |
| 662 | Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Annals of Oncology, 2016, 27, 147-153. | 0.6 | 466 |
| 663 | MicroRNA <i>MIR21</i> and T Cells in Colorectal Cancer. Cancer Immunology Research, 2016, 4, 33-40. | 1.6 | 29 |
| 664 | From T cell â€œexhaustionâ€•to anti-cancer immunity. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1865, 49-57. | 3.3 | 18 |
| 665 | Biomarkers for immunotherapy in genitourinary malignancies. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 205-213. | 0.8 | 14 |
| 666 | Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut, 2017, 66, 794-801. | 6.1 | 377 |
| 667 | Translational aspects in targeting the stromal tumour microenvironment: From bench to bedside. European Journal of Molecular and Clinical Medicine, 2017, 3, 9. | 0.5 | 18 |
| 668 | Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer. Breast Cancer, 2017, 24, 111-120. | 1.3 | 21 |
| 669 | Elements of cancer immunity and the cancerâ€"immune set point. Nature, 2017, 541, 321-330. | 13.7 | 3,558 |
| 670 | Systemic Immunity Is Required for Effective Cancer Immunotherapy. Cell, 2017, 168, 487-502.e15. | 13.5 | 708 |
| 671 | Modification of host dendritic cells by microchimerism-derived extracellular vesicles generates split tolerance. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1099-1104. | 3.3 | 55 |
| 672 | Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut, 2017, 66, 1463-1473. | 6.1 | 173 |
| 673 | Comprehensive screening for PD-L1 expression in thyroid cancer. Endocrine-Related Cancer, 2017, 24, 97-106. | 1.6 | 119 |
| 674 | Cancer immunotherapy â€" immune checkpoint blockade and associated endocrinopathies. Nature Reviews Endocrinology, 2017, 13, 195-207. | 4.3 | 515 |
| 675 | Tumour-associated macrophages as treatment targets in oncology. Nature Reviews Clinical Oncology, 2017, 14, 399-416. | 12.5 | 2,667 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 676 | Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. Modern Pathology, 2017, 30, 577-586. | 2.9 | 132 |
| 677 | High Frequency of Programmed Death-ligand 1ÂExpression in Emphysematous Bullae-associated Lung Adenocarcinomas. Clinical Lung Cancer, 2017, 18, 504-511.e1. | 1.1 | 12 |
| 678 | Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma. European Urology Focus, 2017, 3, 502-509. | 1.6 | 25 |
| 679 | Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncology, The, 2017, 18, 212-220. | 5.1 | 307 |
| 680 | EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer. Clinical Lung Cancer, 2017, 18, 527-534.e1. | 1.1 | 108 |
| 681 | Pharmacological management of relapsed/refractory NSCLC with chemical drugs. Expert Opinion on Pharmacotherapy, 2017, 18, 295-304. | 0.9 | 12 |
| 682 | Experimental animal modeling for immuno-oncology. , 2017, 173, 34-46. | | 44 |
| 683 | Novel immune check point inhibiting antibodies in cancer therapyâ€"Opportunities and challenges. Drug Resistance Updates, 2017, 30, 39-47. | 6.5 | 98 |
| 684 | Prognostic Value of PD-L1 in Breast Cancer: A Meta-Analysis. Breast Journal, 2017, 23, 436-443. | 0.4 | 53 |
| 685 | Tumoral PD-L1 expression in desmoplastic melanoma is associated with depth of invasion, tumor-infiltrating CD8 cytotoxic lymphocytes and the mixed cytomorphological variant. Modern Pathology, 2017, 30, 357-369. | 2.9 | 25 |
| 686 | An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 791-803. | 0.5 | 127 |
| 687 | Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer. Lung Cancer, 2017, 105, 17-22. | 0.9 | 48 |
| 688 | Radiotherapy and immunotherapy: a beneficial liaison?. Nature Reviews Clinical Oncology, 2017, 14, 365-379. | 12.5 | 760 |
| 690 | Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas. European Journal of Cancer, 2017, 75, 141-149. | 1.3 | 84 |
| 691 | Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. Nature Communications, 2017, 8, 14572. | 5.8 | 279 |
| 692 | Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy. OncoImmunology, 2017, 6, e1286437. | 2.1 | 28 |
| 693 | PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. Clinical Cancer Research, 2017, 23, 4270-4279. | 3.2 | 117 |
| 694 | Higher densities of Foxp3+ regulatory T cells are associated with better prognosis in triple-negative breast cancer. Breast Cancer Research and Treatment, 2017, 163, 21-35. | 1.1 | 102 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 695 | Immunotherapy comes of age: Immune aging &amp; checkpoint inhibitors. Journal of Geriatric Oncology, 2017, 8, 229-235. | 0.5 | 108 |
| 696 | The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy. Endocrine-Related Cancer, 2017, 24, R123-R144. | 1.6 | 64 |
| 697 | Enrichment of circulating head and neck tumour cells using spiral microfluidic technology. Scientific Reports, 2017, 7, 42517. | 1.6 | 69 |
| 698 | PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunology, Immunotherapy, 2017, 66, 551-564. | 2.0 | 253 |
| 700 | Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer. Oral Oncology, 2017, 67, 52-60. | 0.8 | 46 |
| 701 | Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters. Clinical Cancer Research, 2017, 23, 4473-4481. | 3.2 | 96 |
| 702 | A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Nonâ€"Small Cell Lung Cancer. JAMA Oncology, 2017, 3, 1051. | 3.4 | 658 |
| 703 | T cell costimulatory receptor CD28 is a primary target for PD-1â€"mediated inhibition. Science, 2017, 355, 1428-1433. | 6.0 | 1,229 |
| 704 | Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer. Oncology, 2017, 92, 283-290. | 0.9 | 36 |
| 705 | Targeting the programmed death-1 pathway in lymphoid neoplasms. Cancer Treatment Reviews, 2017, 54, 99-109. | 3.4 | 27 |
| 706 | PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy. OncoImmunology, 2017, 6, e1294299. | 2.1 | 114 |
| 707 | PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. OncoImmunology, 2017, 6, e1278100. | 2.1 | 65 |
| 708 | Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Science Translational Medicine, 2017, 9, . | 5.8 | 689 |
| 709 | Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. OncoImmunology, 2017, 6, e1253654. | 2.1 | 146 |
| 710 | Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1. Journal of Clinical Pathology, 2017, 70, 255-259. | 1.0 | 97 |
| 711 | Reactivation of dormant anti-tumor immunity â€" a clinical perspective of therapeutic immune checkpoint modulation. Cell Communication and Signaling, 2017, 15, 5. | 2.7 | 34 |
| 712 | PD1 and PD-L1 Immune Checkpoint Inhibitors in Gastrointestinal Cancer. , 2017, , 115-146. | | 0 |
| 713 | LAG-3 Protein Expression in Nonâ€"Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. Journal of Thoracic Oncology, 2017, 12, 814-823. | 0.5 | 192 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 714 | Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials. Oncology, 2017, 92, 50-62. | 0.9 | 180 |
| 715 | Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm. International Journal of Infectious Diseases, 2017, 56, 221-228. | 1.5 | 112 |
| 716 | Applications of Immunogenomics to Cancer. Cell, 2017, 168, 600-612. | 13.5 | 198 |
| 717 | Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities. JAMA Dermatology, 2017, 153, 285. | 2.0 | 39 |
| 718 | The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma. Journal of Thoracic Oncology, 2017, 12, 850-859. | 0.5 | 83 |
| 719 | <scp>TAM</scp> receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy. Immunological Reviews, 2017, 276, 165-177. | 2.8 | 125 |
| 720 | Gene signature driving invasive mucinous adenocarcinoma of the lung. EMBO Molecular Medicine, 2017, 9, 462-481. | 3.3 | 79 |
| 721 | Immunoregulatory functions of <scp>VISTA</scp>. Immunological Reviews, 2017, 276, 66-79. | 2.8 | 154 |
| 722 | Immunotherapy in pancreatic cancer treatment: a new frontier. Therapeutic Advances in Gastroenterology, 2017, 10, 168-194. | 1.4 | 73 |
| 723 | Regulation of PD-L1 expression on murine tumor-associated monocytes and macrophages by locally produced TNF-α. Cancer Immunology, Immunotherapy, 2017, 66, 523-535. | 2.0 | 76 |
| 724 | Exploiting tumor-associated dendritic cell heterogeneity for novel cancer therapies. Journal of Leukocyte Biology, 2017, 102, 317-324. | 1.5 | 32 |
| 725 | T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature, 2017, 545, 60-65. | 13.7 | 1,280 |
| 726 | Immunotherapy: a new treatment paradigm in bladder cancer. Current Opinion in Oncology, 2017, 29, 184-195. | 1.1 | 40 |
| 727 | Papilloma-pseudovirus eradicates intestinal tumours and triples the lifespan of ApcMin/+ mice. Nature Communications, 2017, 8, 15004. | 5.8 | 8 |
| 729 | Targeting the immune system in glioblastoma. Expert Review of Precision Medicine and Drug Development, 2017, 2, 121-131. | 0.4 | 0 |
| 730 | Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation. Science Translational Medicine, 2017, 9, . | 5.8 | 541 |
| 733 | Prognostic implication of CD274 (PD-L1) protein expression in tumor-infiltrating immune cells for microsatellite unstable and stable colorectal cancer. Cancer Immunology, Immunotherapy, 2017, 66, 927-939. | 2.0 | 66 |
| 734 | <scp>PD</scp>‑L1 expression in extrahepatic cholangiocarcinoma. Histopathology, 2017, 71, 383-392. | 1.6 | 62 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 735 | PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison. Clinical Cancer Research, 2017, 23, 4938-4944. | 3.2 | 120 |
| 736 | Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade: A Key Player Against Various Cancers. Archives of Pathology and Laboratory Medicine, 2017, 141, 851-861. | 1.2 | 82 |
| 737 | Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy. Annals of Oncology, 2017, 28, 1658-1666. | 0.6 | 26 |
| 738 | Laser immunotherapy for advanced solid tumors. Proceedings of SPIE, 2017, , . | 0.8 | 0 |
| 739 | Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immunology Research, 2017, 5, 417-424. | 1.6 | 400 |
| 740 | Ubiquitinated Proteins Isolated From Tumor Cells Are Efficient Substrates for Antigen Cross-Presentation. Journal of Immunotherapy, 2017, 40, 155-163. | 1.2 | 5 |
| 741 | Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. Cancer Journal (Sudbury,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf | 1.0 | 8 |
| 742 | Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. Lung Cancer, 2017, 109, 1-8. | 0.9 | 27 |
| 743 | Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Annals of Oncology, 2017, 28, 874-881. | 0.6 | 197 |
| 744 | Post-chemotherapy PD-L1 expression correlates with clinical outcomes in Japanese bladder cancer patients treated with total cystectomy. Medical Oncology, 2017, 34, 117. | 1.2 | 7 |
| 745 | Incidence of Pneumonitis With Use of ProgrammedÂDeath 1 and Programmed Death-Ligand 1 InhibitorsÂinÂNon-Small CellÂLungÂCancer. Chest, 2017, 152, 271-281. | 0.4 | 381 |
| 746 | IDO, PTEN-expressing Tregs and control of antigen-presentation in the murine tumor microenvironment. Cancer Immunology, Immunotherapy, 2017, 66, 1049-1058. | 2.0 | 32 |
| 747 | Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series. Journal of Neuro-Oncology, 2017, 133, 561-569. | 1.4 | 43 |
| 748 | MP34-04 POST-CHEMOTHERAPY PD-L1 EXPRESSION CORRELATES WITH CLINICAL OUTCOMES IN JAPANESE BLADDER CANCER PATIENTS TREATED WITH TOTAL CYSTECTOMY.. Journal of Urology, 2017, 197, . | 0.2 | 0 |
| 749 | Epigenetics and immunotherapy: The current state of play. Molecular Immunology, 2017, 87, 227-239. | 1.0 | 167 |
| 750 | <scp>PD</scp>â€L1 overexpression in ampulla of Vater carcinoma and its preâ€invasive lesions. Histopathology, 2017, 71, 470-474. | 1.6 | 27 |
| 751 | Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. Clinical Cancer Research, 2017, 23, 5024-5033. | 3.2 | 192 |
| 752 | Integrative Analysis Identifies a Novel AXLâ€"PI3 Kinaseâ€"PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer. Clinical Cancer Research, 2017, 23, 2713-2722. | 3.2 | 91 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 753 | Immune Characterization of the Programmed Death Receptor Pathway in High Risk Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, 577-581. | 0.9 | 33 |
| 754 | Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples. Clinical Lung Cancer, 2017, 18, 682-691.e5. | 1.1 | 74 |
| 755 | Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1085-1097. | 0.5 | 202 |
| 756 | Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade. Journal of Thoracic Oncology, 2017, 12, 1268-1279. | 0.5 | 152 |
| 757 | A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice. Cancer Immunology Research, 2017, 5, 468-479. | 1.6 | 117 |
| 758 | Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer. Journal of Molecular Biology, 2017, 429, 1767-1786. | 2.0 | 14 |
| 759 | Checkpoint inhibitors in hematological malignancies. Journal of Hematology and Oncology, 2017, 10, 103. | 6.9 | 106 |
| 760 | Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies. Cancer Immunology, Immunotherapy, 2017, 66, 1113-1121. | 2.0 | 29 |
| 761 | The immune microenvironment and HPV in anal cancer: Rationale to complement chemoradiation with immunotherapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 221-230. | 3.3 | 23 |
| 762 | Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. Cell Reports, 2017, 19, 1189-1201. | 2.9 | 1,256 |
| 763 | Second-line therapy of squamous non-small cell lung cancer: an evolving landscape. Expert Review of Respiratory Medicine, 2017, 11, 469-479. | 1.0 | 11 |
| 764 | The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade. Annals of Oncology, 2017, 28, 1934-1941. | 0.6 | 76 |
| 765 | Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses. Cell, 2017, 169, 750-765.e17. | 13.5 | 937 |
| 766 | Phase I Trial of Intratumoral Injection of *CCL21* Gene–Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration. Clinical Cancer Research, 2017, 23, 4556-4568. | 3.2 | 149 |
| 767 | Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 4993-4998. | 3.3 | 614 |
| 768 | Programmed death–ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor. Cancer Science, 2017, 108, 590-597. | 1.7 | 37 |
| 769 | The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma. Medicine (United States), 2017, 96, e6398. | 0.4 | 43 |
| 770 | PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages. American Journal of Surgical Pathology, 2017, 41, 334-342. | 2.1 | 143 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 771 | Immunotherapy in Lung Cancer. Hematology/Oncology Clinics of North America, 2017, 31, 131-141. | 0.9 | 31 |
| 772 | Primary Resistance to PD-1 Blockade Mediated by *JAK1/2* Mutations. Cancer Discovery, 2017, 7, 188-201. | 7.7 | 997 |
| 773 | Atezolizumab: A PD-L1–Blocking Antibody for Bladder Cancer. Clinical Cancer Research, 2017, 23, 1886-1890. | 3.2 | 189 |
| 774 | PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. Journal of Thoracic Oncology, 2017, 12, 208-222. | 0.5 | 1,067 |
| 775 | PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. Clinical Cancer Research, 2017, 23, 3158-3167. | 3.2 | 426 |
| 776 | Relationship of the Breast Ductal Carcinoma *In Situ* Immune Microenvironment with Clinicopathological and Genetic Features. Clinical Cancer Research, 2017, 23, 5210-5217. | 3.2 | 61 |
| 777 | Transcriptional and epigenetic regulation of T cell hyporesponsiveness. Journal of Leukocyte Biology, 2017, 102, 601-615. | 1.5 | 39 |
| 778 | A Four-Factor Immunoscore System That Predicts Clinical Outcome for Stage II/III Gastric Cancer. Cancer Immunology Research, 2017, 5, 524-534. | 1.6 | 51 |
| 779 | Molecular Targeted Drugs and Treatment of Colorectal Cancer: Recent Progress and Future Perspectives. Cancer Biotherapy and Radiopharmaceuticals, 2017, 32, 149-160. | 0.7 | 93 |
| 780 | The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion. Journal of the National Cancer Institute, 2017, 109, djw283. | 3.0 | 182 |
| 781 | PD-L1 Expression in Pancreatic Cancer. Journal of the National Cancer Institute, 2017, 109, djw304. | 3.0 | 43 |
| 782 | Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: AÂRENAPE study. European Journal of Surgical Oncology, 2017, 43, 1915-1923. | 0.5 | 23 |
| 783 | Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. OncoImmunology, 2017, 6, e1310358. | 2.1 | 111 |
| 784 | Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma. Oncologist, 2017, 22, 963-971. | 1.9 | 145 |
| 785 | Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. Cancer Immunology Research, 2017, 5, 480-492. | 1.6 | 284 |
| 786 | Imaging of Programmed Cell Death Ligand 1: Impact of Protein Concentration on Distribution of Anti-PD-L1 SPECT Agents in an Immunocompetent Murine Model of Melanoma. Journal of Nuclear Medicine, 2017, 58, 1560-1566. | 2.8 | 73 |
| 787 | Immunogenomics: using genomics to personalize cancer immunotherapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 209-219. | 1.4 | 7 |
| 788 | Intratumoral injection of IFN-Î² induces chemokine production in melanoma and augments the therapeutic efficacy of anti-PD-L1 mAb. Biochemical and Biophysical Research Communications, 2017, 490, 521-527. | 1.0 | 15 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 789 | Cancer Immunotherapy Trials Not Immune from Imprecise Selection of Patients. New England Journal of Medicine, 2017, 376, 2483-2485. | 13.9 | 31 |
| 790 | Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer. OncoImmunology, 2017, 6, e1339856. | 2.1 | 8 |
| 791 | <scp>PD</scp>â€1 and <scp>PDâ€L1</scp> in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma. Journal of Cutaneous Pathology, 2017, 44, 740-746. | 0.7 | 32 |
| 792 | Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. British Journal of Cancer, 2017, 117, 203-209. | 2.9 | 38 |
| 793 | Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes. OncoImmunology, 2017, 6, e1312240. | 2.1 | 68 |
| 794 | Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 2017, 357, 409-413. | 6.0 | 4,945 |
| 795 | Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy. Gynecologic Oncology Research and Practice, 2017, 4, 9. | 3.6 | 30 |
| 796 | The microbiome and hepatobiliary-pancreatic cancers. Cancer Letters, 2017, 402, 9-15. | 3.2 | 105 |
| 797 | PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1. Nature Neuroscience, 2017, 20, 917-926. | 7.1 | 148 |
| 798 | Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck. Oral Oncology, 2017, 70, 34-42. | 0.8 | 38 |
| 799 | Immune and molecular correlates in melanoma treated with immune checkpoint blockade. Cancer, 2017, 123, 2143-2153. | 2.0 | 119 |
| 800 | Prognostic value of programmed deathâ€ligand 1 expression in patients with stage <scp>III</scp> colorectal cancer. Cancer Science, 2017, 108, 853-858. | 1.7 | 46 |
| 801 | A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy. Cell Reports, 2017, 19, 1874-1887. | 2.9 | 104 |
| 802 | Programmed deathâ€ligand 1 expression at tumor invasive front is associated with epithelialâ€mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma. Cancer Science, 2017, 108, 1119-1127. | 1.7 | 100 |
| 803 | Assessment of programmed deathâ€ligand 1 expression and tumorâ€associated immune cells in pediatric cancer tissues. Cancer, 2017, 123, 3807-3815. | 2.0 | 135 |
| 804 | Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. Lancet Oncology, The, 2017, 18, 599-610. | 5.1 | 257 |
| 805 | Relevance Between Programmed Death Ligand 1 and Radiologic Invasiveness in Pathologic Stage I Lung Adenocarcinoma. Annals of Thoracic Surgery, 2017, 103, 1750-1757. | 0.7 | 25 |
| 806 | Highlights on immune checkpoint inhibitors in nonâ€"small cell lung cancer. Tumor Biology, 2017, 39, 101042831769501. | 0.8 | 17 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 807 | Immunotherapy in NSCLC: A Promising and Revolutionary Weapon. Advances in Experimental Medicine and Biology, 2017, 995, 97-125. | 0.8 | 99 |
| 808 | Computed Tomography Features of Lung Adenocarcinomas With Programmed Death Ligand 1 Expression. Clinical Lung Cancer, 2017, 18, e375-e383. | 1.1 | 18 |
| 809 | Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment. International Immunopharmacology, 2017, 46, 210-219. | 1.7 | 102 |
| 810 | Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma. Cancer Discovery, 2017, 7, 630-651. | 7.7 | 48 |
| 811 | Overview of Basic Immunology for Clinical Investigators. Advances in Experimental Medicine and Biology, 2017, 995, 1-31. | 0.8 | 4 |
| 812 | Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients. Scientific Reports, 2017, 7, 45124. | 1.6 | 72 |
| 813 | PD-L1 expression in neuroendocrine tumors of the lung. Lung Cancer, 2017, 108, 115-120. | 0.9 | 98 |
| 814 | Prospects and progress of atezolizumab in non-small cell lung cancer. Expert Opinion on Biological Therapy, 2017, 17, 781-789. | 1.4 | 13 |
| 815 | Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. British Journal of Cancer, 2017, 116, 1141-1147. | 2.9 | 112 |
| 816 | Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis. Neuro-Oncology, 2017, 19, 1058-1067. | 0.6 | 38 |
| 817 | CD8 Tâ€cell regulation by T regulatory cells and the programmed cell death protein 1 pathway. Immunology, 2017, 151, 146-153. | 2.0 | 12 |
| 818 | Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer. Journal of Clinical Pathology, 2017, 70, 860-867. | 1.0 | 47 |
| 819 | Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncology, The, 2017, 18, 792-802. | 5.1 | 203 |
| 820 | <scp>CD</scp>70 and <scp>PD</scp>â€‘1 in anaplastic thyroid cancerÂâ€"Âpromising targets for immunotherapy. Histopathology, 2017, 71, 357-365. | 1.6 | 47 |
| 821 | Cytokine-induced senescence for cancer surveillance. Cancer and Metastasis Reviews, 2017, 36, 357-365. | 2.7 | 14 |
| 822 | Tumor Vaccines for Malignant Gliomas. Neurotherapeutics, 2017, 14, 345-357. | 2.1 | 41 |
| 823 | Connecting the Metabolic and Immune Responses to Cancer. Trends in Molecular Medicine, 2017, 23, 451-464. | 3.5 | 55 |
| 824 | Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nature Communications, 2017, 8, 14754. | 5.8 | 268 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 825 | PD-L2: A prognostic marker in chromophobe renal cell carcinoma?. Medical Oncology, 2017, 34, 71. | 1.2 | 17 |
| 826 | Knockdown of PD-L1 in Human Gastric Cancer Cells Inhibits Tumor Progression and Improves the Cytotoxic Sensitivity to CIK Therapy. Cellular Physiology and Biochemistry, 2017, 41, 907-920. | 1.1 | 88 |
| 827 | Molecular genetic and immunotherapeutic targets in metastatic melanoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 281-293. | 1.4 | 16 |
| 828 | Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncology, The, 2017, 18, 587-598. | 5.1 | 261 |
| 829 | The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is now. Critical Reviews in Oncology/Hematology, 2017, 113, 52-62. | 2.0 | 22 |
| 830 | Molecular Pathways: Oncologic Pathways and Their Role in T-cell Exclusion and Immune Evasion—A New Role for the AXL Receptor Tyrosine Kinase. Clinical Cancer Research, 2017, 23, 2928-2933. | 3.2 | 59 |
| 831 | Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma. Journal of Neuro-Oncology, 2017, 132, 359-372. | 1.4 | 8 |
| 832 | PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. Journal of Experimental Medicine, 2017, 214, 895-904. | 4.2 | 614 |
| 833 | Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy?. Expert Opinion on Biological Therapy, 2017, 17, 735-746. | 1.4 | 66 |
| 835 | PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8+ tumor-infiltrating lymphocytes: highly sensitive detection using phosphor-integrated dot staining. International Journal of Clinical Oncology, 2017, 22, 726-733. | 1.0 | 47 |
| 836 | Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection. Biomedicine and Pharmacotherapy, 2017, 90, 24-37. | 2.5 | 45 |
| 837 | Intrahepatic cholangiocarcinoma: current management and emerging therapies. Expert Review of Gastroenterology and Hepatology, 2017, 11, 439-449. | 1.4 | 58 |
| 838 | Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling. OncoImmunology, 2017, 6, e1305535. | 2.1 | 56 |
| 839 | Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response. Biomarker Research, 2017, 5, 12. | 2.8 | 149 |
| 840 | Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Investigational New Drugs, 2017, 35, 529-536. | 1.2 | 128 |
| 841 | Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery. Cancer Immunology Research, 2017, 5, 29-41. | 1.6 | 321 |
| 842 | The emerging role of immune checkpoint inhibition in malignant lymphoma. Haematologica, 2017, 102, 30-42. | 1.7 | 101 |
| 843 | Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet, The, 2017, 389, 67-76. | 6.3 | 1,728 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 844 | Immuno-Oncology: The Third Paradigm in Early Drug Development. Targeted Oncology, 2017, 12, 125-138. | 1.7 | 22 |
| 845 | Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer. Clinical Cancer Research, 2017, 23, 3129-3138. | 3.2 | 191 |
| 846 | Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis. Lung Cancer, 2017, 103, 44-51. | 0.9 | 91 |
| 847 | Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer. Cancer Discovery, 2017, 7, 264-276. | 7.7 | 706 |
| 848 | Rapid PD-L1 detection in tumors with PET using a highly specific peptide. Biochemical and Biophysical Research Communications, 2017, 483, 258-263. | 1.0 | 132 |
| 850 | Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients. OncoImmunology, 2017, 6, e1260214. | 2.1 | 11 |
| 851 | Melanoma exosomes deliver a complex biological payload that upregulates PTPN 11 to suppress T lymphocyte function. Pigment Cell and Melanoma Research, 2017, 30, 203-218. | 1.5 | 39 |
| 852 | Critical Issues in Head and Neck Oncology. , 2017, , . | | 0 |
| 853 | Ex Vivo Engineering of the Tumor Microenvironment. Cancer Drug Discovery and Development, 2017, , . | 0.2 | 4 |
| 854 | Microfluidics and Future of Cancer Diagnostics. Cancer Drug Discovery and Development, 2017, , 55-70. | 0.2 | 1 |
| 855 | Pharmacological and immunological targeting of tumor mesenchymalization. , 2017, 170, 212-225. | | 14 |
| 856 | Potential Predictive Value of *TP53* and *KRAS* Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clinical Cancer Research, 2017, 23, 3012-3024. | 3.2 | 741 |
| 857 | Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016. Journal of Clinical Oncology, 2017, 35, 243-252. | 0.8 | 19 |
| 858 | Pharmacokinetic drug evaluation of atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 225-232. | 1.5 | 20 |
| 859 | Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update. Liver Cancer, 2017, 6, 1-12. | 4.2 | 60 |
| 860 | Immunoplasticity in cutaneous melanoma: beyond pure morphology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 357-369. | 1.4 | 3 |
| 861 | Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. Nature Reviews Drug Discovery, 2017, 16, 264-272. | 21.5 | 204 |
| 862 | Sunitinib in kidney cancer: 10 years of experience and development. Expert Review of Anticancer Therapy, 2017, 17, 129-142. | 1.1 | 30 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 863 | Immunological profiling of molecularly classified high-risk endometrial cancers identifies *POLE*-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. OncoImmunology, 2017, 6, e1264565. | 2.1 | 102 |
| 864 | Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma. Clinical Pharmacology and Therapeutics, 2017, 102, 305-312. | 2.3 | 110 |
| 865 | Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer. Clinical Cancer Research, 2017, 23, 3453-3460. | 3.2 | 52 |
| 866 | Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging. Journal of Nuclear Medicine, 2017, 58, 538-546. | 2.8 | 102 |
| 867 | Localized Multi-Component Delivery Platform Generates Local and Systemic Anti-Tumor Immunity. Advanced Functional Materials, 2017, 27, 1604366. | 7.8 | 40 |
| 868 | Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer. OncoImmunology, 2017, 6, e1257452. | 2.1 | 169 |
| 869 | PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. EMBO Molecular Medicine, 2017, 9, 167-180. | 3.3 | 172 |
| 870 | Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet, The, 2017, 389, 255-265. | 6.3 | 3,872 |
| 871 | Advances in chemical pharmacotherapy to manage advanced breast cancer. Expert Opinion on Pharmacotherapy, 2017, 18, 95-103. | 0.9 | 4 |
| 872 | Emerging biomarkers for PD-1 pathway cancer therapy. Biomarkers in Medicine, 2017, 11, 53-67. | 0.6 | 11 |
| 873 | The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma. Lung Cancer, 2017, 104, 7-15. | 0.9 | 69 |
| 874 | Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment. International Journal of Oncology, 2017, 50, 41-48. | 1.4 | 65 |
| 875 | Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade. Cancer Immunology Research, 2017, 5, 84-91. | 1.6 | 126 |
| 876 | Early Effector T Lymphocytes Coexpress Multiple Inhibitory Receptors in Primary Non–Small Cell Lung Cancer. Cancer Research, 2017, 77, 851-861. | 0.4 | 49 |
| 877 | Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nature Communications, 2017, 8, 1136. | 5.8 | 686 |
| 878 | Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell, 2017, 171, 1259-1271.e11. | 13.5 | 968 |
| 879 | Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein–Barr virus-associated gastric cancer. British Journal of Cancer, 2017, 117, 1753-1760. | 2.9 | 40 |
| 880 | Towards In Silico Prediction of the Immune-Checkpoint Blockade Response. Trends in Pharmacological Sciences, 2017, 38, 1041-1051. | 4.0 | 12 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 881 | PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted?. Expert Review of Molecular Diagnostics, 2017, 17, 1097-1108. | 1.5 | 31 |
| 882 | Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more. Seminars in Immunology, 2017, 31, 55-63. | 2.7 | 98 |
| 883 | Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells. Seminars in Immunology, 2017, 34, 114-122. | 2.7 | 29 |
| 884 | PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung. Radiology and Oncology, 2017, 51, 357-362. | 0.6 | 40 |
| 885 | Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials. ESMO Open, 2017, 2, e000236. | 2.0 | 30 |
| 886 | Metabolic characteristics of programmed cell death–ligand 1–expressing lung cancer on $^{18}$F–fluorodeoxyglucose positron emission tomography/computed tomography. Cancer Medicine, 2017, 6, 2552-2561. | 1.3 | 80 |
| 887 | Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition. Scientific Reports, 2017, 7, 7958. | 1.6 | 43 |
| 888 | Nuclear and Fluorescent Labeled PD-1-Liposome-DOX-$^{64}$Cu/IRDye800CW Allows Improved Breast Tumor Targeted Imaging and Therapy. Molecular Pharmaceutics, 2017, 14, 3978-3986. | 2.3 | 66 |
| 889 | Atezolizumab in invasive and metastatic urothelial carcinoma. Expert Review of Clinical Pharmacology, 2017, 10, 1295-1301. | 1.3 | 20 |
| 890 | Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell, 2017, 171, 934-949.e16. | 13.5 | 1,515 |
| 891 | Danger signals: Chemotherapy enhancers?. Immunological Reviews, 2017, 280, 175-193. | 2.8 | 50 |
| 892 | Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. Expert Review of Molecular Diagnostics, 2017, 17, 1055-1069. | 1.5 | 24 |
| 893 | Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma. Journal of Immunotherapy, 2017, 40, 323-333. | 1.2 | 68 |
| 894 | Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. Nature Communications, 2017, 8, 1050. | 5.8 | 115 |
| 895 | Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues. Scientific Reports, 2017, 7, 13380. | 1.6 | 208 |
| 896 | Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti–PD-1/PD-L1 therapy. Human Pathology, 2017, 70, 49-54. | 1.1 | 38 |
| 897 | The evolutionary nature of the cancer immunotherapy revolution. Future Oncology, 2017, 13, 1565-1567. | 1.1 | 4 |
| 898 | Undifferentiated Pancreatic Carcinomas Display Enrichment for Frequency and Extent of PD-L1 Expression by Tumor Cells. American Journal of Clinical Pathology, 2017, 148, 441-449. | 0.4 | 19 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 899 | Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study. Annals of Oncology, 2017, 28, 3044-3050. | 0.6 | 198 |
| 900 | Circulating tumour cell PD-L1 test for head and neck cancers. Oral Oncology, 2017, 75, 6-7. | 0.8 | 15 |
| 901 | MicroRNA-155 induction via TNF-α and IFN-γ suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells. Journal of Biological Chemistry, 2017, 292, 20683-20693. | 1.6 | 105 |
| 902 | Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas. Archives of Pathology and Laboratory Medicine, 2017, 141, 1529-1532. | 1.2 | 24 |
| 903 | Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading. Cell Death and Disease, 2017, 8, e3004-e3004. | 2.7 | 90 |
| 904 | Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity. OncoImmunology, 2017, 6, e1356150. | 2.1 | 32 |
| 905 | Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma. Drugs, 2017, 77, 1645-1655. | 4.9 | 5 |
| 906 | Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence. Therapeutic Advances in Respiratory Disease, 2017, 11, 353-373. | 1.0 | 28 |
| 907 | PD-1/PD-L1 and immunotherapy for pancreatic cancer. Cancer Letters, 2017, 407, 57-65. | 3.2 | 235 |
| 908 | Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors). European Journal of Cancer, 2017, 84, 202-211. | 1.3 | 29 |
| 909 | Optimizing tumor immune response through combination of radiation and immunotherapy. Medical Oncology, 2017, 34, 165. | 1.2 | 14 |
| 910 | Development of a luciferase reporter Jurkat cell line under the control of endogenous interleukin-2 promoter. Journal of Immunological Methods, 2017, 451, 48-53. | 0.6 | 3 |
| 911 | Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies. Clinical Cancer Research, 2017, 23, 4950-4958. | 3.2 | 46 |
| 912 | Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value. Scientific Reports, 2017, 7, 11671. | 1.6 | 57 |
| 913 | Nivolumab Exposure–Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non–Small Cell Lung Cancer. Clinical Cancer Research, 2017, 23, 5394-5405. | 3.2 | 76 |
| 914 | Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma. Oncology, 2017, 93, 387-394. | 0.9 | 31 |
| 915 | Immunotherapy against endocrine malignancies: immune checkpoint inhibitors lead the way. Endocrine-Related Cancer, 2017, 24, T261-T281. | 1.6 | 33 |
| 916 | Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors. Journal of Clinical Pharmacology, 2017, 57, S26-S42. | 1.0 | 91 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 917 | Novel Immunologic Approaches to Melanoma Treatment. Actas Dermo-sifiliogrÃ¡ficas, 2017, 108, 708-720. | 0.2 | 0 |
| 918 | Relationship of tumor <scp>PD</scp>â€L1 (<scp>CD</scp>274) expression with lower mortality in lung highâ€grade neuroendocrine tumor. Cancer Medicine, 2017, 6, 2347-2356. | 1.3 | 39 |
| 919 | Gastric cancer: Basic aspects. Helicobacter, 2017, 22, e12412. | 1.6 | 29 |
| 920 | Expression of PD-L1 in Hormone-naÃ¯ve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide. Clinical Cancer Research, 2017, 23, 6812-6822. | 3.2 | 77 |
| 921 | Prognostic value of programmed cell death protein 1 expression on CD8+ T lymphocytes in pancreatic cancer. Scientific Reports, 2017, 7, 7848. | 1.6 | 43 |
| 922 | Discovery and application of immune biomarkers for hematological malignancies. Expert Review of Molecular Diagnostics, 2017, 17, 983-1000. | 1.5 | 6 |
| 923 | The Challenge for Development of Valuable Immuno-oncology Biomarkers. Clinical Cancer Research, 2017, 23, 4970-4979. | 3.2 | 76 |
| 924 | From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely. Clinical Cancer Research, 2017, 23, 4980-4991. | 3.2 | 14 |
| 925 | Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity. Clinical Cancer Research, 2017, 23, 4959-4969. | 3.2 | 115 |
| 926 | Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma. OncoImmunology, 2017, 6, e1356153. | 2.1 | 89 |
| 927 | CXCR4 Ligands: The Next Big Hit?. Journal of Nuclear Medicine, 2017, 58, 77S-82S. | 2.8 | 118 |
| 928 | Tumor Dormancy and Recurrence. Cancer Drug Discovery and Development, 2017, , . | 0.2 | 2 |
| 929 | Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell, 2017, 170, 1109-1119.e10. | 13.5 | 1,124 |
| 930 | Atezolizumab for the treatment of non-small cell lung cancer. Expert Review of Clinical Pharmacology, 2017, 10, 935-945. | 1.3 | 34 |
| 931 | Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy. Molecular Imaging, 2017, 16, 153601211771845. | 0.7 | 47 |
| 932 | Immunotherapy in genitourinary cancers: where are we going?. Expert Review of Precision Medicine and Drug Development, 2017, 2, 73-78. | 0.4 | 2 |
| 933 | Tumor-associated immune aggregates in oral cancer: Their cellular composition and potential prognostic significance. Medical Hypotheses, 2017, 108, 17-23. | 0.8 | 6 |
| 934 | PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast. Modern Pathology, 2017, 30, 1551-1560. | 2.9 | 35 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 935 | Programmed death-ligand 1 expression and T790M status in EGFR -mutant non-small cell lung cancer. Lung Cancer, 2017, 111, 182-189. | 0.9 | 30 |
| 936 | Lung cancer as a paradigm for precision oncology in solid tumours. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 221-233. | 1.4 | 14 |
| 937 | The Evolving Role of Companion Diagnostics for Breast Cancer in an Era of Next-Generation Omics. American Journal of Pathology, 2017, 187, 2185-2198. | 1.9 | 17 |
| 938 | TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discovery, 2017, 7, 1088-1097. | 7.7 | 160 |
| 939 | Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: A report from India. Annals of Diagnostic Pathology, 2017, 31, 56-61. | 0.6 | 16 |
| 940 | The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy. Cell Reports, 2017, 20, 854-867. | 2.9 | 258 |
| 941 | The role of intestinal bacteria in the development and progression of gastrointestinal tract neoplasms. Surgical Oncology, 2017, 26, 368-376. | 0.8 | 67 |
| 942 | Melanoma subtypes demonstrate distinct PD-L1 expression profiles. Laboratory Investigation, 2017, 97, 1063-1071. | 1.7 | 156 |
| 943 | Viral-induced Modulation of Multiple Checkpoint Proteins in Cancers. Applied Immunohistochemistry and Molecular Morphology, 2017, 25, 407-414. | 0.6 | 2 |
| 944 | Novedades en inmunología del melanoma. Actas Dermo-sifiliográficas, 2017, 108, 708-720. | 0.2 | 6 |
| 945 | A novel bifunctional anti-PD-L1/TGF-$\beta$ Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells. OncoImmunology, 2017, 6, e1349589. | 2.1 | 137 |
| 946 | Cell genomics and immunosuppressive biomarker expression influence PD-L1 immunotherapy treatment responses in HNSCCâ€"a computational study. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2017, 124, 157-164. | 0.2 | 8 |
| 947 | Programmed deathâ€ligand 1 immunohistochemistry testing for nonâ€small cell lung cancer in practice. Cancer Cytopathology, 2017, 125, 521-528. | 1.4 | 11 |
| 948 | Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2. Structure, 2017, 25, 1163-1174. | 1.6 | 253 |
| 949 | Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Nonâ€"Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1536-1543. | 0.5 | 53 |
| 950 | Modulation of PD-L1 and CD8 Activity in Idiopathic and Infectious Chronic Inflammatory Conditions. Applied Immunohistochemistry and Molecular Morphology, 2017, 25, 100-109. | 0.6 | 24 |
| 951 | Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer. Current Opinion in Oncology, 2017, 29, 97-104. | 1.1 | 37 |
| 952 | Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapyâ€"Summary of Advances and Future Directions for Studying These Drugs. Cancer Journal (Sudbury, Mass ), 2017, 23, 3-9. | 1.0 | 5 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 953 | Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics. Future Oncology, 2017, 13, 1649-1663. | 1.1 | 10 |
| 954 | Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer. ACS Nano, 2017, 11, 8690-8706. | 7.3 | 108 |
| 955 | Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2310-2325. | 3.3 | 46 |
| 956 | Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature, 2017, 549, 106-110. | 13.7 | 501 |
| 958 | PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. Lung Cancer, 2017, 112, 200-215. | 0.9 | 213 |
| 959 | Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. Current Oncology Reports, 2017, 19, 64. | 1.8 | 106 |
| 960 | Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Advances in Anatomic Pathology, 2017, 24, 235-251. | 2.4 | 469 |
| 961 | Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma. Molecular and Clinical Oncology, 2017, 7, 378-382. | 0.4 | 24 |
| 962 | Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data. Clinical Trials, 2017, 14, 611-620. | 0.7 | 7 |
| 963 | Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA. Immunity, 2017, 47, 1083-1099.e6. | 6.6 | 450 |
| 964 | Checkpoint inhibition in pediatric hematologic malignancies. Pediatric Hematology and Oncology, 2017, 34, 379-394. | 0.3 | 23 |
| 965 | Resistance to Targeted Therapies in Breast Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2017, , . | 0.1 | 1 |
| 966 | Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer. Scientific Reports, 2017, 7, 16956. | 1.6 | 29 |
| 967 | DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nature Communications, 2017, 8, 1751. | 5.8 | 497 |
| 968 | Targeting immune checkpoints in breast cancer: an update of early results. ESMO Open, 2017, 2, e000255. | 2.0 | 118 |
| 969 | Novel Early Phase Clinical Trial Design in Oncology. Pharmaceutical Medicine, 2017, 31, 297-307. | 1.0 | 3 |
| 970 | Cardiotoxicity of immune checkpoint inhibitors. ESMO Open, 2017, 2, e000247. | 2.0 | 186 |
| 971 | Differential Expression of Homing Receptor Ligands on Tumor-Associated Vasculature that Control CD8 Effector T-cell Entry. Cancer Immunology Research, 2017, 5, 1062-1073. | 1.6 | 29 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 972 | A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature, 2017, 551, 517-520. | 13.7 | 532 |
| 973 | Polyfunctional response by Imm<scp>TAC</scp> (<scp>IMC</scp>gp100) redirected <scp>CD</scp>8<sup>+</sup> and <scp>CD</scp>4<sup>+</sup> T cells. Immunology, 2017, 152, 425-438. | 2.0 | 53 |
| 974 | Application of Immunohistochemistry in the Diagnosis of Pulmonary and Pleural Neoplasms. Archives of Pathology and Laboratory Medicine, 2017, 141, 1195-1213. | 1.2 | 20 |
| 975 | Posttranscriptional Control of PD-L1 Expression by 17Î²-Estradiol via PI3K/Akt Signaling Pathway in ERÎ±-Positive Cancer Cell Lines. International Journal of Gynecological Cancer, 2017, 27, 196-205. | 1.2 | 68 |
| 977 | Construction of high level prokaryotic expression and purification system of PD-L1 extracellular domain by using Escherichia coli host cell machinery. Immunology Letters, 2017, 190, 34-41. | 1.1 | 9 |
| 978 | Intratumor heterogeneity of immune checkpoints in primary renal cell cancer: Focus on HLA-G/ILT2/ILT4. OncoImmunology, 2017, 6, e1342023. | 2.1 | 42 |
| 979 | Programmed Death Ligand 1 Expression in Paired Nonâ€"Small Cell Lung Cancer Tumor Samples. Clinical Lung Cancer, 2017, 18, e473-e479. | 1.1 | 35 |
| 980 | PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges. Cancer Letters, 2017, 405, 29-37. | 3.2 | 93 |
| 981 | Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models. British Journal of Cancer, 2017, 117, 628-638. | 2.9 | 119 |
| 982 | Sequential Tracking of PD-L1 Expression and RAD50 Induction in Circulating Tumor and Stromal Cells of Lung Cancer Patients Undergoing Radiotherapy. Clinical Cancer Research, 2017, 23, 5948-5958. | 3.2 | 85 |
| 983 | PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies. Human Pathology, 2017, 66, 13-33. | 1.1 | 46 |
| 984 | A checkpoint to pain. Nature Neuroscience, 2017, 20, 897-899. | 7.1 | 7 |
| 985 | Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nature Reviews Clinical Oncology, 2017, 14, 655-668. | 12.5 | 787 |
| 986 | Checkpoint inhibition for advanced mucosal melanoma. European Journal of Dermatology, 2017, 27, 160-165. | 0.3 | 17 |
| 987 | Nuclear IRF-1 expression as a mechanism to assess â€œCapabilityâ€•to express PD-L1 and response to PD-1 therapy in metastatic melanoma. , 2017, 5, 25. | | 35 |
| 988 | Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. , 2017, 5, 44. | | 181 |
| 989 | MLH1 expression predicts the response to preoperative therapy and is associated with PD-L1 expression in esophageal cancer. Oncology Letters, 2017, 14, 958-964. | 0.8 | 15 |
| 990 | PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma. Pathology, 2017, 49, 499-505. | 0.3 | 39 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 991 | PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability. Modern Pathology, 2017, 30, 1411-1421. | 2.9 | 151 |
| 992 | The Evolution of Oncology Companion Diagnostics from Signal Transduction to Immuno-Oncology. Trends in Pharmacological Sciences, 2017, 38, 41-54. | 4.0 | 21 |
| 993 | Programmed Death-Ligand 1 Expression, Microsatellite Instability, Epstein–Barr Virus, and Human Papillomavirus in Nasopharyngeal Carcinomas of Patients from the Philippines. Head and Neck Pathology, 2017, 11, 203-211. | 1.3 | 23 |
| 994 | Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer. Modern Pathology, 2017, 30, 340-349. | 2.9 | 138 |
| 995 | Gene-expression profiling to predict responsiveness to immunotherapy. Cancer Gene Therapy, 2017, 24, 134-140. | 2.2 | 72 |
| 996 | Anti–PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy. Expert Review of Anticancer Therapy, 2017, 17, 47-59. | 1.1 | 35 |
| 997 | Immune-Suppressing Cellular Elements of the Tumor Microenvironment. Annual Review of Cancer Biology, 2017, 1, 241-255. | 2.3 | 25 |
| 998 | Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics. Trends in Pharmacological Sciences, 2017, 38, 25-40. | 4.0 | 87 |
| 999 | Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC). Annals of Oncology, 2017, 28, 651-657. | 0.6 | 134 |
| 1000 | Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. Journal of Cutaneous Pathology, 2017, 44, 158-176. | 0.7 | 186 |
| 1001 | Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. Annals of Oncology, 2017, 28, 57-74. | 0.6 | 45 |
| 1002 | Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer. Bioengineered, 2017, 8, 367-373. | 1.4 | 7 |
| 1003 | Re: Atezolizumab in Patients with Locally Advanced and Metastatic Urothelial Carcinoma who have Progressed Following Treatment with Platinum-based Chemotherapy: A Single-arm, Multicenter, Phase 2 Trial. European Urology, 2017, 71, 299-300. | 0.9 | 2 |
| 1004 | Immunotherapy of melanoma. European Journal of Surgical Oncology, 2017, 43, 594-603. | 0.5 | 21 |
| 1005 | Genomic complexity of multiple myeloma and its clinical implications. Nature Reviews Clinical Oncology, 2017, 14, 100-113. | 12.5 | 413 |
| 1006 | A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1. JAMA Oncology, 2017, 3, 256. | 3.4 | 164 |
| 1007 | Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and <scp>SP</scp>142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system. Histopathology, 2017, 70, 253-263. | 1.6 | 37 |
| 1008 | Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Oncologist, 2017, 22, 81-88. | 1.9 | 128 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 1009 | Lung cancer: current therapies and new targeted treatments. Lancet, The, 2017, 389, 299-311. | 6.3 | 2,267 |
| 1010 | PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2017, 23, 454-465. | 3.2 | 126 |
| 1011 | Pathology and Molecular Pathology of Melanoma. , 2017, , 613-653. | | 1 |
| 1012 | Novel insights and therapeutic interventions for pediatric osteosarcoma. Future Oncology, 2017, 13, 357-368. | 1.1 | 178 |
| 1013 | The pattern and clinicopathological correlates of programmed death-ligand 1 expression in cutaneous squamous cell carcinoma. British Journal of Dermatology, 2017, 176, 1354-1356. | 1.4 | 29 |
| 1014 | Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. Annals of Oncology, 2017, 28, 83-89. | 0.6 | 97 |
| 1015 | Irreversible electroporation inhibits pro-cancer inflammatory signaling in triple negative breast cancer cells. Bioelectrochemistry, 2017, 113, 42-50. | 2.4 | 23 |
| 1016 | Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Annals of Oncology, 2017, 28, 75-82. | 0.6 | 159 |
| 1017 | Immune checkpoint inhibitors for nonsmall cell lung cancer treatment. Journal of the Chinese Medical Association, 2017, 80, 7-14. | 0.6 | 39 |
| 1018 | Assessing PDL-1 and PD-1 in Non–Small Cell Lung Cancer: A Novel Immunoscore Approach. Clinical Lung Cancer, 2017, 18, 220-233.e8. | 1.1 | 72 |
| 1019 | Personalized cancer vaccines: Targeting the cancer mutanome. Vaccine, 2017, 35, 1094-1100. | 1.7 | 63 |
| 1020 | Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer. Clinical Cancer Research, 2017, 23, 370-378. | 3.2 | 150 |
| 1021 | New therapeutic strategies for malignant pleural mesothelioma. Biochemical Pharmacology, 2017, 123, 8-18. | 2.0 | 38 |
| 1022 | A polymorphism in the promoter region of PD-L1 serves as a binding-site for SP1 and is associated with PD-L1 overexpression and increased occurrence of gastric cancer. Cancer Immunology, Immunotherapy, 2017, 66, 309-318. | 2.0 | 45 |
| 1023 | PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 110-120. | 0.5 | 108 |
| 1024 | Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy. Journal of Clinical Oncology, 2017, 35, 709-717. | 0.8 | 829 |
| 1025 | PD‐L1 expression is associated with p16INK4A expression in non‐oropharyngeal head and neck squamous cell carcinoma. Oncology Letters, 2017, 15, 2259-2265. | 0.8 | 11 |
| 1026 | p16Ink4a and p21Cip1/Waf1 promote tumour growth by enhancing myeloid-derived suppressor cells chemotaxis. Nature Communications, 2017, 8, 2050. | 5.8 | 47 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1028 | PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma. Immunotherapy, 2017, 9, 1323-1330. | 1.0 | 64 |
| 1029 | Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update. Oncology, 2017, 93, 147-159. | 0.9 | 83 |
| 1030 | Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer. Molecular and Clinical Oncology, 2017, 8, 310-314. | 0.4 | 22 |
| 1031 | Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy. Therapeutic Advances in Medical Oncology, 2017, 9, 769-779. | 1.4 | 11 |
| 1032 | Tumor Immuno-Environment in Cancer Progression and Therapy. Advances in Experimental Medicine and Biology, 2017, 1036, 1-18. | 0.8 | 31 |
| 1033 | The Breakthroughs in Cancer Immune Checkpoint Based Therapy: A Review of Development in Immune Checkpoint Study and its Application. Combinatorial Chemistry and High Throughput Screening, 2017, 20, 430-439. | 0.6 | 13 |
| 1034 | Multiple Myeloma and the immune microenvironment. Current Cancer Drug Targets, 2017, 17, 1-1. | 0.8 | 59 |
| 1035 | Bioinformatics Approaches to Profile the Tumor Microenvironment for Immunotherapeutic Discovery. Current Pharmaceutical Design, 2017, 23, 4716-4725. | 0.9 | 11 |
| 1036 | Association of the long non-coding RNA MALAT1 with the polycomb repressive complex pathway in T and NK cell lymphoma. Oncotarget, 2017, 8, 31305-31317. | 0.8 | 45 |
| 1037 | Clinical Response to Anti–Programmed Death 1 After Response and Subsequent Progression on Anti–Programmed Death Ligand 1 Therapy. JCO Precision Oncology, 2017, 1, 1-9. | 1.5 | 3 |
| 1038 | How cancers evade the immune system. , 2017, , . | | 0 |
| 1039 | Programmed Cell Death-1/Programmed Death-ligand 1 Pathway. Chinese Medical Journal, 2017, 130, 986-992. | 0.9 | 15 |
| 1040 | Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets. Blood Advances, 2017, 1, 1884-1890. | 2.5 | 40 |
| 1041 | Inferring the Impact of Regulatory Mechanisms that Underpin CD8+ T Cell Control of B16 Tumor Growth In vivo Using Mechanistic Models and Simulation. Frontiers in Pharmacology, 2017, 7, 515. | 1.6 | 3 |
| 1042 | Targeting immune checkpoints in malignant glioma. Oncotarget, 2017, 8, 7157-7174. | 0.8 | 42 |
| 1043 | Immunotherapy in Gastrointestinal Cancers. BioMed Research International, 2017, 2017, 1-17. | 0.9 | 69 |
| 1044 | New PD-L1 inhibitors in non-small cell lung cancer &ndash; impact of atezolizumab. Lung Cancer: Targets and Therapy, 2017, Volume 8, 67-78. | 1.3 | 27 |
| 1045 | Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies. OncoTargets and Therapy, 2017, Volume 10, 2349-2363. | 1.0 | 35 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1046 | The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer. Oncotarget, 2017, 8, 57826-57835. | 0.8 | 24 |
| 1047 | Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review. ImmunoTargets and Therapy, 2017, Volume 6, 73-82. | 2.7 | 121 |
| 1048 | Cancer Immunotherapyâ€"An Emerging Field That Bridges Oncology andÂImmunology Research. , 2017, , 357-394. | | 1 |
| 1049 | New Immunotherapy Strategies in Breast Cancer. International Journal of Environmental Research and Public Health, 2017, 14, 68. | 1.2 | 76 |
| 1050 | Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. World Journal of Gastroenterology, 2017, 23, 4675. | 1.4 | 91 |
| 1051 | PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. Frontiers in Immunology, 2017, 8, 1597. | 2.2 | 225 |
| 1052 | Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications. Theranostics, 2017, 7, 3585-3594. | 4.6 | 214 |
| 1053 | DGK-Î±: A Checkpoint in Cancer-Mediated Immuno-Inhibition and Target for Immunotherapy. Frontiers in Cell and Developmental Biology, 2017, 5, 16. | 1.8 | 27 |
| 1054 | Tumor-Associated Lymphatic Vessels Upregulate PDL1 to Inhibit T-Cell Activation. Frontiers in Immunology, 2017, 8, 66. | 2.2 | 102 |
| 1055 | Bidirectional Crosstalk between Lymphatic Endothelial Cell and T Cell and Its Implications in Tumor Immunity. Frontiers in Immunology, 2017, 8, 83. | 2.2 | 38 |
| 1056 | Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells. Frontiers in Immunology, 2017, 8, 961. | 2.2 | 93 |
| 1057 | Interleukin 6 Present in Inflammatory Ascites from Advanced Epithelial Ovarian Cancer Patients Promotes Tumor Necrosis Factor Receptor 2-Expressing Regulatory T Cells. Frontiers in Immunology, 2017, 8, 1482. | 2.2 | 53 |
| 1058 | Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma. Frontiers in Immunology, 2017, 8, 1617. | 2.2 | 43 |
| 1059 | Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy. Frontiers in Immunology, 2017, 8, 1897. | 2.2 | 55 |
| 1060 | Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer. Frontiers in Oncology, 2017, 7, 67. | 1.3 | 28 |
| 1061 | Update on immune checkpoint inhibitors in gynecological cancers. Journal of Gynecologic Oncology, 2017, 28, e20. | 1.0 | 49 |
| 1062 | Association between PD-L1 Expression on Tumour-Infiltrating Lymphocytes and Overall Survival in Patients with Gastric Cancer. Journal of Cancer, 2017, 8, 1579-1585. | 1.2 | 26 |
| 1063 | Improved resection and prolonged overall survival with PD-1-IRDye800CW fluorescence probe-guided surgery and PD-1 adjuvant immunotherapy in 4T1 mouse model. International Journal of Nanomedicine, 2017, Volume 12, 8337-8351. | 3.3 | 19 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 1064 | Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer. OncoTargets and Therapy, 2017, Volume 10, 1487-1502. | 1.0 | 12 |
| 1065 | Emerging Family of Protein-protein Interaction Inhibitors Targeting PD-1 Checkpoint Pathway. Current Cancer Therapy Reviews, 2017, 13, . | 0.2 | 0 |
| 1066 | Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: Possible association with PD-L1 expression. PLoS ONE, 2017, 12, e0181598. | 1.1 | 31 |
| 1067 | Transcriptional activation of PD-L1 by Sox2 contributes to the proliferation of hepatocellular carcinoma cells. Oncology Reports, 2017, 37, 3061-3067. | 1.2 | 47 |
| 1068 | Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. OncoImmunology, 2017, 6, e1344805. | 2.1 | 142 |
| 1069 | In vitro and in vivo antivirus activity of an anti-programmed death-ligand 1 (PD-L1) rat-bovine chimeric antibody against bovine leukemia virus infection. PLoS ONE, 2017, 12, e0174916. | 1.1 | 33 |
| 1070 | Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma. BMC Cancer, 2017, 17, 618. | 1.1 | 42 |
| 1071 | Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis. BMC Cancer, 2017, 17, 690. | 1.1 | 41 |
| 1072 | Role of microRNA-33a in regulating the expression of PD-1 in lung adenocarcinoma. Cancer Cell International, 2017, 17, 105. | 1.8 | 38 |
| 1073 | Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer. , 2017, 5, 81. | | 33 |
| 1074 | Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma. Chinese Journal of Cancer, 2017, 36, 61. | 4.9 | 42 |
| 1075 | The 150 most important questions in cancer research and clinical oncology series: questions 57â€"66. Chinese Journal of Cancer, 2017, 36, 79. | 4.9 | 6 |
| 1076 | High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers. Oncotarget, 2017, 8, 18021-18030. | 0.8 | 46 |
| 1077 | Melanoma Metamorphoses: Advances in Biology and Therapy. Journal of Cancer Science & Therapy, 2017, 09, . | 1.7 | 2 |
| 1078 | Prognostic and Predictive Value of PD-L1 in Patients with Lung Cancer. , 0, , . | | 0 |
| 1079 | Atezolizumab in advanced non-small cell lung cancer. Journal of Thoracic Disease, 2017, 9, 3603-3606. | 0.6 | 7 |
| 1080 | Sustained Oligoclonal T Cell Expansion Correlates with Durable Response to Immune Checkpoint Blockade in Lung Cancer. Journal of Cancer Science & Therapy, 2017, 9, . | 1.7 | 5 |
| 1081 | Cellular immunity augmentation in mainstream oncologic therapy. Cancer Biology and Medicine, 2017, 14, 121. | 1.4 | 8 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 1082 | Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers. Emerging Topics in Life Sciences, 2017, 1, 471-486. | 1.1 | 5 |
| 1083 | EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release. Oncotarget, 2017, 8, 63901-63910. | 0.8 | 30 |
| 1084 | IFN-Î³â€"related mRNA profile predicts clinical response to PD-1 blockade. Journal of Clinical Investigation, 2017, 127, 2930-2940. | 3.9 | 2,560 |
| 1085 | PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study. Oncotarget, 2017, 8, 98524-98532. | 0.8 | 40 |
| 1086 | Cancer Immunotherapy. , 2017, , 32-65. | | 1 |
| 1087 | PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression. International Journal of Molecular Sciences, 2017, 18, 1331. | 1.8 | 60 |
| 1088 | Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies. Oncotarget, 2017, 8, 44960-44975. | 0.8 | 82 |
| 1089 | Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab. Oncotarget, 2017, 8, 90215-90224. | 0.8 | 68 |
| 1090 | PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes. Medical Science Monitor, 2017, 23, 1208-1216. | 0.5 | 49 |
| 1091 | The mechanism of de novo expression of programmed cell death-ligand 1 in squamous cell carcinoma of the lung. Oncology Reports, 2017, 38, 2189-2196. | 1.2 | 5 |
| 1092 | Programmed cell death ligand 1 protein levels predicted survival of non-small cell lung cancer. Journal of Cancer, 2017, 8, 4075-4082. | 1.2 | 7 |
| 1093 | From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis. World Journal of Clinical Oncology, 2017, 8, 37. | 0.9 | 64 |
| 1094 | Recent advances in the biology and therapy of medullary thyroid carcinoma. F1000Research, 2017, 6, 2184. | 0.8 | 18 |
| 1095 | Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget, 2017, 8, 91779-91794. | 0.8 | 298 |
| 1096 | Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers. Oncotarget, 2017, 8, 41932-41946. | 0.8 | 95 |
| 1097 | Association between PD-L1 expression combined with tumor-infiltrating lymphocytes and the prognosis of patients with advanced hypopharyngeal squamous cell carcinoma. Oncotarget, 2017, 8, 92699-92714. | 0.8 | 29 |
| 1098 | PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma. Oncotarget, 2017, 8, 24644-24651. | 0.8 | 146 |
| 1099 | Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1â€"Selected Advanced Nonâ€"Small-Cell Lung Cancer (BIRCH). Journal of Clinical Oncology, 2017, 35, 2781-2789. | 0.8 | 348 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1100 | Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent. Oncotarget, 2017, 8, 71371-71384. | 0.8 | 85 |
| 1101 | The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy. Oncotarget, 2017, 8, 38850-38862. | 0.8 | 36 |
| 1102 | Tumor PD-L1 status and CD8+ tumor-infiltrating T cells: markers of improved prognosis in oropharyngeal cancer. Oncotarget, 2017, 8, 80443-80452. | 0.8 | 78 |
| 1103 | The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma. Oncotarget, 2017, 8, 16421-16429. | 0.8 | 50 |
| 1104 | The MAPK hypothesis: immune-regulatory effects of MAPK-pathway genetic dysregulations and implications for breast cancer immunotherapy. Emerging Topics in Life Sciences, 2017, 1, 429-445. | 1.1 | 45 |
| 1105 | Anti-PD-1/PD-L1 antibody versus conventional chemotherapy for previously-treated, advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Journal of Thoracic Disease, 2017, 9, 655-665. | 0.6 | 15 |
| 1106 | Immunohistochemistry for predictive biomarkers in non-small cell lung cancer. Translational Lung Cancer Research, 2017, 6, 570-587. | 1.3 | 42 |
| 1107 | Implementing liquid biopsies into clinical decision making for cancer immunotherapy. Oncotarget, 2017, 8, 48507-48520. | 0.8 | 63 |
| 1108 | Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis. JCO Precision Oncology, 2017, 1, 1-15. | 1.5 | 57 |
| 1109 | Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing. Oncotarget, 2017, 8, 3197-3205. | 0.8 | 53 |
| 1110 | A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer. Oncotarget, 2017, 8, 29067-29079. | 0.8 | 29 |
| 1111 | Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. Oncotarget, 2017, 8, 77415-77423. | 0.8 | 68 |
| 1112 | Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. British Journal of Cancer, 2018, 118, 763-769. | 2.9 | 28 |
| 1113 | Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs. Cancer Immunology Research, 2018, 6, 389-401. | 1.6 | 68 |
| 1114 | Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States. European Urology, 2018, 73, 800-806. | 0.9 | 26 |
| 1115 | Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. Cancer Medicine, 2018, 7, 690-697. | 1.3 | 90 |
| 1116 | Targeting MYC in multiple myeloma. Leukemia, 2018, 32, 1295-1306. | 3.3 | 89 |
| 1117 | Atezolizumab for the treatment of colorectal cancer: <i>the latest evidence and clinical potential</i>. Expert Opinion on Biological Therapy, 2018, 18, 449-457. | 1.4 | 25 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1118 | Engineering chimeric antigen receptor-T cells for cancer treatment. Molecular Cancer, 2018, 17, 32. | 7.9 | 57 |
| 1119 | Immunotherapy for thoracic oncology gone viral. Immunotherapy, 2018, 10, 383-390. | 1.0 | 1 |
| 1120 | Systemic immune-inflammation index in germ-cell tumours. British Journal of Cancer, 2018, 118, 831-838. | 2.9 | 70 |
| 1121 | PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma. Expert Review of Clinical Pharmacology, 2018, 11, 345-359. | 1.3 | 27 |
| 1122 | Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach. Clinical Medicine Insights: Oncology, 2018, 12, 117955491875907. | 0.6 | 4 |
| 1123 | Immune cell landscape in therapy-naïve squamous cell and adenocarcinomas of the lung. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 589-598. | 1.4 | 21 |
| 1124 | CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1005-1014. | 1.2 | 64 |
| 1125 | Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors. Molecular Cancer Therapeutics, 2018, 17, 869-882. | 1.9 | 20 |
| 1126 | Treatment of Advanced Non–Small Cell Lung Cancer in 2018. JAMA Oncology, 2018, 4, 569. | 3.4 | 82 |
| 1129 | Clinicopathologic Features and Immune Microenvironment of Non–Small-cell Lung Cancer With Primary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Clinical Lung Cancer, 2018, 19, 352-359.e1. | 1.1 | 15 |
| 1130 | High <scp>IDO</scp>‑1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma. Cancer Science, 2018, 109, 1583-1591. | 1.7 | 53 |
| 1131 | Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 1204-1210. | 0.6 | 64 |
| 1132 | Understanding the tumor immune microenvironment (TIME) for effective therapy. Nature Medicine, 2018, 24, 541-550. | 15.2 | 3,421 |
| 1133 | A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics. Clinical Cancer Research, 2018, 24, 3292-3298. | 3.2 | 41 |
| 1134 | Atezolizumab for the treatment of breast cancer. Expert Opinion on Biological Therapy, 2018, 18, 595-603. | 1.4 | 17 |
| 1135 | T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression. Annals of Oncology, 2018, 29, 1575-1581. | 0.6 | 53 |
| 1136 | Towards predictive biomarkers for immunotherapy response in breast cancer patients. Breast Cancer Management, 2018, 7, BMT05. | 0.2 | 4 |
| 1137 | Clinical implication of programmed cell death-1 ligand-1 expression in tonsillar squamous cell carcinoma in association with intratumoral heterogeneity, human papillomavirus, and epithelial-to-mesenchymal transition. Human Pathology, 2018, 80, 28-39. | 1.1 | 22 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 1138 | Transition of the programmed death 1 pathway from the primary colorectal cancer to its corresponding pulmonary metastasis. Journal of Surgical Oncology, 2018, 117, 1405-1412. | 0.8 | 4 |
| 1139 | Expression of programmed death ligand 1 is associated with poor prognosis in myeloid sarcoma patients. Hematological Oncology, 2018, 36, 591-599. | 0.8 | 14 |
| 1140 | Genetic abrogation of immune checkpoints in antigen-specific cytotoxic T-lymphocyte as a potential alternative to blockade immunotherapy. Scientific Reports, 2018, 8, 5549. | 1.6 | 29 |
| 1141 | PD-L1 immuno-expression assay in thymomas: Study of 84 cases and review of literature. Annals of Diagnostic Pathology, 2018, 34, 135-141. | 0.6 | 18 |
| 1142 | Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer. Cancer Treatment Reviews, 2018, 66, 114-121. | 3.4 | 28 |
| 1143 | Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. Cancer Cell, 2018, 33, 581-598. | 7.7 | 393 |
| 1144 | Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas. Modern Pathology, 2018, 31, 1282-1290. | 2.9 | 39 |
| 1145 | Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E4041-E4050. | 3.3 | 564 |
| 1146 | <scp>PD</scp>–L1 expression in tumour–infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients. Histopathology, 2018, 73, 386-396. | 1.6 | 22 |
| 1147 | Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability. ESMO Open, 2018, 3, e000326. | 2.0 | 52 |
| 1148 | Role of PD-1 during effector CD8 T cell differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4749-4754. | 3.3 | 327 |
| 1149 | Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer. Immunology Letters, 2018, 196, 155-160. | 1.1 | 55 |
| 1150 | Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood, 2018, 131, 1809-1819. | 0.6 | 231 |
| 1151 | Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non–Small Cell Lung Carcinoma. Archives of Pathology and Laboratory Medicine, 2018, 142, 1388-1393. | 1.2 | 3 |
| 1153 | Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung. Journal of Thoracic Oncology, 2018, 13, 636-648. | 0.5 | 67 |
| 1154 | PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements. Lung Cancer, 2018, 118, 36-40. | 0.9 | 81 |
| 1155 | Cytologic–histologic correlation of programmed death–ligand 1 immunohistochemistry in lung carcinomas. Cancer Cytopathology, 2018, 126, 253-263. | 1.4 | 70 |
| 1157 | TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature, 2018, 554, 544-548. | 13.7 | 3,359 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1158 | Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity. Journal of Experimental Medicine, 2018, 215, 859-876. | 4.2 | 150 |
| 1159 | Temozolomide-associated hypermutation in gliomas. Neuro-Oncology, 2018, 20, 1300-1309. | 0.6 | 130 |
| 1160 | Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy. Oncogenesis, 2018, 7, 2. | 2.1 | 68 |
| 1161 | Prognostic Significance of PD-L1+ and CD8+ Immune Cells in HPV+ Oropharyngeal Squamous Cell Carcinoma. Cancer Immunology Research, 2018, 6, 295-304. | 1.6 | 93 |
| 1162 | The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma. Medical Oncology, 2018, 35, 25. | 1.2 | 124 |
| 1163 | Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer. Scientific Reports, 2018, 8, 1922. | 1.6 | 108 |
| 1164 | Tâ€cell crossâ€reactivity may explain the large variation in how cancer patients respond to checkpoint inhibitors. Scandinavian Journal of Immunology, 2018, 87, e12643. | 1.3 | 24 |
| 1165 | Checkpoint molecule expression by B and T cell lymphomas in dogs. Veterinary and Comparative Oncology, 2018, 16, 352-360. | 0.8 | 25 |
| 1166 | Programmed death ligandâ€1 expression as immunotherapeutic target in sinonasal cancer. Head and Neck, 2018, 40, 818-827. | 0.9 | 39 |
| 1167 | Role of immune-checkpoint inhibitors in lung cancer. Therapeutic Advances in Respiratory Disease, 2018, 12, 175346581775007. | 1.0 | 88 |
| 1168 | Cancer Systems Biology. Methods in Molecular Biology, 2018, , . | 0.4 | 8 |
| 1169 | T cell responses to tumor: how dominant assumptions on immune activity led to a neglect of pathological functions, and how evolutionary considerations can help identify testable hypotheses for improving immunotherapy. Cancer Immunology, Immunotherapy, 2018, 67, 989-998. | 2.0 | 5 |
| 1170 | PD-L1 expression is regulated by both DNA methylation and NF-ĸB during EMT signaling in non-small cell lung carcinoma. OncoImmunology, 2018, 7, e1423170. | 2.1 | 150 |
| 1171 | Optimizing Breast Cancer Management. Cancer Treatment and Research, 2018, , . | 0.2 | 2 |
| 1172 | Established, emerging and elusive molecular targets in the treatment of lung cancer. Journal of Pathology, 2018, 244, 565-577. | 2.1 | 15 |
| 1173 | Profiling Tumor Infiltrating Immune Cells with CIBERSORT. Methods in Molecular Biology, 2018, 1711, 243-259. | 0.4 | 1,936 |
| 1174 | Computational immune profiling in lung adenocarcinoma reveals reproducible prognostic associations with implications for immunotherapy. OncoImmunology, 2018, 7, e1431084. | 2.1 | 43 |
| 1175 | Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer. JAMA Oncology, 2018, 4, 537. | 3.4 | 104 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1176 | Epigenetic modifiers as new immunomodulatory therapies in solid tumours. Annals of Oncology, 2018, 29, 812-824. | 0.6 | 73 |
| 1177 | An automated staining protocol for seven-colour immunofluorescence of human tissue sections for diagnostic and prognostic use. Pathology, 2018, 50, 333-341. | 0.3 | 65 |
| 1178 | Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. American Journal of Clinical Pathology, 2018, 149, 253-261. | 0.4 | 22 |
| 1183 | Immune Checkpoint Blockade for Breast Cancer. Cancer Treatment and Research, 2018, 173, 155-165. | 0.2 | 69 |
| 1184 | TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. ESMO Open, 2018, 3, e000257. | 2.0 | 62 |
| 1185 | Immunotherapy, an evolving approach for the management of triple negative breast cancer: Converting non-responders to responders. Critical Reviews in Oncology/Hematology, 2018, 122, 202-207. | 2.0 | 43 |
| 1186 | Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents. Nature Protocols, 2018, 13, 335-357. | 5.5 | 32 |
| 1187 | Mechanisms of Resistance to PD-1 and PD-L1 Blockade. Cancer Journal (Sudbury, Mass ), 2018, 24, 47-53. | 1.0 | 287 |
| 1188 | E3 ubiquitin ligases Cbl‑b and c‑Cbl downregulate <scp>PD</scp>‑L1 in <i><scp>EGFR</scp></i> wild‑type non‑small cell lung cancer. FEBS Letters, 2018, 592, 621-630. | 1.3 | 50 |
| 1189 | PD-1/PD-L1 Axis in Lung Cancer. Cancer Journal (Sudbury, Mass ), 2018, 24, 15-19. | 1.0 | 61 |
| 1190 | Combination Strategies PD-1/PD-L1 Antagonists. Cancer Journal (Sudbury, Mass ), 2018, 24, 54-57. | 1.0 | 1 |
| 1191 | Role of immunotherapy in bladder cancer: past, present and future. Cancer Chemotherapy and Pharmacology, 2018, 81, 629-645. | 1.1 | 35 |
| 1192 | The biology and management of non-small cell lung cancer. Nature, 2018, 553, 446-454. | 13.7 | 2,877 |
| 1193 | Second-Line Treatment Options in Non‑Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. Clinical Lung Cancer, 2018, 19, 301-314. | 1.1 | 7 |
| 1194 | Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. European Urology, 2018, 73, 462-468. | 0.9 | 36 |
| 1195 | Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clinical and Translational Oncology, 2018, 20, 815-826. | 1.2 | 57 |
| 1197 | Stromal PD-L1‑Positive Regulatory T cells and PD-1‑Positive CD8-Positive T cells Define the Response of Different Subsets of Non‑Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy. Journal of Thoracic Oncology, 2018, 13, 521-532. | 0.5 | 119 |
| 1198 | miR-155 in cancer drug resistance and as target for miRNA-based therapeutics. Cancer and Metastasis Reviews, 2018, 37, 33-44. | 2.7 | 152 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 1199 | Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions. Oncologist, 2018, 23, 410-421. | 1.9 | 23 |
| 1200 | Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet, The, 2018, 391, 748-757. | 6.3 | 1,142 |
| 1201 | Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies. Journal of Thoracic Oncology, 2018, 13, 85-96. | 0.5 | 43 |
| 1202 | NK Cell-Based Therapies. , 2018, , 275-288. | | 2 |
| 1203 | Immune Checkpoint Inhibition in Lung Cancer. , 2018, , 333-344. | | 0 |
| 1204 | PD-L1 and Other Immunological Diagnosis Tools. , 2018, , 371-385. | | 2 |
| 1205 | Co-stimulation Agonists via CD137, OX40, GITR, and CD27 for Immunotherapy of Cancer. , 2018, , 429-446. | | 0 |
| 1206 | Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy. Seminars in Cancer Biology, 2018, 52, 26-38. | 4.3 | 49 |
| 1207 | Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma. JAMA Oncology, 2018, 4, 210. | 3.4 | 437 |
| 1208 | Triple-Negative Breast Cancer. , 2018, , . | | 0 |
| 1209 | Pattern of programmed cell death-ligand 1 expression and CD8-positive T-cell infiltration before and after chemoradiotherapy in rectal cancer. European Journal of Cancer, 2018, 91, 11-20. | 1.3 | 55 |
| 1210 | Expression of PD‐L1 correlates with pleomorphic morphology and histological patterns of non‐small‐cell lung carcinomas. Histopathology, 2018, 72, 1024-1032. | 1.6 | 33 |
| 1211 | Precision Molecular Pathology of Bladder Cancer. Molecular Pathology Library, 2018, , . | 0.1 | 0 |
| 1212 | Response to Immunotherapy: Application of Molecular Pathology to Predict Successful Response. Molecular Pathology Library, 2018, , 181-194. | 0.1 | 0 |
| 1213 | Molecular Profiling and Targeted Therapy for Triple-Negative Breast Cancer. , 2018, , 117-140. | | 0 |
| 1215 | Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Clinical Lung Cancer, 2018, 19, e335-e348. | 1.1 | 53 |
| 1216 | TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. Cancer Cell, 2018, 33, 60-74.e6. | 7.7 | 270 |
| 1217 | Sarcomatoid renal cell carcinoma: Biology and treatment advances. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 265-271. | 0.8 | 38 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 1218 | High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nature Medicine, 2018, 24, 144-153. | 15.2 | 564 |
| 1219 | Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC. Cancer Letters, 2018, 418, 1-9. | 3.2 | 61 |
| 1220 | Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity. Journal of Immunology, 2018, 200, 432-442. | 0.4 | 153 |
| 1221 | Immune Regulation in HCC and the Prospect of Immunotherapy. Molecular Pathology Library, 2018, , 175-194. | 0.1 | 0 |
| 1222 | Associations of Tumor PD-1 Ligands, Immunohistochemical Studies, and Textural Features in 18F-FDG PET in Squamous Cell Carcinoma of the Head and Neck. Scientific Reports, 2018, 8, 105. | 1.6 | 47 |
| 1223 | The efficacy and safety of anti‐<scp>PD</scp>‐1/<scp>PD‐L</scp>1 antibodies combined with chemotherapy or <scp>CTLA</scp>4 antibody as a first‐line treatment for advanced lung cancer. International Journal of Cancer, 2018, 142, 2344-2354. | 2.3 | 47 |
| 1224 | Composition of the immune microenvironment differs between carcinomas metastatic to the lungs and primary lung carcinomas. Annals of Diagnostic Pathology, 2018, 33, 62-68. | 0.6 | 4 |
| 1225 | PD-L1 Antibodies for EBV-Positive Gastric Cancer, Going Beyond PD-L1 Expression and Microsatellite Instability. Journal of the National Cancer Institute, 2018, 110, 221-222. | 3.0 | 5 |
| 1226 | Type, Frequency, and Spatial Distribution of Immune Cell Infiltrates in CNS Germinomas: Evidence for Inflammatory and Immunosuppressive Mechanisms. Journal of Neuropathology and Experimental Neurology, 2018, 77, 119-127. | 0.9 | 23 |
| 1227 | A transatlantic perspective on the integration of immuno-oncology prognostic and predictive biomarkers in innovative clinical trial design. Seminars in Cancer Biology, 2018, 52, 158-165. | 4.3 | 4 |
| 1228 | Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy. BMC Cancer, 2018, 18, 225. | 1.1 | 28 |
| 1229 | Immunotherapy and Combination Strategies in Pancreatic Cancer: Current Status and Emerging Trends. Oncology Research and Treatment, 2018, 41, 286-290. | 0.8 | 6 |
| 1230 | Biliary Tract Cancer: Implicated Immune-Mediated Pathways and Their Associated Potential Targets. Oncology Research and Treatment, 2018, 41, 298-304. | 0.8 | 8 |
| 1231 | APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer. Oncogene, 2018, 37, 3924-3936. | 2.6 | 204 |
| 1232 | A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint. OncoImmunology, 2018, 7, e1466016. | 2.1 | 42 |
| 1233 | Integrative Pharmacology: Advancing Development of Effective Immunotherapies. AAPS Journal, 2018, 20, 66. | 2.2 | 10 |
| 1234 | Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types. Biochemical and Biophysical Research Communications, 2018, 500, 621-625. | 1.0 | 44 |
| 1235 | <scp>CD8</scp> lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors. Cancer Reports, 2018, 1, e1002. | 0.6 | 8 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1236 | The current landscape of early drug development for patients with sarcoma in the immunotherapy era. Future Oncology, 2018, 14, 1197-1211. | 1.1 | 11 |
| 1237 | CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-NaÃ¯ve Melanoma Patients and Expand Significantly During Antiâ€"PD-1 Treatment. Clinical Cancer Research, 2018, 24, 3036-3045. | 3.2 | 297 |
| 1239 | Cancer CRISPR Screens In Vivo. Trends in Cancer, 2018, 4, 349-358. | 3.8 | 70 |
| 1240 | PD-L1â€"Independent Mechanisms Control the Resistance of Melanoma to CD4+ T Cell Adoptive Immunotherapy. Journal of Immunology, 2018, 200, 3304-3311. | 0.4 | 6 |
| 1241 | A comparative analysis of immune privilege in pregnancy and cancer in the context of checkpoint blockade immunotherapy. Seminars in Oncology, 2018, 45, 170-175. | 0.8 | 17 |
| 1242 | Immune checkpoint blockade therapy. Journal of Allergy and Clinical Immunology, 2018, 142, 1403-1414. | 1.5 | 79 |
| 1243 | Understanding the Hurdles in Lung Cancer Immunotherapy in the Context of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 835-837. | 2.5 | 1 |
| 1244 | Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Nonâ€"Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 926-937. | 0.5 | 27 |
| 1245 | Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies. Immunity, 2018, 48, 417-433. | 6.6 | 416 |
| 1246 | Programmed death ligand 1 expression and CD8+ tumor-infiltrating lymphocyte density differences between paired primary and brain metastatic lesions in non-small cell lung cancer. Biochemical and Biophysical Research Communications, 2018, 498, 751-757. | 1.0 | 71 |
| 1247 | Biomarker use in lung cancer management: expanding horizons. Biomarkers in Medicine, 2018, 12, 315-320. | 0.6 | 2 |
| 1248 | Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer. Gynecologic Oncology, 2018, 149, 381-387. | 0.6 | 41 |
| 1249 | Concepts for Immunotherapies in Gliomas. Seminars in Neurology, 2018, 38, 062-072. | 0.5 | 26 |
| 1250 | Immune signatures predicting responses to immunomodulatory antibody therapy. Current Opinion in Immunology, 2018, 51, 91-96. | 2.4 | 7 |
| 1251 | Atezolizumab in Japanese Patients With Previously Treated Advanced Nonâ€"Small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study. Clinical Lung Cancer, 2018, 19, e405-e415. | 1.1 | 77 |
| 1252 | Association of PD-L1 and HIF-1Î± Coexpression with Poor Prognosis in Hepatocellular Carcinoma. Translational Oncology, 2018, 11, 559-566. | 1.7 | 52 |
| 1253 | IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut, 2018, 67, 320-332. | 6.1 | 381 |
| 1254 | An Immunoscore Using PD-L1, CD68, and Tumor-infiltrating Lymphocytes (TILs) to Predict Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, 611-619. | 0.6 | 22 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1255 | Current studies of immunotherapy in head and neck cancer. Clinical Otolaryngology, 2018, 43, 13-21. | 0.6 | 63 |
| 1256 | The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC). Breast Cancer, 2018, 25, 34-42. | 1.3 | 88 |
| 1257 | T-cell receptor-engineered T cells for cancer treatment: current status and future directions. Protein and Cell, 2018, 9, 254-266. | 4.8 | 124 |
| 1258 | PD-1 and cancer: molecular mechanisms and polymorphisms. Immunogenetics, 2018, 70, 73-86. | 1.2 | 100 |
| 1259 | PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry. Journal of Clinical Pathology, 2018, 71, 46-51. | 1.0 | 17 |
| 1260 | Clinical decision-making for immunotherapy in metastatic renal cell carcinoma. Current Opinion in Urology, 2018, 28, 29-34. | 0.9 | 11 |
| 1261 | Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. Annals of Oncology, 2018, 29, 193-199. | 0.6 | 162 |
| 1262 | Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value. Clinical Cancer Research, 2018, 24, 407-419. | 3.2 | 203 |
| 1263 | The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. Seminars in Cancer Biology, 2018, 52, 12-15. | 4.3 | 12 |
| 1264 | Systemic Antitumor Immunity by PD-1/PD-L1 Inhibition Is Potentiated by Vascular-Targeted Photodynamic Therapy of Primary Tumors. Clinical Cancer Research, 2018, 24, 592-599. | 3.2 | 75 |
| 1265 | *In-vitro* effect of pembrolizumab on different T regulatory cell subsets. Clinical and Experimental Immunology, 2018, 191, 189-197. | 1.1 | 42 |
| 1266 | T cell inhibitory mechanisms in a model of aggressive Non-Hodgkin's Lymphoma. OncoImmunology, 2018, 7, e1365997. | 2.1 | 2 |
| 1267 | Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy. OncoImmunology, 2018, 7, e1376156. | 2.1 | 14 |
| 1268 | Synthesis and Biologic Evaluation of a Novel ^{18}F-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression. Journal of Nuclear Medicine, 2018, 59, 529-535. | 2.8 | 152 |
| 1269 | CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cellular and Molecular Life Sciences, 2018, 75, 689-713. | 2.4 | 351 |
| 1270 | The diverse functions of the PD1 inhibitory pathway. Nature Reviews Immunology, 2018, 18, 153-167. | 10.6 | 1,210 |
| 1271 | Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy. Cancer Immunology, Immunotherapy, 2018, 67, 141-151. | 2.0 | 58 |
| 1272 | Emerging targets in cancer immunotherapy. Seminars in Cancer Biology, 2018, 52, 39-52. | 4.3 | 240 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 1273 | The PDâ€1 and PDâ€L1 pathway in recurrent respiratory papillomatosis. Laryngoscope, 2018, 128, E27-E32. | 1.1 | 31 |
| 1274 | The application and mechanism of PD pathway blockade for cancer therapy. Postgraduate Medical Journal, 2018, 94, 53-60. | 0.9 | 10 |
| 1275 | Programmed cell death ligand 1 (PDâ€L1) expression is not a predominant feature in Ewing sarcomas. Pediatric Blood and Cancer, 2018, 65, e26719. | 0.8 | 39 |
| 1276 | Immunotherapy and Lung Cancer. , 2018, , 501-511.e3. | | 2 |
| 1277 | The Emerging Role of PD-1/PD-L1â€"Targeting Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma. Annals of Pharmacotherapy, 2018, 52, 60-68. | 0.9 | 5 |
| 1278 | Invasive features of small-sized lung adenocarcinoma adjoining emphysematous bullae. European Journal of Cardio-thoracic Surgery, 2018, 53, 372-378. | 0.6 | 7 |
| 1279 | Immune Modulation Therapy and Imaging: Workshop Report. Journal of Nuclear Medicine, 2018, 59, 410-417. | 2.8 | 23 |
| 1280 | Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors. OncoImmunology, 2018, 7, e1378842. | 2.1 | 65 |
| 1281 | The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma. American Journal of Surgical Pathology, 2018, 42, 183-191. | 2.1 | 63 |
| 1282 | Emerging biomarkers for cancer immunotherapy in melanoma. Seminars in Cancer Biology, 2018, 52, 207-215. | 4.3 | 42 |
| 1283 | Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases. Modern Pathology, 2018, 31, 101-110. | 2.9 | 38 |
| 1284 | Treatment of Advanced Prostate Cancerâ€"A Review of Current Therapies and Future Promise. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a030635. | 2.9 | 128 |
| 1285 | Prognostic value of <scp>PD</scp>â€L1 expression in combination with <scp>CD</scp>8<sup>+</sup><scp>TIL</scp>s density in patients with surgically resected nonâ€small cell lung cancer. Cancer Medicine, 2018, 7, 32-45. | 1.3 | 48 |
| 1286 | Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments. Cancer Letters, 2018, 414, 230-238. | 3.2 | 63 |
| 1287 | Atezolizumab in urothelial bladder carcinoma. Future Oncology, 2018, 14, 331-341. | 1.1 | 10 |
| 1288 | Immunotherapy for Pediatric Malignancies. , 2018, , . | | 0 |
| 1289 | Overcoming Immune Suppression in the Tumor Microenvironment: Implications for Multi-modal Therapy. , 2018, , 13-38. | | 0 |
| 1290 | Molecular Diagnosis and Targeting for Lung Cancer. Current Human Cell Research and Applications, 2018, , 1-32. | 0.1 | 0 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1291 | Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer. Cancer Research, 2018, 78, 475-488. | 0.4 | 61 |
| 1292 | Real life experience with nivolumab for the treatment of non-small cell lung carcinoma. Lung Cancer, 2018, 126, 210-216. | 0.9 | 36 |
| 1294 | The role of STAT3 in leading the crosstalk between human cancers and the immune system. Cancer Letters, 2018, 415, 117-128. | 3.2 | 237 |
| 1295 | Multispectral imaging reveals hyper active TGF-Î² signaling in colorectal cancer. Cancer Biology and Therapy, 2018, 19, 105-112. | 1.5 | 28 |
| 1296 | A Serum Protein Signature Associated with Outcome after Antiâ€"PD-1 Therapy in Metastatic Melanoma. Cancer Immunology Research, 2018, 6, 79-86. | 1.6 | 61 |
| 1297 | Emerging trends in the immunotherapy of pancreatic cancer. Cancer Letters, 2018, 417, 35-46. | 3.2 | 77 |
| 1298 | CD8+ T Cells in Immunotherapy, Radiotherapy, and Chemotherapy. , 2018, , 23-39. | | 7 |
| 1299 | Implications of the tumor immune microenvironment for staging and therapeutics. Modern Pathology, 2018, 31, 214-234. | 2.9 | 278 |
| 1300 | The Toll like receptor 4 ligand cold-inducible RNA-binding protein as vaccination platform against cancer. OncoImmunology, 2018, 7, e1409321. | 2.1 | 15 |
| 1301 | Product review on the Anti-PD-L1 antibody atezolizumab. Human Vaccines and Immunotherapeutics, 2018, 14, 269-276. | 1.4 | 41 |
| 1302 | Nonsmall cell lung cancer from HIV-infected patients expressed programmed cell death-ligand 1 with marked inflammatory infiltrates. Aids, 2018, 32, 461-468. | 1.0 | 21 |
| 1303 | Immune checkpoint inhibitors in advanced nonâ€"small cell lung cancer. Cancer, 2018, 124, 248-261. | 2.0 | 94 |
| 1304 | Molecular classification and precision therapy of cancer: immune checkpoint inhibitors. Frontiers of Medicine, 2018, 12, 229-235. | 1.5 | 53 |
| 1305 | Antiâ€"Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development. Clinical Genitourinary Cancer, 2018, 16, 117-129. | 0.9 | 28 |
| 1306 | Mismatch repairâ€"deficient colorectal cancer: a model of immunogenic and immune cellâ€"rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells. Human Pathology, 2018, 72, 135-143. | 1.1 | 15 |
| 1307 | Immuno-oncology from the perspective of somatic evolution. Seminars in Cancer Biology, 2018, 52, 75-85. | 4.3 | 15 |
| 1308 | Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy. Nature Reviews Urology, 2018, 15, 92-111. | 1.9 | 139 |
| 1309 | Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science, 2018, 359, 582-587. | 6.0 | 834 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 1310 | Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening. Cancer Immunology, Immunotherapy, 2018, 67, 471-481. | 2.0 | 4 |
| 1311 | PD-L1. Journal of Clinical Pathology, 2018, 71, 189-194. | 1.0 | 218 |
| 1312 | Immunotherapeutic Biomarkers and Selection Strategies. Current Cancer Research, 2018, , 69-114. | 0.2 | 0 |
| 1313 | The Significance of the PD-L1 Expression in Non–Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers. Clinical Lung Cancer, 2018, 19, 120-129. | 1.1 | 61 |
| 1315 | Primer on Cancer Immunotherapy and the Targeting of Native Proteins. Current Cancer Research, 2018, , 1-28. | 0.2 | 0 |
| 1316 | Pharmacokinetics and Pharmacodynamics of Immunotherapy. Current Cancer Research, 2018, , 29-67. | 0.2 | 6 |
| 1317 | Combinations of Genomically and Immune-Targeted Therapies in Early-Phase Clinical Trials. Current Cancer Research, 2018, , 243-280. | 0.2 | 0 |
| 1318 | Recent advances in melanoma research via â€œomicsâ€•platforms. Journal of Proteomics, 2018, 188, 152-166. | 1.2 | 13 |
| 1319 | Cyclin Dâ€"CDK4 kinase destabilizes PD-L1 via cullin 3â€"SPOP to control cancer immune surveillance. Nature, 2018, 553, 91-95. | 13.7 | 660 |
| 1320 | Impact of Tumor Purity on Immune Gene Expression and Clustering Analyses across Multiple Cancer Types. Cancer Immunology Research, 2018, 6, 87-97. | 1.6 | 106 |
| 1321 | PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab. OncoImmunology, 2018, 7, e1405206. | 2.1 | 43 |
| 1322 | <scp>PD</scp>â€‹1 expression is mainly regulated by interferon gamma associated with <scp>JAK</scp>â€‹<scp>STAT</scp> pathway in gastric cancer. Cancer Science, 2018, 109, 43-53. | 1.7 | 239 |
| 1323 | Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review. Cancer Letters, 2018, 414, 166-173. | 3.2 | 207 |
| 1324 | Association of programmed death ligandâ€‹1 (PDâ€‹L1) expression with treatment outcomes in patients with <i><scp>BRAF</scp></i> mutationâ€‹positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib. Pigment Cell and Melanoma Research, 2018, 31, 516-522. | 1.5 | 6 |
| 1325 | Perspectives on the integration of Immuno-Oncology Biomarkers and drugs in a Health Care setting. Seminars in Cancer Biology, 2018, 52, 166-177. | 4.3 | 11 |
| 1326 | Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. Clinical Cancer Research, 2018, 24, 1260-1270. | 3.2 | 289 |
| 1327 | The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy. Cancer Immunology, Immunotherapy, 2018, 67, 381-392. | 2.0 | 113 |
| 1328 | Imaging PD-L1 Expression with ImmunoPET. Bioconjugate Chemistry, 2018, 29, 96-103. | 1.8 | 109 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 1329 | Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. British Journal of Cancer, 2018, 118, 312-324. | 2.9 | 184 |
| 1330 | PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. American Journal of Surgical Pathology, 2018, 42, 326-334. | 2.1 | 38 |
| 1331 | Prognostic value of programmed death ligand 1, p53, and Ki-67 in patients with advanced-stage colorectal cancer. Human Pathology, 2018, 71, 20-29. | 1.1 | 33 |
| 1332 | Breast Cancer Immunotherapy: Facts and Hopes. Clinical Cancer Research, 2018, 24, 511-520. | 3.2 | 567 |
| 1333 | Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. Gastric Cancer, 2018, 21, 31-40. | 2.7 | 75 |
| 1334 | A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification. F1000Research, 2017, 6, 296. | 0.8 | 14 |
| 1335 | Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival. JCI Insight, 2018, 3, . | 2.3 | 49 |
| 1336 | HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape. Oncotarget, 2018, 9, 4120-4133. | 0.8 | 66 |
| 1337 | Systemic Therapy for Advanced Urothelial Carcinoma: Current Standards and Treatment Considerations. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 342-353. | 1.8 | 20 |
| 1338 | Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2018, 36, 1611-1618. | 0.8 | 448 |
| 1339 | Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. Journal of Clinical Oncology, 2018, 36, 850-858. | 0.8 | 288 |
| 1340 | Immune Checkpoint Inhibitors in the Management of Lung Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 682-695. | 1.8 | 35 |
| 1341 | Progress in Kidney Cancer Outcomes Through Collaboration, Innovation, and Discovery. Journal of Clinical Oncology, 2018, 36, 3529-3532. | 0.8 | 0 |
| 1342 | Tumor Mutation Burden: Is It Ready for the Clinic?. Journal of Clinical Oncology, 2018, 36, 2978-2979. | 0.8 | 16 |
| 1343 | PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs. Cancer Biology and Medicine, 2018, 15, 434. | 1.4 | 19 |
| 1344 | Immunotherapy in treatment naïve advanced non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, S412-S421. | 0.6 | 13 |
| 1345 | Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types. Journal of Immunology Research, 2018, 2018, 1-13. | 0.9 | 19 |
| 1346 | Immune profiling of microsatellite instability-high and polymerase ɛ (POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy. Journal of Gastrointestinal Oncology, 2018, 9, 404-415. | 0.6 | 49 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 1347 | Do immune checkpoint inhibitors need new studies methodology?. Journal of Thoracic Disease, 2018, 10, S1564-S1580. | 0.6 | 58 |
| 1348 | Immunotherapy in previously treated non-small cell lung cancer (NSCLC). Journal of Thoracic Disease, 2018, 10, S422-S432. | 0.6 | 9 |
| 1349 | Correlation and prognostic significance of PD-L1 and P53 expression in resected primary pulmonary lymphoepithelioma-like carcinoma. Journal of Thoracic Disease, 2018, 10, 1891-1902. | 0.6 | 23 |
| 1350 | Immunotherapy in the Asiatic population: any differences from Caucasian population?. Journal of Thoracic Disease, 2018, 10, S1482-S1493. | 0.6 | 42 |
| 1351 | Efficacy and immune activation of ipilimumab in early-stage lung cancer patients. Journal of Thoracic Disease, 2018, 10, S1945-S1948. | 0.6 | 1 |
| 1352 | Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and clinicians. Translational Lung Cancer Research, 2018, 7, 703-715. | 1.3 | 152 |
| 1354 | Management of Advanced Non–Small Cell Lung Cancer. , 2018, , 99-115. | | 1 |
| 1355 | Tumor microenvironment classification based on T‑cell infiltration and PD‑L1 in patients with mismatch repair‑proficient and ‑deficient colorectal cancer. Oncology Letters, 2018, 17, 2335-2343. | 0.8 | 8 |
| 1356 | Integrating RNA expression and visual features for immune infiltrate prediction. , 2018, , . | | 4 |
| 1357 | Overexpression of Programmed Cell Death-Ligand 1 in Small-Cell Lung Cancer and Survival Analysis. Journal of Cancer Diagnosis, 2018, 03, . | 0.1 | 0 |
| 1359 | A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1–insensitive models of triple-negative breast cancer. JCI Insight, 2018, 3, . | 2.3 | 175 |
| 1360 | An engineered PD-1-based and MMP-2/9-oriented fusion protein exerts potent antitumor effects against melanoma. BMB Reports, 2018, 51, 572-577. | 1.1 | 4 |
| 1361 | Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. Journal of Clinical Investigation, 2018, 128, 4441-4453. | 3.9 | 155 |
| 1362 | Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 157-172. | 0.7 | 40 |
| 1363 | Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single‑agent checkpoint blockade. Clinical and Translational Medicine, 2018, 7, 32. | 1.7 | 29 |
| 1364 | Significance of Tumor Microenvironment Scoring and Immune Biomarkers in Patient Stratification and Cancer Outcomes. , 0, , . | | 11 |
| 1365 | Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer. Frontiers in Immunology, 2018, 9, 3081. | 2.2 | 116 |
| 1366 | Lungen- und Urothelkarzinom. PD-L1-Blockade mit Atezolizumab: Ãœberzeugend wirksam bei jedem PD-L1-Status. Oncology Research and Treatment, 2018, 41, 64-65. | 0.8 | 2 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1367 | Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance. BMC Cancer, 2018, 18, 1082. | 1.1 | 42 |
| 1368 | Immune checkpoint inhibitors and radiotherapy—concept and review of current literature. Annals of Translational Medicine, 2018, 6, 155-155. | 0.7 | 16 |
| 1369 | From Friend to Enemy: Dissecting the Functional Alteration of Immunoregulatory Components during Pancreatic Tumorigenesis. International Journal of Molecular Sciences, 2018, 19, 3584. | 1.8 | 10 |
| 1370 | Clinicopathological analysis of primary intestinal diffuse large B–cell lymphoma: Prognostic evaluation of CD5, PD–L1, and Epstein–Barr virus on tumor cells. Cancer Medicine, 2018, 7, 6051-6063. | 1.3 | 27 |
| 1371 | 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nature Medicine, 2018, 24, 1852-1858. | 15.2 | 468 |
| 1372 | Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer. Journal of Translational Medicine, 2018, 16, 328. | 1.8 | 12 |
| 1373 | Dissecting the Immune Landscape of Acute Myeloid Leukemia. Biomedicines, 2018, 6, 110. | 1.4 | 32 |
| 1374 | PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28–8 and E1L3N). Diagnostic Pathology, 2018, 13, 91. | 0.9 | 48 |
| 1375 | A meta-analysis of nivolumab for the treatment of advanced non-small-cell lung cancer. OncoTargets and Therapy, 2018, Volume 11, 7691-7697. | 1.0 | 6 |
| 1376 | Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies. , 2018, 6, 129. | | 95 |
| 1377 | Non-hematopoietic Control of Peripheral Tissue T Cell Responses: Implications for Solid Tumors. Frontiers in Immunology, 2018, 9, 2662. | 2.2 | 8 |
| 1379 | Management of immunotherapy toxicities in older adults. Seminars in Oncology, 2018, 45, 226-231. | 0.8 | 25 |
| 1380 | The Adrenal Gland as a Sanctuary Site of Metastases After Pembrolizumab Treatment: A Case Series. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1279-1283. | 2.3 | 17 |
| 1381 | Immunotherapy in Non-Small Cell Lung Cancer: Biological Principles and Future Opportunities. Current Molecular Medicine, 2018, 17, 527-540. | 0.6 | 20 |
| 1382 | Î²catenin is a marker of poor clinical characteristics and suppressed immune infiltration in testicular germ cell tumors. BMC Cancer, 2018, 18, 1062. | 1.1 | 20 |
| 1383 | Blocking-Free ELISA Using a Gold Nanoparticle Layer Coated Commercial Microwell Plate. Sensors, 2018, 18, 3537. | 2.1 | 6 |
| 1384 | Current Landscape of Immunotherapy in the Treatment of Solid Tumours, with Future Opportunities and Challenges. Current Oncology, 2018, 25, 373-384. | 0.9 | 109 |
| 1385 | The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies. Current Treatment Options in Oncology, 2018, 19, 70. | 1.3 | 17 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1386 | Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. Nature Communications, 2018, 9, 4664. | 5.8 | 331 |
| 1387 | Tumour-targeting bacteria engineered to fight cancer. Nature Reviews Cancer, 2018, 18, 727-743. | 12.8 | 439 |
| 1388 | Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer. Journal of Oncology, 2018, 2018, 1-14. | 0.6 | 44 |
| 1389 | Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma. JCI Insight, 2018, 3, . | 2.3 | 40 |
| 1390 | New therapeutic targets for pulmonary sarcomatoid carcinomas based on their genomic and phylogenetic profiles. Oncotarget, 2018, 9, 10635-10649. | 0.8 | 41 |
| 1391 | Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer. Frontiers in Medicine, 2018, 5, 351. | 1.2 | 67 |
| 1392 | Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma. Theranostics, 2018, 8, 5690-5702. | 4.6 | 45 |
| 1393 | Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. Nature Communications, 2018, 9, 5361. | 5.8 | 294 |
| 1394 | Overview of Basic Immunology and Translational Relevance for Clinical Investigators. Advances in Experimental Medicine and Biology, 2018, 995, 1-41. | 0.8 | 6 |
| 1395 | Immunotherapy in Lung Cancer: A New Age in Cancer Treatment. Advances in Experimental Medicine and Biology, 2018, 995, 65-95. | 0.8 | 49 |
| 1396 | Organoid Modeling of the Tumor Immune Microenvironment. Cell, 2018, 175, 1972-1988.e16. | 13.5 | 870 |
| 1397 | Immune checkpoint inhibitors in cancer therapy. Journal of Biomedical Research, 2018, 32, 317. | 0.7 | 101 |
| 1399 | Gene landscape and correlation between B-cell infiltration and programmed death ligand 1 expression in lung adenocarcinoma patients from The Cancer Genome Atlas data set. PLoS ONE, 2018, 13, e0208459. | 1.1 | 19 |
| 1400 | The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor. Journal of Translational Medicine, 2018, 16, 273. | 1.8 | 73 |
| 1401 | Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells. Frontiers in Immunology, 2018, 9, 2140. | 2.2 | 92 |
| 1402 | Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment. Journal of Experimental Medicine, 2018, 215, 2748-2759. | 4.2 | 34 |
| 1404 | Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma. Frontiers in Oncology, 2018, 8, 351. | 1.3 | 71 |
| 1405 | Stochastic modeling of tumor progression and immune evasion. Journal of Theoretical Biology, 2018, 458, 148-155. | 0.8 | 15 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1406 | Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives. Drug Design, Development and Therapy, 2018, Volume 12, 2857-2873. | 2.0 | 10 |
| 1407 | Influence of PD-L1 expression in immune cells on the response to radiation therapy in patients with oropharyngeal squamous cell carcinoma. Radiotherapy and Oncology, 2018, 129, 409-414. | 0.3 | 28 |
| 1408 | Advanced pancreatic cancer: The standard of care and new opportunities. Oncology Reviews, 2018, 12, 370. | 0.8 | 10 |
| 1409 | The application of nanotechnology in immune checkpoint blockade for cancer treatment. Journal of Controlled Release, 2018, 290, 28-45. | 4.8 | 67 |
| 1410 | Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy. Trends in Biochemical Sciences, 2018, 43, 1014-1032. | 3.7 | 151 |
| 1412 | Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes and Development, 2018, 32, 1267-1284. | 2.7 | 1,326 |
| 1413 | Pulmonary Toxicities of Anticancer Treatment. , 2018, , 201-215. | | 0 |
| 1414 | Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application. Cancer Immunology Research, 2018, 6, 1122-1128. | 1.6 | 81 |
| 1415 | Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment. International Journal of Nanomedicine, 2018, Volume 13, 6049-6058. | 3.3 | 404 |
| 1416 | Prominent Nucleoli and Non-glandular Feature Are Independent Predictors of PD-L1 Expression in Lung Adenocarcinoma. Anticancer Research, 2018, 38, 6003-6008. | 0.5 | 1 |
| 1417 | Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences. Frontiers in Pharmacology, 2018, 9, 1050. | 1.6 | 48 |
| 1418 | A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell, 2018, 175, 313-326. | 13.5 | 985 |
| 1419 | First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 379, 2220-2229. | 13.9 | 2,228 |
| 1420 | Biosynthetic energy cost for amino acids decreases in cancer evolution. Nature Communications, 2018, 9, 4124. | 5.8 | 27 |
| 1421 | Features of Immune Cells and the Tumor-Associated Stroma Tango as Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma. Gastroenterology, 2018, 155, 1312-1314. | 0.6 | 1 |
| 1422 | Key questions about the checkpoint blockade-are microRNAs an answer?. Cancer Biology and Medicine, 2018, 15, 103. | 1.4 | 36 |
| 1424 | Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (antiâ€"PD-L1). Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E10119-E10126. | 3.3 | 180 |
| 1425 | Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy. Current Clinical Pharmacology, 2018, 13, 76-84. | 0.2 | 9 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 1426 | Diosgenin promotes antitumor immunity and PD-1 antibody efficacy against melanoma by regulating intestinal microbiota. Cell Death and Disease, 2018, 9, 1039. | 2.7 | 68 |
| 1427 | Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy. Respiratory Research, 2018, 19, 197. | 1.4 | 9 |
| 1428 | Limited Phenotypic and Functional Plasticity of Influenza Virus–Specific Memory CD8+T Cells during Activation in an Alternative Cytokine Environment. Journal of Immunology, 2018, 201, 3282-3293. | 0.4 | 2 |
| 1429 | Recent advances in gold and silver nanoparticle based therapies for lung and breast cancers. International Journal of Pharmaceutics, 2018, 553, 483-509. | 2.6 | 54 |
| 1430 | Role of the immunosuppressive microenvironment in immunotherapy. Advances in Radiation Oncology, 2018, 3, 520-526. | 0.6 | 107 |
| 1431 | A novel ternary heterostructure with dramatic SERS activity for evaluation of PD-L1 expression at the single-cell level. Science Advances, 2018, 4, eaau3494. | 4.7 | 63 |
| 1432 | Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments. PLoS ONE, 2018, 13, e0206223. | 1.1 | 149 |
| 1433 | Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study. Journal of Thoracic Oncology, 2018, 13, 1906-1918. | 0.5 | 88 |
| 1434 | FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC. Journal of Thoracic Oncology, 2018, 13, 1733-1742. | 0.5 | 120 |
| 1435 | Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations. Journal of Thoracic Oncology, 2018, 13, 1884-1896. | 0.5 | 78 |
| 1436 | Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment. , 2018, 6, 106. | | 138 |
| 1437 | Checkpoint-inhibition in ovarian cancer: rising star or just a dream?. Journal of Gynecologic Oncology, 2018, 29, e93. | 1.0 | 37 |
| 1438 | Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease. Frontiers in Oncology, 2018, 8, 414. | 1.3 | 65 |
| 1439 | Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer. OncoTargets and Therapy, 2018, Volume 11, 6505-6524. | 1.0 | 47 |
| 1440 | Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3. Science Translational Medicine, 2018, 10, . | 5.8 | 96 |
| 1442 | An assessment of prognostic immunity markers in breast cancer. Npj Breast Cancer, 2018, 4, 35. | 2.3 | 41 |
| 1443 | Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects. Journal of Experimental and Clinical Cancer Research, 2018, 37, 261. | 3.5 | 112 |
| 1444 | PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression. Journal of Clinical Investigation, 2018, 128, 580-588. | 3.9 | 388 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1445 | Radiopharmacology and molecular imaging of PD-L1 expression in cancer. Clinical and Translational Imaging, 2018, 6, 429-439. | 1.1 | 7 |
| 1446 | IFNÎ³-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin. Journal of Experimental Medicine, 2018, 215, 3057-3074. | 4.2 | 134 |
| 1447 | Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial. Annals of Oncology, 2018, 29, 2247-2253. | 0.6 | 101 |
| 1448 | Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine, 2018, 379, 2108-2121. | 13.9 | 3,097 |
| 1449 | Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver. Molecular Therapy, 2018, 26, 2553-2566. | 3.7 | 20 |
| 1450 | New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1. Therapeutic Advances in Respiratory Disease, 2018, 12, 175346661879413. | 1.0 | 35 |
| 1451 | Immunoengineering through cancer vaccines â€" A personalized and multi-step vaccine approach towards precise cancer immunity. Journal of Controlled Release, 2018, 289, 125-145. | 4.8 | 31 |
| 1452 | A Comprehensive Survey of Immune Cytolytic Activity-Associated Gene Co-Expression Networks across 17 Tumor and Normal Tissue Types. Cancers, 2018, 10, 307. | 1.7 | 4 |
| 1453 | Chromogenic Multiplex Immunohistochemistry Reveals Modulation of the Immune Microenvironment Associated with Survival in Elderly Patients with Lung Adenocarcinoma. Cancers, 2018, 10, 326. | 1.7 | 23 |
| 1454 | T Cellâ€"Inflamed versus Non-T Cellâ€"Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunology Research, 2018, 6, 990-1000. | 1.6 | 297 |
| 1455 | The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review. BMC Gastroenterology, 2018, 18, 135. | 0.8 | 44 |
| 1456 | Magnetic resonance imaging and molecular features associated with tumor-infiltrating lymphocytes in breast cancer. Breast Cancer Research, 2018, 20, 101. | 2.2 | 44 |
| 1457 | Combining radiation therapy and cancer immune therapies: From preclinical findings to clinical applications. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2018, 22, 567-580. | 0.6 | 24 |
| 1458 | A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging. Cell, 2018, 174, 1373-1387.e19. | 13.5 | 729 |
| 1459 | Combinations of Bevacizumab With Cancer Immunotherapy. Cancer Journal (Sudbury, Mass ), 2018, 24, 193-204. | 1.0 | 144 |
| 1460 | A Preclinical Assessment of $^{89}$Zr-atezolizumab Identifies a Requirement for Carrier Added Formulations Not Observed with $^{89}$Zr-C4. Bioconjugate Chemistry, 2018, 29, 3476-3482. | 1.8 | 37 |
| 1461 | Prognostic Impact of Immune-Related Gene Expression in Preoperative Peripheral Blood from Gastric Cancer Patients. Annals of Surgical Oncology, 2018, 25, 3755-3763. | 0.7 | 15 |
| 1462 | PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments. Oncotarget, 2018, 9, 8584-8596. | 0.8 | 53 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1463 | Chemotherapy Combines Effectively with Antiâ€"PD-L1 Treatment and Can Augment Antitumor Responses. Journal of Immunology, 2018, 201, 2273-2286. | 0.4 | 38 |
| 1464 | Translational Biomarkers: Application in the Clinical Development of Combination Therapies. , 2018, , 223-248. | | 0 |
| 1465 | Stromal versus tumoral inflammation differentially contribute to metastasis and poor survival in laryngeal squamous cell carcinoma. Oncotarget, 2018, 9, 8415-8426. | 0.8 | 31 |
| 1466 | PD-L1 blockade enhances anti-tumor efficacy of NK cells. OncoImmunology, 2018, 7, e1509819. | 2.1 | 104 |
| 1467 | Precision medicine in cholangiocarcinoma. Translational Gastroenterology and Hepatology, 2018, 3, 40-40. | 1.5 | 61 |
| 1468 | Bringing the Next Generation of Immuno-Oncology Biomarkers to the Clinic. Biomedicines, 2018, 6, 14. | 1.4 | 66 |
| 1470 | EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nature Communications, 2018, 9, 3503. | 5.8 | 224 |
| 1471 | Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer. Medicine (United States), 2018, 97, e11936. | 0.4 | 87 |
| 1472 | Stromal Cells in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2018, 1060, 99-114. | 0.8 | 208 |
| 1473 | T cell receptor sequencing of activated CD8 T cells in the blood identifies tumor-infiltrating clones that expand after PD-1 therapy and radiation in a melanoma patient. Cancer Immunology, Immunotherapy, 2018, 67, 1767-1776. | 2.0 | 51 |
| 1474 | Clinical Trial Design in Immuno-Oncology. , 2018, , 151-173. | | 0 |
| 1475 | Constrained Combinatorial Libraries of Gp2 Proteins Enhance Discovery of PD-L1 Binders. ACS Combinatorial Science, 2018, 20, 423-435. | 3.8 | 16 |
| 1476 | Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer. Cancer Research, 2018, 78, 4282-4291. | 0.4 | 83 |
| 1477 | PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT). American Journal of Surgical Pathology, 2018, 42, 843-854. | 2.1 | 54 |
| 1478 | Prognostic stratification of patients with nasopharyngeal carcinoma based on tumor immune microenvironment. Head and Neck, 2018, 40, 2007-2019. | 0.9 | 47 |
| 1479 | How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies. ESMO Open, 2018, 3, e000357. | 2.0 | 112 |
| 1480 | *STK11/LKB1* Mutations and PD-1 Inhibitor Resistance in *KRAS*-Mutant Lung Adenocarcinoma. Cancer Discovery, 2018, 8, 822-835. | 7.7 | 1,108 |
| 1481 | The potential predictive value of circulating immune cell ratio and tumor marker in atezolizumab treated advanced non-small cell lung cancer patients. Cancer Biomarkers, 2018, 22, 467-476. | 0.8 | 33 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 1482 | Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends in Immunology, 2018, 39, 624-631. | 2.9 | 153 |
| 1483 | Intratumoral immune cells expressing PD-1/PD-L1 and their prognostic implications in cancer: a meta-analysis. International Journal of Biological Markers, 2018, 33, 467-474. | 0.7 | 11 |
| 1484 | Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer. Targeted Oncology, 2018, 13, 399-407. | 1.7 | 16 |
| 1485 | Emerging biomarkers for immune checkpoint inhibition in lung cancer. Seminars in Cancer Biology, 2018, 52, 269-277. | 4.3 | 67 |
| 1486 | JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer. Clinical Breast Cancer, 2018, 18, e1205-e1215. | 1.1 | 46 |
| 1487 | Non-small cell lung cancer brain metastases and the immune system: From brain metastases development to treatment. Cancer Treatment Reviews, 2018, 68, 69-79. | 3.4 | 51 |
| 1488 | Helicase-Driven Activation of NFÎ⁰B-COX2 Pathway Mediates the Immunosuppressive Component of dsRNA-Driven Inflammation in the Human Tumor Microenvironment. Cancer Research, 2018, 78, 4292-4302. | 0.4 | 30 |
| 1489 | A prognostic model, including the <scp>EBV</scp> status of tumor cells, forÂprimary gastric diffuse large Bâ€cell lymphoma in the rituximab era. Cancer Medicine, 2018, 7, 3510-3520. | 1.3 | 23 |
| 1490 | Potent immunogenicity in <i><scp>BRCA</scp>1</i>â€mutated patients with highâ€grade serous ovarian carcinoma. Journal of Cellular and Molecular Medicine, 2018, 22, 3979-3986. | 1.6 | 38 |
| 1491 | The combined presence of CD20â€‰+â€‰B cells and PD-L1â€‰+â€‰tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome. Breast Cancer Research and Treatment, 2018, 171, 273-282. | 1.1 | 65 |
| 1492 | Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Nonâ€"Small-cell Lung Cancer. Clinical Lung Cancer, 2018, 19, 441-449.e4. | 1.1 | 65 |
| 1493 | Combination of fucoidan-based magnetic nanoparticles and immunomodulators enhances tumour-localized immunotherapy. Nature Nanotechnology, 2018, 13, 746-754. | 15.6 | 218 |
| 1494 | Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma. Journal of Immunotherapy, 2018, 41, 399-405. | 1.2 | 32 |
| 1495 | The Immune Landscape of Nonâ€"Small-Cell Lung Cancer. Utility of Cytologic and Histologic Samples Obtained through Minimally Invasive Pulmonary Procedures. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 24-38. | 2.5 | 14 |
| 1496 | Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1. Cancer Medicine, 2018, 7, 3178-3187. | 1.3 | 20 |
| 1497 | Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. Oncogene, 2018, 37, 4639-4661. | 2.6 | 219 |
| 1498 | Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Nonâ€"Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 1156-1170. | 0.5 | 195 |
| 1499 | Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment. Cancer Research, 2018, 78, 5011-5022. | 0.4 | 224 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1500 | Combination Immunotherapy Approaches for Pancreatic Cancer Treatment. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018, 1-7. | 0.8 | 16 |
| 1501 | T Lymphocyte–Based Cancer Immunotherapeutics. International Review of Cell and Molecular Biology, 2018, 341, 201-276. | 1.6 | 22 |
| 1502 | Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types. OncoImmunology, 2018, 7, e1466018. | 2.1 | 51 |
| 1503 | Impact of chemotactic factors and receptors on the cancer immune infiltrate: a bioinformatics study revealing homogeneity and heterogeneity among patient cohorts. OncoImmunology, 2018, 7, e1484980. | 2.1 | 24 |
| 1504 | Early-drug development in the era of immuno-oncology: are we ready to face the challenges?. Annals of Oncology, 2018, 29, 1727-1740. | 0.6 | 20 |
| 1505 | 30 Immunotherapy in advanced NSCLC–from the ʻtsunamiʼ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT). ESMO Open, 2018, 3, e000298. | 2.0 | 10 |
| 1506 | Pediatric Cancer Immunotherapy: Opportunities and Challenges. Paediatric Drugs, 2018, 20, 395-408. | 1.3 | 76 |
| 1507 | Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4+ and CD8+ T-cell Interplay. Cancer Research, 2018, 78, 4943-4956. | 0.4 | 49 |
| 1508 | Systemically Administered Sindbis Virus in Combination with Immune Checkpoint Blockade Induces Curative Anti-tumor Immunity. Molecular Therapy - Oncolytics, 2018, 9, 51-63. | 2.0 | 22 |
| 1509 | Vaccine immunotherapy with ARNAX induces tumor–specific memory T cells and durable anti–tumor immunity in mouse models. Cancer Science, 2018, 109, 2119-2129. | 1.7 | 22 |
| 1510 | Extracellular vesicles and ctDNA in lung cancer: biomarker sources and therapeutic applications. Cancer Chemotherapy and Pharmacology, 2018, 82, 171-183. | 1.1 | 17 |
| 1511 | Immune Characteristics of Chinese Diffuse Large B-Cell Lymphoma Patients: Implications for Cancer Immunotherapies. EBioMedicine, 2018, 33, 94-104. | 2.7 | 10 |
| 1512 | Programmed Cell Death-1 Inhibitor–Induced Type 1 Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3144-3154. | 1.8 | 156 |
| 1513 | Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2018, 13, 1569-1576. | 0.5 | 206 |
| 1514 | The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management. JNCI Cancer Spectrum, 2018, 2, pky021. | 1.4 | 92 |
| 1515 | Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer. Cancers, 2018, 10, 245. | 1.7 | 34 |
| 1516 | microRNA 125a Regulates MHC-I Expression on Esophageal Adenocarcinoma Cells, Associated With Suppression of Antitumor Immune Response and Poor Outcomes of Patients. Gastroenterology, 2018, 155, 784-798. | 0.6 | 70 |
| 1517 | Immune oncology, immune responsiveness and the theory of everything. , 2018, 6, 50. | | 58 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1518 | Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts. Frontiers in Immunology, 2018, 9, 1614. | 2.2 | 23 |
| 1519 | Sno-derived RNAs are prevalent molecular markers of cancer immunity. Oncogene, 2018, 37, 6442-6462. | 2.6 | 28 |
| 1520 | Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. , 2018, 6, 35. | | 172 |
| 1521 | Biomarkers of response to immune checkpoint blockade in cancer treatment. Critical Reviews in Oncology/Hematology, 2018, 130, 108-120. | 2.0 | 61 |
| 1522 | CSF1R-Expressing Tumor-Associated Macrophages, Smoking and Survival in Lung Adenocarcinoma: Analyses Using Quantitative Phosphor-Integrated Dot Staining. Cancers, 2018, 10, 252. | 1.7 | 20 |
| 1523 | Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. Journal of Neuro-Oncology, 2018, 140, 317-328. | 1.4 | 107 |
| 1524 | Nanotechnology-mediated immunochemotherapy combined with docetaxel and PD-L1 antibody increase therapeutic effects and decrease systemic toxicity. Journal of Controlled Release, 2018, 286, 369-380. | 4.8 | 70 |
| 1525 | Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy. Theranostics, 2018, 8, 3559-3570. | 4.6 | 85 |
| 1526 | A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer. Journal of Cancer, 2018, 9, 1200-1206. | 1.2 | 31 |
| 1527 | Epidermal growth factor induces STAT1 expression to exacerbate the IFNrâ€mediated PDâ€L1 axis in epidermal growth factor receptorâ€positive cancers. Molecular Carcinogenesis, 2018, 57, 1588-1598. | 1.3 | 31 |
| 1528 | High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma. OncoImmunology, 2018, 7, e1475874. | 2.1 | 20 |
| 1529 | Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. Therapeutics and Clinical Risk Management, 2018, Volume 14, 1019-1040. | 0.9 | 55 |
| 1530 | Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration. Clinical Cancer Research, 2018, 24, 5368-5380. | 3.2 | 189 |
| 1531 | Biomarkers for Immune Checkpoint Inhibitors in Melanoma. Frontiers in Oncology, 2018, 8, 270. | 1.3 | 47 |
| 1532 | Construction of an antiâ€programmed deathâ€ligand 1 chimeric antigen receptor and determination of its antitumor function with transduced cells. Oncology Letters, 2018, 16, 157-166. | 0.8 | 9 |
| 1533 | Analysis of the Cancer Genome Atlas Data Reveals Novel Putative ncRNAs Targets in Hepatocellular Carcinoma. BioMed Research International, 2018, 2018, 1-9. | 0.9 | 16 |
| 1534 | PD-L1 Expression On tumor Cells Was Associated With Unfavorable Prognosis In Esophageal Squamous Cell Carcinoma. Journal of Cancer, 2018, 9, 2224-2231. | 1.2 | 17 |
| 1535 | Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced nonâ€"small-cell lung cancer. European Journal of Cancer, 2018, 101, 114-122. | 1.3 | 45 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1536 | Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors. Journal of Cancer, 2018, 9, 205-212. | 1.2 | 9 |
| 1537 | Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. European Journal of Cancer, 2018, 101, 201-209. | 1.3 | 41 |
| 1538 | Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer. Frontiers in Immunology, 2018, 9, 394. | 2.2 | 84 |
| 1539 | Type I Interferon-Independent Dendritic Cell Priming and Antitumor T Cell Activation Induced by a Mycoplasma fermentans Lipopeptide. Frontiers in Immunology, 2018, 9, 496. | 2.2 | 16 |
| 1540 | High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple Negative Breast Cancer. Frontiers in Immunology, 2018, 9, 1209. | 2.2 | 114 |
| 1541 | Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatmentâ€"A Review From the Melanoma Perspective and Beyond. Frontiers in Immunology, 2018, 9, 1474. | 2.2 | 174 |
| 1542 | The Expression and Prognostic Impact of Immune Cytolytic Activity-Related Markers in Human Malignancies: A Comprehensive Meta-analysis. Frontiers in Oncology, 2018, 8, 27. | 1.3 | 71 |
| 1543 | DNA Tumor Virus Regulation of Host DNA Methylation and Its Implications for Immune Evasion and Oncogenesis. Viruses, 2018, 10, 82. | 1.5 | 82 |
| 1544 | Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment. Biomedicines, 2018, 6, 26. | 1.4 | 16 |
| 1545 | Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer. Cancers, 2018, 10, 39. | 1.7 | 44 |
| 1546 | PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters. PLoS ONE, 2018, 13, e0196464. | 1.1 | 20 |
| 1547 | Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies. Human Pathology, 2018, 82, 39-45. | 1.1 | 2 |
| 1548 | Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance. International Journal of Molecular Sciences, 2018, 19, 1512. | 1.8 | 16 |
| 1549 | PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations. International Journal of Molecular Sciences, 2018, 19, 1984. | 1.8 | 31 |
| 1550 | Diagnosing Lung Cancer: The Complexities of Obtaining a Tissue Diagnosis in the Era of Minimally Invasive and Personalised Medicine. Journal of Clinical Medicine, 2018, 7, 163. | 1.0 | 50 |
| 1551 | Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation. Cancer Immunology Research, 2018, 6, 1260-1273. | 1.6 | 251 |
| 1552 | Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity. Immunotherapy, 2018, 10, 797-805. | 1.0 | 20 |
| 1553 | Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma. Immunotherapy, 2018, 10, 779-786. | 1.0 | 58 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 1554 | Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes. Cancers, 2018, 10, 62. | 1.7 | 73 |
| 1555 | Cardiorenal complications of immune checkpoint inhibitors. Nature Reviews Nephrology, 2018, 14, 571-588. | 4.1 | 80 |
| 1556 | MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Science Translational Medicine, 2018, 10, . | 5.8 | 425 |
| 1557 | Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4+Foxp3â€ Cellâ€"Mediated Modulation of CD103+ Dendritic Cells. Cancer Immunology Research, 2018, 6, 1069-1081. | 1.6 | 67 |
| 1558 | A clinical analysis of 114 cases of sarcomatoid carcinoma of the lung. Clinical and Experimental Medicine, 2018, 18, 555-562. | 1.9 | 25 |
| 1559 | Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells. Cell Reports, 2018, 24, 379-390.e6. | 2.9 | 140 |
| 1560 | Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice. Future Oncology, 2018, 14, 41-60. | 1.1 | 12 |
| 1561 | Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity. Acta Pharmacologica Sinica, 2018, 39, 1693-1698. | 2.8 | 39 |
| 1562 | Microbial biomarkers for immune checkpoint blockade therapy against cancer. Journal of Gastroenterology, 2018, 53, 999-1005. | 2.3 | 15 |
| 1563 | Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors. Diagnostic Pathology, 2018, 13, 30. | 0.9 | 43 |
| 1564 | Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions. Frontiers in Pharmacology, 2018, 9, 185. | 1.6 | 277 |
| 1565 | Immunotherapy in Advanced Gastric Cancer: An Overview of the Emerging Strategies. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018, 1-8. | 0.8 | 15 |
| 1566 | Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNÎ³ secretion. Cancer Letters, 2018, 430, 47-56. | 3.2 | 117 |
| 1567 | Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. Cancer Treatment Reviews, 2018, 66, 104-113. | 3.4 | 78 |
| 1568 | Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer. BMC Cancer, 2018, 18, 4. | 1.1 | 85 |
| 1569 | Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells. BMC Cancer, 2018, 18, 149. | 1.1 | 36 |
| 1570 | VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma. BMC Cancer, 2018, 18, 511. | 1.1 | 66 |
| 1571 | Liquid biomarkers in melanoma: detection and discovery. Molecular Cancer, 2018, 17, 8. | 7.9 | 74 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1572 | PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. Journal of Hematology and Oncology, 2018, 11, 16. | 6.9 | 96 |
| 1573 | Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. , 2018, 6, 4. | | 118 |
| 1574 | ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nature Medicine, 2018, 24, 556-562. | 15.2 | 372 |
| 1575 | Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. Cell, 2018, 173, 1755-1769.e22. | 13.5 | 261 |
| 1576 | Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism. Endocrine Connections, 2018, 7, R196-R211. | 0.8 | 10 |
| 1577 | Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. , 2018, 6, 37. | | 174 |
| 1578 | Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: Relationship with sidedness and prognosis. OncoImmunology, 2018, 7, e1465165. | 2.1 | 59 |
| 1579 | CIMT 2018: Pushing frontiers in cancer immunotherapy â€" Report on the 16th Annual Meeting of the Association for Cancer Immunotherapy. Human Vaccines and Immunotherapeutics, 2018, 14, 2864-2873. | 1.4 | 1 |
| 1580 | Molecular Pathogenesis of Gastric Adenocarcinoma. , 2018, , . | | 0 |
| 1581 | Human cancer evolution in the context of a human immune system in mice. Molecular Oncology, 2018, 12, 1797-1810. | 2.1 | 11 |
| 1582 | Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Annals of Translational Medicine, 2018, 6, 144-144. | 0.7 | 19 |
| 1583 | Translational Research in Cutaneous Melanoma: New Therapeutic Perspectives. Anti-Cancer Agents in Medicinal Chemistry, 2018, 18, 166-181. | 0.9 | 10 |
| 1584 | Fraxinellone has anticancer activity in vivo by inhibiting programmed cell death-ligand 1 expression by reducing hypoxia-inducible factor-1Î± and STAT3. Pharmacological Research, 2018, 135, 166-180. | 3.1 | 51 |
| 1585 | A comprehensive review of the role of immune checkpoint inhibitors in brain metastasis of renal cell carcinoma origin. Critical Reviews in Oncology/Hematology, 2018, 130, 60-69. | 2.0 | 20 |
| 1586 | A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nature Communications, 2018, 9, 3196. | 5.8 | 145 |
| 1587 | Next Generation Cancer Vaccinesâ€"Make It Personal!. Vaccines, 2018, 6, 52. | 2.1 | 20 |
| 1588 | DNA Mismatch Repair Protein Immunohistochemistry and MLH1 Promotor Methylation Testing for Practical Molecular Classification and the Prediction of Prognosis in Endometrial Cancer. Cancers, 2018, 10, 279. | 1.7 | 15 |
| 1589 | Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes. Nature Communications, 2018, 9, 3417. | 5.8 | 87 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1590 | Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Molecular Cancer, 2018, 17, 129. | 7.9 | 536 |
| 1591 | Urothelial carcinoma: the evolving landscape of immunotherapy for patients with advanced disease. Research and Reports in Urology, 2018, Volume 10, 7-16. | 0.6 | 22 |
| 1592 | Targeting the PD-1/PD-L1 Axis for the Treatment of Non-Small-Cell Lung Cancer. Current Oncology, 2018, 25, 324-334. | 0.9 | 56 |
| 1593 | Effect of anthracycline and taxane on the expression of programmed cell death ligand-1 and galectin-9 in triple-negative breast cancer. Pathology Research and Practice, 2018, 214, 1626-1631. | 1.0 | 18 |
| 1594 | Mouse models in the era of large human tumour sequencing studies. Open Biology, 2018, 8, . | 1.5 | 7 |
| 1595 | Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients. Clinical Cancer Research, 2018, 24, 6345-6354. | 3.2 | 43 |
| 1596 | A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncology, The, 2018, 19, 1180-1191. | 5.1 | 811 |
| 1597 | Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy. Frontiers in Immunology, 2018, 9, 1774. | 2.2 | 125 |
| 1598 | New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment. Biomedicines, 2018, 6, 87. | 1.4 | 8 |
| 1599 | Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discovery, 2018, 8, 1069-1086. | 7.7 | 2,128 |
| 1600 | Relative Efficacy of Checkpoint Inhibitors for Advanced NSCLC According to Programmed Death-Ligand-1 Expression: A Systematic Review and Network Meta-Analysis. Scientific Reports, 2018, 8, 11738. | 1.6 | 21 |
| 1601 | Checkpoint blockadeâ€based immunotherapy in the context of tumor microenvironment: Opportunities and challenges. Cancer Medicine, 2018, 7, 4517-4529. | 1.3 | 34 |
| 1602 | Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. Lancet Respiratory Medicine,the, 2018, 6, 771-781. | 5.2 | 167 |
| 1603 | Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors. Cancer Management and Research, 2018, Volume 10, 2475-2488. | 0.9 | 22 |
| 1604 | Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer. Frontiers in Immunology, 2018, 9, 1613. | 2.2 | 83 |
| 1605 | M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors. ACS Nano, 2018, 12, 8977-8993. | 7.3 | 286 |
| 1606 | Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine, 2018, 24, 749-757. | 15.2 | 900 |
| 1607 | Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. New England Journal of Medicine, 2018, 378, 2288-2301. | 13.9 | 2,808 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 1608 | Impact of tumor microenvironment composition on therapeutic responses and clinical outcomes in cancer. Future Oncology, 2018, 14, 1409-1421. | 1.1 | 38 |
| 1609 | Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF). Oncologist, 2018, 23, 1407-e136. | 1.9 | 127 |
| 1610 | Immunobiology of theÂMelanoma Microenvironment. , 2018, , 133-142. | | 0 |
| 1612 | DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy. Anti-Cancer Drugs, 2018, 29, 774-785. | 0.7 | 12 |
| 1613 | Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clinical Cancer Research, 2018, 24, 5347-5356. | 3.2 | 253 |
| 1614 | Prevalence of Enhancer of Zeste Homolog 2 in Patients with Resected Small Cell Lung Cancer. Anticancer Research, 2018, 38, 3707-3711. | 0.5 | 9 |
| 1615 | Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Annals of Oncology, 2018, 29, 1741-1747. | 0.6 | 56 |
| 1616 | Indoleamine-2,3-Dioxygenase in Nonâ€"Small Cell Lung Cancer. American Journal of Surgical Pathology, 2018, 42, 1216-1223. | 2.1 | 36 |
| 1617 | *MET*-Oncogenic and *JAK2*-Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer. Clinical Cancer Research, 2018, 24, 4579-4587. | 3.2 | 71 |
| 1618 | Immune checkpoint inhibition in gastric cancer: A systematic review. Journal of Cellular Immunotherapy, 2018, 4, 49-55. | 0.6 | 7 |
| 1619 | NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. PLoS ONE, 2018, 13, e0193640. | 1.1 | 5 |
| 1620 | Novel patented markers of immune checkpoint inhibitor efficacy. Pharmaceutical Patent Analyst, 2018, 7, 129-131. | 0.4 | 0 |
| 1621 | Recent progress in therapeutic antibodies for cancer immunotherapy. Current Opinion in Chemical Biology, 2018, 44, 56-65. | 2.8 | 21 |
| 1622 | Non-conventional Inhibitory CD4+Foxp3â˜'PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity. Cancer Cell, 2018, 33, 1017-1032.e7. | 7.7 | 112 |
| 1623 | Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue. Current Medicinal Chemistry, 2018, 25, 1327-1339. | 1.2 | 99 |
| 1624 | Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment. Liver Cancer, 2019, 8, 110-120. | 4.2 | 46 |
| 1625 | Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective. Clinical Pharmacology and Therapeutics, 2019, 105, 582-597. | 2.3 | 8 |
| 1626 | New horizons in breast cancer: the promise of immunotherapy. Clinical and Translational Oncology, 2019, 21, 117-125. | 1.2 | 21 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 1627 | Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer. Archives of Pathology and Laboratory Medicine, 2019, 143, 330-337. | 1.2 | 377 |
| 1628 | A <scp>PK/PD</scp> Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumabâ€Treated nonâ€small Cell Lung Cancer Patients. Clinical Pharmacology and Therapeutics, 2019, 105, 486-495. | 2.3 | 23 |
| 1629 | Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. Oncogene, 2019, 38, 390-405. | 2.6 | 149 |
| 1630 | Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy. Cellular and Molecular Immunology, 2019, 16, 28-39. | 4.8 | 57 |
| 1631 | Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer. Annals of Surgery, 2019, 270, 309-316. | 2.1 | 191 |
| 1632 | Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer. Cancer Letters, 2019, 464, 5-14. | 3.2 | 148 |
| 1633 | Immune Cytolytic Activity Is Associated With Genetic and Clinical Properties of Glioma. Frontiers in Immunology, 2019, 10, 1756. | 2.2 | 35 |
| 1635 | Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. MAbs, 2019, 11, 1443-1451. | 2.6 | 97 |
| 1636 | Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors. Advances in Therapy, 2019, 36, 2638-2678. | 1.3 | 145 |
| 1637 | USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity. Cancer Immunology Research, 2019, 7, 1580-1590. | 1.6 | 94 |
| 1638 | Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study. Frontiers in Immunology, 2019, 10, 1848. | 2.2 | 56 |
| 1639 | Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer. Scientific Reports, 2019, 9, 11131. | 1.6 | 21 |
| 1640 | Immune Checkpoint Inhibitor Dosing: Can We Go Lower Without Compromising Clinical Efficacy?. Journal of Global Oncology, 2019, 5, 1-5. | 0.5 | 36 |
| 1641 | Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8<sup>+</sup> Tumor-infiltrating Lymphocytes in Esophageal Squamous Cell Carcinoma. Anticancer Research, 2019, 39, 4539-4548. | 0.5 | 44 |
| 1642 | Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC. Cells, 2019, 8, 809. | 1.8 | 76 |
| 1643 | Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133). Clinical Lung Cancer, 2019, 20, 469-476.e1. | 1.1 | 26 |
| 1644 | Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society. Lung Cancer, 2019, 136, 65-73. | 0.9 | 8 |
| 1645 | PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis. Future Oncology, 2019, 15, 1667-1678. | 1.1 | 13 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 1646 | Avelumab in gastric cancer. Immunotherapy, 2019, 11, 759-768. | 1.0 | 17 |
| 1647 | Real–world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer. Cancer, 2019, 125, 4019-4032. | 2.0 | 115 |
| 1648 | Targeting self- and neoepitopes with a modular self-adjuvanting cancer vaccine. JCI Insight, 2019, 4, . | 2.3 | 28 |
| 1649 | Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 364. | 3.5 | 63 |
| 1650 | Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. Cancer Cell, 2019, 36, 168-178.e4. | 7.7 | 240 |
| 1651 | <p>Clinical genetic features and related survival implications in patients with surgically resectedÂlarge-cell lung cancer</p>. Cancer Management and Research, 2019, Volume 11, 5489-5499. | 0.9 | 5 |
| 1652 | Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment. Science Translational Medicine, 2019, 11, . | 5.8 | 147 |
| 1653 | Targeting PD-1 in cancer: Biological insights with a focus on breast cancer. Critical Reviews in Oncology/Hematology, 2019, 142, 35-43. | 2.0 | 18 |
| 1654 | Role of tumor gene mutations in treatment response to immune checkpoint blockades. Precision Clinical Medicine, 2019, 2, 100-109. | 1.3 | 11 |
| 1655 | Smoking history influences the prognostic value of peripheral naÃ¯ve CD4+ T cells in advanced non-small cell lung cancer. Cancer Cell International, 2019, 19, 176. | 1.8 | 8 |
| 1656 | Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: Comparative assessment of primary and metastatic sites. Lung Cancer, 2019, 134, 202-209. | 0.9 | 35 |
| 1657 | Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma. Journal of Hematology and Oncology, 2019, 12, 75. | 6.9 | 84 |
| 1658 | A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an &lt;i&gt;EGFR&lt;/i&gt; Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages. Internal Medicine, 2019, 58, 3033-3037. | 0.3 | 7 |
| 1659 | Personalized medicine: From diagnostic to adaptive. Biomedical Journal, 2022, 45, 132-142. | 1.4 | 8 |
| 1660 | Symmetry-based ligand design and evaluation of small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 interaction. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2464-2467. | 1.0 | 14 |
| 1661 | Possible Biomarkers for Cancer Immunotherapy. Cancers, 2019, 11, 935. | 1.7 | 35 |
| 1662 | Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean melanoma patients. Journal of Cancer, 2019, 10, 3070-3078. | 1.2 | 10 |
| 1663 | The Mechanism of Anti–PD-L1 Antibody Efficacy against PD-L1–Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector. Cancer Discovery, 2019, 9, 1422-1437. | 7.7 | 210 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1664 | Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1. Nature Communications, 2019, 10, 3345. | 5.8 | 94 |
| 1665 | Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer. , 2019, 7, 198. | | 28 |
| 1666 | Rational combinations of immunotherapy with radiotherapy in ovarian cancer. Lancet Oncology, The, 2019, 20, e417-e433. | 5.1 | 89 |
| 1667 | Engineering nanoparticles to locally activate T cells in the tumor microenvironment. Science Immunology, 2019, 4, . | 5.6 | 180 |
| 1668 | Zinc(II) phthalocyanines as photosensitizers for antitumor photodynamic therapy. International Journal of Biochemistry and Cell Biology, 2019, 114, 105575. | 1.2 | 90 |
| 1669 | MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer. Cancer Research, 2019, 79, 5812-5825. | 0.4 | 6 |
| 1670 | Costimulatory Molecules and Immune Checkpoints Are Differentially Expressed on Different Subsets of Dendritic Cells. Frontiers in Immunology, 2019, 10, 1325. | 2.2 | 55 |
| 1671 | Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent. Cancers, 2019, 11, 872. | 1.7 | 50 |
| 1672 | Rationally designed peptide-conjugated gold/platinum nanosystem with active tumor-targeting for enhancing tumor photothermal-immunotherapy. Journal of Controlled Release, 2019, 308, 29-43. | 4.8 | 82 |
| 1673 | Therapeutic Implication of Genomic Landscape of Adult Metastatic Sarcoma. JCO Precision Oncology, 2019, 3, 1-25. | 1.5 | 12 |
| 1674 | Recent Findings in the Regulation of Programmed Death Ligand 1 Expression. Frontiers in Immunology, 2019, 10, 1337. | 2.2 | 85 |
| 1675 | Reduced CTL motility and activity in avascular tumor areas. Cancer Immunology, Immunotherapy, 2019, 68, 1287-1301. | 2.0 | 21 |
| 1676 | Adjuvant Chemotherapy Increases Programmed Death-Ligand 1 (PD-L1) Expression in Non–small Cell Lung Cancer Recurrence. Clinical Lung Cancer, 2019, 20, 391-396. | 1.1 | 36 |
| 1677 | Development of 99mTc-conjugated JS001 antibody for in vivo mapping of PD-1 distribution in murine. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2178-2181. | 1.0 | 8 |
| 1678 | Optimizing panel-based tumor mutational burden (TMB) measurement. Annals of Oncology, 2019, 30, 1496-1506. | 0.6 | 123 |
| 1679 | Elevated platelet-to-lymphocyte corresponds with poor outcome in patients with advanced cancer receiving anti-PD-1 therapy. International Immunopharmacology, 2019, 74, 105707. | 1.7 | 11 |
| 1680 | Future Research Goals in Immunotherapy. Surgical Oncology Clinics of North America, 2019, 28, 505-518. | 0.6 | 2 |
| 1681 | Supporting the stratification of non-small cell lung carcinoma for Anti PD-L1 immunotherapy with digital image registration. , 2019, , . | | 1 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1682 | PLAC8 overexpression correlates with PD-L1 upregulation and acquired resistance to chemotherapies in gallbladder carcinoma. Biochemical and Biophysical Research Communications, 2019, 516, 983-990. | 1.0 | 12 |
| 1683 | Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a PhaseÂII Study. Journal of Thoracic Oncology, 2019, 14, 1447-1457. | 0.5 | 136 |
| 1684 | Aggregable Nanoparticles-Enabled Chemotherapy and Autophagy Inhibition Combined with Anti-PD-L1 Antibody for Improved Glioma Treatment. Nano Letters, 2019, 19, 8318-8332. | 4.5 | 142 |
| 1685 | Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors. ESMO Open, 2019, 4, e000531. | 2.0 | 60 |
| 1686 | Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer. Lung Cancer, 2019, 138, 109-115. | 0.9 | 38 |
| 1687 | Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors. Journal of Cancer Research and Clinical Oncology, 2019, 145, 3021-3036. | 1.2 | 20 |
| 1688 | Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130). Japanese Journal of Clinical Oncology, 2019, 49, 1083-1091. | 0.6 | 32 |
| 1689 | NK Cell-Fc Receptors Advance Tumor Immunotherapy. Journal of Clinical Medicine, 2019, 8, 1667. | 1.0 | 17 |
| 1690 | Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges. Cancers, 2019, 11, 1554. | 1.7 | 73 |
| 1691 | The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis. Frontiers in Oncology, 2019, 9, 897. | 1.3 | 29 |
| 1692 | Clinicopathological importance of colorectal medullary carcinoma. European Surgery - Acta Chirurgica Austriaca, 2019, 51, 308-314. | 0.3 | 1 |
| 1693 | Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials. Targeted Oncology, 2019, 14, 631-637. | 1.7 | 1 |
| 1694 | Expression of PD-1/PD-L1 in primary breast tumours and metastatic axillary lymph nodes and its correlation with clinicopathological parameters. Scientific Reports, 2019, 9, 14356. | 1.6 | 56 |
| 1695 | Monoclonal Antibodies in Dermatooncologyâ€"State of the Art and Future Perspectives. Cancers, 2019, 11, 1420. | 1.7 | 9 |
| 1696 | Immunomodulatory aspects in the progression and treatment of oral malignancy. Japanese Dental Science Review, 2019, 55, 113-120. | 2.0 | 33 |
| 1697 | The adequacy of tissue microarrays in the assessment of inter- and intra-tumoural heterogeneity of infiltrating lymphocyte burden in leiomyosarcoma. Scientific Reports, 2019, 9, 14602. | 1.6 | 22 |
| 1698 | Fucosylated Î±1-acid glycoprotein as a biomarker to predict prognosis following tumor immunotherapy of patients with lung cancer. Scientific Reports, 2019, 9, 14503. | 1.6 | 16 |
| 1699 | Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. British Journal of Cancer, 2019, 121, 809-818. | 2.9 | 232 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 1700 | Immune checkpoint inhibitors for treatment of thymic epithelial tumors: how to maximize benefit and optimize risk?. Mediastinum, 2019, 3, 35-35. | 0.6 | 38 |
| 1701 | Cervical cancer patients that respond to chemoradiation therapy display an intense tumor infiltrating immune profile before treatment. Experimental and Molecular Pathology, 2019, 111, 104314. | 0.9 | 19 |
| 1702 | Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors. Journal of Oncology, 2019, 2019, 1-11. | 0.6 | 6 |
| 1703 | The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PDâ€L1 expression and tumorâ€infiltrating lymphocytes. Cancer Medicine, 2019, 8, 7207-7218. | 1.3 | 35 |
| 1704 | Road map to best practices. , 2019, , 241-273. | | 2 |
| 1705 | Gastric Cancer in the Era of Immune Checkpoint Blockade. Journal of Oncology, 2019, 2019, 1-11. | 0.6 | 23 |
| 1706 | Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration. Cell Reports, 2019, 29, 2338-2354.e7. | 2.9 | 74 |
| 1707 | Radium-223 mechanism of action: implications for use in treatment combinations. Nature Reviews Urology, 2019, 16, 745-756. | 1.9 | 71 |
| 1708 | Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC). Artificial Cells, Nanomedicine and Biotechnology, 2019, 47, 4194-4201. | 1.9 | 6 |
| 1709 | Translational Research and Onco-Omics Applications in the Era of Cancer Personal Genomics. Advances in Experimental Medicine and Biology, 2019, , . | 0.8 | 0 |
| 1710 | Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. Cancer Cell, 2019, 36, 471-482. | 7.7 | 280 |
| 1711 | B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer. Cell, 2019, 179, 1191-1206.e21. | 13.5 | 291 |
| 1712 | Evaluation of clear cell subtypes of ovarian and uterine malignancies with anti-PD-L1 and anti-PD1 immunohistochemical expression and their association with stage and survival. Gynecologic Oncology, 2019, 155, 483-488. | 0.6 | 10 |
| 1713 | Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports. BMC Cancer, 2019, 19, 1019. | 1.1 | 48 |
| 1714 | The Role of TLRs in Anti-cancer Immunity and Tumor Rejection. Frontiers in Immunology, 2019, 10, 2388. | 2.2 | 198 |
| 1715 | Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies. Frontiers in Immunology, 2019, 10, 2664. | 2.2 | 214 |
| 1716 | Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review. Frontiers in Pharmacology, 2019, 10, 1173. | 1.6 | 35 |
| 1717 | The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort. Journal of Translational Medicine, 2019, 17, 357. | 1.8 | 88 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 1718 | Intratumoral Cytotoxic T-Lymphocyte Density and PD-L1 Expression Are Prognostic Biomarkers for Patients with Colorectal Cancer. Medicina (Lithuania), 2019, 55, 723. | 0.8 | 18 |
| 1719 | Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma. International Immunopharmacology, 2019, 77, 105999. | 1.7 | 43 |
| 1720 | Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer. , 2019, 7, 302. | | 72 |
| 1721 | Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer Cells. Cancers, 2019, 11, 1597. | 1.7 | 77 |
| 1722 | Analysis of PDâ€L1 expression and T cell infiltration in different molecular subgroups of diffuse midline gliomas. Neuropathology, 2019, 39, 413-424. | 0.7 | 14 |
| 1723 | <p>Decreased IFIT2 Expression In Human Non-Small-Cell Lung Cancer Tissues Is Associated With Cancer Progression And Poor Survival Of The Patients</p>. OncoTargets and Therapy, 2019, Volume 12, 8139-8149. | 1.0 | 12 |
| 1724 | Î±vÎ²3-integrin regulates PD-L1 expression and is involved in cancer immune evasion. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 20141-20150. | 3.3 | 57 |
| 1725 | Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling. Cancer Medicine, 2019, 8, 7322-7329. | 1.3 | 46 |
| 1726 | A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors. Clinical Cancer Research, 2019, 25, 6614-6622. | 3.2 | 106 |
| 1727 | Oncolytic adenovirus programmed by synthetic gene circuit for cancer immunotherapy. Nature Communications, 2019, 10, 4801. | 5.8 | 56 |
| 1728 | Impact of tumor microenvironment on the efficacy of epidermal growth factor receptorâ€tyrosine kinase inhibitors in patients with <i><scp>EGFR</scp></i>â€mutant nonâ€small cell lung cancer. Cancer Science, 2019, 110, 3244-3254. | 1.7 | 32 |
| 1729 | Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy. , 2019, 7, 270. | | 74 |
| 1730 | Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab. , 2019, 7, 274. | | 26 |
| 1731 | Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies. Genes and Diseases, 2019, 6, 232-246. | 1.5 | 44 |
| 1732 | Radiation as an In Situ Auto-Vaccination: Current Perspectives and Challenges. Vaccines, 2019, 7, 100. | 2.1 | 30 |
| 1733 | Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. Clinical Cancer Research, 2019, 25, 6061-6072. | 3.2 | 58 |
| 1734 | PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer. , 2019, 7, 228. | | 26 |
| 1735 | Pembrolizumab in lung cancer: current evidenceÂand future perspectives. Future Oncology, 2019, 15, 3327-3336. | 1.1 | 4 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1736 | Integrin-Mediated TGFβ Activation Modulates the Tumour Microenvironment. Cancers, 2019, 11, 1221. | 1.7 | 62 |
| 1737 | Blockade of ErbB2 and PD-L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy. OncoImmunology, 2019, 8, e1648171. | 2.1 | 31 |
| 1738 | Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. BMC Cancer, 2019, 19, 857. | 1.1 | 88 |
| 1739 | Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes. Frontiers in Oncology, 2019, 9, 883. | 1.3 | 40 |
| 1740 | Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. Journal of Hematology and Oncology, 2019, 12, 92. | 6.9 | 485 |
| 1741 | Circulating biomarkers predictive of tumor response to cancer immunotherapy. Expert Review of Molecular Diagnostics, 2019, 19, 895-904. | 1.5 | 28 |
| 1742 | Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance. Immunity, 2019, 51, 548-560.e4. | 6.6 | 88 |
| 1743 | A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer. Lung Cancer, 2019, 136, 122-128. | 0.9 | 38 |
| 1744 | Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8+ T Cells in HCC. Molecular Therapy, 2019, 27, 1906-1918. | 3.7 | 35 |
| 1745 | Shedding light on complexity of protein–protein interactions in cancer. Current Opinion in Chemical Biology, 2019, 53, 75-81. | 2.8 | 7 |
| 1746 | Next-Generation Sequencing May Discriminate Extreme Long-term versus Short-term Survival in Patients with Metastatic Small Cell Lung Cancer (SCLC). Translational Oncology, 2019, 12, 1539-1548. | 1.7 | 3 |
| 1747 | Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy. Molecules, 2019, 24, 3214. | 1.7 | 106 |
| 1748 | Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology. Frontiers in Immunology, 2019, 10, 2109. | 2.2 | 32 |
| 1749 | Autoantibody-Based Diagnostic Biomarkers: Technological Approaches to Discovery and Validation. , 0, , . | | 7 |
| 1750 | Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients. Cancer Immunology, Immunotherapy, 2019, 68, 1585-1596. | 2.0 | 37 |
| 1751 | Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment. , 2019, 7, 249. | | 61 |
| 1752 | DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. Nature Communications, 2019, 10, 4278. | 5.8 | 263 |
| 1753 | Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer. , 2019, 7, 252. | | 57 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 1754 | The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer. British Journal of Cancer, 2019, 121, 647-658. | 2.9 | 23 |
| 1755 | Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils. Journal of Experimental and Clinical Cancer Research, 2019, 38, 411. | 3.5 | 115 |
| 1756 | Analysis of Predictive Biomarkers in Patients With Lung Adenocarcinoma From Southern Brazil Reveals a Distinct Profile From Other Regions of the Country. Journal of Global Oncology, 2019, 5, 1-9. | 0.5 | 13 |
| 1757 | Integrating network pharmacology and bioinformatics analysis to explore the mechanism of Yupingfengsan in treating lung adenocarcinoma. European Journal of Integrative Medicine, 2019, 31, 100967. | 0.8 | 5 |
| 1758 | Germline genetic host factors as predictive biomarkers in immuno-oncology. Immuno-Oncology Technology, 2019, 2, 14-21. | 0.2 | 2 |
| 1759 | Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer. , 2019, 7, 245. | | 66 |
| 1760 | Immune checkpoint inhibitor therapy for pediatric cancers: A mini review of endocrine adverse events. Clinical Pediatric Endocrinology, 2019, 28, 59-68. | 0.4 | 15 |
| 1761 | Clinical and immune profiling for cancer of unknown primary site. , 2019, 7, 251. | | 26 |
| 1762 | Preoperative Radiomic Approach to Evaluate Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma Patients Using Contrast-Enhanced Computed Tomography. Annals of Surgical Oncology, 2019, 26, 4537-4547. | 0.7 | 62 |
| 1763 | PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy. Journal of Cancer Research and Clinical Oncology, 2019, 145, 3055-3065. | 1.2 | 24 |
| 1764 | VCAM-1 Density and Tumor Perfusion Predict T-cell Infiltration and Treatment Response in Preclinical Models. Neoplasia, 2019, 21, 1036-1050. | 2.3 | 17 |
| 1765 | Comparing three different anti-PD-L1 antibodies for immunohistochemical evaluation of small cell lung cancer. Lung Cancer, 2019, 137, 108-112. | 0.9 | 10 |
| 1766 | Checkpoint inhibition in advanced gastroesophageal cancer: clinical trial data, molecular subtyping, predictive biomarkers, and the potential of combination therapies. Translational Gastroenterology and Hepatology, 2019, 4, 63-63. | 1.5 | 12 |
| 1767 | IL6 Modulates the Immune Status of the Tumor Microenvironment to Facilitate Metastatic Colonization of Colorectal Cancer Cells. Cancer Immunology Research, 2019, 7, 1944-1957. | 1.6 | 61 |
| 1768 | &lt;p&gt;Positive correlation between programmed death ligand-1 and p53 in triple-negative breast cancer&lt;/p&gt;. OncoTargets and Therapy, 2019, Volume 12, 7193-7201. | 1.0 | 9 |
| 1769 | Current Perspectives in Cancer Immunotherapy. Cancers, 2019, 11, 1472. | 1.7 | 149 |
| 1770 | Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts. Journal of Thoracic Oncology, 2019, 14, 1935-1947. | 0.5 | 69 |
| 1771 | Gastrin vaccine improves response to immune checkpoint antibody in murine pancreatic cancer by altering the tumor microenvironment. Cancer Immunology, Immunotherapy, 2019, 68, 1635-1648. | 2.0 | 13 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1772 | Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 1807-1817. | 0.5 | 27 |
| 1773 | Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors. International Journal of Molecular Sciences, 2019, 20, 4654. | 1.8 | 29 |
| 1774 | Comparison of survivor scores for differentiation therapy of cancer to those for checkpoint inhibition: Half full or half empty. Tumor Biology, 2019, 41, 101042831987374. | 0.8 | 3 |
| 1775 | The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials. Translational Lung Cancer Research, 2019, 8, 413-428. | 1.3 | 95 |
| 1776 | Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. Cancer Chemotherapy and Pharmacology, 2019, 84, 1257-1267. | 1.1 | 58 |
| 1777 | OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers. Translational Lung Cancer Research, 2019, 8, 352-366. | 1.3 | 38 |
| 1778 | Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma. Medical Oncology, 2019, 36, 21. | 1.2 | 32 |
| 1779 | Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. , 2019, 7, 18. | | 72 |
| 1780 | First-line checkpoint inhibitors for wild-type advanced non-small-cell cancer: a pair-wise and network meta-analysis. Immunotherapy, 2019, 11, 311-320. | 1.0 | 8 |
| 1781 | The evolving role of immuno€oncology for the treatment of head and neck cancer. Laryngoscope Investigative Otolaryngology, 2019, 4, 62-69. | 0.6 | 3 |
| 1782 | Immune control by amino acid catabolism during tumorigenesis andÂtherapy. Nature Reviews Cancer, 2019, 19, 162-175. | 12.8 | 170 |
| 1783 | Prognostic Values of CD38+CD101+PD1+CD8+ T Cells in Pancreatic Cancer. Immunological Investigations, 2019, 48, 466-479. | 1.0 | 24 |
| 1784 | Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action. Immunotherapy, 2019, 11, 429-441. | 1.0 | 44 |
| 1785 | Immunotherapy Toxicity. Hematology/Oncology Clinics of North America, 2019, 33, 275-290. | 0.9 | 23 |
| 1786 | Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression. Journal of Cancer, 2019, 10, 211-222. | 1.2 | 29 |
| 1787 | Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. Cancer Immunology, Immunotherapy, 2019, 68, 553-561. | 2.0 | 57 |
| 1788 | Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition. Neuro-Oncology, 2019, 21, 730-741. | 0.6 | 63 |
| 1789 | Anti€PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment. Cancer Research, 2019, 79, 1493-1506. | 0.4 | 118 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 1790 | A Positive Correlation Between the EZH2 and PD-L1 Expression in Resected Lung Adenocarcinomas. Annals of Thoracic Surgery, 2019, 107, 393-400. | 0.7 | 33 |
| 1791 | Fragment-based screening of programmed death ligand 1 (PD-L1). Bioorganic and Medicinal Chemistry Letters, 2019, 29, 786-790. | 1.0 | 48 |
| 1792 | Metastatic immune infiltrates correlate with those of the primary tumour in canine osteosarcoma. Veterinary and Comparative Oncology, 2019, 17, 242-252. | 0.8 | 15 |
| 1793 | Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy. Frontiers of Medicine, 2019, 13, 32-44. | 1.5 | 25 |
| 1794 | Immunotherapy for genitourinary tumors. International Journal of Urology, 2019, 26, 326-333. | 0.5 | 8 |
| 1795 | PDâ€1/PDâ€L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway. Cell Proliferation, 2019, 52, e12571. | 2.4 | 94 |
| 1796 | Success of immune checkpoint blockade therapies â€" mechanisms and implications for hepatology. Zeitschrift Fur Gastroenterologie, 2019, 57, 74-86. | 0.2 | 2 |
| 1797 | &lt;p&gt;Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data&lt;/p&gt;. Cancer Management and Research, 2019, Volume 11, 4297-4312. | 0.9 | 47 |
| 1798 | &lt;p&gt;Relationship between Helicobacter pylori and expression of programmed death-1 and its ligand in gastric intraepithelial neoplasia and early-stage gastric cancer&lt;/p&gt;. Cancer Management and Research, 2019, Volume 11, 3909-3919. | 0.9 | 20 |
| 1799 | Liquid biopsy for lung cancer immunotherapy (Review). Oncology Letters, 2019, 17, 4751-4760. | 0.8 | 14 |
| 1800 | Recent advances in the clinical development of immune checkpoint blockade therapy. Cellular Oncology (Dordrecht), 2019, 42, 609-626. | 2.1 | 76 |
| 1801 | Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?. Frontiers in Immunology, 2019, 10, 1181. | 2.2 | 20 |
| 1802 | Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. Gynecologic Oncology, 2019, 154, 314-322. | 0.6 | 101 |
| 1803 | Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy. International Journal of Pharmaceutics, 2019, 566, 731-744. | 2.6 | 41 |
| 1804 | Cellâ€blocks are suitable material for programmed cell death ligandâ€1 immunohistochemistry: Comparison of cellâ€blocks and matched surgical resection specimens in lung cancer. Cytopathology, 2019, 30, 578-585. | 0.4 | 15 |
| 1805 | Circulating Lymphocytes, PD-L1 Expression on Tumor-infiltrating Lymphocytes, and Survival of Colorectal Cancer Patients with Different Mismatch Repair Gene Status. Journal of Cancer, 2019, 10, 1745-1754. | 1.2 | 19 |
| 1806 | PDâ€L1 detection in histology specimens and matched pleural fluid cell blocks of patients with NSCLC. Respirology, 2019, 24, 1198-1203. | 1.3 | 24 |
| 1807 | CD8[+] PD-1[+] T-cells and PD-L1[+] circulating tumor cells in chemotherapy-naÃ¯ve non-small cell lung cancer: towards their clinical relevance?. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591985319. | 1.4 | 13 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 1808 | PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma. Journal of Ovarian Research, 2019, 12, 56. | 1.3 | 30 |
| 1809 | New designs in early clinical drug development. Annals of Oncology, 2019, 30, 1460-1465. | 0.6 | 14 |
| 1810 | Lung adenocarcinoma-intrinsic GBE1 signaling inhibits anti-tumor immunity. Molecular Cancer, 2019, 18, 108. | 7.9 | 54 |
| 1811 | Analysis of the transcriptomic features of microsatellite instability subtype colon cancer. BMC Cancer, 2019, 19, 605. | 1.1 | 10 |
| 1812 | Off-label use of common predictive biomarkers in gastrointestinal malignancies: a critical appraisal. Diagnostic Pathology, 2019, 14, 62. | 0.9 | 4 |
| 1813 | A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors. Oncology, 2019, 97, 102-111. | 0.9 | 67 |
| 1814 | A carrier-free multiplexed gene editing system applicable for suspension cells. Biomaterials, 2019, 217, 119298. | 5.7 | 26 |
| 1815 | Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nature Medicine, 2019, 25, 929-935. | 15.2 | 188 |
| 1816 | The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 1046-1060. | 0.5 | 52 |
| 1817 | *In Situ* Nanoadjuvant-Assembled Tumor Vaccine for Preventing Long-Term Recurrence. ACS Nano, 2019, 13, 7442-7462. | 7.3 | 104 |
| 1818 | Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1[+]triple negative breast cancer cells. OncoImmunology, 2019, 8, e1624128. | 2.1 | 37 |
| 1819 | Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Head and Neck Cancer. Clinical Cancer Research, 2019, 25, 5315-5328. | 3.2 | 81 |
| 1820 | A novel model of controlling PD-L1 expression in ALK+ anaplastic large cell lymphoma revealed by CRISPR screening. Blood, 2019, 134, 171-185. | 0.6 | 47 |
| 1821 | Microenvironment and tumor inflammatory features improve prognostic prediction in gastroâ€enteroâ€pancreatic neuroendocrine neoplasms. Journal of Pathology: Clinical Research, 2019, 5, 217-226. | 1.3 | 29 |
| 1822 | Patterns of immune-cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors. Cancer Immunology, Immunotherapy, 2019, 68, 1121-1132. | 2.0 | 13 |
| 1823 | Application of PD-1 Blockade in Cancer Immunotherapy. Computational and Structural Biotechnology Journal, 2019, 17, 661-674. | 1.9 | 333 |
| 1824 | Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma. Frontiers in Immunology, 2019, 10, 990. | 2.2 | 86 |
| 1825 | MicroRNAs aid the assessment of programmed death ligandï¿½1 expression in patients with nonâ€small cell lung cancer. Oncology Letters, 2019, 17, 5193-5200. | 0.8 | 14 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 1826 | Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNÎ³ signaling in non-small cell lung cancer. PLoS ONE, 2019, 14, e0216864. | 1.1 | 11 |
| 1827 | PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma. , 2019, 60, 2388. | | 30 |
| 1828 | Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. Journal of Hematology and Oncology, 2019, 12, 54. | 6.9 | 416 |
| 1829 | Plaque Psoriasis Flare and Peripheral Edema in a Patient Treated With Atezolizumab. Actas Dermo-sifiliogrÃ¡ficas, 2019, 110, 410-411. | 0.2 | 0 |
| 1830 | High-Plex Predictive Marker Discovery for Melanoma Immunotherapyâ€"Treated Patients Using Digital Spatial Profiling. Clinical Cancer Research, 2019, 25, 5503-5512. | 3.2 | 117 |
| 1831 | Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod. Scientific Reports, 2019, 9, 8572. | 1.6 | 36 |
| 1832 | Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events. Frontiers in Medicine, 2019, 6, 119. | 1.2 | 145 |
| 1833 | Immunotherapy in Gynecologic Cancers: What We Know Now and Where We Are Headed. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, e126-e140. | 1.8 | 28 |
| 1834 | Individualized precision treatment: Targeting TAM in HCC. Cancer Letters, 2019, 458, 86-91. | 3.2 | 53 |
| 1835 | Prognostic impact of p16 and PD-L1 expression in patients with oropharyngeal squamous cell carcinoma receiving a definitive treatment. Journal of Clinical Pathology, 2019, 72, 542-549. | 1.0 | 26 |
| 1836 | Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade. Pharmacological Research, 2019, 145, 104258. | 3.1 | 115 |
| 1837 | Development of immune checkpoint therapy for cancer. Journal of Experimental Medicine, 2019, 216, 1244-1254. | 4.2 | 125 |
| 1838 | Imaging of Activated T Cells as an Early Predictor of Immune Response to Anti-PD-1 Therapy. Cancer Research, 2019, 79, 3455-3465. | 0.4 | 60 |
| 1839 | Biomarker Testing for Patients With Advanced Nonâ€"Small Cell Lung Cancer: Real-World Issues and Tough Choices. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 531-542. | 1.8 | 210 |
| 1840 | Frontline Therapy for <i>BRAF</i>-Mutated Metastatic Melanoma: How Do You Choose, and Is There One Correct Answer?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 564-571. | 1.8 | 42 |
| 1841 | Prognosis of Early-stage Part-solid and Pure-solid Lung Adenocarcinomas. Anticancer Research, 2019, 39, 2665-2670. | 0.5 | 9 |
| 1842 | Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 924-937. | 5.1 | 1,133 |
| 1843 | Clinical significance of programmed deathâ€1 and programmed deathâ€ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma. Cancer Science, 2019, 110, 1820-1828. | 1.7 | 45 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 1844 | Pembrolizumab for the Treatment of Hepatocellular Carcinoma. Liver Cancer, 2019, 8, 143-154. | 4.2 | 25 |
| 1845 | Coexpression of Inhibitory Receptors Enriches for Activated and Functional CD8+ T Cells in Murine Syngeneic Tumor Models. Cancer Immunology Research, 2019, 7, 963-976. | 1.6 | 36 |
| 1846 | Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors. Expert Review of Molecular Diagnostics, 2019, 19, 517-529. | 1.5 | 15 |
| 1847 | Programmed cell death ligandâ€1 (PDâ€L1) expression in extrahepatic biliary tract cancers: a comparative study using 22C3, SP263 and E1L3N antiâ€PDâ€L1 antibodies. Histopathology, 2019, 75, 526-536. | 1.6 | 17 |
| 1848 | Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negativeÂoperated breast cancers. Breast Cancer, 2019, 26, 738-747. | 1.3 | 21 |
| 1849 | Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity. Clinical Cancer Research, 2019, 25, 4808-4819. | 3.2 | 66 |
| 1850 | IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. Future Oncology, 2019, 15, 1951-1961. | 1.1 | 58 |
| 1851 | Light-sheet microscopy in the near-infrared II window. Nature Methods, 2019, 16, 545-552. | 9.0 | 151 |
| 1852 | PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 193. | 3.5 | 61 |
| 1853 | Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches. Journal of Pathology, 2019, 249, 151-165. | 2.1 | 80 |
| 1854 | Efficient development and expression of scFv recombinant proteins against PD-L1 surface domain and potency in cancer therapy. Cytotechnology, 2019, 71, 705-722. | 0.7 | 7 |
| 1855 | Computational analysis of hot spots and binding mechanism in the PD-1/PD-L1 interaction. RSC Advances, 2019, 9, 14944-14956. | 1.7 | 23 |
| 1856 | The Discovery of Biomarkers in Cancer Immunotherapy. Computational and Structural Biotechnology Journal, 2019, 17, 484-497. | 1.9 | 31 |
| 1857 | PDâ€L1, B7â€H3 and VISTA are highly expressed in gestational trophoblastic neoplasia. Histopathology, 2019, 75, 421-430. | 1.6 | 43 |
| 1858 | Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience. Therapeutic Advances in Urology, 2019, 11, 175628721983928. | 0.9 | 13 |
| 1859 | The Interplay of Autophagy and Tumor Microenvironment in Colorectal Cancerâ€"Ways of Enhancing Immunotherapy Action. Cancers, 2019, 11, 533. | 1.7 | 37 |
| 1861 | Managing cardiotoxicity associated with immune checkpoint inhibitors. Chronic Diseases and Translational Medicine, 2019, 5, 6-14. | 0.9 | 52 |
| 1862 | Restriction of PD-1 function by *cis* -PD-L1/CD80 interactions is required for optimal T cell responses. Science, 2019, 364, 558-566. | 6.0 | 262 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1863 | Recent Advances on Electrochemical Biosensing Strategies toward Universal Point‑of‑Care Systems. Angewandte Chemie, 2019, 131, 12483-12496. | 1.6 | 57 |
| 1864 | Can CpG methylation serve as surrogate markers for immune infiltration in cancer?. Advances in Cancer Research, 2019, 143, 351-384. | 1.9 | 19 |
| 1865 | Beyond PD-L1 Markers for Lung Cancer Immunotherapy. International Journal of Molecular Sciences, 2019, 20, 1915. | 1.8 | 61 |
| 1866 | Efficient evolved antibody mimetic designed ankyrin repeat proteins against programmed death-ligand 1 on E. coli surface display. Biochemical Engineering Journal, 2019, 148, 1-8. | 1.8 | 1 |
| 1867 | Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice. Nature Communications, 2019, 10, 2025. | 5.8 | 404 |
| 1868 | Emerging therapies for small cell lung cancer. Journal of Hematology and Oncology, 2019, 12, 47. | 6.9 | 273 |
| 1869 | Antigen Priming with Enantiospecific Cationic Lipid Nanoparticles Induces Potent Antitumor CTL Responses through Novel Induction of a Type I IFN Response. Journal of Immunology, 2019, 202, 3524-3536. | 0.4 | 34 |
| 1870 | Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials. JAMA Oncology, 2019, 5, 1008. | 3.4 | 526 |
| 1871 | Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. Trends in Immunology, 2019, 40, 511-523. | 2.9 | 180 |
| 1872 | The relationship between the PD-L1 expression of surgically resected and fine-needle aspiration specimens for patients with pancreatic cancer. Journal of Gastroenterology, 2019, 54, 1019-1028. | 2.3 | 6 |
| 1873 | Management of immune related adverse events induced by immune checkpoint inhibition. Cancer Letters, 2019, 456, 80-87. | 3.2 | 36 |
| 1874 | Neddylation inhibition upregulates PD‑L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma. International Journal of Cancer, 2019, 145, 763-774. | 2.3 | 33 |
| 1875 | Recent Advances on Electrochemical Biosensing Strategies toward Universal Point‑of‑Care Systems. Angewandte Chemie - International Edition, 2019, 58, 12355-12368. | 7.2 | 155 |
| 1876 | Immune-phenotyping of pleomorphic dermal sarcomas suggests this entity as a potential candidate for immunotherapy. Cancer Immunology, Immunotherapy, 2019, 68, 973-982. | 2.0 | 21 |
| 1877 | Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncology, The, 2019, 20, 849-861. | 5.1 | 368 |
| 1878 | Relationship between the expressions of PD-L1 and tumour-associated fibroblasts in gastric cancer. Artificial Cells, Nanomedicine and Biotechnology, 2019, 47, 1036-1042. | 1.9 | 14 |
| 1879 | Complementing the Cancer-Immunity Cycle. Frontiers in Immunology, 2019, 10, 774. | 2.2 | 136 |
| 1880 | Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma. , 2019, 7, 113. | | 31 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 1881 | Bibliometric analysis of global research on PD-1 and PD-L1 in the field of cancer. International Immunopharmacology, 2019, 72, 374-384. | 1.7 | 109 |
| 1882 | Cancer nanomedicine for combination cancer immunotherapy. Nature Reviews Materials, 2019, 4, 398-414. | 23.3 | 658 |
| 1883 | Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. Journal of Hematology and Oncology, 2019, 12, 42. | 6.9 | 58 |
| 1884 | Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer. PLoS ONE, 2019, 14, e0215381. | 1.1 | 73 |
| 1885 | Dynamic host immune response in virus-associated cancers. Communications Biology, 2019, 2, 109. | 2.0 | 34 |
| 1886 | The density of Tbet+ tumor-infiltrating T lymphocytes reflects an effective and druggable preexisting adaptive antitumor immune response in colorectal cancer, irrespective of the microsatellite status. OncoImmunology, 2019, 8, e1562834. | 2.1 | 7 |
| 1887 | PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications. International Journal of Molecular Sciences, 2019, 20, 1405. | 1.8 | 36 |
| 1888 | Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. Expert Review of Clinical Pharmacology, 2019, 12, 453-470. | 1.3 | 28 |
| 1889 | Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma. Cancer Immunology Research, 2019, 7, 805-812. | 1.6 | 22 |
| 1890 | Management of Locally Advanced Lung Cancer. , 2019, , 57-86. | | 1 |
| 1891 | Lung Adenocarcinoma. , 2019, , 103-114. | | 2 |
| 1892 | The neoepitope landscape of breast cancer: implications for immunotherapy. BMC Cancer, 2019, 19, 200. | 1.1 | 68 |
| 1893 | Macrophage Origin, Metabolic Reprogramming and IL-1 Signaling: Promises and Pitfalls in Lung Cancer. Cancers, 2019, 11, 298. | 1.7 | 10 |
| 1894 | Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes. Clinical Cancer Research, 2019, 25, 4592-4602. | 3.2 | 447 |
| 1895 | Clinicopathological, immune and molecular correlates of <i>PD-L2</i> methylation in gastric adenocarcinomas. Epigenomics, 2019, 11, 639-653. | 1.0 | 17 |
| 1896 | HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti–PD-L1 Therapy. Molecular Cancer Therapeutics, 2019, 18, 900-908. | 1.9 | 72 |
| 1897 | PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives. Frontiers of Medicine, 2019, 13, 438-450. | 1.5 | 32 |
| 1898 | Interferon-Î³ upregulates Î"42PD1 expression on human monocytes via the PI3K/AKT pathway. Immunobiology, 2019, 224, 388-396. | 0.8 | 4 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 1899 | Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.. Expert Opinion on Biological Therapy, 2019, 19, 443-455. | 1.4 | 26 |
| 1900 | Size Matters: The Functional Role of the CEACAM1 Isoform Signature and Its Impact for NK Cell-Mediated Killing in Melanoma. Cancers, 2019, 11, 356. | 1.7 | 37 |
| 1901 | Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1613-1623. | 1.2 | 66 |
| 1902 | Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration. European Urology Oncology, 2019, 2, 12-20. | 2.6 | 17 |
| 1903 | Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer. Molecular Therapy - Oncolytics, 2019, 13, 1-6. | 2.0 | 26 |
| 1904 | Targeting immune cells for cancer therapy. Redox Biology, 2019, 25, 101174. | 3.9 | 151 |
| 1905 | Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. Annals of Oncology, 2019, 30, 1134-1142. | 0.6 | 113 |
| 1906 | Biomarkers in immune checkpoint inhibition therapy for cancer patients: what is the role of lymphocyte subsets and PD1/PD-L1?. Translational Medicine Communications, 2019, 4, . | 0.5 | 3 |
| 1907 | Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC). , 2019, 7, 65. | | 108 |
| 1908 | Endoplasmic Reticulum Stress Causes Liver Cancer Cells to Release Exosomal miRâ€23aâ€3p and Upâ€regulate Programmed Death Ligand 1 Expression in Macrophages. Hepatology, 2019, 70, 241-258. | 3.6 | 304 |
| 1909 | RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade. EBioMedicine, 2019, 41, 146-155. | 2.7 | 31 |
| 1910 | Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma. Frontiers in Oncology, 2019, 8, 656. | 1.3 | 32 |
| 1911 | Host tissue determinants of tumour immunity. Nature Reviews Cancer, 2019, 19, 215-227. | 12.8 | 150 |
| 1912 | Comparison of 22C3 PharmDx and SP263 Assays to Test PD-L1 Expression in NSCLC. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 663-666. | 0.6 | 8 |
| 1913 | The role of immune checkpoint inhibitors in advanced non-small cell lung cancer. Expert Review of Respiratory Medicine, 2019, 13, 435-447. | 1.0 | 7 |
| 1914 | Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy. Immunotherapy, 2019, 11, 515-529. | 1.0 | 17 |
| 1915 | The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 2019, 10, 139. | 1.6 | 76 |
| 1916 | Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. Journal of Clinical Oncology, 2019, 37, 2162-2170. | 0.8 | 202 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 1917 | Extracellular Vesicle–Based Therapeutic Targeting of Î²â€‘Catenin to Modulate Anticancer Immune Responses in Hepatocellular Cancer. Hepatology Communications, 2019, 3, 525-541. | 2.0 | 38 |
| 1918 | FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway. Journal of Immunology, 2019, 202, 3065-3075. | 0.4 | 111 |
| 1920 | PD-L1 Expression Is Associated With VEGFA and LADC Patients' Survival. Frontiers in Oncology, 2019, 9, 189. | 1.3 | 21 |
| 1921 | The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patientsâ€™ sex. International Journal of Cancer, 2019, 145, 2840-2849. | 2.3 | 60 |
| 1922 | Immune-enrichment of non-small cell lung cancer baseline biopsies for multiplex profiling define prognostic immune checkpoint combinations for patient stratification. , 2019, 7, 86. |  | 11 |
| 1923 | MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1. Gastroenterology, 2019, 156, 1849-1861.e13. | 0.6 | 131 |
| 1924 | PDâ€‘L1 promotes head and neck squamous cell carcinoma cell growth through mTOR signaling. Oncology Reports, 2019, 41, 2833-2843. | 1.2 | 15 |
| 1925 | Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer. Cancer Biology and Therapy, 2019, 20, 1105-1112. | 1.5 | 22 |
| 1926 | A study of PDâ€‘L1 expression in intravascular large B cell lymphoma: correlation with clinical and pathological features. Histopathology, 2019, 75, 282-286. | 1.6 | 17 |
| 1927 | Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells. Cancer Cell International, 2019, 19, 68. | 1.8 | 22 |
| 1928 | Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy. Immunotherapy, 2019, 11, 577-584. | 1.0 | 18 |
| 1929 | Heterogeneity of PD-L1 expression and CD8 tumor-infiltrating lymphocytes among subtypes of cutaneous adnexal carcinomas. Cancer Immunology, Immunotherapy, 2019, 68, 951-960. | 2.0 | 17 |
| 1930 | Immunotherapy for High-Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons. World Neurosurgery, 2019, 124, 397-409. | 0.7 | 19 |
| 1931 | Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy. Frontiers in Immunology, 2019, 10, 333. | 2.2 | 234 |
| 1932 | &lt;p&gt;Safety and efficacy of atezolizumab in the treatment of cancers: a systematic review and pooled-analysis&lt;/p&gt;. Drug Design, Development and Therapy, 2019, Volume 13, 523-538. | 2.0 | 23 |
| 1933 | Met inhibition revokes IFNÎ³-induction of PD-1 ligands in MET-amplified tumours. British Journal of Cancer, 2019, 120, 527-536. | 2.9 | 34 |
| 1934 | Multi-omics Perspective on the Tumor Microenvironment based on PD-L1 and CD8 T-Cell Infiltration in Urothelial Cancer. Journal of Cancer, 2019, 10, 697-707. | 1.2 | 16 |
| 1935 | Choline acetyltransferaseâ€"expressing T cells are required to control chronic viral infection. Science, 2019, 363, 639-644. | 6.0 | 90 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 1936 | Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort. European Journal of Cancer, 2019, 109, 154-161. | 1.3 | 64 |
| 1937 | CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy. Human Vaccines and Immunotherapeutics, 2019, 15, 1126-1132. | 1.4 | 42 |
| 1938 | Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status. PLoS ONE, 2019, 14, e0211866. | 1.1 | 16 |
| 1939 | Efficacy of PD-1 blockade in cervical cancer is related to a CD8+FoxP3+CD25+ T-cell subset with operational effector functions despite high immune checkpoint levels. , 2019, 7, 43. | | 42 |
| 1940 | Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. Clinical Cancer Research, 2019, 25, 3220-3228. | 3.2 | 179 |
| 1941 | Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. , 2019, 7, 37. | | 123 |
| 1942 | Accumulation of exhausted CD8+ T cells in extramammary Paget's disease. PLoS ONE, 2019, 14, e0211135. | 1.1 | 12 |
| 1943 | The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nature Reviews Cancer, 2019, 19, 133-150. | 12.8 | 1,657 |
| 1944 | Therapeutic Cancer Vaccines—T Cell Responses and Epigenetic Modulation. Frontiers in Immunology, 2018, 9, 3109. | 2.2 | 26 |
| 1945 | A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nature Medicine, 2019, 25, 454-461. | 15.2 | 466 |
| 1946 | Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma. Current Oncology Reports, 2019, 21, 24. | 1.8 | 16 |
| 1947 | Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review. Current Problems in Cancer, 2019, 43, 487-494. | 1.0 | 9 |
| 1948 | PD-L1 expression patterns in tumour cells and their association with CD8$^+$ tumour infiltrating lymphocytes in clear cell renal cell carcinoma. Journal of Cancer, 2019, 10, 1154-1161. | 1.2 | 18 |
| 1949 | Treatment of Pulmonary Adenocarcinoma With Immune Checkpoint Inhibitors. , 2019, , 151-171. | | 0 |
| 1950 | PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy. Journal of Cellular Physiology, 2019, 234, 16824-16837. | 2.0 | 279 |
| 1951 | Radiotherapy and Cisplatin Increase Immunotherapy Efficacy by Enabling Local and Systemic Intratumoral T-cell Activity. Cancer Immunology Research, 2019, 7, 670-682. | 1.6 | 53 |
| 1952 | Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression. Breast Cancer Research, 2019, 21, 28. | 2.2 | 59 |
| 1953 | Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis. Cancer Reports, 2019, 2, e1160. | 0.6 | 26 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 1954 | EGFR‑targeted therapy alters the tumor microenvironment in EGFR‑driven lung tumors: Implications for combination therapies. International Journal of Cancer, 2019, 145, 1432-1444. | 2.3 | 112 |
| 1955 | Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma. Clinical Genitourinary Cancer, 2019, 17, e513-e521. | 0.9 | 31 |
| 1956 | Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer. Science Translational Medicine, 2019, 11, . | 5.8 | 169 |
| 1957 | The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy. Journal of Clinical Investigation, 2019, 129, 3347-3360. | 3.9 | 82 |
| 1958 | CTHRC1 and PD‑1/PD‑L1 expression predicts tumor recurrence in prostate cancer. Molecular Medicine Reports, 2019, 20, 4244-4252. | 1.1 | 11 |
| 1960 | Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers. Journal of Gastrointestinal Oncology, 2019, 10, 1099-1109. | 0.6 | 44 |
| 1961 | PD-L1 and tumor-associated macrophages in de novo DLBCL. Blood Advances, 2019, 3, 531-540. | 2.5 | 57 |
| 1962 | PD-L1 regulation by SDH5 via β-catenin/ZEB1 signaling. OncoImmunology, 2019, 8, 1655361. | 2.1 | 14 |
| 1963 | EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma. , 2019, 7, 300. | | 114 |
| 1964 | Melanoma and Vitiligo: In Good Company. International Journal of Molecular Sciences, 2019, 20, 5731. | 1.8 | 40 |
| 1965 | Interleukin-18 Is a Prognostic Biomarker Correlated with CD8+ T Cell and Natural Killer Cell Infiltration in Skin Cutaneous Melanoma. Journal of Clinical Medicine, 2019, 8, 1993. | 1.0 | 31 |
| 1966 | Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC. Targeted Oncology, 2019, 14, 759-768. | 1.7 | 21 |
| 1967 | PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways. Immunity, 2019, 51, 1059-1073.e9. | 6.6 | 229 |
| 1968 | Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2019, 629, xxi-xl. | 0.4 | 1 |
| 1969 | Computational STAT3 activity inference reveals its roles in the pancreatic tumor microenvironment. Scientific Reports, 2019, 9, 18257. | 1.6 | 7 |
| 1970 | Reliability of PD-L1 assays using small tissue samples compared with surgical specimens. Medicine (United States), 2019, 98, e14972. | 0.4 | 15 |
| 1971 | An Exceptional Responder to Nivolumab in Metastatic Non-Small-Cell Lung Cancer: A Case Report and Literature Review of Long-Term Survivors. Case Reports in Oncological Medicine, 2019, 2019, 1-7. | 0.2 | 3 |
| 1972 | Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy. Nature Communications, 2019, 10, 5421. | 5.8 | 151 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 1973 | Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response. Radiology Imaging Cancer, 2019, 1, e190031. | 0.7 | 22 |
| 1974 | Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Nonâ€"Small Cell Lung Cancer. Clinical Cancer Research, 2019, 25, 6623-6632. | 3.2 | 96 |
| 1975 | MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment. , 2019, 7, 327. | | 88 |
| 1976 | &lt;p&gt;Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy&lt;/p&gt;. OncoTargets and Therapy, 2019, Volume 12, 10263-10273. | 1.0 | 25 |
| 1977 | Phosphorylation of PD-1-Y248 is a marker of PD-1-mediated inhibitory function in human T cells. Scientific Reports, 2019, 9, 17252. | 1.6 | 20 |
| 1978 | BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma. Journal of Translational Medicine, 2019, 17, 386. | 1.8 | 32 |
| 1979 | Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer. , 2019, 7, 314. | | 30 |
| 1980 | PD-L1 Detectionâ€"Pearls and Pitfalls Associated With Current Methodologies Focusing on Entities Relevant to Dermatopathology. American Journal of Dermatopathology, 2019, 41, 539-565. | 0.3 | 8 |
| 1981 | Melanoma. Anti-Cancer Drugs, 2019, 30, 543-553. | 0.7 | 1 |
| 1982 | Deep and Durable Response With Combination CTLA-4 and PD-1 Blockade in Mismatch Repair (MMR)-proficient Endometrial Cancer. Journal of Immunotherapy, 2019, 42, 51-54. | 1.2 | 16 |
| 1983 | Checkpoint Inhibitorâ€"Associated Autoimmunity. Journal of Clinical Rheumatology, 2019, Publish Ahead of Print, . | 0.5 | 0 |
| 1984 | Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies. Liver Cancer, 2019, 8, 413-426. | 4.2 | 40 |
| 1985 | A Tumor-Specific Super-Enhancer Drives Immune Evasion by Guiding Synchronous Expression of PD-L1 and PD-L2. Cell Reports, 2019, 29, 3435-3447.e4. | 2.9 | 33 |
| 1986 | Identification of responders to immune checkpoint therapy: which biomarkers have the highest value?. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 52-56. | 1.3 | 23 |
| 1987 | In vivo molecular imaging for immunotherapy using ultra-bright near-infrared-IIb rare-earth nanoparticles. Nature Biotechnology, 2019, 37, 1322-1331. | 9.4 | 398 |
| 1988 | &lt;p&gt;Primary Pulmonary Lymphoepithelioma-Like Carcinoma Response Favorably To Nivolumab: A Case Report&lt;/p&gt;. OncoTargets and Therapy, 2019, Volume 12, 8595-8600. | 1.0 | 23 |
| 1989 | Association of increased B7 protein expression by infiltrating immune cells with progression of gastric carcinogenesis. Medicine (United States), 2019, 98, e14663. | 0.4 | 21 |
| 1990 | Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP). Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 699-714. | 0.6 | 36 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 1991 | Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. Cancers, 2019, 11, 1926. | 1.7 | 27 |
| 1992 | Immunotherapy â€" Strategies for Expanding Its Role in the Treatment of All Major Tumor Sites. Cureus, 2019, 11, e5938. | 0.2 | 9 |
| 1993 | An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature, 2019, 576, 465-470. | 13.7 | 510 |
| 1994 | The Prognostic Value of Programmed Death-Ligand 1 in a Chinese Cohort With Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2019, 9, 879. | 1.3 | 6 |
| 1995 | High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation. , 2019, 7, 357. | | 52 |
| 1996 | Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma. Veterinary and Comparative Oncology, 2019, 17, 49-60. | 0.8 | 33 |
| 1997 | Immunomodulators targeting the PDâ€1/PDâ€L1 proteinâ€protein interaction: From antibodies to small molecules. Medicinal Research Reviews, 2019, 39, 265-301. | 5.0 | 128 |
| 1998 | Improving efficacy of cancer immunotherapy through targeting of macrophages. Human Vaccines and Immunotherapeutics, 2019, 15, 189-192. | 1.4 | 10 |
| 1999 | Toxicities in Immune Checkpoint Inhibitors. , 2019, , 205-226. | | 2 |
| 2000 | Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer. JAMA Oncology, 2019, 5, 74. | 3.4 | 557 |
| 2001 | Urologic Malignancies. , 2019, , 115-133. | | 0 |
| 2002 | Gynecologic Malignancies. , 2019, , 135-155. | | 0 |
| 2003 | Immune Checkpoint Inhibitors. , 2019, , 1-17. | | 2 |
| 2004 | MicroRNA-497-5p down-regulation increases PD-L1 expression in clear cell renal cell carcinoma. Journal of Drug Targeting, 2019, 27, 67-74. | 2.1 | 49 |
| 2005 | The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer. Lung Cancer, 2019, 128, 113-119. | 0.9 | 11 |
| 2006 | Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy. British Journal of Cancer, 2019, 120, 346-355. | 2.9 | 16 |
| 2007 | Long-term survival in patients with advanced nonâ€"small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study. European Journal of Cancer, 2019, 107, 124-132. | 1.3 | 85 |
| 2008 | Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. Drugs, 2019, 79, 21-42. | 4.9 | 54 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 2009 | Microphthalmia-Associated Transcription Factor (MITF) Regulates Immune Cell Migration into Melanoma. Translational Oncology, 2019, 12, 350-360. | 1.7 | 27 |
| 2010 | Programmed death ligandâ€‘1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder. Cancer Science, 2019, 110, 489-498. | 1.7 | 66 |
| 2011 | Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. Journal of the National Cancer Institute, 2019, 111, 118-128. | 3.0 | 49 |
| 2012 | Molecular profiling in muscleâ€‘invasive bladder cancer: more than the sum of its parts. Journal of Pathology, 2019, 247, 563-573. | 2.1 | 63 |
| 2013 | Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer. Cancer Immunology, Immunotherapy, 2019, 68, 517-527. | 2.0 | 39 |
| 2014 | Immune Checkpoint Inhibitors in the Treatment of Gastroesophageal Cancer. Drugs, 2019, 79, 1-10. | 4.9 | 18 |
| 2015 | Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 199-224. | 3.3 | 53 |
| 2016 | Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. Lung Cancer, 2019, 128, 105-112. | 0.9 | 126 |
| 2017 | Immunotherapy strategies for mesothelioma â€" the role of tumor specific neoantigens in a new era of precision medicine. Expert Review of Respiratory Medicine, 2019, 13, 181-192. | 1.0 | 13 |
| 2018 | Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma. Immunotherapy, 2019, 11, 21-35. | 1.0 | 16 |
| 2019 | Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nature Reviews Drug Discovery, 2019, 18, 197-218. | 21.5 | 2,005 |
| 2020 | <scp>PD</scp>â€‘1 and <scp>IDO</scp> expression in cervical and vulvar invasive and intraepithelial squamous neoplasias: implications for combination immunotherapy. Histopathology, 2019, 74, 256-268. | 1.6 | 42 |
| 2021 | T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers. Modern Pathology, 2019, 32, 576-584. | 2.9 | 29 |
| 2022 | Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features. Modern Pathology, 2019, 32, 524-531. | 2.9 | 13 |
| 2023 | Functional Nanomaterials Optimized to Circumvent Tumor Immunological Tolerance. Advanced Functional Materials, 2019, 29, 1806087. | 7.8 | 21 |
| 2024 | The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC. Lung Cancer, 2019, 127, 153-163. | 0.9 | 77 |
| 2025 | The Reciprocity between Radiotherapy and Cancer Immunotherapy. Clinical Cancer Research, 2019, 25, 1709-1717. | 3.2 | 95 |
| 2026 | The clinical role of the TME in solid cancer. British Journal of Cancer, 2019, 120, 45-53. | 2.9 | 380 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 2027 | The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 543-555. | 0.8 | 21 |
| 2028 | Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma. Journal of Thoracic Oncology, 2019, 14, 25-36. | 0.5 | 68 |
| 2029 | Autophagy inhibitor enhance ZnPc/BSA nanoparticle induced photodynamic therapy by suppressing PD-L1 expression in osteosarcoma immunotherapy. Biomaterials, 2019, 192, 128-139. | 5.7 | 96 |
| 2030 | Current status of immunotherapy in metastatic colorectal cancer. International Journal of Colorectal Disease, 2019, 34, 13-25. | 1.0 | 106 |
| 2031 | Expression and significance of CD47, PD1 and PDL1 in T-cell acute lymphoblastic lymphoma/leukemia. Pathology Research and Practice, 2019, 215, 265-271. | 1.0 | 33 |
| 2032 | The prognostic role of tumor associated glycoprotein 72 (TAG-72) in stage II and III colorectal adenocarcinoma. Pathology Research and Practice, 2019, 215, 171-176. | 1.0 | 17 |
| 2033 | Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma. Cancer Immunology Research, 2019, 7, 458-465. | 1.6 | 43 |
| 2034 | Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Annals of Oncology, 2019, 30, 219-235. | 0.6 | 340 |
| 2035 | Near‑infrared fluorescence‑labeled anti‑PD‑L1‑mAb for tumor imaging in human colorectal cancer xenografted mice. Journal of Cellular Biochemistry, 2019, 120, 10239-10247. | 1.2 | 14 |
| 2036 | Clinicopathologic Features of Thymoma With the Expression of Programmed Death‑Ligand 1. Annals of Thoracic Surgery, 2019, 107, 418-424. | 0.7 | 19 |
| 2037 | The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice. Cancer Immunology, Immunotherapy, 2019, 68, 455-466. | 2.0 | 31 |
| 2038 | Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 463-474. | 1.4 | 16 |
| 2039 | Predictive value of MLH1 and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer. Gastric Cancer, 2019, 22, 785-792. | 2.7 | 50 |
| 2040 | Translation control of the immune checkpoint in cancer and its therapeutic targeting. Nature Medicine, 2019, 25, 301-311. | 15.2 | 184 |
| 2041 | Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer. Annals of Oncology, 2019, 30, 424-430. | 0.6 | 44 |
| 2042 | Correlate tumor mutation burden with immune signatures in human cancers. BMC Immunology, 2019, 20, 4. | 0.9 | 149 |
| 2043 | Lactic Acid Bacteria as a Live Delivery System for the in situ Production of Nanobodies in the Human Gastrointestinal Tract. Frontiers in Microbiology, 2019, 9, . | 1.5 | 21 |
| 2044 | Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up. JAMA Oncology, 2019, 5, 334. | 3.4 | 206 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 2045 | RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma. Journal of Neuro-Oncology, 2019, 141, 95-102. | 1.4 | 5 |
| 2046 | T lymphocyte subsets in cancer immunity: Friends or foes. Journal of Leukocyte Biology, 2019, 105, 243-255. | 1.5 | 110 |
| 2047 | A Novel Engineered Small Protein for Positron Emission Tomography Imaging of Human Programmed Death Ligand-1: Validation in Mouse Models and Human Cancer Tissues. Clinical Cancer Research, 2019, 25, 1774-1785. | 3.2 | 30 |
| 2048 | Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer. World Journal of Urology, 2019, 37, 1773-1784. | 1.2 | 22 |
| 2049 | Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC. JAMA Oncology, 2019, 5, 195. | 3.4 | 235 |
| 2050 | <i>miR–155</i> expression in antitumor immunity: The higher the better?. Genes Chromosomes and Cancer, 2019, 58, 208-218. | 1.5 | 29 |
| 2051 | Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade. Cancer Immunology, Immunotherapy, 2019, 68, 163-174. | 2.0 | 58 |
| 2052 | The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging. Clinical Cancer Research, 2019, 25, 1196-1205. | 3.2 | 85 |
| 2053 | The lung microenvironment: an important regulator of tumour growth and metastasis. Nature Reviews Cancer, 2019, 19, 9-31. | 12.8 | 692 |
| 2054 | Expression of PD–L1 in tumor–associated nerves correlates with reduced CD8<sup>+</sup> tumor–associated lymphocytes and poor prognosis in prostate cancer. International Journal of Cancer, 2019, 144, 3099-3110. | 2.3 | 45 |
| 2055 | Clinical significance of ≥ 50% PD–L1 expression with the SP263 monoclonal antibody in non–small cell lung cancer patients. Thoracic Cancer, 2019, 10, 175-182. | 0.8 | 4 |
| 2056 | Checkpoint-modulating immunotherapies in tumor treatment: Targets, drugs, and mechanisms. International Immunopharmacology, 2019, 67, 160-175. | 1.7 | 33 |
| 2057 | How I treat MDS after hypomethylating agent failure. Blood, 2019, 133, 521-529. | 0.6 | 61 |
| 2058 | Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression. Molecular Cell, 2019, 73, 22-35.e6. | 4.5 | 174 |
| 2059 | Cancer immunoediting and resistance to T cell-based immunotherapy. Nature Reviews Clinical Oncology, 2019, 16, 151-167. | 12.5 | 1,093 |
| 2060 | PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer. Biomedicine and Pharmacotherapy, 2019, 110, 312-318. | 2.5 | 204 |
| 2061 | Metal Drugs and the Anticancer Immune Response. Chemical Reviews, 2019, 119, 1519-1624. | 23.0 | 237 |
| 2062 | Tumor Lysate–Loaded Lipid Hybrid Nanovaccine Collaborated with an Immune Checkpoint Antagonist for Combination Immunotherapy. Advanced Healthcare Materials, 2019, 8, e1800837. | 3.9 | 20 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 2063 | Size matters: Dissecting key parameters for panelâ€based tumor mutational burden analysis. International Journal of Cancer, 2019, 144, 848-858. | 2.3 | 131 |
| 2064 | Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway. Journal of Medicinal Chemistry, 2019, 62, 1715-1730. | 2.9 | 92 |
| 2065 | PD-L1 expression on tumor cells associated with favorable prognosis in surgically resected esophageal squamous cell carcinoma. Human Pathology, 2019, 84, 291-298. | 1.1 | 18 |
| 2066 | Increased CD3+ T cells with a low FOXP3+/CD8+ T cell ratio can predict anti-PD-1 therapeutic response in non-small cell lung cancer patients. Modern Pathology, 2019, 32, 367-375. | 2.9 | 31 |
| 2067 | Long-Term Survival in Patients Responding to Antiâ€"PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. Clinical Cancer Research, 2019, 25, 946-956. | 3.2 | 96 |
| 2068 | Identification of PD-L2, B7-H3 and CTLA-4 immune checkpoint proteins in genetic subtypes of meningioma. OncoImmunology, 2019, 8, e1512943. | 2.1 | 31 |
| 2069 | FcÎ³R interaction is not required for effective antiâ€PDâ€L1 immunotherapy but can add additional benefit depending on the tumor model. International Journal of Cancer, 2019, 144, 345-354. | 2.3 | 12 |
| 2070 | Mechanisms of Resistance to Immune Checkpoint Blockade. American Journal of Clinical Dermatology, 2019, 20, 41-54. | 3.3 | 83 |
| 2071 | Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Antiâ€"PD-1/PD-L1 Therapy in Nonâ€"Small-Cell Lung Cancer. Clinical Lung Cancer, 2019, 20, 88-96.e6. | 1.1 | 90 |
| 2072 | Immune Microenvironment Differences Between Squamous and Non-squamous Nonâ€"small-cell Lung Cancer and Their Influence on the Prognosis. Clinical Lung Cancer, 2019, 20, 48-58. | 1.1 | 42 |
| 2073 | The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer. European Urology, 2019, 75, 435-444. | 0.9 | 97 |
| 2074 | N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. Neuro-Oncology, 2019, 21, 95-105. | 0.6 | 100 |
| 2075 | Immune response and evasion mechanisms in lip carcinogenesis: An immunohistochemical study. Archives of Oral Biology, 2019, 98, 99-107. | 0.8 | 11 |
| 2076 | Characterization of PD-L1 Immunohistochemical Expression in Cell Blocks With Different Specimen Fixation and Processing Methods. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 107-113. | 0.6 | 31 |
| 2077 | Distinct contribution of PD-L1 suppression by spatial expression of PD-L1 on tumor and non-tumor cells. Cellular and Molecular Immunology, 2019, 16, 392-400. | 4.8 | 28 |
| 2078 | Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 92-100. | 0.6 | 144 |
| 2079 | Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy. Journal of Drug Targeting, 2019, 27, 244-256. | 2.1 | 86 |
| 2080 | Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment. Cellular and Molecular Immunology, 2019, 16, 401-409. | 4.8 | 105 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 2081 | Tumor inherent interferons: Impact on immune reactivity and immunotherapy. Cytokine, 2019, 118, 42-47. | 1.4 | 17 |
| 2082 | Role of Ancillary Techniques in Fluid Cytology. Acta Cytologica, 2020, 64, 52-62. | 0.7 | 20 |
| 2083 | Cancer Immunology. , 2020, , 84-96.e5. |  | 0 |
| 2084 | The emerging role of epigenetic therapeutics in immuno-oncology. Nature Reviews Clinical Oncology, 2020, 17, 75-90. | 12.5 | 260 |
| 2085 | Advances in nanomedical applications: diagnostic, therapeutic, immunization, and vaccine production. Environmental Science and Pollution Research, 2020, 27, 19200-19213. | 2.7 | 101 |
| 2086 | Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses. Acta Pharmaceutica Sinica B, 2020, 10, 723-733. | 5.7 | 102 |
| 2087 | Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy. Clinical Cancer Research, 2020, 26, 970-977. | 3.2 | 200 |
| 2088 | A retrospective analysis of 1,717 paranasal sinus fungus ball cases from 2008 to 2017. Laryngoscope, 2020, 130, 75-79. | 1.1 | 22 |
| 2089 | Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. Oncologist, 2020, 25, e147-e159. | 1.9 | 220 |
| 2090 | Immune checkpoint inhibition for the treatment of renal cell carcinoma. Expert Opinion on Biological Therapy, 2020, 20, 83-94. | 1.4 | 14 |
| 2091 | Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma. American Journal of Clinical Dermatology, 2020, 21, 1-11. | 3.3 | 13 |
| 2092 | Effects of Decalcifying Agents of Variable Duration on PD-L1 Immunohistochemistry. American Journal of Clinical Pathology, 2020, 153, 258-265. | 0.4 | 12 |
| 2093 | Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray. Laboratory Investigation, 2020, 100, 4-15. | 1.7 | 52 |
| 2094 | Quantitative evaluation of tumor-specific T cells in tumors and lymphoid tissues. Methods in Enzymology, 2020, 635, 149-166. | 0.4 | 4 |
| 2095 | Current Immunotherapeutic Strategies in Cancer. Recent Results in Cancer Research, 2020, , . | 1.8 | 4 |
| 2096 | Clinical interest of PD-L1 immuno-histochemistry expression as a predictive factor of Bacillus Calmette Guerin (BCG) efficacy in refractory high-risk non-muscle-invasive bladder cancer (NMIBC). World Journal of Urology, 2020, 38, 1517-1524. | 1.2 | 8 |
| 2097 | Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma. Journal of Gastroenterology, 2020, 55, 39-50. | 2.3 | 26 |
| 2098 | Combined NK Cell Therapy and Radiation Therapy Exhibit Long-Term Therapeutic and Antimetastatic Effects in a Human Triple Negative Breast Cancer Model. International Journal of Radiation Oncology Biology Physics, 2020, 108, 115-125. | 0.4 | 30 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 2099 | Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC). Cancer, 2020, 126, 260-270. | 2.0 | 202 |
| 2100 | Small-bowel carcinomas associated with celiac disease: transcriptomic profiling shows predominance of microsatellite instability-immune and mesenchymal subtypes. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 711-723. | 1.4 | 13 |
| 2101 | Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells. Gastroenterology, 2020, 158, 664-678.e24. | 0.6 | 55 |
| 2102 | Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma. Pigment Cell and Melanoma Research, 2020, 33, 390-402. | 1.5 | 19 |
| 2103 | Immunohistochemistry and special stains in gastrointestinal pathology practice. Diagnostic Histopathology, 2020, 26, 22-32. | 0.2 | 7 |
| 2104 | Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non–small cell lung cancer. Journal of Pathology, 2020, 250, 19-29. | 2.1 | 92 |
| 2105 | Prevalence of NRAS Mutation, PD-L1 Expression and Amplification, and Overall Survival Analysis in 36 Primary Vaginal Melanomas. Oncologist, 2020, 25, e291-e301. | 1.9 | 13 |
| 2106 | Association of combined <scp>PD</scp>‐L1 expression and tumour‐infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 984-994. | 1.3 | 31 |
| 2107 | Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer. Future Oncology, 2020, 16, 4439-4453. | 1.1 | 29 |
| 2108 | Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival. Cancer Chemotherapy and Pharmacology, 2020, 85, 265-272. | 1.1 | 47 |
| 2109 | The renal adverse effects of cancer immunotherapy. Journal of Nephrology, 2020, 33, 467-481. | 0.9 | 6 |
| 2110 | Current issues and perspectives in PD-1 blockade cancer immunotherapy. International Journal of Clinical Oncology, 2020, 25, 790-800. | 1.0 | 120 |
| 2111 | Tumor immune microenvironment modulation-based drug delivery strategies for cancer immunotherapy. Nanoscale, 2020, 12, 413-436. | 2.8 | 49 |
| 2112 | A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 563-572. | 3.3 | 20 |
| 2113 | Stromal PD-1+ tumor-associated macrophages predict poor prognosis in lung adenocarcinoma. Human Pathology, 2020, 97, 68-79. | 1.1 | 22 |
| 2114 | Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation–positive melanoma receiving adjuvant vemurafenib. Annals of Oncology, 2020, 31, 153-159. | 0.6 | 25 |
| 2115 | ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application. Cancer Letters, 2020, 473, 148-155. | 3.2 | 31 |
| 2116 | Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1302-1313. | 3.3 | 55 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 2117 | Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 896-908. | 1.8 | 124 |
| 2118 | Blocking PD-L1 for anti-liver cancer immunity: USP22 represents a critical cotarget. Cellular and Molecular Immunology, 2020, 17, 677-679. | 4.8 | 17 |
| 2119 | Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer. JAMA Oncology, 2020, 6, 375. | 3.4 | 215 |
| 2120 | Heterogeneity of PD-L1 Expression in Lung Mixed Adenocarcinomas and Adenosquamous Carcinomas. American Journal of Surgical Pathology, 2020, 44, 378-386. | 2.1 | 23 |
| 2121 | Precision Medicine in Lung Cancer Treatment. Surgical Oncology Clinics of North America, 2020, 29, 15-21. | 0.6 | 23 |
| 2122 | A Pretargeted Imaging Strategy for Immune Checkpoint Ligand PD-L1 Expression in Tumor Based on Bioorthogonal Diels-Alder Click Chemistry. Molecular Imaging and Biology, 2020, 22, 842-853. | 1.3 | 16 |
| 2123 | Programmed Cell Death-1/Ligand-1 PET Imaging. PET Clinics, 2020, 15, 35-43. | 1.5 | 34 |
| 2124 | CTLA4 blockade promotes vessel normalization in breast tumors *via* the accumulation of eosinophils. International Journal of Cancer, 2020, 146, 1730-1740. | 2.3 | 51 |
| 2125 | Targeting innate sensing in the tumor microenvironment to improve immunotherapy. Cellular and Molecular Immunology, 2020, 17, 13-26. | 4.8 | 76 |
| 2126 | PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells. American Journal of Surgical Pathology, 2020, 44, 174-181. | 2.1 | 52 |
| 2127 | Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with *EGFR* mutations. Expert Review of Respiratory Medicine, 2020, 14, 125-136. | 1.0 | 51 |
| 2128 | Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor. Molecular Immunology, 2020, 117, 201-215. | 1.0 | 116 |
| 2129 | The Programmed Death Pathway in Ocular Adnexal Sebaceous Carcinoma. Ophthalmic Plastic and Reconstructive Surgery, 2020, 36, 74-79. | 0.4 | 8 |
| 2130 | Radiomics of 18F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1168-1182. | 3.3 | 115 |
| 2131 | Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer. Cancer Immunology, Immunotherapy, 2020, 69, 127-134. | 2.0 | 37 |
| 2132 | The programmed cell death protein-1/programmed cell death ligand 1 expression, CD3+ T cell infiltration, NY-ESO-1 expression, and microsatellite instability phenotype in primary cutaneous melanoma and mucosal melanoma and their clinical significance and prognostic value: a study of 89 consecutive cases. Melanoma Research, 2020, 30, 85-101. | 0.6 | 5 |
| 2133 | Spatial proximity between T and PD-L1 expressing cells as a prognostic biomarker for oropharyngeal squamous cell carcinoma. British Journal of Cancer, 2020, 122, 539-544. | 2.9 | 35 |
| 2134 | Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 932-941. | 1.3 | 33 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 2135 | Prognostic implications of immune classification in a multicentre cohort of patients with small intestinal adenocarcinoma. Pathology, 2020, 52, 228-235. | 0.3 | 6 |
| 2136 | Expression of Programmed Cell Death Ligand 1 and Associated Lymphocyte Infiltration in Olfactory Neuroblastoma. World Neurosurgery, 2020, 135, e187-e193. | 0.7 | 19 |
| 2137 | Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria. Clinical Cancer Research, 2020, 26, 1846-1855. | 3.2 | 70 |
| 2138 | Adaptive Immune Resistance to Intravesical BCG in Non–Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. Clinical Cancer Research, 2020, 26, 882-891. | 3.2 | 98 |
| 2139 | Structure and Optimization of Checkpoint Inhibitors. Cancers, 2020, 12, 38. | 1.7 | 37 |
| 2140 | Immune checkpoint inhibitors combined with chemotherapy for the treatment of advanced pancreatic cancer patients. Cancer Immunology, Immunotherapy, 2020, 69, 365-372. | 2.0 | 18 |
| 2141 | Granzyme B nanoreporter for early monitoring of tumor response to immunotherapy. Science Advances, 2020, 6, . | 4.7 | 49 |
| 2142 | A Novel Bispecific Antibody with PD-L1–assisted OX40 Activation for Cancer Treatment. Molecular Cancer Therapeutics, 2020, 19, 2564-2574. | 1.9 | 10 |
| 2143 | The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188451. | 3.3 | 36 |
| 2144 | Prognostic and Clinical Value of Interleukin 6 and CD45$^{+}$CD14$^{+}$ Inflammatory Cells with PD-L1$^{+}$/PD-L2$^{+}$ Expression in Patients with Different Manifestation of Ovarian Cancer. Journal of Immunology Research, 2020, 2020, 1-16. | 0.9 | 10 |
| 2145 | Comprehensive Immuno-Molecular Profiles for Liposarcoma: Roles of Programmed Death Ligand 1, Microsatellite Instability, and PIK3CA. Oncology, 2020, 98, 817-826. | 0.9 | 4 |
| 2146 | Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors. AAPS Journal, 2020, 22, 132. | 2.2 | 27 |
| 2147 | Therapeutic vaccines for colorectal cancer: The progress and future prospect. International Immunopharmacology, 2020, 88, 106944. | 1.7 | 31 |
| 2148 | Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncology, The, 2020, 21, 1283-1295. | 5.1 | 213 |
| 2149 | Searching for the real function of mTOR signaling in the regulation of PD-L1 expression. Translational Oncology, 2020, 13, 100847. | 1.7 | 20 |
| 2150 | A CT-derived deep neural network predicts for programmed death ligand-1 expression status in advanced lung adenocarcinomas. Annals of Translational Medicine, 2020, 8, 930-930. | 0.7 | 13 |
| 2151 | Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma. Nature Communications, 2020, 11, 4878. | 5.8 | 27 |
| 2152 | The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes. Cancer Cell, 2020, 38, 685-700.e8. | 7.7 | 299 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 2153 | Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. Biomedicine and Pharmacotherapy, 2020, 130, 110621. | 2.5 | 8 |
| 2154 | Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy. , 2020, 8, e001191. | | 40 |
| 2155 | The Confounders of Cancer Immunotherapy: Roles of Lifestyle, Metabolic Disorders and Sociological Factors. Cancers, 2020, 12, 2983. | 1.7 | 56 |
| 2156 | Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8. , 2020, 8, e001378. | | 51 |
| 2157 | Bayesian inference using Hamiltonian Monte–Carlo algorithm for nonlinear joint modeling in the context of cancer immunotherapy. Statistics in Medicine, 2020, 39, 4853-4868. | 0.8 | 11 |
| 2158 | Genomics-based immuno-oncology: bridging the gap between immunology and tumor biology. Human Molecular Genetics, 2020, 29, R214-R225. | 1.4 | 3 |
| 2159 | The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who do not receive definitive surgery of the tumor. Clinical and Translational Radiation Oncology, 2020, 24, 34-40. | 0.9 | 11 |
| 2160 | CTNNB1 mutation suppresses infiltration of immune cells in hepatocellular carcinoma through miRNA-mediated regulation of chemokine expression. International Immunopharmacology, 2020, 89, 107043. | 1.7 | 18 |
| 2161 | Sarcomatoid renal cell carcinoma: biology, natural history and management. Nature Reviews Urology, 2020, 17, 659-678. | 1.9 | 76 |
| 2162 | Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant. Frontiers in Immunology, 2020, 11, 577869. | 2.2 | 147 |
| 2163 | Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nature Medicine, 2020, 26, 1845-1851. | 15.2 | 193 |
| 2164 | An update on colorectal cancer microenvironment, epigenetic and immunotherapy. International Immunopharmacology, 2020, 89, 107041. | 1.7 | 45 |
| 2165 | Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome. Cytotherapy, 2020, 22, 204-213. | 0.3 | 9 |
| 2166 | High versus low dose irradiation for tumor immune reprogramming. Current Opinion in Biotechnology, 2020, 65, 268-283. | 3.3 | 13 |
| 2167 | Recent advances of molecular mechanisms of regulating PD-L1 expression in melanoma. International Immunopharmacology, 2020, 88, 106971. | 1.7 | 7 |
| 2168 | Upregulation of PD-L1 expression promotes epithelial-to-mesenchymal transition in sorafenib-resistant hepatocellular carcinoma cells. Gastroenterology Report, 2020, 8, 390-398. | 0.6 | 25 |
| 2169 | Radiogenomics for predicting p53 status, PD-L1 expression, and prognosis with machine learning in pancreatic cancer. British Journal of Cancer, 2020, 123, 1253-1261. | 2.9 | 59 |
| 2170 | Cross–Link–Functionalized Nanoparticles for Rapid Excretion in Nanotheranostic Applications. Angewandte Chemie, 2020, 132, 20733-20741. | 1.6 | 6 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 2171 | Pancreatic undifferentiated carcinoma with osteoclast-like giant cells curatively resected after pembrolizumab therapy for lung metastases: a case report. BMC Gastroenterology, 2020, 20, 220. | 0.8 | 17 |
| 2172 | Immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC): current perspectives and future prospects. Molecular Biology Reports, 2020, 47, 6269-6280. | 1.0 | 7 |
| 2173 | Ambient PM Toxicity Is Correlated with Expression Levels of Specific MicroRNAs. Environmental Science &amp; Technology, 2020, 54, 10227-10236. | 4.6 | 17 |
| 2174 | Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death–Ligand 1 Interaction as Potential Anticancer Agents. Journal of Medicinal Chemistry, 2020, 63, 8338-8358. | 2.9 | 50 |
| 2175 | A patient with melanoma that became sensitized to immunotherapy after treatment with a CDK4/6 inhibitor. Immunotherapy, 2020, 12, 861-867. | 1.0 | 4 |
| 2176 | Characterization of Neoantigen Load Subgroups in Gynecologic and Breast Cancers. Frontiers in Bioengineering and Biotechnology, 2020, 8, 702. | 2.0 | 8 |
| 2177 | Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093790. | 1.4 | 49 |
| 2178 | Cross‐Link‐Functionalized Nanoparticles for Rapid Excretion in Nanotheranostic Applications. Angewandte Chemie - International Edition, 2020, 59, 20552-20560. | 7.2 | 35 |
| 2179 | Local injection of CCL19-expressing mesenchymal stem cells augments the therapeutic efficacy of anti-PD-L1 antibody by promoting infiltration of immune cells. , 2020, 8, e000582. | | 23 |
| 2180 | Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy. , 2020, 8, e000967. | | 67 |
| 2181 | Programmed death ligand‐1 expression in gastrointestinal cancer: Clinical significance and future challenges. Annals of Gastroenterological Surgery, 2020, 4, 369-378. | 1.2 | 10 |
| 2182 | A novel method for analysis of the electrostatic complementarity of protein-protein interaction based on fragment molecular orbital method. Chemical Physics Letters, 2020, 761, 138103. | 1.2 | 6 |
| 2183 | Tumor Microenvironment and Immunotherapy Response in Head and Neck Cancer. Cancers, 2020, 12, 3377. | 1.7 | 35 |
| 2184 | &lt;p&gt;PD-L1 Expression is Highly Associated with Tumor-Associated Macrophage Infiltration in Nasopharyngeal Carcinoma&lt;/p&gt;. Cancer Management and Research, 2020, Volume 12, 11585-11596. | 0.9 | 17 |
| 2185 | Programmed Cell Death Ligand 1 Expression in Resected Non–Small Cell Lung Cancer. Clinical Lung Cancer, 2020, 22, e555-e562. | 1.1 | 1 |
| 2186 | Immune Phenotypes of Nasopharyngeal Cancer. Cancers, 2020, 12, 3428. | 1.7 | 7 |
| 2187 | Antagonistic Inflammatory Phenotypes Dictate Tumor Fate and Response to Immune Checkpoint Blockade. Immunity, 2020, 53, 1215-1229.e8. | 6.6 | 131 |
| 2188 | Obesity and metabolic syndrome related macrophage promotes PD-L1 expression in TNBC through IL6/JAK/STAT pathway and can be reversed by telmisartan. Cancer Biology and Therapy, 2020, 21, 1179-1190. | 1.5 | 10 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 2189 | Tumor Infiltrating Effector Memory Antigen-Specific CD8+ T Cells Predict Response to Immune Checkpoint Therapy. Frontiers in Immunology, 2020, 11, 584423. | 2.2 | 39 |
| 2190 | Organotypic Modeling of the Tumor Landscape. Frontiers in Cell and Developmental Biology, 2020, 8, 606039. | 1.8 | 10 |
| 2191 | ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1â€"SHP2 Signaling Pathway in Non-Small Cell Lung Cancer. Frontiers in Immunology, 2020, 11, 527750. | 2.2 | 7 |
| 2192 | Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects. Cancers, 2020, 12, 3456. | 1.7 | 12 |
| 2193 | Machine learning: an approach to preoperatively predict PD-1/PD-L1 expression and outcome in intrahepatic cholangiocarcinoma using MRI biomarkers. ESMO Open, 2020, 5, e000910. | 2.0 | 38 |
| 2194 | Expression of AKT and p-AKT protein in lung adenocarcinoma and its correlation with PD-L1 protein and prognosis. Annals of Translational Medicine, 2020, 8, 1172-1172. | 0.7 | 8 |
| 2195 | Panâ€cancer population pharmacokinetics and exposureâ€safety and â€efficacy analyses of atezolizumab in patients with high tumor mutational burden. Pharmacology Research and Perspectives, 2020, 8, e00685. | 1.1 | 8 |
| 2196 | Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy. , 2020, 8, e001392. | | 27 |
| 2197 | &lt;p&gt;Pretreatment CT-Based Radiomics Signature as a Potential Imaging Biomarker for Predicting the Expression of PD-L1 and CD8+TILs in ESCC&lt;/p&gt;. OncoTargets and Therapy, 2020, Volume 13, 12003-12013. | 1.0 | 29 |
| 2198 | Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial. Lancet Oncology, The, 2020, 21, 1653-1660. | 5.1 | 89 |
| 2199 | Optimization of Liposomes for Antigen Targeting to Splenic CD169+ Macrophages. Pharmaceutics, 2020, 12, 1138. | 2.0 | 15 |
| 2200 | Characterizing heterogeneity of nonâ€small cell lung tumour microenvironment to identify signature prognostic genes. Journal of Cellular and Molecular Medicine, 2020, 24, 14608-14618. | 1.6 | 10 |
| 2201 | PDâ€L1 expression patterns in oral cancer as an integrated approach for further prognostic classification. Oral Diseases, 2021, 27, 1699-1710. | 1.5 | 8 |
| 2202 | PD-1 Regulates GABAergic Neurotransmission and GABA-Mediated Analgesia and Anesthesia. IScience, 2020, 23, 101570. | 1.9 | 23 |
| 2203 | Circulating Interleukin-4 Is Associated with a Systemic T Cell Response against Tumor-Associated Antigens in Treatment-NaÃ¯ve Patients with Resectable Non-Small-Cell Lung Cancer. Cancers, 2020, 12, 3496. | 1.7 | 3 |
| 2204 | Overcoming Immune Evasion in Melanoma. International Journal of Molecular Sciences, 2020, 21, 8984. | 1.8 | 88 |
| 2205 | SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. , 2020, 8, e000705. | | 20 |
| 2206 | Cancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy. Journal of Immunology Research, 2020, 2020, 1-13. | 0.9 | 76 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 2207 | Nicotinamide N-Methyltransferase Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric Cancer. Frontiers in Genetics, 2020, 11, 580299. | 1.1 | 11 |
| 2208 | Roles for the FCRL6 Immunoreceptor in Tumor Immunology. Frontiers in Immunology, 2020, 11, 575175. | 2.2 | 16 |
| 2209 | Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors. Archivum Immunologiae Et Therapiae Experimentalis, 2020, 68, 36. | 1.0 | 26 |
| 2210 | Clinical Challenges of Immune Checkpoint Inhibitors. Cancer Cell, 2020, 38, 326-333. | 7.7 | 286 |
| 2211 | Immune Landscape in Tumor Microenvironment: Implications for Biomarker Development and Immunotherapy. International Journal of Molecular Sciences, 2020, 21, 5521. | 1.8 | 25 |
| 2212 | &lt;p&gt;Tumor-Associated CD163&lt;sup&gt;+&lt;/sup&gt; M2 Macrophage Infiltration is Highly Associated with PD-L1 Expression in Cervical Cancer&lt;/p&gt;. Cancer Management and Research, 2020, Volume 12, 5831-5843. | 0.9 | 8 |
| 2213 | Improving Cancer Immunotherapy by Cell Membrane–Camouflaged Nanoparticles. Advanced Functional Materials, 2020, 30, 2004397. | 7.8 | 123 |
| 2214 | Autophagy-related gene expression classification defines three molecular subtypes with distinct clinical and microenvironment cell infiltration characteristics in colon cancer. International Immunopharmacology, 2020, 87, 106757. | 1.7 | 14 |
| 2215 | A multidimensional precision medicine approach identifies an autism subtype characterized by dyslipidemia. Nature Medicine, 2020, 26, 1375-1379. | 15.2 | 49 |
| 2216 | Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment—Current Progress, Strategy, and Future Perspective. Frontiers in Immunology, 2020, 11, 1508. | 2.2 | 60 |
| 2217 | Comprehensive Analysis of the Immune Implication of ACK1 Gene in Non-small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 1132. | 1.3 | 20 |
| 2218 | Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?. Frontiers in Oncology, 2020, 10, 1193. | 1.3 | 13 |
| 2219 | Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study. Clinical Cancer Research, 2020, 26, 5631-5637. | 3.2 | 31 |
| 2220 | Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma. Heliyon, 2020, 6, e04117. | 1.4 | 5 |
| 2221 | PD-L1 Expression Affects Neoantigen Presentation. IScience, 2020, 23, 101238. | 1.9 | 9 |
| 2222 | Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer. Npj Breast Cancer, 2020, 6, 29. | 2.3 | 26 |
| 2223 | Enhanced Immunogenicity of Engineered HER2 Antigens Potentiates Antitumor Immune Responses. Vaccines, 2020, 8, 403. | 2.1 | 2 |
| 2224 | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence. Signal Transduction and Targeted Therapy, 2020, 5, 137. | 7.1 | 79 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 2225 | Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial. Oral Oncology, 2020, 111, 104928. | 0.8 | 9 |
| 2226 | Tumor mutational burden related classifier is predictive of response to PD-L1 blockade in locally advanced and metastatic urothelial carcinoma. International Immunopharmacology, 2020, 87, 106818. | 1.7 | 10 |
| 2227 | Tumor inhibition or tumor promotion? The duplicity of CXCR3 in cancer. Journal of Leukocyte Biology, 2020, 108, 673-685. | 1.5 | 26 |
| 2228 | Mechanism of acquired resistance to nivolumab in lung squamous cell carcinoma: case report and review of the literature. Immunotherapy, 2020, 12, 957-964. | 1.0 | 7 |
| 2229 | High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer. Scientific Reports, 2020, 10, 12348. | 1.6 | 48 |
| 2230 | Programmed cell death ligand†1 and cytotoxic T cell infiltrates in metastatic cutaneous squamous cell carcinoma of the head and neck. Head and Neck, 2020, 42, 3226-3234. | 0.9 | 3 |
| 2231 | The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models. BMC Cancer, 2020, 20, 738. | 1.1 | 9 |
| 2232 | The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China. Experimental Hematology and Oncology, 2020, 9, 17. | 2.0 | 21 |
| 2233 | Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers. Biomedicine and Pharmacotherapy, 2020, 130, 110626. | 2.5 | 25 |
| 2234 | Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence. Advanced Science, 2020, 7, 2001447. | 5.6 | 30 |
| 2235 | Immune Oncology Biomarkers in Lung Cancer: an Overview. Current Oncology Reports, 2020, 22, 107. | 1.8 | 8 |
| 2236 | Interleukin-17†"induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer. Journal of Experimental Medicine, 2020, 217, . | 4.2 | 219 |
| 2237 | A Potential Predictive Biomarker for Miller/Payne Grading: PD-L1 Expression before Neoadjuvant Chemotherapy in Breast Cancer. Oncology Research and Treatment, 2020, 43, 573-583. | 0.8 | 1 |
| 2238 | &lt;p&gt;Toll-Like Receptor 9 Agonists in Cancer&lt;/p&gt;. OncoTargets and Therapy, 2020, Volume 13, 10039-10061. | 1.0 | 74 |
| 2239 | Identification of a costimulatory molecule-based signature for predicting prognosis risk and immunotherapy response in patients with lung adenocarcinoma. OncoImmunology, 2020, 9, 1824641. | 2.1 | 38 |
| 2240 | Chemokine biology on immune checkpoint†"targeted therapies. European Journal of Cancer, 2020, 137, 260-271. | 1.3 | 13 |
| 2241 | <p>Biomarkers for Inflammatory Breast Cancer: Diagnostic and Therapeutic Utility</p>. Breast Cancer: Targets and Therapy, 2020, Volume 12, 153-163. | 1.0 | 5 |
| 2242 | Tumor-Infiltrating Lymphocyte-Based Risk Score for Predicting Prognosis in Gastric Cancer. Frontiers in Oncology, 2020, 10, 522015. | 1.3 | 8 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 2243 | Î²-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion. Journal of Experimental Medicine, 2020, 217, . | 4.2 | 108 |
| 2244 | Gene expression analysis in formalin fixed paraffin embedded melanomas is associated with density of corresponding immune cells in those tissues. Scientific Reports, 2020, 10, 18336. | 1.6 | 6 |
| 2245 | Autoimmunity linked protein phosphatase PTPN22 as a target for cancer immunotherapy. , 2020, 8, e001439. | | 30 |
| 2246 | Ramucirumab in Combination with Pembrolizumab in Treatment-NaÃ¯ve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial. Cancers, 2020, 12, 2985. | 1.7 | 21 |
| 2247 | Imaging findings of immune checkpoint inhibitor associated pancreatitis. European Journal of Radiology, 2020, 131, 109250. | 1.2 | 24 |
| 2248 | ACKR4 restrains antitumor immunity by regulating CCL21. Journal of Experimental Medicine, 2020, 217, . | 4.2 | 25 |
| 2249 | Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomarker Research, 2020, 8, 34. | 2.8 | 266 |
| 2250 | Prognostic Value of Programmed Cell Death-Ligand 1 Expression in Tumor-Infiltrating Lymphocytes and Viral Load in Peripheral Blood Mononuclear Cells for Epsteinâ€"Barr Virusâ€"Positive Nasopharyngeal Carcinoma. Clinical Chemistry, 2020, 66, 1219-1227. | 1.5 | 12 |
| 2251 | Low ARID1A Expression is Associated with Poor Prognosis in Hepatocellular Carcinoma. Cells, 2020, 9, 2002. | 1.8 | 25 |
| 2252 | The application of artificial intelligence and radiomics in lung cancer. Precision Clinical Medicine, 2020, 3, 214-227. | 1.3 | 25 |
| 2253 | Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592094092. | 1.4 | 86 |
| 2254 | PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nature Communications, 2020, 11, 4835. | 5.8 | 290 |
| 2255 | Conserved Interferon-Î³ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell, 2020, 38, 500-515.e3. | 7.7 | 203 |
| 2256 | Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. Nature Communications, 2020, 11, 4858. | 5.8 | 124 |
| 2257 | CD8+ tumorâ€infiltrating lymphocytes within the primary tumor of patients with synchronous de novo metastatic colorectal carcinoma do not track with survival. Clinical and Translational Immunology, 2020, 9, e1155. | 1.7 | 8 |
| 2258 | CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade. Cancer Research, 2020, 80, 5063-5075. | 0.4 | 21 |
| 2259 | Immuneâ€related signature predicts the prognosis and immunotherapy benefit in bladder cancer. Cancer Medicine, 2020, 9, 7729-7741. | 1.3 | 35 |
| 2260 | Predictive value of CD8 / FOXP3 ratio combined with PDâ€L1 expression for radiosensitivity in patients with squamous cell carcinoma of the larynx receiving definitive radiation therapy. Head and Neck, 2020, 42, 3518-3530. | 0.9 | 6 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 2261 | Comprehensive molecular analyses of a TNF family-based signature with regard to prognosis, immune features, and biomarkers for immunotherapy in lung adenocarcinoma. EBioMedicine, 2020, 59, 102959. | 2.7 | 51 |
| 2262 | Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma. OncoImmunology, 2020, 9, 1792036. | 2.1 | 31 |
| 2263 | Integrated Genomic Characterization of the Human Immunome in Cancer. Cancer Research, 2020, 80, 4854-4867. | 0.4 | 11 |
| 2264 | Changes in immune parameters between pre-treatment and recurrence after (chemo) radiation therapy in patients with head and neck cancer. Scientific Reports, 2020, 10, 11973. | 1.6 | 4 |
| 2265 | Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody. Molecular Cancer Therapeutics, 2020, 19, 2105-2116. | 1.9 | 10 |
| 2266 | Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. Prostate, 2020, 80, 1273-1296. | 1.2 | 16 |
| 2267 | A novel scoring method based on RNAâ€Seq immunograms describing individual cancerâ€immunity interactions. Cancer Science, 2020, 111, 4031-4040. | 1.7 | 32 |
| 2268 | Voluntary wheel running can lead to modulation of immune checkpoint molecule expression. Acta OncolÃ³gica, 2020, 59, 1447-1454. | 0.8 | 18 |
| 2270 | Heat Shock Proteins and PD-1/PD-L1 as Potential Therapeutic Targets in Myeloproliferative Neoplasms. Cancers, 2020, 12, 2592. | 1.7 | 8 |
| 2271 | Phage Display Derived Monoclonal Antibodies: From Bench to Bedside. Frontiers in Immunology, 2020, 11, 1986. | 2.2 | 146 |
| 2272 | Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer. Journal of Experimental and Clinical Cancer Research, 2020, 39, 180. | 3.5 | 38 |
| 2273 | Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade. Science Translational Medicine, 2020, 12, . | 5.8 | 34 |
| 2274 | Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer. Frontiers in Oncology, 2020, 10, 1644. | 1.3 | 48 |
| 2275 | Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma. Cancers, 2020, 12, 2495. | 1.7 | 12 |
| 2276 | PrognosisÂof Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors. Frontiers in Pharmacology, 2020, 11, 1213. | 1.6 | 28 |
| 2277 | &lt;p&gt;Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy&lt;/p&gt;. Drug Design, Development and Therapy, 2020, Volume 14, 3625-3649. | 2.0 | 80 |
| 2278 | Microneedles loaded with anti-PD-1â€"cisplatin nanoparticles for synergistic cancer immuno-chemotherapy. Nanoscale, 2020, 12, 18885-18898. | 2.8 | 67 |
| 2279 | Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes. , 2020, 8, e000271. | | 29 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 2281 | Cytoreduction and the Optimization Of Immune Checkpoint Inhibition with Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2020, 108, 17-26. | 0.4 | 18 |
| 2282 | Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patientsâ€"Literature Review. Cancers, 2020, 12, 2314. | 1.7 | 13 |
| 2283 | Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines. , 2020, 8, e000873. | | 49 |
| 2284 | PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages. Frontiers in Immunology, 2020, 11, 588552. | 2.2 | 80 |
| 2285 | PD-L1 expression with respect to driver mutations in non-small cell lung cancer in an Asian population: a large study of 1370 cases in China. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592096584. | 1.4 | 13 |
| 2286 | Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade. Cell Death and Disease, 2020, 11, 1062. | 2.7 | 32 |
| 2287 | Co-localization of CD169 $^+$ macrophages and cancer cells in lymph node metastases of breast cancer patients is linked to improved prognosis and PDL1 expression. OncoImmunology, 2020, 9, 1848067. | 2.1 | 9 |
| 2288 | Beyond Blocking: Engineering RNAi-Mediated Targeted Immune Checkpoint Nanoblocker Enables T-Cell-Independent Cancer Treatment. ACS Nano, 2020, 14, 17524-17534. | 7.3 | 26 |
| 2289 | Genomic investigation of co-targeting tumor immune microenvironment and immune checkpoints in pan-cancer immunotherapy. Npj Precision Oncology, 2020, 4, 29. | 2.3 | 11 |
| 2290 | Role of Hypoxia and the Adenosine System in Immune Evasion and Prognosis of Patients with Brain Metastases of Melanoma: A Multiplex Whole Slide Immunofluorescence Study. Cancers, 2020, 12, 3753. | 1.7 | 11 |
| 2291 | Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade. IScience, 2020, 23, 101584. | 1.9 | 15 |
| 2292 | PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC. Analytical Cellular Pathology, 2020, 2020, 1-7. | 0.7 | 3 |
| 2293 | iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and antiâ€"PD-1 therapy. Science Translational Medicine, 2020, 12, . | 5.8 | 133 |
| 2294 | Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?. Frontiers in Cell and Developmental Biology, 2020, 8, 582370. | 1.8 | 48 |
| 2295 | Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer. Nature Communications, 2020, 11, 5583. | 5.8 | 99 |
| 2296 | Therapeutic Vaccines and Cancer Immunotherapy. Vaccines, 2020, 8, 596. | 2.1 | 6 |
| 2297 | Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer. JAMA Network Open, 2020, 3, e2015748. | 2.8 | 36 |
| 2298 | The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy. Vaccines, 2020, 8, 203. | 2.1 | 38 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 2299 | Immune suppression caused by PD-L2 expression on tumor cells in gastric cancer. Gastric Cancer, 2020, 23, 961-973. | 2.7 | 21 |
| 2300 | PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nature Communications, 2020, 11, 2135. | 5.8 | 114 |
| 2301 | The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation. , 2020, 8, e000155. | | 140 |
| 2302 | Opportunities for using in silico–based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors. British Journal of Clinical Pharmacology, 2020, 86, 1769-1777. | 1.1 | 25 |
| 2303 | Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?. British Journal of Cancer, 2020, 123, 207-215. | 2.9 | 50 |
| 2304 | Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy. British Journal of Cancer, 2020, 123, 392-402. | 2.9 | 28 |
| 2305 | Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response. British Journal of Clinical Pharmacology, 2020, 86, 1736-1752. | 1.1 | 10 |
| 2306 | Prognostic Significance of PD-1, PD-L1 and CD8 Gene Expression Levels in Gastric Cancer. Oncology, 2020, 98, 501-511. | 0.9 | 15 |
| 2307 | Immune checkpoints in hematologic malignancies: What made the immune cells and clinicians exhausted!. Journal of Cellular Physiology, 2020, 235, 9080-9097. | 2.0 | 19 |
| 2308 | A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer. Journal of Experimental and Clinical Cancer Research, 2020, 39, 87. | 3.5 | 32 |
| 2309 | PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake. Frontiers in Pharmacology, 2020, 11, 722. | 1.6 | 65 |
| 2310 | In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma. , 2020, 8, e000204. | | 35 |
| 2311 | Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance. Oncologist, 2020, 25, e1481-e1491. | 1.9 | 92 |
| 2312 | Identification and Analysis of Dysfunctional Genes and Pathways in CD8+ T Cells of Non-Small Cell Lung Cancer Based on RNA Sequencing. Frontiers in Genetics, 2020, 11, 352. | 1.1 | 6 |
| 2313 | The role of ‹scp›CDK6‹/scp› in cancer. International Journal of Cancer, 2020, 147, 2988-2995. | 2.3 | 93 |
| 2314 | Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. New England Journal of Medicine, 2020, 382, 1894-1905. | 13.9 | 3,828 |
| 2315 | Improving the Diagnostic Accuracy of the PD-L1 Test with Image Analysis and Multiplex Hybridization. Cancers, 2020, 12, 1114. | 1.7 | 34 |
| 2316 | The safety of atezolizumab plus chemotherapy for the treatment of metastatic lung cancer. Expert Opinion on Drug Safety, 2020, 19, 775-783. | 1.0 | 2 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 2317 | Immunotherapy-related hepatitis and thrombocytopaenia induced by the very low dose of only 90Âmg of atezolizumab. European Journal of Cancer, 2020, 133, 22-24. | 1.3 | 6 |
| 2318 | Principles of Immunotherapy in Non-Small Cell Lung Cancer. Thoracic Surgery Clinics, 2020, 30, 187-198. | 0.4 | 19 |
| 2319 | Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e275-e291. | 1.8 | 32 |
| 2321 | Systematic profiling of immune signatures identifies prognostic predictors in lung adenocarcinoma. Cellular Oncology (Dordrecht), 2020, 43, 681-694. | 2.1 | 7 |
| 2322 | Blocking immunosuppressive neutrophils deters pY696-EZH2â€"driven brain metastases. Science Translational Medicine, 2020, 12, . | 5.8 | 64 |
| 2323 | The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies. Frontiers in Immunology, 2020, 11, 784. | 2.2 | 339 |
| 2324 | Immunotherapy for platinum-resistant ovarian cancer. Gynecologic Oncology, 2020, 158, 484-488. | 0.6 | 40 |
| 2325 | RAS-targeted therapies: is the undruggable drugged?. Nature Reviews Drug Discovery, 2020, 19, 533-552. | 21.5 | 569 |
| 2326 | Design, synthesis and biological evaluation of 2-methyl-(1,1â€²-biphenyl)-pyrimidine conjugates. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127328. | 1.0 | 7 |
| 2327 | Prevalence of <scp>PDâ€L1</scp> expression in head and neck squamous precancerous lesions: a systematic review and metaâ€analysis. Head and Neck, 2020, 42, 3018-3030. | 0.9 | 23 |
| 2328 | PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nature Cancer, 2020, 1, 681-691. | 5.7 | 240 |
| 2329 | Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design. Future Oncology, 2020, 16, 1525-1536. | 1.1 | 50 |
| 2330 | High expression of PKM2 synergizes with PD-L1 in tumor cells and immune cells to predict worse survival in human lung adenocarcinoma. Journal of Cancer, 2020, 11, 4442-4452. | 1.2 | 18 |
| 2331 | Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer. Cell, 2020, 181, 1612-1625.e13. | 13.5 | 436 |
| 2332 | Regulation of PD-1 in T cells for cancer immunotherapy. European Journal of Pharmacology, 2020, 881, 173240. | 1.7 | 27 |
| 2333 | Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1. Journal of Translational Medicine, 2020, 18, 220. | 1.8 | 20 |
| 2334 | The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who received definitive surgery of the pancreatic tumor: a retrospective analysis of the National Cancer Database. Radiation Oncology, 2020, 15, 139. | 1.2 | 7 |
| 2335 | Advances in the Treatment of Nonâ€"Small Cell Lung Cancer. Clinics in Chest Medicine, 2020, 41, 237-247. | 0.8 | 50 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 2336 | Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. , 2020, 8, e000453. | | 80 |
| 2337 | Finding the hot spot: identifying immune sensitive gastrointestinal tumors. Translational Gastroenterology and Hepatology, 2020, 5, 48-48. | 1.5 | 6 |
| 2338 | Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment. Gene Expression, 2020, 20, 53-65. | 0.5 | 65 |
| 2339 | CD8$^+$CD73$^+$ T cells in the tumor microenvironment of head and neck cancer patients are linked to diminished T cell infiltration and activation in tumor tissue. European Journal of Immunology, 2020, 50, 2055-2066. | 1.6 | 7 |
| 2340 | Immune Cell Profiling in Cancer Using Multiplex Immunofluorescence and DigitalÂAnalysis Approaches. , 0, , . | | 0 |
| 2341 | Clinical relevance and prognostic significance of PD-1/PD-Ls in non-metastatic bladder cancer: A role for PD-L2. Molecular Immunology, 2020, 124, 35-41. | 1.0 | 8 |
| 2342 | Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice. Frontiers in Immunology, 2020, 11, 1088. | 2.2 | 61 |
| 2343 | Dysregulated m6A-Related Regulators Are Associated With Tumor Metastasis and Poor Prognosis in Osteosarcoma. Frontiers in Oncology, 2020, 10, 769. | 1.3 | 61 |
| 2344 | Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 2020, 21, 4071. | 1.8 | 23 |
| 2345 | Immunotherapy as a second-line or later treatment modality for advanced non-small cell lung cancer: A review of safety and efficacy. Critical Reviews in Oncology/Hematology, 2020, 152, 103009. | 2.0 | 10 |
| 2346 | An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses. Nature Communications, 2020, 11, 1395. | 5.8 | 124 |
| 2347 | PD-1-Mediated PI3K/Akt/mTOR, Caspase 9/Caspase 3 and ERK Pathways Are Involved in Regulating the Apoptosis and Proliferation of CD4+ and CD8+ T Cells During BVDV Infection in vitro. Frontiers in Immunology, 2020, 11, 467. | 2.2 | 15 |
| 2348 | Multicentric Analytical and Inter-observer Comparability of Four Clinically Developed Programmed Death-ligand 1 Immunohistochemistry Assays in Advanced Clear-cell Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, e629-e642. | 0.9 | 8 |
| 2349 | Characterization of PD-L1 binding sites by a combined FMO/GRID-DRY approach. Journal of Computer-Aided Molecular Design, 2020, 34, 897-914. | 1.3 | 15 |
| 2350 | ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis. Cancer Cell, 2020, 37, 324-339.e8. | 7.7 | 126 |
| 2351 | Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy. Frontiers in Immunology, 2020, 11, 364. | 2.2 | 50 |
| 2352 | Association of MSH2 Expression With Tumor Mutational Burden and the Immune Microenvironment in Lung Adenocarcinoma. Frontiers in Oncology, 2020, 10, 168. | 1.3 | 22 |
| 2353 | Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies. Frontiers in Cell and Developmental Biology, 2020, 8, 155. | 1.8 | 32 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 2354 | Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Science Translational Medicine, 2020, 12, . | 5.8 | 229 |
| 2355 | Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2020, 635, xix-xxxviii. | 0.4 | 0 |
| 2356 | KEYNOTE-032: A Randomized Phase I Study of Pembrolizumab in Chinese Patients with Advanced Non-Small Cell Lung Cancer. Oncologist, 2020, 25, 650-e1145. | 1.9 | 11 |
| 2357 | Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents. Journal of Clinical Medicine, 2020, 9, 675. | 1.0 | 57 |
| 2358 | Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer. Critical Reviews in Oncology/Hematology, 2020, 149, 102927. | 2.0 | 15 |
| 2359 | Bidirectional signals of PD-L1 in T cells that fraternize with cancer cells. Nature Immunology, 2020, 21, 365-366. | 7.0 | 14 |
| 2360 | Epithelial-mesenchymal transition gene signature is associated with prognosis and tumor microenvironment in head and neck squamous cell carcinoma. Scientific Reports, 2020, 10, 3652. | 1.6 | 68 |
| 2361 | Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. Journal of the National Cancer Institute, 2020, 112, 562-573. | 3.0 | 45 |
| 2362 | Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2020, 636, xvii-xxxvi. | 0.4 | 0 |
| 2363 | Melanoma immunotherapy: strategies to overcome pharmacological resistance. Expert Review of Anticancer Therapy, 2020, 20, 289-304. | 1.1 | 13 |
| 2364 | Primary CNS lymphoma commonly expresses immune response biomarkers. Neuro-Oncology Advances, 2020, 2, vdaa018. | 0.4 | 24 |
| 2365 | Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer. Translational Lung Cancer Research, 2020, 9, 111-138. | 1.3 | 27 |
| 2366 | Challenges in the treatment of breast cancer brain metastases: evidence, unresolved questions, and a practical algorithm. Clinical and Translational Oncology, 2020, 22, 1698-1709. | 1.2 | 9 |
| 2367 | Immunotherapeutic Potential of TGF-Î² Inhibition and Oncolytic Viruses. Trends in Immunology, 2020, 41, 406-420. | 2.9 | 55 |
| 2368 | Tumor Microenvironment. Cancer Treatment and Research, 2020, , . | 0.2 | 12 |
| 2369 | Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Science Translational Medicine, 2020, 12, . | 5.8 | 108 |
| 2370 | Role of tumor microenvironment in the regulation of PDâ€‑L1: A novel role in resistance to cancer immunotherapy. Journal of Cellular Physiology, 2020, 235, 6496-6506. | 2.0 | 19 |
| 2371 | Targeting Toll-like receptor 3 in dendritic cells for cancer immunotherapy. Expert Opinion on Biological Therapy, 2020, 20, 937-946. | 1.4 | 19 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 2372 | Therapeutic and Prophylactic Antitumor Activity of an Oral Inhibitor of Fucosylation in Spontaneous Mammary Cancers. Molecular Cancer Therapeutics, 2020, 19, 1102-1109. | 1.9 | 12 |
| 2373 | Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. Journal of Thoracic Oncology, 2020, 15, 914-947. | 0.5 | 119 |
| 2374 | NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors. Cancer Research, 2020, 80, 1846-1860. | 0.4 | 189 |
| 2375 | Predictive biomarkers in clinical practice: State of the art and perspectives in solid tumors. International Journal of Biological Markers, 2020, 35, 16-19. | 0.7 | 0 |
| 2376 | Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer. Frontiers in Immunology, 2020, 11, 125. | 2.2 | 53 |
| 2377 | Determinants of Resistance to Checkpoint Inhibitors. International Journal of Molecular Sciences, 2020, 21, 1594. | 1.8 | 39 |
| 2378 | Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy. Frontiers in Immunology, 2020, 11, 223. | 2.2 | 54 |
| 2379 | Quantitative, qualitative and spatial analysis of lymphocyte infiltration in periampullary and pancreatic adenocarcinoma. International Journal of Cancer, 2020, 146, 3461-3473. | 2.3 | 39 |
| 2380 | 18F-FDG maximum standard uptake value predicts PD-L1 expression on tumor cells or tumor-infiltrating immune cells in non-small cell lung cancer. Annals of Nuclear Medicine, 2020, 34, 322-328. | 1.2 | 15 |
| 2381 | Anti-tumor effects of anti-PD-1 antibody, pembrolizumab, in humanized NSG PDX mice xenografted with dedifferentiated liposarcoma. Cancer Letters, 2020, 478, 56-69. | 3.2 | 32 |
| 2382 | Correlation of PD-L1 expression with immunohistochemically determined molecular profile in endometrial carcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 845-856. | 1.4 | 17 |
| 2383 | Modulation of the PD-1/PD-L1 immune checkpoint axis during inflammation-associated lung tumorigenesis. Carcinogenesis, 2020, 41, 1518-1528. | 1.3 | 23 |
| 2384 | Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma. Modern Pathology, 2020, 33, 2221-2232. | 2.9 | 23 |
| 2385 | Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition. OncoImmunology, 2020, 9, 1761229. | 2.1 | 22 |
| 2386 | PD-L1+ exosomes from bone marrow-derived cells of tumor-bearing mice inhibit antitumor immunity. Cellular and Molecular Immunology, 2021, 18, 2402-2409. | 4.8 | 23 |
| 2387 | Role of DNA repair defects in predicting immunotherapy response. Biomarker Research, 2020, 8, 23. | 2.8 | 47 |
| 2388 | Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors. Journal of Leukocyte Biology, 2020, 108, 1067-1079. | 1.5 | 50 |
| 2389 | LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures. OncoImmunology, 2020, 9, 1736792. | 2.1 | 36 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 2390 | <p>Tumor Mutational Burden and PD-L1 Expression in Non-Small-Cell Lung Cancer (NSCLC) in Southwestern China</p>. OncoTargets and Therapy, 2020, Volume 13, 5191-5198. | 1.0 | 3 |
| 2391 | Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers. Nanomaterials, 2020, 10, 1274. | 1.9 | 26 |
| 2392 | SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer. Future Oncology, 2020, 16, 1801-1813. | 1.1 | 8 |
| 2393 | News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors. Seminars in Cancer Biology, 2022, 79, 18-43. | 4.3 | 35 |
| 2394 | Photodynamic Therapy and Immune Checkpoint Blockade<sup>â€</sup>. Photochemistry and Photobiology, 2020, 96, 954-961. | 1.3 | 54 |
| 2395 | Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities. Cancer Treatment Reviews, 2020, 88, 102054. | 3.4 | 76 |
| 2396 | Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resistance Updates, 2020, 53, 100715. | 6.5 | 275 |
| 2397 | Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review. Frontiers in Immunology, 2020, 11, 1036. | 2.2 | 10 |
| 2398 | Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer. Clinical Lung Cancer, 2020, 21, 455-463.e4. | 1.1 | 13 |
| 2399 | Molecular Bases of Drug Resistance in Hepatocellular Carcinoma. Cancers, 2020, 12, 1663. | 1.7 | 112 |
| 2400 | Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment. Advances in Cancer Research, 2020, 147, 1-57. | 1.9 | 32 |
| 2401 | Use of checkpoint inhibitors in gray zone lymphoma. Hematology/ Oncology and Stem Cell Therapy, 2020, , . | 0.6 | 3 |
| 2402 | Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma. Clinical Epigenetics, 2020, 12, 94. | 1.8 | 26 |
| 2403 | The Unmet Needs of the Diagnosis, Staging, and Treatment of Gastrointestinal Tumors. Seminars in Nuclear Medicine, 2020, 50, 389-398. | 2.5 | 5 |
| 2404 | Metaâ€analysis of immuneâ€related adverse events of immune checkpoint inhibitor therapy in cancer patients. Thoracic Cancer, 2020, 11, 2406-2430. | 0.8 | 40 |
| 2405 | Development and applications of computer image analysis algorithmsÂforÂscoring of PD-L1 immunohistochemistry. Immuno-Oncology Technology, 2020, 6, 2-8. | 0.2 | 26 |
| 2406 | Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis. Disease Markers, 2020, 2020, 1-16. | 0.6 | 11 |
| 2407 | &lt;p&gt;PD-L1 and miR-34a are Prognostic Factors for Primary Gastric Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP&lt;/p&gt;. Cancer Management and Research, 2020, Volume 12, 4999-5008. | 0.9 | 7 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 2408 | The impact of PD-L1â€‰N-linked glycosylation on cancer therapy and clinical diagnosis. Journal of Biomedical Science, 2020, 27, 77. | 2.6 | 89 |
| 2409 | Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer. Seminars in Cancer Biology, 2022, 79, 44-57. | 4.3 | 104 |
| 2410 | Presence of a 34-gene signature is a favorable prognostic marker in squamous non-small cell lung carcinoma. Journal of Translational Medicine, 2020, 18, 271. | 1.8 | 8 |
| 2411 | &lt;p&gt;BTLA Expression in Stage Iâ€"III Nonâ€"Small-Cell Lung Cancer and Its Correlation with PD-1/PD-L1 and Clinical Outcomes&lt;/p&gt;. OncoTargets and Therapy, 2020, Volume 13, 215-224. | 1.0 | 38 |
| 2412 | Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1217-1225. | 1.2 | 42 |
| 2413 | Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers. Breast Cancer Research and Treatment, 2020, 180, 369-377. | 1.1 | 33 |
| 2414 | Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies. European Journal of Cancer, 2020, 128, 119-128. | 1.3 | 50 |
| 2415 | &lt;p&gt;Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer&lt;/p&gt;. OncoTargets and Therapy, 2020, Volume 13, 667-683. | 1.0 | 24 |
| 2416 | Synergizing systemic responses by combining immunotherapy with radiotherapy in metastatic non-small cell lung cancer: The potential of the abscopal effect. Lung Cancer, 2020, 142, 106-113. | 0.9 | 28 |
| 2417 | Pembrolizumabâ€"axitinibâ€"induced tumor lysis syndrome in a patient with metastatic renal cancer. Clinical Case Reports (discontinued), 2020, 8, 704-708. | 0.2 | 5 |
| 2418 | The promise of immunotherapy in the treatment of young adults with oral tongue cancer. Laryngoscope Investigative Otolaryngology, 2020, 5, 235-242. | 0.6 | 4 |
| 2419 | Correlation of PD-L1 expression on tumor cell and tumor infiltrating immune cell with 18F-fluorodeoxyglucose uptake on PET/computed tomography in surgically resected pulmonary adenocarcinoma. Nuclear Medicine Communications, 2020, 41, 252-259. | 0.5 | 5 |
| 2420 | Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity. Nature Communications, 2020, 11, 951. | 5.8 | 34 |
| 2421 | Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report. Thoracic Cancer, 2020, 11, 1094-1098. | 0.8 | 10 |
| 2422 | Antiâ€"PD-1 treatment impairs opioid antinociception in rodents and nonhuman primates. Science Translational Medicine, 2020, 12, . | 5.8 | 54 |
| 2424 | The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppressive monocyte induction. Neuro-Oncology, 2020, 22, 967-978. | 0.6 | 62 |
| 2425 | Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions. Expert Review of Precision Medicine and Drug Development, 2020, 5, 59-65. | 0.4 | 13 |
| 2426 | HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties. MAbs, 2020, 12, 1724751. | 2.6 | 25 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 2427 | Analytical Performance of an Immunoprofiling Assay Based on RNA Models. Journal of Molecular Diagnostics, 2020, 22, 555-570. | 1.2 | 6 |
| 2428 | Panaxadiol inhibits programmed cell death-ligand 1 expression and tumour proliferation via hypoxia-inducible factor (HIF)-1α and STAT3 in human colon cancer cells. Pharmacological Research, 2020, 155, 104727. | 3.1 | 60 |
| 2429 | Resistance to Checkpoint Inhibition in Cancer Immunotherapy. Translational Oncology, 2020, 13, 100738. | 1.7 | 173 |
| 2430 | Prognostic Biomarkers for Melanoma Immunotherapy. Current Oncology Reports, 2020, 22, 25. | 1.8 | 13 |
| 2431 | VISTA: Coming of age as a multi-lineage immune checkpoint. Clinical and Experimental Immunology, 2020, 200, 120-130. | 1.1 | 66 |
| 2432 | Yap suppresses T-cell function and infiltration in the tumor microenvironment. PLoS Biology, 2020, 18, e3000591. | 2.6 | 58 |
| 2433 | Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2020, 631, xxiii-xlii. | 0.4 | 1 |
| 2434 | Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade. Science Translational Medicine, 2020, 12, . | 5.8 | 117 |
| 2435 | Targeting the orphan nuclear receptor NR2F6 in T cells primes tumors for immune checkpoint therapy. Cell Communication and Signaling, 2020, 18, 8. | 2.7 | 16 |
| 2436 | Fatty acid synthase is a prognostic marker and associated with immune infiltrating in gastric cancers precision medicine. Biomarkers in Medicine, 2020, 14, 185-199. | 0.6 | 15 |
| 2437 | The importance of exosomal PDL1 in tumour immune evasion. Nature Reviews Immunology, 2020, 20, 209-215. | 10.6 | 360 |
| 2438 | Chemoradiation and granulocyte-colony or granulocyte macrophage-colony stimulating factors (G-CSF or GM-CSF): time to think out of the box?. British Journal of Radiology, 2020, 93, 20190147. | 1.0 | 14 |
| 2439 | Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in <i>EGFR</i> Mutation–Positive Non–Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 2037-2046. | 3.2 | 142 |
| 2440 | Current Status and Future Perspectives of Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Comprehensive Review. Cancers, 2020, 12, 192. | 1.7 | 30 |
| 2441 | Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection. International Journal of Molecular Sciences, 2020, 21, 556. | 1.8 | 21 |
| 2442 | Association between radiotherapy-induced alteration of programmed death ligand 1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy. Strahlentherapie Und Onkologie, 2020, 196, 725-735. | 1.0 | 23 |
| 2443 | Baseline derived neutrophil-to-lymphocyte ratio as a prognostic biomarker for non-colorectal gastrointestinal cancer patients treated with immune checkpoint blockade. Clinical Immunology, 2020, 212, 108345. | 1.4 | 18 |
| 2444 | Molecular Imaging for Cancer Immunotherapy: Seeing Is Believing. Bioconjugate Chemistry, 2020, 31, 404-415. | 1.8 | 31 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 2445 | Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma. BMC Cancer, 2020, 20, 58. | 1.1 | 25 |
| 2446 | Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment. Diagnostic Pathology, 2020, 15, 6. | 0.9 | 55 |
| 2447 | Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination. International Journal of Cancer, 2020, 147, 1509-1518. | 2.3 | 44 |
| 2448 | Intratumoral delivery of CCL25 enhances immunotherapy against triple-negative breast cancer by recruiting CCR9 <sup>+</sup> T cells. Science Advances, 2020, 6, eaax4690. | 4.7 | 51 |
| 2449 | Biomarkers for immunotherapy response in head and neck cancer. Cancer Treatment Reviews, 2020, 84, 101977. | 3.4 | 153 |
| 2450 | Prognostic value and clinicopathological characteristics of PD-L1 overexpression in non-Hodgkin lymphoma: a meta-analysis. BMC Cancer, 2020, 20, 59. | 1.1 | 8 |
| 2451 | An Exon Signature to Estimate the Tumor Mutational Burden of Right-sided Colon Cancer Patients. Journal of Cancer, 2020, 11, 883-892. | 1.2 | 5 |
| 2452 | Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis. World Journal of Surgical Oncology, 2020, 18, 15. | 0.8 | 58 |
| 2453 | A Four-Chemokine Signature Is Associated with a T-cellâ€"Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 1997-2010. | 3.2 | 91 |
| 2454 | &lt;p&gt;Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle&lt;/p&gt;. OncoTargets and Therapy, 2020, Volume 13, 83-94. | 1.0 | 27 |
| 2455 | Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response. Journal of Clinical Medicine, 2020, 9, 286. | 1.0 | 50 |
| 2456 | Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials. Immunity, 2020, 52, 36-54. | 6.6 | 127 |
| 2457 | Top 10 Challenges in Cancer Immunotherapy. Immunity, 2020, 52, 17-35. | 6.6 | 1,177 |
| 2458 | Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer. Cellular and Molecular Life Sciences, 2020, 77, 3693-3710. | 2.4 | 48 |
| 2459 | Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2020, 632, xxiii-xlii. | 0.4 | 0 |
| 2460 | Characterization of the tumor immune infiltrate by multiparametric flow cytometry and unbiased high-dimensional data analysis. Methods in Enzymology, 2020, 632, 309-337. | 0.4 | 6 |
| 2461 | A novel IFNÎ±-induced long noncoding RNA negatively regulates immunosuppression by interrupting H3K27 acetylation in head and neck squamous cell carcinoma. Molecular Cancer, 2020, 19, 4. | 7.9 | 54 |
| 2462 | Tumor Timeâ€"Course Predicts Overall Survival in Nonâ€"Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Followâ€"Up Time. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 115-123. | 1.3 | 8 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 2463 | Long‑term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer. Cancer Science, 2020, 111, 1676-1684. | 1.7 | 21 |
| 2464 | Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer. Lung Cancer Management, 2020, 9, LMT26. | 1.5 | 9 |
| 2465 | Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma. Cancers, 2020, 12, 1089. | 1.7 | 119 |
| 2466 | New directions in chimeric antigen receptor T cell [CAR‑T] therapy and related flow cytometry. Cytometry Part B - Clinical Cytometry, 2020, 98, 299-327. | 0.7 | 28 |
| 2467 | Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell, 2020, 37, 720-734.e13. | 7.7 | 74 |
| 2468 | Retrospective analysis of the prognostic value of PD-L1 expression and 18F-FDG PET/CT metabolic parameters in colorectal cancer. Journal of Cancer, 2020, 11, 2864-2873. | 1.2 | 15 |
| 2469 | Integrating the immune microenvironment of prostate cancerÂinduced bone disease. Molecular Carcinogenesis, 2020, 59, 822-829. | 1.3 | 9 |
| 2470 | Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment. International Journal of Clinical Oncology, 2020, 25, 801-809. | 1.0 | 115 |
| 2471 | Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. Annals of Oncology, 2020, 31, 582-589. | 0.6 | 69 |
| 2472 | Advances in theranostic biomarkers for tumor immunotherapy. Current Opinion in Chemical Biology, 2020, 56, 79-90. | 2.8 | 27 |
| 2473 | Atezolizumab for the treatment of renal cell carcinoma. Expert Opinion on Biological Therapy, 2020, 20, 679-686. | 1.4 | 0 |
| 2474 | Identification of Potential Biomarkers for Anti-PD-1 Therapy in Melanoma by Weighted Correlation Network Analysis. Genes, 2020, 11, 435. | 1.0 | 14 |
| 2475 | A$_{2A}$R Antagonism with DZD2269 Augments Antitumor Efficacy of Irradiation in Murine Model. Journal of Cancer, 2020, 11, 3685-3692. | 1.2 | 12 |
| 2476 | Reprograming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma. Cancer Science, 2020, 111, 1899-1909. | 1.7 | 54 |
| 2477 | Contribution of Macrophages and T Cells in Skeletal Metastasis. Cancers, 2020, 12, 1014. | 1.7 | 19 |
| 2478 | Central memory phenotype drives success of checkpoint inhibition in combination with CAR T cells. Molecular Carcinogenesis, 2020, 59, 724-735. | 1.3 | 8 |
| 2479 | Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge. Science China Life Sciences, 2020, 63, 1499-1514. | 2.3 | 20 |
| 2480 | Treatment outcomes of patients with adenocarcinoma of the uterine cervix after definitive radiotherapy and the prognostic impact of tumor-infiltrating CD8+ lymphocytes in pre-treatment biopsy specimens: a multi-institutional retrospective study. Journal of Radiation Research, 2020, 61, 275-284. | 0.8 | 20 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 2481 | A gene signature for immune subtyping of desert, excluded, and inflamed ovarian tumors. American Journal of Reproductive Immunology, 2020, 84, e13244. | 1.2 | 18 |
| 2482 | Microenvironmental Determinants of Pancreatic Cancer. Physiological Reviews, 2020, 100, 1707-1751. | 13.1 | 156 |
| 2483 | Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy. Cancer Communications, 2020, 40, 135-153. | 3.7 | 339 |
| 2484 | The Complexity of Targeting Chemokines to Promote a Tumor Immune Response. Inflammation, 2020, 43, 1201-1208. | 1.7 | 17 |
| 2485 | PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC. Signal Transduction and Targeted Therapy, 2020, 5, 38. | 7.1 | 75 |
| 2486 | Mechanismâ€based treatment of cancer with immune checkpoint inhibitor therapies. British Journal of Clinical Pharmacology, 2020, 86, 1690-1702. | 1.1 | 26 |
| 2487 | Development and validation of the immune signature to predict distant metastasis in patients with nasopharyngeal carcinoma. , 2020, 8, e000205. | | 26 |
| 2488 | High-dimensional immune-profiling in cancer: implications for immunotherapy. , 2020, 8, e000363. | | 49 |
| 2489 | Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models. , 2020, 8, e000400. | | 21 |
| 2490 | A Th1/IFNÎ³ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Nonâ€"Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 1725-1735. | 3.2 | 13 |
| 2491 | Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Nonâ€"Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling. Clinical Cancer Research, 2020, 26, 4360-4368. | 3.2 | 73 |
| 2492 | A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy. Liver Cancer, 2020, 9, 119-137. | 4.2 | 45 |
| 2493 | PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma. BMC Cancer, 2020, 20, 277. | 1.1 | 34 |
| 2494 | Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. Journal of Hematology and Oncology, 2020, 13, 29. | 6.9 | 146 |
| 2495 | Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast. Breast Cancer Research, 2020, 22, 32. | 2.2 | 34 |
| 2496 | Circulating PD-1 mRNA in Peripheral Blood is a Potential Biomarker for Predicting Survival of Breast Cancer Patients. Annals of Surgical Oncology, 2020, 27, 4035-4043. | 0.7 | 7 |
| 2497 | Deciphering the tumor microenvironment through radiomics in non-small cell lung cancer: Correlation with immune profiles. PLoS ONE, 2020, 15, e0231227. | 1.1 | 43 |
| 2498 | Lack of Association Between Radiographic Tumor Burden and Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer. Oncologist, 2020, 25, 515-522. | 1.9 | 7 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 2499 | Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain. Journal of the American Academy of Dermatology, 2020, 83, 860-869. | 0.6 | 5 |
| 2500 | Biomarkers for predicting the outcome of various cancer immunotherapies. Critical Reviews in Oncology/Hematology, 2021, 157, 103161. | 2.0 | 10 |
| 2501 | Regulation of PD-L1 expression in K-ras-driven cancers through ROS-mediated FGFR1 signaling. Redox Biology, 2021, 38, 101780. | 3.9 | 42 |
| 2502 | PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a 177Lu-labeled α̂PD-L1 antibody. Theranostics, 2021, 11, 304-315. | 4.6 | 22 |
| 2503 | Associations among the mutational landscape, immune microenvironment, and prognosis in Chinese patients with hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2021, 70, 377-389. | 2.0 | 25 |
| 2504 | Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC: an analysis of pre- and post-treatment biopsies in the multi-center SAKK19/09 study. Cancer Immunology, Immunotherapy, 2021, 70, 405-415. | 2.0 | 8 |
| 2505 | Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2021, 70, 417-429. | 2.0 | 43 |
| 2506 | Programmed cell death protein 1/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinoma. Histopathology, 2021, 78, 381-391. | 1.6 | 13 |
| 2507 | Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression. Journal of Cancer Research and Clinical Oncology, 2021, 147, 245-251. | 1.2 | 47 |
| 2508 | Model‐Informed Drug Development of the Masked Anti‐PD‐L1 Antibody CX‐072. Clinical Pharmacology and Therapeutics, 2021, 109, 383-393. | 2.3 | 10 |
| 2509 | PD-L1 and VEGFR-2 expression in synchronous metastatic renal cell carcinoma treated with targeted therapy following cytoreductive nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 78.e9-78.e16. | 0.8 | 4 |
| 2510 | Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy. Blood, 2021, 137, 216-231. | 0.6 | 40 |
| 2511 | The Stone Guest: How Does pH Affect Binding Properties of PD‐1/PD‐L1 Inhibitors?. ChemMedChem, 2021, 16, 568-577. | 1.6 | 9 |
| 2512 | Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC. Journal of Thoracic Oncology, 2021, 16, 289-298. | 0.5 | 35 |
| 2513 | PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines. Journal of Advanced Research, 2021, 29, 45-54. | 4.4 | 31 |
| 2514 | Of immune checkpoint maladies and remedies: The throwing of jabs in the oncogenic ring of PDAC. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188483. | 3.3 | 7 |
| 2515 | PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab. Lung Cancer, 2021, 151, 76-83. | 0.9 | 10 |
| 2516 | Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis. Journal of Hepatology, 2021, 74, 700-715. | 1.8 | 60 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 2517 | Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial. Clinical Cancer Research, 2021, 27, 1267-1277. | 3.2 | 21 |
| 2518 | Expression of programmed cell death ligandâ€‘1 by immune cells in the microenvironment is a favorable prognostic factor for primary diffuse large Bâ€‘cell lymphoma of the central nervous system. Neuropathology, 2021, 41, 99-108. | 0.7 | 8 |
| 2519 | Checkpoint inhibitors in NSCLC for the elderly: current challenges and perspectives. Expert Review of Anticancer Therapy, 2021, 21, 315-323. | 1.1 | 7 |
| 2520 | Advanced Melanoma. Hematology/Oncology Clinics of North America, 2021, 35, 111-128. | 0.9 | 5 |
| 2521 | Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Clinical Cancer Research, 2021, 27, 1048-1057. | 3.2 | 129 |
| 2522 | The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: Recent advances and opportunities. Critical Reviews in Oncology/Hematology, 2021, 157, 103160. | 2.0 | 26 |
| 2523 | Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing. Acta Pharmaceutica Sinica B, 2021, 11, 694-707. | 5.7 | 56 |
| 2524 | Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer. Modern Pathology, 2021, 34, 532-541. | 2.9 | 63 |
| 2525 | Intrahepatic cholangiocarcinoma: MRI texture signature as predictive biomarkers of immunophenotyping and survival. European Radiology, 2021, 31, 3661-3672. | 2.3 | 20 |
| 2526 | Overcoming immune resistance by sequential prodrug nanovesicles for promoting chemoimmunotherapy of cancer. Nano Today, 2021, 36, 101025. | 6.2 | 45 |
| 2527 | Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis. Journal of Cancer Research and Clinical Oncology, 2021, 147, 459-468. | 1.2 | 4 |
| 2528 | Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging hsa-miR-194-5p induces immunosuppression in hepatocellular carcinoma. Hepatology International, 2021, 15, 444-458. | 1.9 | 62 |
| 2529 | Phenylboronic-acid-based nanocomplex as a feasible delivery platform of immune checkpoint inhibitor for potent cancer immunotherapy. Journal of Controlled Release, 2021, 330, 1168-1177. | 4.8 | 17 |
| 2530 | PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies. Trends in Molecular Medicine, 2021, 27, 207-219. | 3.5 | 23 |
| 2531 | Lower Airway Dysbiosis Affects Lung Cancer Progression. Cancer Discovery, 2021, 11, 293-307. | 7.7 | 139 |
| 2532 | Immunostimulatory nanoparticle incorporating two immune agonists for the treatment of pancreatic tumors. Journal of Controlled Release, 2021, 330, 1095-1105. | 4.8 | 34 |
| 2533 | Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study. Annals of Oncology, 2021, 32, 384-394. | 0.6 | 70 |
| 2534 | Acid-activatible micelleplex delivering siRNA-PD-L1 for improved cancer immunotherapy of CDK4/6 inhibition. Chinese Chemical Letters, 2021, 32, 1929-1936. | 4.8 | 31 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 2535 | Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy. Bioorganic and Medicinal Chemistry, 2021, 30, 115951. | 1.4 | 7 |
| 2536 | Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial. Journal of Thoracic Oncology, 2021, 16, 653-664. | 0.5 | 251 |
| 2538 | Molecular profiling of longâ€term responders to immune checkpoint inhibitors in advanced nonâ€small cell lung cancer. Molecular Oncology, 2021, 15, 887-900. | 2.1 | 24 |
| 2539 | Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis. EBioMedicine, 2021, 63, 103137. | 2.7 | 44 |
| 2540 | Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect. Journal of Materials Chemistry B, 2021, 9, 746-756. | 2.9 | 27 |
| 2541 | Characterization of a single chain variable fragment of nivolumab that targets PD-1 and blocks PD-L1 binding. Protein Expression and Purification, 2021, 177, 105766. | 0.6 | 7 |
| 2542 | In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1. Molecular Imaging and Biology, 2021, 23, 241-249. | 1.3 | 23 |
| 2543 | <i>SMARCA4</i> mutations in <i>KRAS</i>â€mutant lung adenocarcinoma: a multiâ€cohort analysis. Molecular Oncology, 2021, 15, 462-472. | 2.1 | 29 |
| 2544 | PD-L1 expression in tumor-infiltrating lymphocytes (TILs) as an independent predictor of prognosis in patients with pN0 bladder cancer undergoing radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 195.e15-195.e23. | 0.8 | 6 |
| 2545 | Comprehensive Phenotyping of Dendritic Cells in Cancer Patients by Flow Cytometry. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2021, 99, 218-230. | 1.1 | 6 |
| 2546 | A balance score between immune stimulatory and suppressive microenvironments identifies mediators of tumour immunity and predicts pan-cancer survival. British Journal of Cancer, 2021, 124, 760-769. | 2.9 | 13 |
| 2547 | PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice. Gastroenterology, 2021, 160, 781-796. | 0.6 | 67 |
| 2548 | Prognostic Value of Tumor Proportion Score in Salivary Gland Carcinoma. Laryngoscope, 2021, 131, E1481-E1488. | 1.1 | 15 |
| 2549 | Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response. Briefings in Bioinformatics, 2021, 22, . | 3.2 | 147 |
| 2550 | Integrating proteomics into precision oncology. International Journal of Cancer, 2021, 148, 1438-1451. | 2.3 | 15 |
| 2551 | Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance. Annual Review of Pharmacology and Toxicology, 2021, 61, 85-112. | 4.2 | 50 |
| 2552 | Organized immune cell interactions within tumors sustain a productive T-cell response. International Immunology, 2021, 33, 27-37. | 1.8 | 8 |
| 2553 | Magnifying endoscopy with crystal violet staining for immune checkpoint inhibitorâ€associated colitis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1180-1186. | 1.4 | 1 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 2554 | Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies. Clinical and Translational Oncology, 2021, 23, 882-891. | 1.2 | 5 |
| 2555 | Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors. Cellular and Molecular Life Sciences, 2021, 78, 867-887. | 2.4 | 9 |
| 2556 | Current methods in translational cancer research. Cancer and Metastasis Reviews, 2021, 40, 7-30. | 2.7 | 21 |
| 2557 | Intratumoral Immunotherapy: From Trial Design to Clinical Practice. Clinical Cancer Research, 2021, 27, 665-679. | 3.2 | 69 |
| 2558 | Reinvigorating exhausted CD8$^+$ cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy. Medicinal Research Reviews, 2021, 41, 156-201. | 5.0 | 56 |
| 2559 | Development of nomograms to predict therapeutic response and prognosis of non-small cell lung cancer patients treated with anti-PD-1 antibody. Cancer Immunology, Immunotherapy, 2021, 70, 533-546. | 2.0 | 16 |
| 2560 | Flavonoids nanoparticles in cancer: Treatment, prevention and clinical prospects. Seminars in Cancer Biology, 2021, 69, 200-211. | 4.3 | 129 |
| 2561 | PD-L1 status in breast cancer: Current view and perspectives. Seminars in Cancer Biology, 2021, 72, 146-154. | 4.3 | 69 |
| 2562 | Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation. Journal of Immunology Research, 2021, 2021, 1-18. | 0.9 | 7 |
| 2563 | Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer. MAbs, 2021, 13, 1857100. | 2.6 | 12 |
| 2564 | Modulation of Signaling Pathways by Immunotherapeutics in Lung Cancer. , 2021, , 241-261. | | 0 |
| 2565 | Tumor β‐catenin expression is associated with immune evasion in non‐small cell lung cancer with high tumor mutation burden. Oncology Letters, 2021, 21, 203. | 0.8 | 13 |
| 2566 | Rethinking immune checkpoint blockade: 'Beyond the T cell'. , 2021, 9, e001460. | | 76 |
| 2567 | PD‐L1+ dendritic cells in the tumor microenvironment correlate with good prognosis and CD8+ T cell infiltration in colon cancer. Cancer Science, 2021, 112, 1173-1183. | 1.7 | 27 |
| 2568 | Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding. OncoImmunology, 2021, 10, 1958590. | 2.1 | 16 |
| 2569 | Real‐world efficacy of atezolizumab in non‐small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti‐PD‐1 antibody. Thoracic Cancer, 2021, 12, 613-618. | 0.8 | 16 |
| 2570 | Near-Infrared-II Nanoparticles for Cancer Imaging of Immune Checkpoint Programmed Death-Ligand 1 and Photodynamic/Immune Therapy. ACS Nano, 2021, 15, 515-525. | 7.3 | 86 |
| 2571 | Human and mouse PD-L1: similar molecular structure, but different druggability profiles. IScience, 2021, 24, 101960. | 1.9 | 45 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 2572 | Cancer Immunology. , 2021, , . | | 0 |
| 2573 | Exploration of the relationship between tumor mutation burden and immune infiltrates in colon adenocarcinoma. International Journal of Medical Sciences, 2021, 18, 685-694. | 1.1 | 4 |
| 2574 | Targeting TGFβ signal transduction for cancer therapy. Signal Transduction and Targeted Therapy, 2021, 6, 8. | 7.1 | 186 |
| 2575 | Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors. Cancer Immunology, Immunotherapy, 2021, 70, 2209-2221. | 2.0 | 32 |
| 2576 | Identification of biomarkers related to Tumor-Infiltrating Lymphocytes (TILs) infiltration with gene co-expression network in colorectal cancer. Bioengineered, 2021, 12, 1676-1688. | 1.4 | 9 |
| 2577 | Recent Advances and Future Directions in Clinical Management of Head and Neck Squamous Cell Carcinoma. Cancers, 2021, 13, 338. | 1.7 | 70 |
| 2578 | Genetic engineering cellular vesicles expressing CD64 as checkpoint antibody carrier for cancer immunotherapy. Theranostics, 2021, 11, 6033-6043. | 4.6 | 22 |
| 2579 | Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients. Annals of Translational Medicine, 2021, 9, 33-33. | 0.7 | 16 |
| 2580 | Heat shock factor 5 correlated with immune infiltration serves as a prognostic biomarker in lung adenocarcinoma. International Journal of Medical Sciences, 2021, 18, 448-458. | 1.1 | 5 |
| 2581 | Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1. , 2021, 9, e001698. | | 78 |
| 2582 | The combination strategy with epigenetic therapy, chemotherapy, and immunotherapy. , 2021, , 85-102. | | 0 |
| 2583 | Flow cytometry detection of cell type-specific expression of programmed death receptor ligand-1 (PD-L1) in colorectal cancer specimens. Heliyon, 2021, 7, e05880. | 1.4 | 3 |
| 2584 | B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines. Human Vaccines and Immunotherapeutics, 2021, 17, 1910-1922. | 1.4 | 9 |
| 2586 | Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics, 2021, 11, 5365-5386. | 4.6 | 324 |
| 2587 | For which lung cancer patients is re-administration of immune checkpoint inhibitors effective?. Journal of Rural Medicine: JRM, 2021, 16, 256-262. | 0.2 | 2 |
| 2588 | Prevalence of programmed death ligand-1 in patients diagnosed with non-small cell lung cancer in Lebanon. SAGE Open Medicine, 2021, 9, 205031212110437. | 0.7 | 1 |
| 2589 | Concomitant Proton Pump Inhibitors and Immune Checkpoint Inhibitors Increase Nephritis Frequency. In Vivo, 2021, 35, 2831-2840. | 0.6 | 12 |
| 2590 | Fcγ receptorsâ€"Master regulators of antibody therapy. , 2021, , 195-225. | | 0 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 2591 | PD-L1 Detection on Circulating Melanoma Cells. Methods in Molecular Biology, 2021, 2265, 223-233. | 0.4 | 1 |
| 2592 | Baseline lesion number as an efficacy predictive and independent prognostic factor and its joint utility with TMB for PD-1 inhibitor treatment in advanced gastric cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592198899. | 1.4 | 17 |
| 2593 | Association of Peripheral Blood Biomarkers With Response to Anti-PD-1 Immunotherapy for Patients With dMMR Metastatic Colorectal Cancer: A Multicenter Cohort Study. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 2595 | Distinctive genomic characteristics in POLE/POLD1-mutant cancers can potentially predict beneficial clinical outcomes in patients who receive immune checkpoint inhibitor. Annals of Translational Medicine, 2021, 9, 129-129. | 0.7 | 24 |
| 2596 | Tumor infiltrating lymphocyte clusters are associated with response to immune checkpoint inhibition in BRAF V600E/K mutated malignant melanomas. Scientific Reports, 2021, 11, 1834. | 1.6 | 27 |
| 2597 | Checkpoint-Inhibitoren. Springer Reference Medizin, 2021, , 1-11. | 0.0 | 0 |
| 2598 | Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring <i>STK11</i> or <i>KEAP1</i> mutation. OncoImmunology, 2021, 10, 1865670. | 2.1 | 9 |
| 2599 | Single-cell transcriptome analysis of the heterogeneous effects of differential expression of tumor PD-L1 on responding TCR-T cells. Theranostics, 2021, 11, 4957-4974. | 4.6 | 4 |
| 2600 | Innovative immunotherapy targeting at PD-1/PD-L1 signaling pathway: mechanism, efficacy and safety analysis of monotherapy and combination therapies in non-small cell lung cancer (NSCLC) treatment. E3S Web of Conferences, 2021, 267, 02026. | 0.2 | 0 |
| 2601 | Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patients. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2741-2750. | 1.2 | 4 |
| 2602 | Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1. Nature Communications, 2021, 12, 1222. | 5.8 | 62 |
| 2603 | Immune Checkpoint Inhibitors: Cardiotoxicity in Pre-clinical Models and Clinical Studies. Frontiers in Cardiovascular Medicine, 2021, 8, 619650. | 1.1 | 17 |
| 2604 | m6A regulator-mediated methylation modification patterns and characteristics of immunity and stemness in low-grade glioma. Briefings in Bioinformatics, 2021, 22, . | 3.2 | 57 |
| 2605 | Tumor Microenvironment, HLA Class I and APM Expression in HPV-Negative Oral Squamous Cell Carcinoma. Cancers, 2021, 13, 620. | 1.7 | 11 |
| 2606 | Potential Mechanism of Immune Evasion Associated with the Master Regulator ASCL2 in Microsatellite Stability in Colorectal Cancer. Journal of Immunology Research, 2021, 2021, 1-12. | 0.9 | 9 |
| 2607 | Evolving Status of Clinical Immunotherapy with Oncolytic Adenovirus. Clinical Cancer Research, 2021, 27, 2979-2988. | 3.2 | 17 |
| 2608 | Lights and Shadows in Immuno-Oncology Drug Development. Cancers, 2021, 13, 691. | 1.7 | 0 |
| 2609 | Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2459-2469. | 1.2 | 3 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 2610 | IMpower132: Atezolizumab plus platinum–based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients. Cancer Science, 2021, 112, 1534-1544. | 1.7 | 24 |
| 2611 | Synthetic TILs: Engineered Tumor-Infiltrating Lymphocytes With Improved Therapeutic Potential. Frontiers in Oncology, 2020, 10, 593848. | 1.3 | 12 |
| 2612 | PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade. European Journal of Cancer, 2021, 144, 317-325. | 1.3 | 13 |
| 2613 | Impact of cancer evolution on immune surveillance and checkpoint inhibitor response. Seminars in Cancer Biology, 2022, 84, 89-102. | 4.3 | 21 |
| 2614 | Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy. ESMO Open, 2021, 6, 100046. | 2.0 | 25 |
| 2615 | Clinical significance of checkpoint regulator "Programmed death ligand-1 (PD-L1)" expression in meningioma: review of the current status. Journal of Neuro-Oncology, 2021, 151, 443-449. | 1.4 | 13 |
| 2616 | Development and validation of a PD-L1/PD-1/CD8 axis-based classifier to predict cancer survival of upper tract urothelial carcinoma after radical nephroureterectomy. Cancer Immunology, Immunotherapy, 2021, 70, 2657-2668. | 2.0 | 4 |
| 2617 | Reprogramming Transcription Factors Oct4 and Sox2 Induce a BRD-Dependent Immunosuppressive Transcriptome in GBM-Propagating Cells. Cancer Research, 2021, 81, 2457-2469. | 0.4 | 31 |
| 2618 | Immunotherapeutic advances in gastric cancer. Surgery Today, 2021, 51, 1727-1735. | 0.7 | 14 |
| 2619 | Nanotechnology-based platforms to improve immune checkpoint blockade efficacy in cancer therapy. Future Oncology, 2021, 17, 711-722. | 1.1 | 10 |
| 2620 | PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nature Reviews Clinical Oncology, 2021, 18, 345-362. | 12.5 | 646 |
| 2621 | Harnessing non-destructive 3D pathology. Nature Biomedical Engineering, 2021, 5, 203-218. | 11.6 | 74 |
| 2622 | Perspectives on Oncolytic Salmonella in Cancer Immunotherapy—A Promising Strategy. Frontiers in Immunology, 2021, 12, 615930. | 2.2 | 12 |
| 2624 | Expression and Prognostic Value of Tumor-Infiltrating Lymphocytes and PD-L1 in Hepatocellular Carcinoma. OncoTargets and Therapy, 2021, Volume 14, 1377-1385. | 1.0 | 11 |
| 2625 | Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity. Journal of Experimental and Clinical Cancer Research, 2021, 40, 74. | 3.5 | 19 |
| 2626 | Associations of PD-L1, PD-L2, and HLA class I expression with responses to immunotherapy in patients with advanced sarcoma: post hoc analysis of a phase 1/2 trial. Clinical and Translational Oncology, 2021, 23, 1620-1629. | 1.2 | 2 |
| 2627 | Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments. Frontiers in Immunology, 2020, 11, 569117. | 2.2 | 26 |
| 2628 | Syngeneic tobacco carcinogen–induced mouse lung adenocarcinoma model exhibits PD-L1 expression and high tumor mutational burden. JCI Insight, 2021, 6, . | 2.3 | 13 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 2629 | First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Cancers, 2021, 13, 931. | 1.7 | 26 |
| 2630 | What is the prospect of indoleamine 2,3-dioxygenase 1Âinhibition in cancer? Extrapolation from the past. Journal of Experimental and Clinical Cancer Research, 2021, 40, 60. | 3.5 | 22 |
| 2631 | PD-L1 in Breast Cancer: The Road to the Perfect Biomarker Is Fraught With Uncertainty. Journal of the National Cancer Institute, 2021, 113, 951-952. | 3.0 | 3 |
| 2632 | Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update. International Journal of Molecular Sciences, 2021, 22, 1807. | 1.8 | 8 |
| 2633 | The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpointÂinhibitors. ESMO Open, 2021, 6, 100008. | 2.0 | 5 |
| 2634 | Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. Clinical Cancer Research, 2021, 27, 3360-3369. | 3.2 | 47 |
| 2635 | PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma. Npj Precision Oncology, 2021, 5, 10. | 2.3 | 57 |
| 2636 | Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?. Frontiers in Pharmacology, 2021, 12, 572845. | 1.6 | 6 |
| 2637 | Differential expression of PD-L1 between primary and metastatic epithelial ovarian cancer and its clinico-pathological correlation. Scientific Reports, 2021, 11, 3750. | 1.6 | 22 |
| 2638 | Immunogenic Cell Death Inducing Fluorinated Mitochondriaâ€Disrupting Helical Polypeptide Synergizes with PDâ€L1 Immune Checkpoint Blockade. Advanced Science, 2021, 8, 2001308. | 5.6 | 31 |
| 2639 | Molecular and pathological analyses of gastric stump cancer by next-generation sequencing and immunohistochemistry. Scientific Reports, 2021, 11, 4165. | 1.6 | 3 |
| 2640 | Atezolizumab and bevacizumab combination compared with sorafenib as the firstâ€line systemic treatment for patients with unresectable hepatocellular carcinoma: A costâ€effectiveness analysis in China and the United states. Liver International, 2021, 41, 1097-1104. | 1.9 | 43 |
| 2641 | Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). Journal of Clinical Oncology, 2021, 39, 619-630. | 0.8 | 317 |
| 2642 | Non-canonical PD-1 signaling in cancer and its potential implications in clinic. , 2021, 9, e001230. | | 15 |
| 2643 | Mechanisms of immunogenic cell death and immune checkpoint blockade therapy. Kaohsiung Journal of Medical Sciences, 2021, 37, 448-458. | 0.8 | 15 |
| 2644 | In silico analysis of resveratrol induced PD-L1 dimerisation. Journal of the Belarusian State University Biology, 2021, , 39-47. | 0.2 | 0 |
| 2645 | Nanofitins targeting heat shock protein 110: An innovative immunotherapeutic modality in cancer. International Journal of Cancer, 2021, 148, 3019-3031. | 2.3 | 16 |
| 2646 | Results of a Doseâ€Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Nonâ€"Small Cell Lung Cancer. Clinical Pharmacology in Drug Development, 2021, 10, 1142-1155. | 0.8 | 8 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 2647 | Biomimetic Nanoemulsion for Synergistic Photodynamicâ€‹Immunotherapy Against Hypoxic Breast Tumor. Angewandte Chemie, 2021, 133, 10742-10748. | 1.6 | 13 |
| 2648 | Long-term efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients harboring MET exon 14 skipping mutations. International Journal of Clinical Oncology, 2021, 26, 1065-1072. | 1.0 | 3 |
| 2649 | Identification of Stemness Characteristics Associated With the Immune Microenvironment and Prognosis in Gastric Cancer. Frontiers in Oncology, 2021, 11, 626961. | 1.3 | 18 |
| 2650 | Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation. European Journal of Medicinal Chemistry, 2021, 213, 113170. | 2.6 | 32 |
| 2651 | An integrated model of N6-methyladenosine regulators to predict tumor aggressiveness and immune evasion in pancreatic cancer. EBioMedicine, 2021, 65, 103271. | 2.7 | 33 |
| 2652 | Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities. Annals of Translational Medicine, 2021, 9, 423-423. | 0.7 | 6 |
| 2654 | Immunotherapy and predictive immunologic profile: the tip of the iceberg. Medical Oncology, 2021, 38, 51. | 1.2 | 4 |
| 2655 | Bladder preservation therapy in combination with atezolizumab and radiation therapy for invasive bladder cancer (BPT-ART) â€“ A study protocol for an open-label, phase II, multicenter study. Contemporary Clinical Trials Communications, 2021, 21, 100724. | 0.5 | 3 |
| 2656 | Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy. Neoplasia, 2021, 23, 281-293. | 2.3 | 18 |
| 2657 | NFÎºB-Activated COX2/PGE2/EP4 Axis Controls the Magnitude and Selectivity of BCG-Induced Inflammation in Human Bladder Cancer Tissues. Cancers, 2021, 13, 1323. | 1.7 | 13 |
| 2658 | Risk Signature Related to Immunotherapy Reaction of Hepatocellular Carcinoma Based on the Immune-Related Genes Associated With CD8+ T Cell Infiltration. Frontiers in Molecular Biosciences, 2021, 8, 602227. | 1.6 | 3 |
| 2659 | Identification ACTA2 and KDR as key proteins for prognosis of PDâ€‘1/PDâ€‘L1 blockade therapy in melanoma. Animal Models and Experimental Medicine, 2021, 4, 138-150. | 1.3 | 4 |
| 2660 | Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19â€“IL2 cures poorly immunogenic tumors when combined with radiotherapy. , 2021, 9, e001764. | | 23 |
| 2661 | Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment. Nature Communications, 2021, 12, 1503. | 5.8 | 45 |
| 2662 | Anticancer nanocage platforms for combined immunotherapy designed to harness immune checkpoints and deliver anticancer drugs. Biomaterials, 2021, 270, 120685. | 5.7 | 29 |
| 2663 | Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors. Frontiers in Immunology, 2021, 12, 619209. | 2.2 | 13 |
| 2664 | Virus-specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis. Nature Communications, 2021, 12, 1439. | 5.8 | 39 |
| 2665 | Association between PD-L1 expression and 18F-FDG uptake in ovarian cancer. Annals of Nuclear Medicine, 2021, 35, 415-420. | 1.2 | 3 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 2666 | Clinical benefit of neoadjuvant antiâ€PDâ€1/PDâ€L1 utilization among different tumors. MedComm, 2021, 2, 60-68. | 3.1 | 16 |
| 2667 | A combination of PDâ€‘1/PDâ€L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review). Molecular Medicine Reports, 2021, 23, . | 1.1 | 16 |
| 2668 | Immunotherapy for pancreatic cancer: chasing the light at the end of the tunnel. Cellular Oncology (Dordrecht), 2021, 44, 261-278. | 2.1 | 16 |
| 2669 | Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIBâ€"IVM1c melanoma. , 2021, 9, e001621. | | 32 |
| 2670 | Biomimetic Nanoemulsion for Synergistic Photodynamicâ€Immunotherapy Against Hypoxic Breast Tumor. Angewandte Chemie - International Edition, 2021, 60, 10647-10653. | 7.2 | 96 |
| 2671 | Cutaneous Squamous Cell Carcinoma in the Age of Immunotherapy. Cancers, 2021, 13, 1148. | 1.7 | 19 |
| 2672 | The Targeting Effect of Cetuximab Combined with PD-L1 Blockade against EGFR-Expressing Tumors in a Tailored CD16-CAR T-Cell Reporter System. Cancer Investigation, 2021, 39, 1-12. | 0.6 | 5 |
| 2673 | Cost-effectiveness Analysis of Atezolizumab Plus Nab-Paclitaxel for Advanced PD-L1 Positive Triple-Negative Breast Cancer in Japan. Clinical Drug Investigation, 2021, 41, 381-389. | 1.1 | 7 |
| 2674 | Clinical impact of probiotics on the efficacy of <scp>antiâ€PD</scp>â€1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting. International Journal of Cancer, 2021, 149, 473-482. | 2.3 | 35 |
| 2675 | T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors. Nature Communications, 2021, 12, 1402. | 5.8 | 85 |
| 2676 | The Mechanisms Leading to Distinct Responses to PD-1/PD-L1 Blockades in Colorectal Cancers With Different MSI Statuses. Frontiers in Oncology, 2021, 11, 573547. | 1.3 | 11 |
| 2677 | Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 657615. | 1.3 | 29 |
| 2678 | Anti-Tumor Efficacy of PD-L1 Targeted Alpha-Particle Therapy in a Human Melanoma Xenograft Model. Cancers, 2021, 13, 1256. | 1.7 | 6 |
| 2679 | Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas. Frontiers in Oncology, 2021, 11, 596290. | 1.3 | 18 |
| 2680 | Immunotherapy in Adrenocortical Carcinoma: Predictors of Response, Efficacy, Safety, and Mechanisms of Resistance. Biomedicines, 2021, 9, 304. | 1.4 | 16 |
| 2681 | Therapeutic applications of the cancer immunoediting hypothesis. Seminars in Cancer Biology, 2022, 78, 63-77. | 4.3 | 29 |
| 2682 | Nanomedicineâ€Boosting Tumor Immunogenicity for Enhanced Immunotherapy. Advanced Functional Materials, 2021, 31, 2011171. | 7.8 | 84 |
| 2683 | Meta-analysis of the Efficacy and Tolerability of Immune Checkpoint Inhibitors Combined With Chemotherapy in First-line Treatment of Small Cell Lung Cancer. Clinical Therapeutics, 2021, 43, 582-593.e2. | 1.1 | 4 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------| 
| 2684 | Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade. Frontiers in Oncology, 2021, 11, 617335. | 1.3 | 49 |
| 2685 | Human papillomavirus-mediated carcinogenesis and tumor progression. Genome Instability & Disease, 2021, 2, 71-91. | 0.5 | 0 |
| 2686 | Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study. Translational Lung Cancer Research, 2021, 10, 1594-1607. | 1.3 | 17 |
| 2687 | Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma. JAMA Network Open, 2021, 4, e214846. | 2.8 | 42 |
| 2688 | Pathological Findings of the Host Immune Reaction in the Tumor Microenvironment of Gastroenteropancreatic Neuroendocrine Neoplasms. Internal Medicine, 2021, 60, 977-983. | 0.3 | 3 |
| 2689 | Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US. Frontiers in Public Health, 2021, 9, 650392. | 1.3 | 5 |
| 2690 | PD-1/PD-L1 Expression Levels and Prognostic Significance in Chronic Lymphocytic Leukemia. Acibadem Universitesi Saglik Bilimleri Dergisi, 2021, 12, . | 0.0 | 0 |
| 2691 | Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy. Frontiers in Immunology, 2021, 12, 679117. | 2.2 | 22 |
| 2692 | Vascular normalisation as the stepping stone into tumour microenvironment transformation. British Journal of Cancer, 2021, 125, 324-336. | 2.9 | 44 |
| 2693 | PD-L1 expression in recurrent head and neck squamous cell carcinoma. European Archives of Oto-Rhino-Laryngology, 2022, 279, 343-351. | 0.8 | 6 |
| 2694 | Time-dependent population PK models of single-agent atezolizumab in patients with cancer. Cancer Chemotherapy and Pharmacology, 2021, 88, 211-221. | 1.1 | 13 |
| 2695 | The Ratio of IP10 to IL-8 in Plasma Reflects and Predicts the Response of Patients With Lung Cancer to Anti-PD-1 Immunotherapy Combined With Chemotherapy. Frontiers in Immunology, 2021, 12, 665147. | 2.2 | 11 |
| 2696 | Antibody Libraries as Tools to Discover Functional Antibodies and Receptor Pleiotropism. International Journal of Molecular Sciences, 2021, 22, 4123. | 1.8 | 8 |
| 2697 | Malignant Pleural Effusionsâ€"A Window Into Local Anti-Tumor T Cell Immunity?. Frontiers in Oncology, 2021, 11, 672747. | 1.3 | 9 |
| 2698 | Trials and tribulations of pancreatic cancer immunotherapy. Cancer Letters, 2021, 504, 1-14. | 3.2 | 37 |
| 2699 | Anti-angiogenic agents â€" overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. Nature Reviews Clinical Oncology, 2021, 18, 527-540. | 12.5 | 162 |
| 2700 | Prognostic role of proliferating CD8+ cytotoxic Tcells in human cancers. Cellular Oncology (Dordrecht), 2021, 44, 793-803. | 2.1 | 29 |
| 2701 | Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab. Lung Cancer, 2021, 154, 105-112. | 0.9 | 15 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 2702 | Depleting Tumor Cells Expressing Immune Checkpoint Ligandsâ€"A New Approach to Combat Cancer. Cells, 2021, 10, 872. | 1.8 | 2 |
| 2703 | Cell signaling in cutaneous Tâ€cell lymphoma microenvironment: promising targets for molecularâ€specific treatment. International Journal of Dermatology, 2021, 60, 1462-1480. | 0.5 | 10 |
| 2704 | Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma. Cancer Cell International, 2021, 21, 196. | 1.8 | 18 |
| 2705 | Co-delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapy. Nature Communications, 2021, 12, 2425. | 5.8 | 75 |
| 2706 | Radiotherapy, immunotherapy, and the tumour microenvironment: Turning an immunosuppressive milieu into a therapeutic opportunity. Cancer Letters, 2021, 502, 84-96. | 3.2 | 80 |
| 2707 | Endogenous Stimuliâ€Activatable Nanomedicine for Immune Theranostics for Cancer. Advanced Functional Materials, 2021, 31, 2100386. | 7.8 | 36 |
| 2708 | Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells. European Journal of Pharmacology, 2021, 897, 173960. | 1.7 | 5 |
| 2709 | Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients. Cancer Immunology, Immunotherapy, 2021, 70, 3513-3524. | 2.0 | 26 |
| 2710 | Esophageal cancer responsive to the combination of immune cell therapy and low-dose nivolumab: two case reports. Journal of Medical Case Reports, 2021, 15, 191. | 0.4 | 3 |
| 2711 | Gene coexpression network approach to develop an immune prognostic model for pancreatic adenocarcinoma. World Journal of Surgical Oncology, 2021, 19, 112. | 0.8 | 5 |
| 2712 | Molecular Mechanism of Small-Molecule Inhibitors in Blocking the PD-1/PD-L1 Pathway through PD-L1 Dimerization. International Journal of Molecular Sciences, 2021, 22, 4766. | 1.8 | 21 |
| 2713 | Cancer-secreted exosomal miR-1468-5p promotes tumor immune escape via the immunosuppressive reprogramming of lymphatic vessels. Molecular Therapy, 2021, 29, 1512-1528. | 3.7 | 73 |
| 2714 | Systematic Assessment of Transcriptomic Biomarkers for Immune Checkpoint Blockade Response in Cancer Immunotherapy. Cancers, 2021, 13, 1639. | 1.7 | 13 |
| 2715 | PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity. Genome Biology, 2021, 22, 104. | 3.8 | 42 |
| 2717 | Post-Translational Regulations of Foxp3 in Treg Cells and Their Therapeutic Applications. Frontiers in Immunology, 2021, 12, 626172. | 2.2 | 34 |
| 2718 | Identifying Genomic Alterations in Small Cell Lung Cancer Using the Liquid Biopsy of Bronchial Washing Fluid. Frontiers in Oncology, 2021, 11, 647216. | 1.3 | 4 |
| 2719 | Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2021, 22, 4710. | 1.8 | 22 |
| 2720 | Small-Molecule Natural Product Physachenolide C Potentiates Immunotherapy Efficacy by Targeting BET Proteins. Cancer Research, 2021, 81, 3374-3386. | 0.4 | 11 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 2721 | Addressing resistance to immune checkpoint inhibitor therapy:Âan urgent unmet need. Future Oncology, 2021, 17, 1401-1439. | 1.1 | 17 |
| 2722 | Immunotherapy Combined With Radiation Therapy for Genitourinary Malignancies. Frontiers in Oncology, 2021, 11, 663852. | 1.3 | 19 |
| 2723 | Safety and Efficacy of Personalized Cancer Vaccines in Combination With Immune Checkpoint Inhibitors in Cancer Treatment. Frontiers in Oncology, 2021, 11, 663264. | 1.3 | 19 |
| 2725 | Highly Multiplexed Phenotyping of Immunoregulatory Proteins in the Tumor Microenvironment by CODEX Tissue Imaging. Frontiers in Immunology, 2021, 12, 687673. | 2.2 | 59 |
| 2726 | The role of exosomal PD-L1 in tumor immunotherapy. Translational Oncology, 2021, 14, 101047. | 1.7 | 31 |
| 2727 | Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 667-673. | 0.6 | 11 |
| 2728 | Hepatitis B Virus Pre-S Gene Deletions and Pre-S Deleted Proteins: Clinical and Molecular Implications in Hepatocellular Carcinoma. Viruses, 2021, 13, 862. | 1.5 | 11 |
| 2729 | Immuneâ€related genes and gene sets for predicting the response to antiâ€programmed death 1 therapy in patients with primary or metastatic nonâ€small cell lung cancer. Oncology Letters, 2021, 22, 540. | 0.8 | 8 |
| 2730 | Identification of immune subtypes of cervical squamous cell carcinoma predicting prognosis and immunotherapy responses. Journal of Translational Medicine, 2021, 19, 222. | 1.8 | 9 |
| 2731 | Immunotherapy and radiation for high-grade glioma: a narrative review. Translational Cancer Research, 2021, 10, 2537-2570. | 0.4 | 6 |
| 2732 | Noninvasive evaluation of tumor immune microenvironment in patients with clear cell renal cell carcinoma using metabolic parameter from preoperative 2-[18F]FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4054-4066. | 3.3 | 8 |
| 2733 | Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives. Frontiers in Oncology, 2021, 11, 648139. | 1.3 | 18 |
| 2735 | Lenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study. Cancer Management and Research, 2021, Volume 13, 4233-4240. | 0.9 | 17 |
| 2736 | Reversing T-cell exhaustion in immunotherapy: a review on current approaches and limitations. Expert Opinion on Therapeutic Targets, 2021, 25, 347-363. | 1.5 | 25 |
| 2737 | Characterization of Renal Cell Carcinoma Heterotypic 3D Co-Cultures with Immune Cell Subsets. Cancers, 2021, 13, 2551. | 1.7 | 12 |
| 2738 | Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome. Clinical and Translational Oncology, 2021, 23, 2237-2252. | 1.2 | 7 |
| 2739 | Radiomic biomarkers of tumor immune biology and immunotherapy response. Clinical and Translational Radiation Oncology, 2021, 28, 97-115. | 0.9 | 22 |
| 2740 | PD-L1 as a prognostic and predictive biomarker in neuroendocrine tumors of the lung: state of the art and future perspectives. Minerva Respiratory Medicine, 2021, 60, . | 0.1 | 4 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------| 
| 2741 | Near infrared photoimmunotherapy of cancer; possible clinical applications. Nanophotonics, 2021, 10, 3135-3151. | 2.9 | 19 |
| 2742 | A case of immune checkpoint inhibitor-associated myocarditis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma. Clinical Journal of Gastroenterology, 2021, 14, 1233-1239. | 0.4 | 8 |
| 2743 | Emerging Mechanisms and Treatment Progress on Liver Metastasis of Colorectal Cancer. OncoTargets and Therapy, 2021, Volume 14, 3013-3036. | 1.0 | 10 |
| 2744 | Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. European Urology, 2021, 79, 665-673. | 0.9 | 20 |
| 2745 | Poly(I:C) enhances the efficacy of phagocytosis checkpoint blockade immunotherapy by inducing IL-6 production. Journal of Leukocyte Biology, 2021, 110, 1197-1208. | 1.5 | 9 |
| 2746 | Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma. Bioscience Reports, 2021, 41, . | 1.1 | 39 |
| 2747 | Turning tumors from cold to inflamed to improve immunotherapy response. Cancer Treatment Reviews, 2021, 101, 102227. | 3.4 | 42 |
| 2748 | Applications of single-cell and bulk RNA sequencing in onco-immunology. European Journal of Cancer, 2021, 149, 193-210. | 1.3 | 62 |
| 2749 | Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2022, 71, 25-38. | 2.0 | 15 |
| 2750 | A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis. Annals of Oncology, 2021, 32, 652-660. | 0.6 | 56 |
| 2751 | Genome profiling of mismatch repair genes in eight types of tumors. Cell Cycle, 2021, 20, 1-16. | 1.3 | 0 |
| 2752 | Pearls and Pitfalls in the Imaging of Targeted Therapy and Immunotherapy in Lung Cancer. Seminars in Ultrasound, CT and MRI, 2021, 42, 552-562. | 0.7 | 0 |
| 2753 | Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non–Small Cell Lung Cancer: Results From the Randomized OAK Trial. Clinical Lung Cancer, 2022, 23, 21-33. | 1.1 | 12 |
| 2754 | Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study. Clinical Breast Cancer, 2021, 21, 539-551. | 1.1 | 13 |
| 2755 | PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects. International Journal of Molecular Sciences, 2021, 22, 5123. | 1.8 | 61 |
| 2756 | Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy. Cancer Cell International, 2021, 21, 262. | 1.8 | 31 |
| 2757 | Prognostic and Therapeutic Implications of Immune Classification by CD8+ Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Sinonasal Squamous Cell Carcinoma. International Journal of Molecular Sciences, 2021, 22, 6926. | 1.8 | 12 |
| 2758 | Atezolizumab-induced anaphylactic shock in a patient with hepatocellular carcinoma undergoing immunotherapy: A case report. World Journal of Clinical Cases, 2021, 9, 4110-4115. | 0.3 | 6 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 2759 | Classification of Non-Small Cell Lung Cancer's Tumor Immune Micro-Environment and Strategies to Augment Its Response to Immune Checkpoint Blockade. Cancers, 2021, 13, 2924. | 1.7 | 18 |
| 2760 | PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines. Biomedicine and Pharmacotherapy, 2021, 138, 111436. | 2.5 | 30 |
| 2761 | Notch signaling inhibitor and anti-PD-L1 antibody combination therapies decelerate tumor progression in pancreatic cancer. Journal of Pancreatology, 2021, 4, 106-114. | 0.3 | 3 |
| 2762 | Explant Modeling of the Immune Environment of Head and Neck Cancer. Frontiers in Oncology, 2021, 11, 611365. | 1.3 | 6 |
| 2763 | Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images. , 2021, 9, e002118. | | 75 |
| 2764 | Integrating endobronchial ultrasound bronchoscopy with molecular testing of immunotherapy biomarkers in non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 2779-2787. | 1.3 | 4 |
| 2765 | Correlation Between 18F-FDG Uptake and Immune Cell Infiltration in Metastatic Brain Lesions. Frontiers in Oncology, 2021, 11, 618705. | 1.3 | 5 |
| 2766 | Glyoxalase-1-Dependent Methylglyoxal Depletion Sustains PD-L1 Expression in Metastatic Prostate Cancer Cells: A Novel Mechanism in Cancer Immunosurveillance Escape and a Potential Novel Target to Overcome PD-L1 Blockade Resistance. Cancers, 2021, 13, 2965. | 1.7 | 14 |
| 2767 | PD-L1 detection on circulating tumor-derived extracellular vesicles (T-EVs) from patients with lung cancer. Translational Lung Cancer Research, 2021, 10, 2441-2451. | 1.3 | 19 |
| 2768 | Biomarkers for Diagnosis, Prognosis and Response to Immunotherapy in Melanoma. Cancers, 2021, 13, 2875. | 1.7 | 14 |
| 2769 | Pulmonary metastasectomy in renal cell carcinoma: Predictive and prognostic elements from paired histopathological analysis of primary tumors and respective metastases. Journal of Onco-Nephrology, 2021, 5, 96-104. | 0.3 | 0 |
| 2771 | Novel anti-GARP antibody DS-1055a augments anti-tumor immunity by depleting highly suppressive GARP+ regulatory T cells. International Immunology, 2021, 33, 435-446. | 1.8 | 14 |
| 2772 | Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors. Expert Opinion on Biological Therapy, 2021, 21, 1575-1590. | 1.4 | 7 |
| 2773 | Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 2021, 27, 4557-4565. | 3.2 | 61 |
| 2774 | Molecular determinants of response to PD-L1 blockade across tumor types. Nature Communications, 2021, 12, 3969. | 5.8 | 79 |
| 2775 | Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment. ELife, 2021, 10, . | 2.8 | 127 |
| 2776 | Expression of programmed death ligand 1 (PD-L1) in urothelial bladder carcinoma (immunohistochemical and histopathological study). Egyptian Journal of Medical Research, 2021, 2, 250-261. | 0.1 | 0 |
| 2777 | Trials of Immunotherapy in Triple Negative Breast Cancer. Current Breast Cancer Reports, 2021, 13, 171-185. | 0.5 | 1 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 2778 | Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 2937-2954. | 1.3 | 19 |
| 2779 | SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy. ESMO Open, 2021, 6, 100152. | 2.0 | 6 |
| 2780 | Profiling of 520 Candidate Genes in 50 Surgically Treated Chinese Small Cell Lung Cancer Patients. Frontiers in Oncology, 2021, 11, 644434. | 1.3 | 7 |
| 2781 | Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell, 2021, 39, 845-865.e7. | 7.7 | 503 |
| 2782 | Why MUC16 mutations lead to a better prognosis: A study based on The Cancer Genome Atlas gastric cancer cohort. World Journal of Clinical Cases, 2021, 9, 4143-4158. | 0.3 | 6 |
| 2783 | Immune infiltration phenotypes of prostate adenocarcinoma and their clinical implications. Cancer Medicine, 2021, 10, 5358-5374. | 1.3 | 3 |
| 2784 | Frontline Maintenance Treatment for Ovarian Cancer. Current Oncology Reports, 2021, 23, 97. | 1.8 | 3 |
| 2785 | Cancer‐associated fibroblasts: Key players in shaping the tumor immune microenvironment. Immunological Reviews, 2021, 302, 241-258. | 2.8 | 87 |
| 2786 | CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy. Cancer Gene Therapy, 2022, 29, 722-733. | 2.2 | 10 |
| 2787 | Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors. Translational Lung Cancer Research, 2021, 10, 2842-2857. | 1.3 | 28 |
| 2788 | Immunotherapy in breast cancer: A clinician's perspective. Journal of the National Cancer Center, 2021, 1, 47-57. | 3.0 | 16 |
| 2789 | Cancer immunotherapy: it's time to better predict patients' response. British Journal of Cancer, 2021, 125, 927-938. | 2.9 | 63 |
| 2790 | Mimicking Pathogens to Augment the Potency of Liposomal Cancer Vaccines. Pharmaceutics, 2021, 13, 954. | 2.0 | 7 |
| 2791 | Evaluating the impacts of emerging cancer therapies on ovarian function. Current Opinion in Endocrine and Metabolic Research, 2021, 18, 15-28. | 0.6 | 6 |
| 2792 | Prognostic Impact of Memory CD8(+) T Cells on Immunotherapy in Human Cancers: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 698076. | 1.3 | 9 |
| 2793 | A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2021, 27, 4746-4756. | 3.2 | 22 |
| 2794 | A cyclodextrin-based nanoformulation achieves co-delivery of ginsenoside Rg3 and quercetin for chemo-immunotherapy in colorectal cancer. Acta Pharmaceutica Sinica B, 2022, 12, 378-393. | 5.7 | 63 |
| 2795 | A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 2766-2778. | 1.3 | 9 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 2796 | Challenges and Opportunities in the Statistical Analysis of Multiplex Immunofluorescence Data. Cancers, 2021, 13, 3031. | 1.7 | 21 |
| 2797 | Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas. Aging, 2021, 13, 15444-15458. | 1.4 | 10 |
| 2798 | Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nature Reviews Clinical Oncology, 2021, 18, 625-644. | 12.5 | 148 |
| 2799 | Mechanism of action of PDâ€‘1 receptor/ligand targeted cancer immunotherapy. European Journal of Immunology, 2021, 51, 1911-1920. | 1.6 | 31 |
| 2800 | Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy. Annals of Allergy, Asthma and Immunology, 2021, 126, 630-638. | 0.5 | 23 |
| 2801 | Radiosensitivity index emerges as a potential biomarker for combined radiotherapy and immunotherapy. Npj Genomic Medicine, 2021, 6, 40. | 1.7 | 16 |
| 2803 | TMB in NSCLC: A Broken Dream?. International Journal of Molecular Sciences, 2021, 22, 6536. | 1.8 | 31 |
| 2804 | Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer. Nature Reviews Urology, 2021, 18, 543-555. | 1.9 | 20 |
| 2805 | Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer. , 2021, 9, e002356. | | 35 |
| 2806 | Immunocompetent cancer-on-chip models to assess immuno-oncology therapy. Advanced Drug Delivery Reviews, 2021, 173, 281-305. | 6.6 | 38 |
| 2807 | Pembrolizumab for the treatment of renal cell carcinoma. Expert Opinion on Biological Therapy, 2021, 21, 1157-1164. | 1.4 | 2 |
| 2808 | Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma. Frontiers in Oncology, 2021, 11, 658690. | 1.3 | 15 |
| 2809 | Prognostic value of programmed cell death ligandâ€‘1 expression in the tumorâ€‘infiltrating immune cells of patients with lung cancer: A metaâ€‘analysis. Molecular and Clinical Oncology, 2021, 15, 167. | 0.4 | 0 |
| 2810 | The clinical impact of three validated PD-L1 immunohistochemistry assays as a prognostic factor in small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 2539-2550. | 1.3 | 6 |
| 2811 | Study of <sup>89</sup>Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Nonâ€"Small Cell Lung Cancer. Journal of Nuclear Medicine, 2022, 63, 362-367. | 2.8 | 44 |
| 2812 | Programmed cell death-ligand 1 expression predicts poor treatment response and prognostic value in esophageal squamous cell carcinoma patients without esophagectomy. Aging, 2021, 13, 18827-18838. | 1.4 | 3 |
| 2813 | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer. , 2021, 9, e002552. | | 16 |
| 2814 | Targeted inhibition of FGF19/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma. Hepatology International, 2021, 15, 1236-1246. | 1.9 | 6 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 2815 | Treatment strategies for hepatocellular carcinoma with extrahepatic metastasis. World Journal of Clinical Cases, 2021, 9, 5754-5768. | 0.3 | 9 |
| 2816 | IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. Journal of Thoracic Oncology, 2021, 16, 1909-1924. | 0.5 | 212 |
| 2817 | Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. Nature Reviews Drug Discovery, 2022, 21, 495-508. | 21.5 | 120 |
| 2819 | Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab. Scientific Reports, 2021, 11, 13912. | 1.6 | 10 |
| 2820 | Identification of Prognostic miRNAs Associated With Immune Cell Tumor Infiltration Predictive of Clinical Outcomes in Patients With Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 705869. | 1.3 | 4 |
| 2821 | Predictive biomarkers of inhibitors immune checkpoints therapy in malignant tumors. Russian Journal of Pediatric Hematology and Oncology, 2021, 8, 73-83. | 0.1 | 2 |
| 2822 | Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder. Scientific Reports, 2021, 11, 14244. | 1.6 | 9 |
| 2823 | Carnosic acid-induced co-self-assembly of metal-peptide complexes into a nanocluster-based framework with tumor-specific accumulation for augmented immunotherapy. Chemical Engineering Journal, 2021, 416, 129141. | 6.6 | 19 |
| 2824 | Tumor microenvironment disparity in multiple primary lung cancers: Impact of non-intrinsic factors, histological subtypes, and genetic aberrations. Translational Oncology, 2021, 14, 101102. | 1.7 | 8 |
| 2825 | Engineered extracellular vesicles for concurrent Anti-PDL1 immunotherapy and chemotherapy. Bioactive Materials, 2022, 9, 251-265. | 8.6 | 30 |
| 2826 | CD8+ T cell differentiation and dysfunction in cancer. Nature Reviews Immunology, 2022, 22, 209-223. | 10.6 | 345 |
| 2827 | LDHâ€A negatively regulates dMMR in colorectal cancer. Cancer Science, 2021, 112, 3050-3063. | 1.7 | 14 |
| 2828 | Case Report: A Squamous Cell Lung Carcinoma Patient Who Responded to Neoadjuvant Immunochemotherapy but Died From Anastomosis Leakage or/and irAEs: Immune Microenvironment and Genomic Features Changes. Frontiers in Oncology, 2021, 11, 674328. | 1.3 | 1 |
| 2829 | Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma. Leukemia, 2022, 36, 138-154. | 3.3 | 28 |
| 2830 | Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma. BMC Cancer, 2021, 21, 876. | 1.1 | 35 |
| 2831 | Targeted Glucose or Glutamine Metabolic Therapy Combined With PD-1/PD-L1 Checkpoint Blockade Immunotherapy for the Treatment of Tumors - Mechanisms and Strategies. Frontiers in Oncology, 2021, 11, 697894. | 1.3 | 19 |
| 2832 | Immunotherapy: New insights in breast cancer treatment. Human Antibodies, 2021, 29, 193-202. | 0.6 | 3 |
| 2833 | Evolving Dynamic Biomarkers for Prediction of Immune Responses to Checkpoint Inhibitors in Cancer. , 0, , . | | 4 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 2834 | Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer. Cancers, 2021, 13, 3738. | 1.7 | 7 |
| 2835 | Mucin-type sialyl-Tn antigen is associated with PD-L1 expression and predicts poor clinical prognosis in breast cancer. Gland Surgery, 2021, 10, 2159-2169. | 0.5 | 4 |
| 2836 | ATM/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy in prostate cancer. , 2021, 9, e001758. | | 10 |
| 2837 | Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors. Scientific Reports, 2021, 11, 15312. | 1.6 | 15 |
| 2838 | Identification and Validation of Immune-Related LncRNA Prognostic Signature for Lung Adenocarcinoma. Frontiers in Genetics, 2021, 12, 681277. | 1.1 | 16 |
| 2839 | Biomarkers and Gene Signatures to Predict Durable Response to Pembrolizumab in Non-Small Cell Lung Cancer. Cancers, 2021, 13, 3828. | 1.7 | 6 |
| 2840 | Tumor PD-L1 expression is associated with outcomes in stage III non-small cell lung cancer (NSCLC) patients treated with consolidation durvalumab. Translational Lung Cancer Research, 2021, 10, 3071-3078. | 1.3 | 11 |
| 2841 | An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nature Medicine, 2021, 27, 1250-1261. | 15.2 | 159 |
| 2842 | Induction Strategy for Locally Advanced Thymoma. Frontiers in Oncology, 2021, 11, 704220. | 1.3 | 8 |
| 2843 | Dissecting immune cell stat regulation network reveals biomarkers to predict ICB therapy responders in melanoma. Journal of Translational Medicine, 2021, 19, 296. | 1.8 | 4 |
| 2844 | Pre-clinical evaluation of immunoPET imaging using agonist CD40 monoclonal antibody in pancreatic tumor-bearing mice. Nuclear Medicine and Biology, 2021, 98-99, 8-17. | 0.3 | 2 |
| 2845 | Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study. , 2021, 9, e002197. | | 44 |
| 2846 | Advances of Targeted Therapy for Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 719896. | 1.3 | 23 |
| 2847 | Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma. Thyroid, 2021, 31, 1076-1085. | 2.4 | 96 |
| 2848 | Cytologic Investigations for the Diagnosis of Malignant Pleural Effusion in Non–small Cell Lung Cancer. Journal of Bronchology and Interventional Pulmonology, 2021, 28, 310-321. | 0.8 | 6 |
| 2850 | Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma. Pharmacogenomics, 2021, 22, 703-726. | 0.6 | 3 |
| 2851 | Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells. World Journal of Stem Cells, 2021, 13, 795-824. | 1.3 | 7 |
| 2852 | Horizon Scanning in Cancer Genomics: How Advances in Genomic Medicine Will Change Cancer Care Over the Next Decade. Current Genetic Medicine Reports, 2021, 9, 37-46. | 1.9 | 1 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 2853 | Update on recent key publications in lung oncology: picking up speed. European Respiratory Review, 2021, 30, 200300. | 3.0 | 1 |
| 2854 | Detection of Immune Checkpoint Receptors â€" A Current Challenge in Clinical Flow Cytometry. Frontiers in Immunology, 2021, 12, 694055. | 2.2 | 22 |
| 2855 | Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment. Journal of Inflammation Research, 2021, Volume 14, 4217-4228. | 1.6 | 20 |
| 2856 | Infiltration of NK and plasma cells is associated with a distinct immune subset in nonâ€small cell lung cancer. Journal of Pathology, 2021, 255, 243-256. | 2.1 | 17 |
| 2857 | Evaluating the efficacy and safety of immune checkpoint inhibitors by detecting the exposure-response: An inductive review. International Immunopharmacology, 2021, 97, 107703. | 1.7 | 1 |
| 2858 | Bromodomainâ€containing protein 9 is a prognostic biomarker associated with immune infiltrates and promotes tumor malignancy through activating notch signaling pathway in negative <scp>HIF</scp>â€2Î± clear cell renal cell carcinoma. IUBMB Life, 2021, 73, 1334-1347. | 1.5 | 9 |
| 2859 | Visualization of the Interfacial Electrostatic Complementarity: A Method for Analysis of Proteinâ€"Protein Interaction Based on Ab Initio Quantum Chemical Calculations. Journal of Chemical Theory and Computation, 2021, 17, 5600-5610. | 2.3 | 5 |
| 2860 | Which factors matter the most? Revisiting and dissecting antibody therapeutic doses. Drug Discovery Today, 2021, 26, 1980-1990. | 3.2 | 3 |
| 2861 | In Situ Overexpression of Matricellular Mechanical Proteins Demands Functional Immune Signature and Mitigates Non-Small Cell Lung Cancer Progression. Frontiers in Immunology, 2021, 12, 714230. | 2.2 | 4 |
| 2862 | Discovery of Oral Anticancer 1,2-Bis(hydroxymethyl)benzo[g]pyrrolo[2,1-a]phthalazine Hybrids That Inhibit Angiogenesis and Induce DNA Cross-Links. Journal of Medicinal Chemistry, 2021, 64, 12469-12486. | 2.9 | 4 |
| 2863 | Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis. Molecules, 2021, 26, 4848. | 1.7 | 5 |
| 2864 | Toward personalized treatment approaches for non-small-cell lung cancer. Nature Medicine, 2021, 27, 1345-1356. | 15.2 | 338 |
| 2865 | LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. Science Translational Medicine, 2021, 13, . | 5.8 | 54 |
| 2866 | Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma. International Journal of Oral Science, 2021, 13, 24. | 3.6 | 107 |
| 2867 | Immunotherapy Treatment for Triple Negative Breast Cancer. Pharmaceuticals, 2021, 14, 763. | 1.7 | 30 |
| 2868 | Programmed cell death ligand-1 expression and survival in a cohort of patients with non-small cell lung cancer receiving first-line through third-line therapy in Denmark. Cancer Epidemiology, 2021, 73, 101976. | 0.8 | 2 |
| 2869 | The interplay of obesity, gut microbiome and diet in the immune check point inhibitors therapy era. Seminars in Cancer Biology, 2021, 73, 356-376. | 4.3 | 32 |
| 2870 | Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice. Cancers, 2021, 13, 3958. | 1.7 | 29 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 2871 | The Antitumor Activity of CAR-T-PD1 Cells Enhanced by HPV16mE7-Pulsed and SOCS1-Silenced DCs in Cervical Cancer Models. Cancer Management and Research, 2021, Volume 13, 6045-6053. | 0.9 | 8 |
| 2872 | Prognostic Impact of YKL-40 Immunohistochemical Expression in Patients with Colorectal Cancer. Current Oncology, 2021, 28, 3139-3149. | 0.9 | 7 |
| 2873 | Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms. Clinical Cancer Research, 2021, 27, 4265-4276. | 3.2 | 23 |
| 2874 | Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma. Scientific Reports, 2021, 11, 16460. | 1.6 | 3 |
| 2875 | DDX39B Predicts Poor Survival and Associated with Clinical Benefit of Anti-PD-L1 Therapy in ccRCC. Current Cancer Drug Targets, 2021, 21, 849-859. | 0.8 | 4 |
| 2876 | Challenges and Future Perspectives of Immunotherapy in Pancreatic Cancer. Cancers, 2021, 13, 4235. | 1.7 | 16 |
| 2877 | First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Annals of Oncology, 2021, 32, 983-993. | 0.6 | 205 |
| 2878 | TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. Cancer Immunology Research, 2021, 9, 1202-1213. | 1.6 | 71 |
| 2879 | The calcium-binding protein S100B reduces IL6 production in malignant melanoma via inhibition of RSK cellular signaling. PLoS ONE, 2021, 16, e0256238. | 1.1 | 1 |
| 2880 | Predicting Response to Programmed Cell Death Protein-1 or Programmed Death-Ligand 1 Blockade in NSCLCâ€"Is Multiplex Immunohistochemistry or Immunofluorescence the Answer?. Journal of Thoracic Oncology, 2021, 16, 1247-1249. | 0.5 | 2 |
| 2881 | Outcomes in primary cutaneous diffuse large Bâ€cell lymphoma, leg type. Hematological Oncology, 2021, 39, 658-663. | 0.8 | 8 |
| 2882 | Radiotherapy in Oral Cancers: Current Perspective and Future Directions. , 0, , . | | 1 |
| 2883 | Establishing standardized immune phenotyping of metastatic melanoma by digital pathology. Laboratory Investigation, 2021, 101, 1561-1570. | 1.7 | 15 |
| 2884 | Evaluation of TTV replication as a biomarker of immune checkpoint inhibitors efficacy in melanoma patients. PLoS ONE, 2021, 16, e0255972. | 1.1 | 1 |
| 2885 | Clinical decision support algorithm based on machine learning to assess the clinical response to antiâ€"programmed death-1 therapy in patients with nonâ€"small-cell lung cancer. European Journal of Cancer, 2021, 153, 179-189. | 1.3 | 16 |
| 2886 | Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFÎ²/PD-L1 blockade-treated squamous cell carcinoma. Communications Biology, 2021, 4, 1005. | 2.0 | 10 |
| 2888 | Quality Is King: Fundamental Insights into Tumor Antigenicity from Virus-Associated Merkel Cell Carcinoma. Journal of Investigative Dermatology, 2021, 141, 1897-1905. | 0.3 | 6 |
| 2889 | Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies. Pharmaceuticals, 2021, 14, 884. | 1.7 | 17 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 2890 | Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical application. Immunotherapy, 2021, 13, 1031-1051. | 1.0 | 14 |
| 2891 | Biomarkers in metastatic melanoma of the skin: can we more accurately choose the tactics of treating our patients?. Meditsinskiy Sovet, 2021, , 48-63. | 0.1 | 2 |
| 2892 | Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition–overall survival modeling framework. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1171-1182. | 1.3 | 15 |
| 2893 | The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors. BMC Cancer, 2021, 21, 969. | 1.1 | 13 |
| 2895 | Current Trends of Immunotherapy in the Treatment of Cutaneous Melanoma: A Review. Dermatology and Therapy, 2021, 11, 1481-1496. | 1.4 | 12 |
| 2896 | A mechanism of cooling hot tumors: Lactate attenuates inflammation in dendritic cells. IScience, 2021, 24, 103067. | 1.9 | 8 |
| 2897 | Comprehensive immunomolecular profiling of endometrial carcinoma: A tertiary retrospective study. Gynecologic Oncology, 2021, 162, 694-701. | 0.6 | 9 |
| 2898 | Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. Cancer Discovery, 2022, 12, 108-133. | 7.7 | 165 |
| 2899 | PD-1/PD-L1 Checkpoints and Resveratrol: A Controversial New Way for a Therapeutic Strategy. Cancers, 2021, 13, 4509. | 1.7 | 10 |
| 2900 | Application of Immunoprofiling Using Multiplexed Immunofluorescence Staining Identifies the Prognosis of Patients with High-Grade Serous Ovarian Cancer. International Journal of Molecular Sciences, 2021, 22, 9638. | 1.8 | 4 |
| 2901 | Chemokine C€C motif ligand 21 synergized with programmed death€ligand 1 blockade restrains tumor growth. Cancer Science, 2021, 112, 4457-4469. | 1.7 | 10 |
| 2902 | Adaptive NK Cell Therapy Modulated by Anti-PD-1 Antibody in Gastric Cancer Model. Frontiers in Pharmacology, 2021, 12, 733075. | 1.6 | 14 |
| 2903 | The Pandora's box of novel technologies that may revolutionize lung cancer. Lung Cancer, 2021, 159, 34-41. | 0.9 | 12 |
| 2904 | Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-negative metastatic breast cancer. Scientific Reports, 2021, 11, 19154. | 1.6 | 17 |
| 2905 | Expression, prognostic significance and therapeutic implications of PD€L1 in gliomas. Neuropathology and Applied Neurobiology, 2022, 48, . | 1.8 | 8 |
| 2906 | Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach. , 2022, 231, 107986. | | 30 |
| 2907 | Atezolizumab: an investigational agent for the treatment of biliary tract cancer. Expert Opinion on Investigational Drugs, 2021, 30, 1007-1015. | 1.9 | 2 |
| 2908 | The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies. Frontiers in Immunology, 2021, 12, 737311. | 2.2 | 28 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 2909 | Liquid Biopsy Biomarkers for Immunotherapy in Non-Small Cell Lung Carcinoma: Lessons Learned and the Road Ahead. Journal of Personalized Medicine, 2021, 11, 971. | 1.1 | 5 |
| 2910 | PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma. International Immunopharmacology, 2021, 98, 107870. | 1.7 | 13 |
| 2911 | FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy. Scientific Reports, 2021, 11, 18795. | 1.6 | 11 |
| 2912 | Integrated Bioinformatics and Experimental Approaches Identified the Role of NPPA in the Proliferation and the Malignant Behavior of Breast Cancer. Journal of Immunology Research, 2021, 2021, 1-17. | 0.9 | 0 |
| 2913 | Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer. Breast Cancer: Targets and Therapy, 2021, Volume 13, 539-557. | 1.0 | 4 |
| 2914 | Immunogenomic characterization in gastric cancer identifies microenvironmental and immunotherapeutically relevant gene signatures. Immunity, Inflammation and Disease, 2022, 10, 43-59. | 1.3 | 4 |
| 2915 | Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer. Life, 2021, 11, 1029. | 1.1 | 8 |
| 2916 | NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images. Cancers, 2021, 13, 4543. | 1.7 | 14 |
| 2917 | Metabolic Modifications, Inflammation, and Cancer Immunotherapy. Frontiers in Oncology, 2021, 11, 703681. | 1.3 | 8 |
| 2918 | The Landscape of Immune Cells Indicates Prognosis and Applicability of Checkpoint Therapy in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 744951. | 1.3 | 9 |
| 2919 | A Radiomic Approach to Access Tumor Immune Status by CD8+TRMs on Surgically Resected Non-Small-Cell Lung Cancer. OncoTargets and Therapy, 2021, Volume 14, 4921-4931. | 1.0 | 4 |
| 2920 | Role of the PDâ€1/PDâ€L1 Signaling in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: Recent Insights and Future Directions. Molecular Neurobiology, 2021, 58, 6249-6271. | 1.9 | 15 |
| 2921 | Considerations for the delivery of STING ligands in cancer immunotherapy. Journal of Controlled Release, 2021, 339, 235-247. | 4.8 | 18 |
| 2922 | Towards Personalized Treatment Strategies for Esophageal Adenocarcinoma; A Review on the Molecular Characterization of Esophageal Adenocarcinoma and Current Research Efforts on Individualized Curative Treatment Regimens. Cancers, 2021, 13, 4881. | 1.7 | 6 |
| 2923 | Combined tumorâ€associated macrophages biomarker predicting extremely poor outcome of patients with primary central nervous system lymphoma. Hematological Oncology, 2021, 39, 625-638. | 0.8 | 2 |
| 2924 | Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma. Frontiers in Oncology, 2021, 11, 741993. | 1.3 | 9 |
| 2925 | ImmunoPET: harnessing antibodies for imaging immune cells. Molecular Imaging and Biology, 2022, 24, 181-197. | 1.3 | 15 |
| 2926 | Bioinformatics-guided analysis uncovers TIGIT as an epigenetically regulated immunomodulator affecting immunotherapeutic sensitivity of gastric cancer. Cancer Biomarkers, 2022, 33, 349-358. | 0.8 | 5 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 2927 | TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Frontiers in Immunology, 2021, 12, 667875. | 2.2 | 11 |
| 2928 | Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target. Journal of Hematology and Oncology, 2021, 14, 147. | 6.9 | 52 |
| 2929 | Engineering Nanorobots for Tumorâ€Targeting Drug Delivery: From Dynamic Control to Stimuliâ€Responsive Strategy. ChemBioChem, 2021, 22, 3369-3380. | 1.3 | 10 |
| 2930 | Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. Cell, 2021, 184, 4753-4771.e27. | 13.5 | 99 |
| 2931 | Motility Dynamics of T Cells in Tumor-Draining Lymph Nodes: A Rational Indicator of Antitumor Response and Immune Checkpoint Blockade. Cancers, 2021, 13, 4616. | 1.7 | 13 |
| 2932 | Glucocorticoid and PD-1 Cross-Talk: Does the Immune System Become Confused?. Cells, 2021, 10, 2333. | 1.8 | 13 |
| 2933 | Improving Targeted Delivery and Antitumor Efficacy with Engineered Tumor Necrosis Factor-Related Apoptosis Ligand-Affibody Fusion Protein. Molecular Pharmaceutics, 2021, 18, 3854-3861. | 2.3 | 2 |
| 2934 | Genomic Heterogeneity of Pancreatic Ductal Adenocarcinoma and Its Clinical Impact. Cancers, 2021, 13, 4451. | 1.7 | 15 |
| 2935 | Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy. World Journal of Surgical Oncology, 2021, 19, 264. | 0.8 | 21 |
| 2937 | MRTF-A-NF-Î²B/p65 axis-mediated PDL1 transcription and expression contributes to immune evasion of non-small-cell lung cancer via TGF-Î². Experimental and Molecular Medicine, 2021, 53, 1366-1378. | 3.2 | 22 |
| 2938 | Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2). Clinical and Translational Science, 2022, 15, 141-157. | 1.5 | 13 |
| 2939 | Dynamic serum biomarkers to predict the efficacy of PD-1 in patients with nasopharyngeal carcinoma. Cancer Cell International, 2021, 21, 518. | 1.8 | 7 |
| 2940 | Current strategies for intratumoural immunotherapy â€" Beyond immune checkpoint inhibition. European Journal of Cancer, 2021, 157, 493-510. | 1.3 | 28 |
| 2941 | Characterization of gastric cancer stem-like molecular features, immune and pharmacogenomic landscapes. Briefings in Bioinformatics, 2022, 23, . | 3.2 | 11 |
| 2942 | A reservoir of stem-like CD8 + T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response. Science Immunology, 2021, 6, eabg7836. | 5.6 | 123 |
| 2943 | Development of a multiplex immuno-oncology biomarker and digital pathology workflow for assessment of urothelial carcinoma. Pathology Research and Practice, 2021, 226, 153607. | 1.0 | 2 |
| 2944 | Enhanced anti-tumor response elicited by a novel oncolytic HSV-1 engineered with an anti-PD-1 antibody. Cancer Letters, 2021, 518, 49-58. | 3.2 | 17 |
| 2945 | A novel mechanism of lung cancer inhibition by methionine enkephalin through remodeling the immune status of the tumor microenvironment. International Immunopharmacology, 2021, 99, 107999. | 1.7 | 6 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 2946 | Development of bifunctional anti-PD-L1 antibody MMAE conjugate with cytotoxicity and immunostimulation. Bioorganic Chemistry, 2021, 116, 105366. | 2.0 | 11 |
| 2947 | Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma. Lung Cancer, 2021, 161, 163-170. | 0.9 | 6 |
| 2948 | Advance of nano anticancer therapies targeted on tumor-associated macrophages. Coordination Chemistry Reviews, 2021, 446, 214126. | 9.5 | 6 |
| 2949 | Anti-tumor effects of valproate zinc complexes on a lung cancer cell line. Polyhedron, 2021, 208, 115415. | 1.0 | 0 |
| 2950 | Overexpression of transposable elements is associated with immune evasion and poor outcome in colorectal cancer. European Journal of Cancer, 2021, 157, 94-107. | 1.3 | 12 |
| 2951 | New insights into exosome mediated tumor-immune escape: Clinical perspectives and therapeutic strategies. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188624. | 3.3 | 29 |
| 2952 | Combinatorial therapy in tumor microenvironment: Where do we stand?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188585. | 3.3 | 48 |
| 2953 | Endocrinopathies Associated With Immune Checkpoint Inhibitors. , 2022, , 301-314. | | 0 |
| 2954 | Nucleic acid biomarker technology for cancer immunotherapy. , 2022, , 331-356. | | 0 |
| 2955 | Expanded human NK cells from lung cancer patients sensitize patients' PDL1â^'negative tumors to PD1-blockade therapy. , 2021, 9, e001933. | | 22 |
| 2956 | A Novel Immunotype-based Risk Stratification Model Predicts Postoperative Prognosis and Adjuvant TACE Benefit in Chinese Patients with Hepatocellular Carcinoma. Journal of Cancer, 2021, 12, 2866-2876. | 1.2 | 3 |
| 2957 | Spatially Resolved and Quantitative Analysis of the Immunological Landscape in Human Meningiomas. Journal of Neuropathology and Experimental Neurology, 2021, 80, 150-159. | 0.9 | 9 |
| 2958 | Phage Display Technology as a Powerful Platform for Antibody Drug Discovery. Viruses, 2021, 13, 178. | 1.5 | 32 |
| 2959 | Asymmetric organocatalysis: an enabling technology for medicinal chemistry. Chemical Society Reviews, 2021, 50, 1522-1586. | 18.7 | 219 |
| 2960 | Clinical Significance of PD-L1 Expression and CD8-Positive Tumor-Infiltrating Lymphocytes in Patients with Cavitary Lung Adenocarcinoma. Oncologie, 2021, 23, 439-452. | 0.2 | 1 |
| 2961 | The role of tumor-associated macrophages in primary hepatocellular carcinoma and its related targeting therapy. International Journal of Medical Sciences, 2021, 18, 2109-2116. | 1.1 | 28 |
| 2962 | Immune Checkpoint Inhibitors as an Armor for Targeted Immunotherapy of Colorectal Cancer. , 2021, , 309-326. | | 0 |
| 2963 | The Potential of T Cell Factor 1 in Sustaining CD8+ T Lymphocyte-Directed Anti-Tumor Immunity. Cancers, 2021, 13, 515. | 1.7 | 3 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 2964 | Tertiary lymphoid structure signatures are associated with survival and immunotherapy response in muscle-invasive bladder cancer. OncoImmunology, 2021, 10, 1915574. | 2.1 | 21 |
| 2965 | Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma. Cancer Medicine, 2021, 10, 1562-1575. | 1.3 | 16 |
| 2966 | PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity. OncoImmunology, 2021, 10, 1943180. | 2.1 | 54 |
| 2967 | A Novel Prognostic Model of Early-Stage Lung Adenocarcinoma Integrating Methylation and Immune Biomarkers. Frontiers in Genetics, 2020, 11, 634634. | 1.1 | 18 |
| 2968 | Immune Resistance in Lung Adenocarcinoma. Cancers, 2021, 13, 384. | 1.7 | 82 |
| 2969 | Removal of N-Linked Glycosylation Enhances PD-L1 Detection in Colon Cancer: Validation Research Based on Immunohistochemistry Analysis. Technology in Cancer Research and Treatment, 2021, 20, 153303382110194. | 0.8 | 8 |
| 2970 | New cytometry tools for immune monitoring during cancer immunotherapy. Cytometry Part B - Clinical Cytometry, 2021, 100, 10-18. | 0.7 | 11 |
| 2971 | Hyperprogression: A novel response pattern under immunotherapy. Clinical and Translational Medicine, 2020, 10, e167. | 1.7 | 22 |
| 2972 | Status of Immune Oncology: Challenges and Opportunities. Methods in Molecular Biology, 2020, 2055, 3-21. | 0.4 | 6 |
| 2973 | Overview of Tissue Imaging Methods. Methods in Molecular Biology, 2020, 2055, 455-465. | 0.4 | 23 |
| 2974 | Personalized Neo-Epitope Vaccines for Cancer Treatment. Recent Results in Cancer Research, 2020, 214, 153-167. | 1.8 | 9 |
| 2975 | Immuno-Oncology in theÂEra of Personalized Medicine. Advances in Experimental Medicine and Biology, 2019, 1168, 117-129. | 0.8 | 4 |
| 2976 | CCL21 Programs Immune Activity in Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1231, 67-78. | 0.8 | 15 |
| 2977 | The Paradox of Cancer Immune Exclusion: Immune Oncology Next Frontier. Cancer Treatment and Research, 2020, 180, 173-195. | 0.2 | 48 |
| 2978 | Overview of Basic Immunology and Clinical Application. Advances in Experimental Medicine and Biology, 2020, 1244, 1-36. | 0.8 | 8 |
| 2979 | Novel Trial Designs for Early Phase Clinical Trials. , 2020, , 85-93. | | 1 |
| 2980 | Immuno-oncology of Dormant Tumours. Cancer Drug Discovery and Development, 2017, , 51-60. | 0.2 | 1 |
| 2981 | Future Paradigm of Breast Cancer Resistance and Treatment. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 155-178. | 0.1 | 2 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 2982 | Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond. Advances in Experimental Medicine and Biology, 2020, 1248, 33-59. | 0.8 | 232 |
| 2983 | Rational Discovery of Response Biomarkers: Candidate Prognostic Factors and Biomarkers for Checkpoint Inhibitor-Based Immunotherapy. Advances in Experimental Medicine and Biology, 2020, 1248, 143-166. | 0.8 | 3 |
| 2984 | Brote de psoriasis en placas y edema perifÃ©rico en un paciente tratado con atezolizumab. Actas Dermo-sifiliogrÃ¡ficas, 2019, 110, 410-411. | 0.2 | 6 |
| 2986 | Human pDCs Are Superior to cDC2s in Attracting Cytolytic Lymphocytes in Melanoma Patients Receiving DC Vaccination. Cell Reports, 2020, 30, 1027-1038.e4. | 2.9 | 29 |
| 2987 | The prognostic landscape of adaptive immune resistance signatures and infiltrating immune cells in the tumor microenvironment of uveal melanoma. Experimental Eye Research, 2020, 196, 108069. | 1.2 | 22 |
| 2988 | The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer. International Immunopharmacology, 2020, 80, 106247. | 1.7 | 28 |
| 2989 | Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. Journal of Thoracic Oncology, 2020, 15, 1449-1459. | 0.5 | 109 |
| 2990 | Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1â€"Selected Advanced Nonâ€"Small-Cell Lung Cancer (BIRCH). Journal of Clinical Oncology, 2017, 35, 2781-2789. | 0.8 | 24 |
| 2991 | Targeting MYC in multiple myeloma. Leukemia, 0, , . | 3.3 | 2 |
| 2992 | Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma. British Journal of Cancer, 2018, 119, 80-88. | 2.9 | 74 |
| 2993 | Molecular and nanoengineering approaches towards activatable cancer immunotherapy. Chemical Society Reviews, 2020, 49, 4234-4253. | 18.7 | 228 |
| 2994 | p110Î´ PI3K as a therapeutic target of solid tumours. Clinical Science, 2020, 134, 1377-1397. | 1.8 | 15 |
| 2995 | Cancer immune resistance: can theories converge?. Emerging Topics in Life Sciences, 2017, 1, 411-419. | 1.1 | 13 |
| 2996 | Atezolizumab for First-Line Treatment of PD-L1â€"Selected Patients with NSCLC. New England Journal of Medicine, 2020, 383, 1328-1339. | 13.9 | 959 |
| 2997 | Atezolizumab for the treatment of breast cancer. Expert Review of Anticancer Therapy, 2020, 20, 151-158. | 1.1 | 60 |
| 2998 | Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy. OncoImmunology, 2021, 10, 1864909. | 2.1 | 18 |
| 2999 | PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2. Journal of Cell Biology, 2020, 219, . | 2.3 | 65 |
| 3000 | Clinical correlates for immune checkpoint therapy: significance for CNS malignancies. Neuro-Oncology Advances, 2021, 3, vdaa161. | 0.4 | 11 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 3001 | Expression of PD-1/PD-L1 and P53 in hepatocellular carcinoma. Egyptian Journal of Pathology, 2018, 38, 131-138. | 0.0 | 1 |
| 3002 | Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 258-264. | 0.6 | 21 |
| 3003 | PD-L1 Expression in Endocervical Adenocarcinoma. American Journal of Surgical Pathology, 2021, 45, 742-752. | 2.1 | 10 |
| 3004 | The interesting relationship between APOBEC3 deoxycytidine deaminases and cancer: a long road ahead. Open Biology, 2020, 10, 200188. | 1.5 | 27 |
| 3011 | CD20<sup>+</sup> tumor–infiltrating immune cells and CD204<sup>+</sup> M2 macrophages are associated with prognosis in thymic carcinoma. Cancer Science, 2020, 111, 1921-1932. | 1.7 | 28 |
| 3012 | PD-L1 expression is an unfavourable prognostic indicator in Asian renal cell carcinomas. Journal of Clinical Pathology, 2020, 73, 463-469. | 1.0 | 5 |
| 3013 | Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer. , 2020, 8, e001607. | | 4 |
| 3015 | Cancer-Associated Fibroblasts Affect Intratumoral CD8+ and FoxP3+ T Cells Via IL6 in the Tumor Microenvironment. Clinical Cancer Research, 2018, 24, 4820-4833. | 3.2 | 225 |
| 3016 | Recurrent HNSCC Harbor an Immunosuppressive Tumor Immune Microenvironment Suggesting Successful Tumor Immune Evasion. Clinical Cancer Research, 2021, 27, 632-644. | 3.2 | 49 |
| 3017 | Targeting tumor-resident mast cells for effective anti-melanoma immune responses. JCI Insight, 2019, 4, . | 2.3 | 36 |
| 3018 | PD-L1 on invasive fibroblasts drives fibrosis in a humanized model of idiopathic pulmonary fibrosis. JCI Insight, 2019, 4, . | 2.3 | 64 |
| 3019 | Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer. JCI Insight, 2020, 5, . | 2.3 | 43 |
| 3020 | Multiparametric profiling of non–small-cell lung cancers reveals distinct immunophenotypes. JCI Insight, 2016, 1, e89014. | 2.3 | 110 |
| 3021 | Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy. JCI Insight, 2017, 2, . | 2.3 | 62 |
| 3022 | Peptide-based PET quantifies target engagement of PD-L1 therapeutics. Journal of Clinical Investigation, 2019, 129, 616-630. | 3.9 | 94 |
| 3023 | Galectin-1–driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance. Journal of Clinical Investigation, 2019, 129, 5553-5567. | 3.9 | 94 |
| 3024 | Time to dissect the autoimmune etiology of cancer antibody immunotherapy. Journal of Clinical Investigation, 2020, 130, 51-61. | 3.9 | 66 |
| 3025 | Pembrolizumab plus allogeneic NK cells in advanced non–small cell lung cancer patients. Journal of Clinical Investigation, 2020, 130, 2560-2569. | 3.9 | 77 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 3026 | Dinaciclib induces immunogenic cell death and enhances anti-PD1–mediated tumor suppression. Journal of Clinical Investigation, 2018, 128, 644-654. | 3.9 | 144 |
| 3027 | Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression. Journal of Clinical Investigation, 2018, 128, 805-815. | 3.9 | 423 |
| 3028 | Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. Journal of Clinical Investigation, 2019, 129, 1785-1800. | 3.9 | 266 |
| 3029 | Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance. Journal of Clinical Investigation, 2019, 129, 1278-1294. | 3.9 | 102 |
| 3030 | The host protecting the tumor from the host — targeting PD–L1 expressed by host cells. Journal of Clinical Investigation, 2018, 128, 570-572. | 3.9 | 15 |
| 3031 | Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. Journal of Clinical Investigation, 2018, 128, 4654-4668. | 3.9 | 591 |
| 3032 | Nivolumab Immunotherapy in Malignant Mesothelioma: A Case Report Highlighting a New Opportunity for Exceptional Outcomes. American Journal of Case Reports, 2018, 19, 783-789. | 0.3 | 3 |
| 3033 | A Case Report of Atezolizumab Induced Tumor Lysis Syndrome. American Journal of Case Reports, 2019, 20, 785-789. | 0.3 | 9 |
| 3034 | Tumor Lysis Syndrome After a Single Dose of Atezolizumab with Nab-Paclitaxel: A Case Report and Review of Literature. American Journal of Case Reports, 2020, 21, e925248. | 0.3 | 4 |
| 3035 | A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification. F1000Research, 2017, 6, 296. | 0.8 | 14 |
| 3036 | Cancer Genomics. F1000Research, 2015, 4, 1162. | 0.8 | 2 |
| 3037 | PD-L1 and Survival in Solid Tumors: A Meta-Analysis. PLoS ONE, 2015, 10, e0131403. | 1.1 | 288 |
| 3038 | The Relationship of Immune Cell Signatures to Patient Survival Varies within and between Tumor Types. PLoS ONE, 2015, 10, e0138726. | 1.1 | 24 |
| 3039 | Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice. PLoS ONE, 2016, 11, e0150084. | 1.1 | 35 |
| 3040 | Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells. PLoS ONE, 2016, 11, e0162925. | 1.1 | 63 |
| 3041 | PD-L1 Status in Refractory Lymphomas. PLoS ONE, 2016, 11, e0166266. | 1.1 | 47 |
| 3042 | Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis. PLoS ONE, 2017, 12, e0176822. | 1.1 | 64 |
| 3043 | Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. PLoS ONE, 2017, 12, e0189848. | 1.1 | 190 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 3044 | The Future of Combining Carbon-Ion Radiotherapy with Immunotherapy: Evidence and Progress in Mouse Models. International Journal of Particle Therapy, 2016, 3, 61-70. | 0.9 | 37 |
| 3045 | The immune tumour microenvironment of neuroendocrine tumours and its implications for immune checkpoint inhibitors. Endocrine-Related Cancer, 2020, 27, R329-R343. | 1.6 | 13 |
| 3046 | Melanoma Immunotherapy: Mechanisms and Opportunities. Investigative Dermatology and Venereology Research, 2016, 2, 1-7. | 0.1 | 1 |
| 3047 | Immune Checkpoint Inhibitors in the Treatment of Melanoma: From Basic Science to Clinical Application. , 0, , 121-142. | | 31 |
| 3048 | Role of tumor microenvironment in the efficacy of BCG therapy. Trends in Research, 2020, 3, . | 0.2 | 8 |
| 3049 | Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer. Bosnian Journal of Basic Medical Sciences, 2019, 19, 227-233. | 0.6 | 76 |
| 3050 | Transcriptome-wide association study of inflammatory biologic age. Aging, 2017, 9, 2288-2301. | 1.4 | 12 |
| 3051 | Risk score based on expression of five novel genes predicts survival in soft tissue sarcoma. Aging, 2020, 12, 3807-3827. | 1.4 | 24 |
| 3052 | Development of a prognostic index and screening of potential biomarkers based on immunogenomic landscape analysis of colorectal cancer. Aging, 2020, 12, 5832-5857. | 1.4 | 34 |
| 3053 | Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma. Oncotarget, 2016, 7, 47252-47264. | 0.8 | 79 |
| 3054 | PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications. Oncotarget, 2016, 7, 59976-59986. | 0.8 | 56 |
| 3055 | Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor. Oncotarget, 2016, 7, 64967-64976. | 0.8 | 42 |
| 3056 | T-cell epitope strength in WAP-T mouse mammary carcinomas is an important determinant in PD1/PD-L1 immune checkpoint blockade therapy. Oncotarget, 2016, 7, 64543-64559. | 0.8 | 6 |
| 3057 | Prognostic value of *PDL1* expression in pancreatic cancer. Oncotarget, 2016, 7, 71198-71210. | 0.8 | 81 |
| 3058 | Programmed death-ligand 1 is upregulated in intrahepatic lymphoepithelioma-like cholangiocarcinoma. Oncotarget, 2016, 7, 69749-69759. | 0.8 | 20 |
| 3059 | Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody. Oncotarget, 2017, 8, 8807-8817. | 0.8 | 68 |
| 3060 | Overexpression of B7-H3 correlates with aggressive clinicopathological characteristics in non-small cell lung cancer. Oncotarget, 2016, 7, 81750-81756. | 0.8 | 22 |
| 3061 | IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination. Oncotarget, 2017, 8, 2659-2671. | 0.8 | 41 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 3062 | Autologous reconstitution of human cancer and immune system <i>in vivo</i>. Oncotarget, 2017, 8, 2053-2068. | 0.8 | 20 |
| 3063 | Independent prognostic role of PD-L1 expression in patients with esophageal squamous cell carcinoma. Oncotarget, 2017, 8, 8315-8329. | 0.8 | 19 |
| 3064 | Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. Oncotarget, 2017, 8, 13320-13328. | 0.8 | 60 |
| 3065 | The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer. Oncotarget, 2017, 8, 15584-15592. | 0.8 | 101 |
| 3066 | Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic. Oncotarget, 2017, 8, 14416-14427. | 0.8 | 70 |
| 3067 | PD-1 mRNA expression in peripheral blood cells and its modulation characteristics in cancer patients. Oncotarget, 2017, 8, 50782-50791. | 0.8 | 10 |
| 3068 | Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients. Oncotarget, 2017, 8, 26356-26367. | 0.8 | 54 |
| 3069 | Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma. Oncotarget, 2017, 8, 30175-30189. | 0.8 | 69 |
| 3070 | PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC). Oncotarget, 2017, 8, 26845-26857. | 0.8 | 55 |
| 3071 | Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response. Oncotarget, 2017, 8, 47400-47411. | 0.8 | 21 |
| 3072 | Genetic defects of the IRF1-mediated major histocompatibility complex class I antigen presentation pathway occur prevalently in the <i>JAK2</i> gene in non-small cell lung cancer. Oncotarget, 2017, 8, 60975-60986. | 0.8 | 15 |
| 3073 | Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma. Oncotarget, 2017, 8, 44418-44433. | 0.8 | 95 |
| 3074 | PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma. Oncotarget, 2017, 8, 54722-54734. | 0.8 | 39 |
| 3075 | Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis. Oncotarget, 2017, 8, 59901-59914. | 0.8 | 64 |
| 3076 | Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma. Oncotarget, 2017, 8, 97920-97927. | 0.8 | 69 |
| 3077 | SHP2 negatively regulates HLA-ABC and PD-L1 expression via STAT1 phosphorylation in prostate cancer cells. Oncotarget, 2017, 8, 53518-53530. | 0.8 | 33 |
| 3078 | Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resection. Oncotarget, 2017, 8, 82399-82414. | 0.8 | 19 |
| 3079 | PD-L1 expression on immune cells is a favorable prognostic factor for vulvar squamous cell carcinoma patients. Oncotarget, 2017, 8, 89903-89912. | 0.8 | 31 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 3080 | PD-L1 expression and CD8+ tumor-infiltrating lymphocytes are associated with ALK rearrangement and clinicopathological features in inflammatory myofibroblastic tumors. Oncotarget, 2017, 8, 89465-89474. | 0.8 | 13 |
| 3081 | Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer. Oncotarget, 2017, 8, 103117-103128. | 0.8 | 84 |
| 3082 | Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. Oncotarget, 2018, 9, 10284-10293. | 0.8 | 44 |
| 3083 | Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. Oncotarget, 2017, 8, 111836-111846. | 0.8 | 44 |
| 3084 | Microsatellite stability and mismatch repair proficiency in nasopharyngeal carcinoma may not predict programmed death-1 blockade resistance. Oncotarget, 2017, 8, 113287-113293. | 0.8 | 3 |
| 3085 | Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer. Oncotarget, 2018, 9, 4375-4384. | 0.8 | 26 |
| 3086 | Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis. Oncotarget, 2018, 9, 13920-13933. | 0.8 | 60 |
| 3087 | T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G. Oncotarget, 2018, 9, 6536-6549. | 0.8 | 37 |
| 3088 | A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma. Oncotarget, 2018, 9, 6993-7009. | 0.8 | 31 |
| 3089 | Efficacy of PD-1/PD-L1 inhibitors against pretreated advanced cancer: a systematic review and meta-analysis. Oncotarget, 2018, 9, 11846-11857. | 0.8 | 2 |
| 3090 | Molecular and clinical features of the <i>TP53</i> signature gene expression profile in early-stage breast cancer. Oncotarget, 2018, 9, 14193-14206. | 0.8 | 11 |
| 3091 | Correlation of <i>MET</i> gene amplification and <i>TP53</i> mutation with PD-L1 expression in non-small cell lung cancer. Oncotarget, 2018, 9, 13682-13693. | 0.8 | 39 |
| 3092 | PD-L1 expression in medulloblastoma: an evaluation by subgroup. Oncotarget, 2018, 9, 19177-19191. | 0.8 | 45 |
| 3093 | Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma. Oncotarget, 2018, 9, 20769-20780. | 0.8 | 20 |
| 3094 | PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients. Oncotarget, 2018, 9, 32024-32035. | 0.8 | 25 |
| 3095 | STAT1 deficiency supports PD-1/PD-L1 signaling resulting in dysfunctional TNFÎ± mediated immune responses in a model of NSCLC. Oncotarget, 2018, 9, 37157-37172. | 0.8 | 10 |
| 3096 | Immune response characterization of endometrial cancer. Oncotarget, 2019, 10, 982-992. | 0.8 | 13 |
| 3097 | Modes of immunosuppression in glioblastoma microenvironment. Oncotarget, 2019, 10, 920-921. | 0.8 | 5 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------| 
| 3098 | The impact of systemic precision medicine and immunotherapy treatments on brain metastases. Oncotarget, 2019, 10, 6739-6753. | 0.8 | 13 |
| 3099 | Survival correlation of immune response in human cancers. Oncotarget, 2019, 10, 6885-6897. | 0.8 | 3 |
| 3100 | The metastatic infiltration at the metastasis/brain parenchyma-interface is very heterogeneous and has a significant impact on survival in a prospective study. Oncotarget, 2015, 6, 29254-29267. | 0.8 | 77 |
| 3101 | Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1. Oncotarget, 2015, 6, 19819-19825. | 0.8 | 80 |
| 3102 | Genomic amplification of 9p24.1 targeting *JAK2*, *PD-L1*, and *PD-L2* is enriched in high-risk triple negative breast cancer. Oncotarget, 2015, 6, 26483-26493. | 0.8 | 118 |
| 3103 | Multistep, effective drug distribution within solid tumors. Oncotarget, 2015, 6, 39564-39577. | 0.8 | 22 |
| 3104 | The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients. Oncotarget, 2015, 6, 19393-19404. | 0.8 | 61 |
| 3105 | Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget, 2016, 7, 1486-1499. | 0.8 | 212 |
| 3106 | Gene copy number variations in the leukocyte genome of hepatocellular carcinoma patients with integrated hepatitis B virus DNA. Oncotarget, 2016, 7, 8006-8018. | 0.8 | 2 |
| 3107 | Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget, 2016, 7, 13587-13598. | 0.8 | 485 |
| 3108 | PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Oncotarget, 2016, 7, 15901-15914. | 0.8 | 125 |
| 3109 | PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. Oncotarget, 2016, 7, 19738-19747. | 0.8 | 134 |
| 3110 | The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures. Oncotarget, 2016, 7, 15033-15046. | 0.8 | 24 |
| 3111 | *CD274/PD-L1* gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity. Oncotarget, 2016, 7, 12024-12034. | 0.8 | 141 |
| 3112 | The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response. Oncotarget, 2016, 7, 29794-29803. | 0.8 | 48 |
| 3113 | Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization. Oncotarget, 2016, 7, 25050-25063. | 0.8 | 6 |
| 3114 | Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA *in situ* hybridization and its clinical significance. Oncotarget, 2016, 7, 39671-39679. | 0.8 | 37 |
| 3115 | Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies. , 2019, 2, 980-993. | | 9 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 3116 | Biomarkers of resistance to immune checkpoint inhibitors in non-small-cell lung cancer: myth or reality?. , 2020, 3, 276-286. | | 3 |
| 3117 | Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors. Cancer Biology and Medicine, 2020, 17, 626-639. | 1.4 | 7 |
| 3118 | What does the future hold for immunotherapy in cancer?. Annals of Translational Medicine, 2016, 4, 177-177. | 0.7 | 9 |
| 3119 | The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics. Annals of Translational Medicine, 2016, 4, 267-267. | 0.7 | 17 |
| 3120 | Towards tumor immunodiagnostics. Annals of Translational Medicine, 2016, 4, 263-263. | 0.7 | 11 |
| 3121 | Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer. Annals of Translational Medicine, 2017, 5, 376-376. | 0.7 | 79 |
| 3122 | Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4â€"a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors. Annals of Translational Medicine, 2017, 5, 467-467. | 0.7 | 12 |
| 3123 | Next frontiers in systemic therapy for soft tissue sarcoma. Chinese Clinical Oncology, 2018, 7, 43-43. | 0.4 | 11 |
| 3124 | Challenges of the phase I drug development in non-small cell lung cancer. Chinese Clinical Oncology, 2019, 8, 25-25. | 0.4 | 10 |
| 3125 | Immunotherapy for thymoma. Journal of Thoracic Disease, 2020, 12, 7635-7641. | 0.6 | 14 |
| 3126 | High CCR4 expression in the tumor microenvironment is a poor prognostic indicator in lung adenocarcinoma. Journal of Thoracic Disease, 2018, 10, 4741-4750. | 0.6 | 20 |
| 3127 | Epigenetic regulation of PD-L1 expression and pancreatic cancer response to checkpoint immunotherapy. Translational Cancer Research, 2017, 6, S652-S654. | 0.4 | 8 |
| 3128 | Characterization of PD-L1 protein expression and CD8+ tumor-infiltrating lymphocyte density, and their associations with clinical outcome in small-cell lung cancer. Translational Lung Cancer Research, 2019, 8, 748-759. | 1.3 | 22 |
| 3129 | Integration of stereotactic radiosurgery or whole brain radiation therapy with immunotherapy for treatment of brain metastases. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 448-466. | 0.7 | 6 |
| 3130 | &lt;p&gt;Increased Expression of Programmed Death Ligand 1 in Hepatocellular Carcinoma of Patients with Hepatitis B Virus Pre-S2 Mutant&lt;/p&gt;. Journal of Hepatocellular Carcinoma, 2020, Volume 7, 385-401. | 1.8 | 8 |
| 3131 | Neoadjuvant Therapy is Essential for Resectable Pancreatic Cancer. Current Medicinal Chemistry, 2020, 26, 7196-7211. | 1.2 | 9 |
| 3132 | Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules. Current Medicinal Chemistry, 2020, 27, 2402-2448. | 1.2 | 12 |
| 3133 | Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy. Current Medicinal Chemistry, 2020, 27, 2792-2813. | 1.2 | 12 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 3134 | Targeting PD-L1 Protein: Translation, Modification and Transport. Current Protein and Peptide Science, 2018, 20, 82-91. | 0.7 | 20 |
| 3135 | The Influence of Host Factors on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers. Current Cancer Drug Targets, 2015, 15, 652-664. | 0.8 | 33 |
| 3136 | Cancer Immunology and Immunotherapy. Anticancer Research, 2016, 36, 5593-5606. | 0.5 | 69 |
| 3137 | Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme. Anticancer Research, 2017, 37, 21-33. | 0.5 | 105 |
| 3138 | Antibiotic Use Does Not Appear to Influence Response to Nivolumab. Anticancer Research, 2017, 37, 3195-3200. | 0.5 | 83 |
| 3139 | Programmed Cell Death Ligand 1 Expression in Primary Central Nervous System Lymphomas: A Clinicopathological Study. , 2017, 37, 5655-5666. | | 26 |
| 3140 | Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression. Anticancer Research, 2018, 38, 107-112. | 0.5 | 31 |
| 3141 | Advances in the discovery of novel biomarkers for cancer: spotlight on protein <i>N</i>-glycosylation. Biomarkers in Medicine, 2020, 14, 1031-1045. | 0.6 | 8 |
| 3142 | Immune check point inhibitors for metastatic urothelial carcinoma: current evidence-based approach for urology daily practice. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 205-216. | 3.9 | 1 |
| 3143 | Cancer management in the era of immunotherapy: much more than meets the eye. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 141-142. | 0.4 | 1 |
| 3144 | Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy. Radiology and Oncology, 2018, 52, 281-288. | 0.6 | 22 |
| 3145 | Friend or Foe? Recent Strategies to Target Myeloid Cells in Cancer. Frontiers in Cell and Developmental Biology, 2020, 8, 351. | 1.8 | 45 |
| 3146 | Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy. International Journal of Molecular Sciences, 2020, 21, 7139. | 1.8 | 33 |
| 3147 | Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?. World Journal of Gastroenterology, 2018, 24, 2137-2151. | 1.4 | 99 |
| 3148 | Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond. World Journal of Gastroenterology, 2018, 24, 2686-2697. | 1.4 | 23 |
| 3149 | Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression. World Journal of Gastroenterology, 2020, 26, 3737-3749. | 1.4 | 23 |
| 3151 | Atezolizumab alleviates the immunosuppressionÂinduced by PDâ€L1â€positive neutrophils and improves the survival of mice during sepsis. Molecular Medicine Reports, 2020, 23, . | 1.1 | 14 |
| 3152 | Role and mechanism of programmed deathâ€ligandï¿½1 in hypoxiaâ€induced liver cancer immune escape (Review). Oncology Letters, 2020, 19, 2595-2601. | 0.8 | 14 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 3153 | Mechanistic insight of predictive biomarkers for antitumor PDâ€‘1/PDâ€‘L1 blockade: A paradigm shift towards immunome evaluation (Review). Oncology Reports, 2020, 44, 424-437. | 1.2 | 18 |
| 3154 | Novel Approaches to Pediatric Cancer: Immunotherapy. AIMS Medical Science, 2015, 2, 104-117. | 0.2 | 1 |
| 3155 | Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. Journal of Gastrointestinal Oncology, 2015, 6, 561-9. | 0.6 | 61 |
| 3156 | New strategies in immunotherapy for non-small cell lung cancer. Translational Lung Cancer Research, 2015, 4, 553-9. | 1.3 | 35 |
| 3157 | Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity. Translational Lung Cancer Research, 2015, 4, 721-7. | 1.3 | 26 |
| 3158 | Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role. Translational Lung Cancer Research, 2015, 4, 728-42. | 1.3 | 48 |
| 3159 | Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer. Translational Lung Cancer Research, 2015, 4, 756-62. | 1.3 | 8 |
| 3160 | Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis. Translational Lung Cancer Research, 2015, 4, 743-51. | 1.3 | 31 |
| 3161 | Upcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors. Chinese Clinical Oncology, 2015, 4, 48. | 0.4 | 5 |
| 3162 | Predictive factors for immunotherapy in melanoma. Annals of Translational Medicine, 2015, 3, 208. | 0.7 | 27 |
| 3163 | Immune checkpoint inhibitors: therapeutic advances in melanoma. Annals of Translational Medicine, 2015, 3, 267. | 0.7 | 47 |
| 3164 | Comparison of laboratory-developed test &amp; validated assay of programmed death ligand-1 immunohistochemistry in non-small-cell lung carcinoma. Indian Journal of Medical Research, 2019, 150, 376. | 0.4 | 5 |
| 3165 | Evaluation of PD-L1 and PD-1 expression in aggressive eyelid sebaceous gland carcinoma and its clinical significance. Indian Journal of Ophthalmology, 2019, 67, 1983. | 0.5 | 10 |
| 3166 | Multi-Field-of-View Deep Learning Model Predicts Nonsmall Cell Lung Cancer Programmed Death-Ligand 1 Status from Whole-Slide Hematoxylin and Eosin Images. Journal of Pathology Informatics, 2019, 10, 24. | 0.8 | 70 |
| 3167 | Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials. Translational Oncogenomics, 2015, Suppl. 1, 1-11. | 1.7 | 19 |
| 3168 | Dynamics of Soluble Programmed Death-Ligand 1 (sPDL1) during Chemotherapy and Its Prognostic Implications in Cancer Patients: Biomarker Development in Immuno-oncology. Cancer Research and Treatment, 2019, 51, 832-840. | 1.3 | 11 |
| 3169 | Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer. Cancer Research and Treatment, 2019, 51, 1086-1097. | 1.3 | 59 |
| 3170 | Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response. Cancer Research and Treatment, 2020, 52, 594-603. | 1.3 | 55 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 3172 | Overview of Research and Development for Anticancer Drugs. Journal of Cancer Therapy, 2016, 07, 762-772. | 0.1 | 21 |
| 3173 | Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy. World Journal of Gastrointestinal Oncology, 2020, 12, 173-181. | 0.8 | 172 |
| 3174 | Immunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategies. World Journal of Gastrointestinal Oncology, 2015, 7, 338. | 0.8 | 41 |
| 3175 | Targeted therapy for advanced gastric cancer: A review of current status and future prospects. World Journal of Gastrointestinal Oncology, 2015, 7, 401. | 0.8 | 23 |
| 3176 | Anti program death-1/anti program death-ligand 1 in digestive cancers. World Journal of Gastrointestinal Oncology, 2015, 7, 95. | 0.8 | 53 |
| 3177 | Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings. World Journal of Gastrointestinal Pathophysiology, 2019, 10, 17-28. | 0.5 | 26 |
| 3178 | Progress in immunotherapy for small cell lung cancer. World Journal of Clinical Oncology, 2020, 11, 370-377. | 0.9 | 6 |
| 3179 | Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations. World Journal of Clinical Oncology, 2017, 8, 230. | 0.9 | 52 |
| 3180 | Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors. World Journal of Clinical Oncology, 2017, 8, 320. | 0.9 | 8 |
| 3181 | A primer on tumour immunology and prostate cancer immunotherapy. Canadian Urological Association Journal, 2016, 10, 60. | 0.3 | 10 |
| 3182 | Increased Tim-3 expression on TILs during treatment with the Anchored GM-CSF vaccine and anti-PD-1 antibodies is inversely correlated with response in prostate cancer. Journal of Cancer, 2020, 11, 648-656. | 1.2 | 25 |
| 3183 | Assays for predicting and monitoring responses to lung cancer immunotherapy. Cancer Biology and Medicine, 2015, 12, 87-95. | 1.4 | 35 |
| 3184 | Tumor immune microenvironment characterization and response to anti-PD-1 therapy. Cancer Biology and Medicine, 2015, 12, 74-8. | 1.4 | 60 |
| 3185 | Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints. Cancer Biology and Medicine, 2015, 12, 79-86. | 1.4 | 28 |
| 3186 | Advances in immunotherapy for treatment of lung cancer. Cancer Biology and Medicine, 2015, 12, 209-22. | 1.4 | 50 |
| 3187 | Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction. ELife, 2019, 8, . | 2.8 | 214 |
| 3188 | Cancer systems immunology. ELife, 2020, 9, . | 2.8 | 14 |
| 3189 | Second-line treatment options in hepatocellular carcinoma. Drugs in Context, 2019, 8, 1-13. | 1.0 | 32 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------| 
| 3190 | Robust and accurate quantification of biomarkers of immune cells in lung cancer micro-environment using deep convolutional neural networks. PeerJ, 2019, 7, e6335. | 0.9 | 24 |
| 3191 | COL6A6 inhibits the proliferation and metastasis of non-small cell lung cancer through the JAK signalling pathway. Translational Cancer Research, 2021, 10, 4514-4522. | 0.4 | 6 |
| 3192 | The efficacy of immune checkpoint inhibitors in thoracic malignancies. European Respiratory Review, 2021, 30, 200387. | 3.0 | 5 |
| 3193 | Programmed death (PD)â€‘1/PDâ€‘ligand 1 blockade mediates antiangiogenic effects by tumorâ€‘derived CXCL10/11 as a potential predictive biomarker. Cancer Science, 2021, 112, 4853-4866. | 1.7 | 6 |
| 3194 | A Complex Metabolic Network Confers Immunosuppressive Functions to Myeloid-Derived Suppressor Cells (MDSCs) within the Tumour Microenvironment. Cells, 2021, 10, 2700. | 1.8 | 25 |
| 3195 | Molecular Mechanism of Food-Derived Polyphenols on PD-L1 Dimerization: A Molecular Dynamics Simulation Study. International Journal of Molecular Sciences, 2021, 22, 10924. | 1.8 | 12 |
| 3196 | The Upregulation of Molecules Related to Tumor Immune Escape in Human Pituitary Adenomas. Frontiers in Endocrinology, 2021, 12, 726448. | 1.5 | 11 |
| 3197 | Metabolic Molecule PLA2G2D Is a Potential Prognostic Biomarker Correlating With Immune Cell Infiltration and the Expression of Immune Checkpoint Genes in Cervical Squamous Cell Carcinoma. Frontiers in Oncology, 2021, 11, 755668. | 1.3 | 11 |
| 3198 | Metabolic regulation by PD-1 signaling promotes long-lived quiescent CD8 T cell memory in mice. Science Translational Medicine, 2021, 13, eaba6006. | 5.8 | 33 |
| 3200 | IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. Journal of Thoracic Oncology, 2022, 17, 309-323. | 0.5 | 114 |
| 3201 | Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC. BMC Medicine, 2021, 19, 239. | 2.3 | 11 |
| 3202 | Titin Mutation Is Associated With Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Squamous Cell Carcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 761758. | 1.8 | 14 |
| 3203 | Review of the recent clinical trials for PD-1/PD-L1 based lung cancer immunotherapy. Expert Review of Anticancer Therapy, 2021, 21, 1355-1370. | 1.1 | 6 |
| 3204 | Ubiquitination in T-Cell Activation and Checkpoint Inhibition: New Avenues for Targeted Cancer Immunotherapy. International Journal of Molecular Sciences, 2021, 22, 10800. | 1.8 | 17 |
| 3205 | Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell, 2021, 184, 5309-5337. | 13.5 | 588 |
| 3206 | Conjugation of glucosylated polymer chains to checkpoint blockade antibodies augments their efficacy and specificity for glioblastoma. Nature Biomedical Engineering, 2021, 5, 1274-1287. | 11.6 | 33 |
| 3207 | Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses. Cancer Immunology Research, 2021, 9, 1465-1475. | 1.6 | 8 |
| 3208 | Progress of Phototherapy Applications in the Treatment of Bone Cancer. International Journal of Molecular Sciences, 2021, 22, 11354. | 1.8 | 30 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 3209 | Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study. Cancer Immunology, Immunotherapy, 2022, 71, 1393-1402. | 2.0 | 11 |
| 3210 | Exploring microsatellite instability in patients with advanced hepatocellular carcinoma and its tumor microenvironment. JGH Open, 2021, 5, 1266-1274. | 0.7 | 9 |
| 3211 | Immunotherapeutic Advances for NSCLC. Biologics: Targets and Therapy, 2021, Volume 15, 399-417. | 3.0 | 9 |
| 3212 | Licorice extract inhibits growth of non-small cell lung cancer by down-regulating CDK4-Cyclin D1 complex and increasing CD8+ T cell infiltration. Cancer Cell International, 2021, 21, 529. | 1.8 | 15 |
| 3213 | Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188636. | 3.3 | 27 |
| 3214 | Adaptive resistance in tumors to anti-PD-1 therapy through re-immunosuppression by upregulation of GPNMB expression. International Immunopharmacology, 2021, 101, 108199. | 1.7 | 5 |
| 3215 | Inflammation and Lung Cancer: Addressing Inflammation with Immunotherapy. , 2015, , 191-209. | | 0 |
| 3216 | Patient Selection and Monitoring for Immunotherapies: Challenges for Immune Checkpoint Antibody and Cell Therapies. , 2015, , 85-101. | | 0 |
| 3217 | Improving of Antitumor Immunity and Therapeutic Efficacy of Cancer Vaccines and Adoptive Immunotherapies Using Monoclonal Antibodies. MOJ Immunology, 2015, 2, . | 11.0 | 0 |
| 3219 | CCL-21. , 2016, , 1-9. | | 0 |
| 3220 | Genomic Markers in ER-Negative Breast Cancer. , 2016, , 283-298. | | 0 |
| 3221 | Biomarkers in Head and Neck Cancer. , 2016, , 149-162. | | 0 |
| 3222 | Reinstating endogenous antitumor immunity: The concept of therapeutic management of cancer. Forum of Clinical Oncology, 2016, 7, 4-16. | 0.1 | 0 |
| 3223 | LIGHTing tumor up for checkpoint blockade. Oncotarget, 2016, 7, 48857-48858. | 0.8 | 0 |
| 3224 | How Checkpoint Inhibitors Are Changing the Treatment Paradigm in Solid Tumors: What Advanced Practitioners in Oncology Need to Know. Journal of the Advanced Practitioner in Oncology, 2016, 7, . | 0.2 | 3 |
| 3227 | Surgical Considerations and Emergencies in the Cancer Patient Receiving Immunotherapy. , 2017, , 31-44. | | 0 |
| 3229 | Targeted Therapies and ImmunotherapyImmunotherapy in bladder cancer in Bladder Cancer. , 2017, , 111-122. | | 0 |
| 3230 | Immunotherapy for Renal Cell Cancer (RCC). , 2017, , 295-317. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 3231 | The Current Status of Immunotherapy Using anti PD-1 or PD-L1 Antibodies. Japanese Journal of Lung Cancer, 2017, 57, 75-80. | 0.0 | 0 |
| 3232 | Patient-Derived Xenografts From Lung Cancer and Their Potential Applications. , 2017, , 273-289. | | 0 |
| 3233 | Immunotherapy for Gynecologic Cancer. Comprehensive Gynecology and Obstetrics, 2017, , 69-85. | 0.0 | 0 |
| 3235 | Immunotherapy and Lung Cancer: Programmed Death 1 and Its Ligand as a Target for Therapy. Molecular Pathology Library, 2018, , 257-273. | 0.1 | 0 |
| 3236 | REVIEW OF APPROACHES TO IMMUNOTHERAPY IN ONCOLOGY. IssledovaniÃ¢ I Praktika V Medicine, 2017, 4, 51-65. | 0.1 | 4 |
| 3238 | The Association Between Chemotherapy Immediately Before Nivolumab and Outcomes Thereafter. , 2017, 37, 5885-5891. | | 9 |
| 3239 | Immunotherapy Approaches to Breast Cancer. Current Breast Cancer Reports, 2017, 9, 227-235. | 0.5 | 0 |
| 3240 | Cellular Automata (CA) Model for Protein. , 2018, , 291-325. | | 1 |
| 3241 | CCL-21. , 2018, , 790-799. | | 0 |
| 3242 | Dynamic changes in PD-1 and PD-L1 expressions in cases with Hodgkin Lymphoma. Clinical Research and Trials, 2018, 4, . | 0.1 | 1 |
| 3243 | Immunotherapy in the drug treatment of patients with triple-negative metastatic breast cancer. Onkologiya Zhurnal Imeni P A Gertsena, 2018, 7, 60. | 0.0 | 0 |
| 3244 | Competing Immune Biomarkers in the Selection of First-line Therapy in Non-small Cell Lung Cancer. Oncology & Hematology Review, 2018, 14, 67. | 0.2 | 0 |
| 3245 | Immunosenescence and Cancer Immunotherapy at Old Age: Basics. , 2018, , 1-20. | | 1 |
| 3247 | ULTRASOUND TUMOR ABLATION: IMMUNE EFFECTS AND PERSPECTIVES OF INTEGRATION IN THE MODERN TREATMENT OF ADVANCED CANCER. Malignant Tumours, 2018, 8, 31-42. | 0.1 | 0 |
| 3248 | Expression of immunomodulator programmed death ligand 1 and fork head box protein 3 in squamous cell carcinoma of cervix. Egyptian Journal of Pathology, 2018, 38, 52-60. | 0.0 | 0 |
| 3249 | The investigation of PD-L1 expression as a prognostic marker for uterine sarcoma.. Morphologia, 2018, 12, 62-71. | 0.1 | 0 |
| 3251 | Genomics Role in Cancer Immunosurveillance: Impact on Immunotherapy Response. International Journal of Cancer Management, 2018, In Press, . | 0.2 | 1 |
| 3252 | Checkpoint Inhibitors in the Treatment of Metastatic Melanoma. , 2019, , 1-24. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 3253 | Immunology of Melanoma. , 2019, , 1-32. | | 0 |
| 3254 | Clinical Trials and Novel/Emerging Treatment. , 2019, , 183-208. | | 1 |
| 3259 | Analysis of PD-L1 expression in salivary duct carcinoma with its efficacy as a tumor marker. Korean Society for Head and Neck Oncology, 2019, 35, 13-20. | 0.1 | 0 |
| 3261 | Programmed death ligand 1 (PD-L1) expression in parathyroid tumors. Endocrine Connections, 2019, 8, 887-897. | 0.8 | 7 |
| 3262 | Chronic nicotine exposure affects programmed death-ligand 1 expression and sensitivity to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer. Translational Cancer Research, 2019, 8, S378-S388. | 0.4 | 3 |
| 3263 | Clinicopathological correlation of immune response in human cancers. Oncotarget, 2019, 10, 5859-5870. | 0.8 | 0 |
| 3264 | Exhaustive Review on Lung Cancers: Novel Technologies. Current Medical Imaging, 2019, 15, 873-883. | 0.4 | 1 |
| 3265 | Experience of using atezolizumab in 1st line therapy of metastatic urothelial cancer. Onkourologiya, 2019, 15, 113-119. | 0.1 | 0 |
| 3267 | Immunosenescence and Cancer Immunotherapy at Old Age: Basics. , 2020, , 71-90. | | 1 |
| 3268 | Checkpoint Inhibitors in the Treatment of Metastatic Melanoma. , 2020, , 1141-1164. | | 0 |
| 3269 | Immunotherapy in Pediatric Solid Tumors. Clinical Pediatric Hematology-Oncology, 2020, 27, 22-31. | 0.0 | 1 |
| 3270 | The Laboratory Evaluation of Melanoma. , 2021, , 29-60. | | 0 |
| 3273 | Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma. Journal of Nanobiotechnology, 2021, 19, 355. | 4.2 | 33 |
| 3274 | Abscopal Effects in Metastatic Cancer: Is a Predictive Approach Possible to Improve Individual Outcomes?. Journal of Clinical Medicine, 2021, 10, 5124. | 1.0 | 10 |
| 3275 | Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients. International Journal of Molecular Sciences, 2021, 22, 11563. | 1.8 | 16 |
| 3276 | Lack of CD8 <sup>+</sup> T cell effector differentiation during priming mediates checkpoint blockade resistance in non–small cell lung cancer. Science Immunology, 2021, 6, eabi8800. | 5.6 | 58 |
| 3277 | Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers. Cancers, 2021, 13, 5415. | 1.7 | 13 |
| 3278 | Comparison of metabolic and immunologic responses to transarterial chemoembolization with different chemoembolic regimens in a rabbit VX2 liver tumor model. European Radiology, 2022, 32, 2437-2447. | 2.3 | 9 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 3279 | Dynamics of Early Serum Tumour Markers and Neutrophil-to-Lymphocyte Ratio Predict Response to PD-1/PD-L1 Inhibitors in Advanced Non-Small-Cell Lung Cancer. Cancer Management and Research, 2021, Volume 13, 8241-8255. | 0.9 | 11 |
| 3280 | CHI3L1 regulates PD-L1 and antiâ€"CHI3L1â€"PD-1 antibody elicits synergistic antitumor responses. Journal of Clinical Investigation, 2021, 131, . | 3.9 | 25 |
| 3281 | Synergy between <i>Toxoplasma gondii</i> type I Î"<i>GRA17</i> immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors. , 2021, 9, e002970. | | 19 |
| 3282 | Immunology of Melanoma. , 2020, , 41-72. | | 0 |
| 3284 | Immunometabolism and Its Potential to Improve the Current Limitations of Immunotherapy. Methods in Molecular Biology, 2020, 2184, 233-263. | 0.4 | 1 |
| 3286 | EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma. Aging, 2021, 13, 598-618. | 1.4 | 10 |
| 3287 | Prognostic value of programmed cell death ligand-1 expression in breast cancer. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 | 0.4 | 5 |
| 3288 | ARID1A Deficiency Is Associated With High Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma. Hepatology Communications, 2021, 5, 675-688. | 2.0 | 17 |
| 3289 | Remarkable response to combined immunochemotherapy in patients with metastatic triple-negative breast cancer. Immunotherapy, 2020, 12, 1293-1302. | 1.0 | 0 |
| 3290 | Immunology and Immunotherapy of Ovarian Cancer. , 2020, , 487-540. | | 0 |
| 3292 | Efficacy Considerations in Phase I Trials. , 2020, , 159-183. | | 0 |
| 3293 | Identification of Immune-Desert Phenotypes in Head and Neck Squamous Cell Carcinoma With a Nine-Gene Signature Prediction Model Using Bioinformatics Methods. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 3294 | CHAPTER 10. Intratumoral Fibrosis: Emerging Concepts and Therapeutic Opportunities. RSC Drug Discovery Series, 2020, , 259-306. | 0.2 | 1 |
| 3295 | PD-L1 expression in immune cells is a favorable prognostic factor for nasopharyngeal carcinoma. Indian Journal of Cancer, 2020, . | 0.2 | 1 |
| 3297 | Immunohistochemical Validation of Rare Tissues and Antigens With Low Frequency of Occurrence: Recommendations From The Anatomic Pathology Patient Interest Association (APPIA). Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 327-334. | 0.6 | 1 |
| 3298 | Cancer-cell-biomimetic nanoparticles systemically eliminate hypoxia tumors by synergistic chemotherapy and checkpoint blockade immunotherapy. Acta Pharmaceutica Sinica B, 2022, 12, 2103-2119. | 5.7 | 24 |
| 3299 | PD1/PDL1 expression is associated with increased TIM3 expression and tumor-infiltrating T lymphocytes in fibroblastic tumors. Clinical and Translational Oncology, 2022, 24, 586-596. | 1.2 | 1 |
| 3300 | Light-controlled elimination of PD-L1+ cells. Journal of Photochemistry and Photobiology B: Biology, 2021, 225, 112355. | 1.7 | 5 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 3301 | Myeloid antigen-presenting cell niches sustain antitumor TÂcells and license PD-1 blockade via CD28 costimulation. Cancer Cell, 2021, 39, 1623-1642.e20. | 7.7 | 64 |
| 3302 | Immune Modulating Antibodyâ€"Drug Conjugate (IM-ADC) for Cancer Immunotherapy. Journal of Medicinal Chemistry, 2021, 64, 15716-15726. | 2.9 | 35 |
| 3303 | miRNA as a Modulator of Immunotherapy and Immune Response in Melanoma. Biomolecules, 2021, 11, 1648. | 1.8 | 15 |
| 3304 | Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer. Genome Medicine, 2021, 13, 175. | 3.6 | 12 |
| 3305 | Effectiveness and safety of immune checkpoint inhibitors in combination with palliative radiotherapy in advanced melanoma: A systematic review. Critical Reviews in Oncology/Hematology, 2021, 167, 103499. | 2.0 | 0 |
| 3306 | Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nature Communications, 2021, 12, 6375. | 5.8 | 22 |
| 3307 | CPIâ€203 improves the efficacy of antiâ€PDâ€1 therapy by inhibiting the induced PDâ€L1 overexpression in liver cancer. Cancer Science, 2022, 113, 28-40. | 1.7 | 5 |
| 3309 | Development of an immune-related signature for predicting survival outcome and immunotherapy response in osteosarcoma. Aging, 2021, 13, 24155-24170. | 1.4 | 1 |
| 3310 | Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling. ELife, 2021, 10, . | 2.8 | 8 |
| 3312 | Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy. Radiology and Oncology, 2018, . | 0.6 | 0 |
| 3316 | Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Nonâ€"Small Cell Lung Cancer. Cancer Journal (Sudbury, Mass ), 2020, 26, 507-516. | 1.0 | 4 |
| 3317 | Current trends in the immunotherapy of metastatic and recurrent squamous cell carcinoma of the head and neck. Opuholi Golovy I Sei, 2020, 10, 41-47. | 0.1 | 0 |
| 3318 | Introducing, OncoTarget. Oncotarget, 2010, 1, 2-2. | 0.8 | 1 |
| 3319 | Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors. Onkologie (Czech Republic), 2020, 14, 205-212. | 0.0 | 0 |
| 3320 | Pathological significance of abnormal recepteur dâ€™origine nantais and programmed death ligand 1 expression in colorectal cancer. World Journal of Gastrointestinal Oncology, 2020, 12, 1216-1236. | 0.8 | 1 |
| 3321 | CD8 + T Cell Infiltration Predicts Chemoradiosensitivity in Nasopharyngeal or Oropharyngeal Cancer. Laryngoscope, 2021, 131, E1179-E1189. | 1.1 | 9 |
| 3322 | PD-L1 expression associated with better response to EGFR tyrosine kinase inhibitors. Cancer Biology and Medicine, 2015, 12, 71-3. | 1.4 | 7 |
| 3323 | Changes in tumor-antigen expression profile as human small-cell lung cancers progress. Cancer Biology and Medicine, 2015, 12, 96-105. | 1.4 | 1 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 3324 | Role of "oncogenic nexus" of CIP2A in breast oncogenesis: how does it work?. American Journal of Cancer Research, 2015, 5, 2872-91. | 1.4 | 10 |
| 3325 | Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis. International Journal of Clinical and Experimental Medicine, 2015, 8, 14595-603. | 1.3 | 57 |
| 3326 | Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer. Translational Lung Cancer Research, 2015, 4, 704-12. | 1.3 | 8 |
| 3327 | Shedding light on the molecular determinants of response to anti-PD-1 therapy. Translational Lung Cancer Research, 2015, 4, 816-9. | 1.3 | 18 |
| 3328 | B7-H3 expression associates with tumor invasion and patient's poor survival in human esophageal cancer. American Journal of Translational Research (discontinued), 2015, 7, 2646-60. | 0.0 | 26 |
| 3329 | PD-1, PD-L1 and PD-L2 expression in mouse prostate cancer. American Journal of Clinical and Experimental Urology, 2016, 4, 1-8. | 0.4 | 22 |
| 3330 | Immunotherapy for lung cancer: advances and prospects. American Journal of Clinical and Experimental Immunology, 2016, 5, 1-20. | 0.2 | 28 |
| 3331 | MafB silencing in macrophages does not influence the initiation and growth of lung cancer induced by urethane. EXCLI Journal, 2017, 16, 914-920. | 0.5 | 2 |
| 3332 | How Checkpoint Inhibitors Are Changing the Treatment Paradigm in Solid Tumors: What Advanced Practitioners in Oncology Need to Know. Journal of the Advanced Practitioner in Oncology, 2016, 7, 498-509. | 0.2 | 6 |
| 3336 | New advances in immunotherapy for non-small cell lung cancer. American Journal of Translational Research (discontinued), 2018, 10, 2234-2245. | 0.0 | 26 |
| 3338 | Promising clinical application of ctDNA in evaluating immunotherapy efficacy. American Journal of Cancer Research, 2018, 8, 1947-1956. | 1.4 | 6 |
| 3339 | PD-L1 instead of PD-1 status is associated with the clinical features in human primary prostate tumors. American Journal of Clinical and Experimental Urology, 2019, 7, 159-169. | 0.4 | 13 |
| 3341 | Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinoma. American Journal of Cancer Research, 2020, 10, 564-571. | 1.4 | 5 |
| 3344 | Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease. Clinical Advances in Hematology and Oncology, 2017, 15, 466-477. | 0.3 | 3 |
| 3345 | Assessment for prognostic value of differentially expressed genes in immune microenvironment of clear cell renal cell carcinoma. American Journal of Translational Research (discontinued), 2020, 12, 5416-5432. | 0.0 | 4 |
| 3346 | BLM interaction with EZH2 regulates MDM2 expression and is a poor prognostic biomarker for prostate cancer. American Journal of Cancer Research, 2021, 11, 1347-1368. | 1.4 | 1 |
| 3347 | Immune cytolytic activity is associated with reduced intra-tumoral genetic heterogeneity and with better clinical outcomes in triple negative breast cancer. American Journal of Cancer Research, 2021, 11, 3628-3644. | 1.4 | 3 |
| 3348 | Laboratory biomarkers of an effective antitumor immune response. Clinical significance.. Cancer Treatment and Research Communications, 2021, 29, 100489. | 0.7 | 2 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 3349 | Nanomaterials targeting tumor associated macrophages for cancer immunotherapy. Journal of Controlled Release, 2022, 341, 272-284. | 4.8 | 41 |
| 3350 | The oncolytic virus VT09X optimizes immune checkpoint therapy in low immunogenic melanoma. Immunology Letters, 2022, 241, 15-22. | 1.1 | 3 |
| 3351 | Cluster of Differentiation 274 Antigen Immunohistochemical Expression in Tumor and Peri-tumor Cells of Hodgkin and Non-Hodgkin Lymphoma and Clinicopathological Relation (Single-center Study). Open Access Macedonian Journal of Medical Sciences, 2021, 9, 1011-1018. | 0.1 | 0 |
| 3352 | Sodium Alginate Hydrogel-Mediated Cancer Immunotherapy for Postoperative <i>In Situ</i> Recurrence and Metastasis. ACS Biomaterials Science and Engineering, 2021, 7, 5717-5726. | 2.6 | 20 |
| 3353 | Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary. Annals of Oncology, 2022, 33, 216-226. | 0.6 | 31 |
| 3354 | Association of CSMD1 with Tumor Mutation Burden and Other Clinical Outcomes in Gastric Cancer. International Journal of General Medicine, 2021, Volume 14, 8293-8299. | 0.8 | 4 |
| 3355 | Chemokine level predicts the therapeutic effect of anti-PD-1 antibody (nivolumab) therapy for malignant melanoma. Archives of Dermatological Research, 2021, , 1. | 1.1 | 1 |
| 3356 | The SETDB1â€"TRIM28 Complex Suppresses Antitumor Immunity. Cancer Immunology Research, 2021, 9, 1413-1424. | 1.6 | 24 |
| 3357 | PD-L1 and Notch as novel biomarkers in pancreatic sarcomatoid carcinoma: a pilot study. Expert Opinion on Therapeutic Targets, 2021, 25, 1007-1016. | 1.5 | 13 |
| 3358 | IL-34, the rationale for its expression in physiological and pathological conditions. Seminars in Immunology, 2021, 54, 101517. | 2.7 | 12 |
| 3359 | Prognostic Value of Tissue-Resident Memory T Cells and Tumor Microenvironmental Features in Resected Pancreatic Adenocarcinoma. , 2021, , . | | 2 |
| 3360 | Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis. International Journal of Clinical Oncology, 2022, 27, 59-71. | 1.0 | 19 |
| 3361 | TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment. , 2022, 9, e003134. | | 32 |
| 3362 | Second-Order Semi-Parametric Inference for Multivariate Log Gaussian Cox Processes. Journal of the Royal Statistical Society Series C: Applied Statistics, 2022, 71, 244-268. | 0.5 | 2 |
| 3363 | Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review. Cell Communication and Signaling, 2021, 19, 117. | 2.7 | 25 |
| 3364 | BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment. Cancer Research, 2022, 82, 264-277. | 0.4 | 8 |
| 3365 | Checkpoint Inhibition in Bladder Cancer: Clinical Expectations, Current Evidence, and Proposal of Future Strategies Based on a Tumor-Specific Immunobiological Approach. Cancers, 2021, 13, 6016. | 1.7 | 19 |
| 3366 | APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cellâ€"Mediated Antitumor Immune Responses. Cancer Immunology Research, 2022, 10, 70-86. | 1.6 | 20 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 3367 | B7–H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression. Oncogene, 2022, 41, 704-717. | 2.6 | 15 |
| 3368 | Evaluation of the programmed death-ligand 1 mRNA expression and immunopositivity and their correlation with survival outcomes in Indian lung cancer patients. Human Cell, 2021, , 1. | 1.2 | 0 |
| 3369 | Natural Killer and T Cell Infiltration in Canine Osteosarcoma: Clinical Implications and Translational Relevance. Frontiers in Veterinary Science, 2021, 8, 771737. | 0.9 | 1 |
| 3370 | Cancer-Immunity Cycle and Therapeutic Interventions- Opportunities for Including Pet Dogs With Cancer. Frontiers in Oncology, 2021, 11, 773420. | 1.3 | 10 |
| 3371 | A case of long-term complete remission of locally advanced T4 bladder cancer treated with pembrolizumab. Urology Case Reports, 2022, 41, 101959. | 0.1 | 1 |
| 3372 | Single-cell transcriptome identifies molecular subtype of autism spectrum disorder impacted by de novo loss-of-function variants regulating glial cells. Human Genomics, 2021, 15, 68. | 1.4 | 20 |
| 3373 | Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review. World Journal of Gastrointestinal Oncology, 2021, 13, 1813-1832. | 0.8 | 11 |
| 3374 | Targeting acute myeloid leukemia through multimodal immunotherapeutic approaches. Leukemia and Lymphoma, 2021, , 1-10. | 0.6 | 1 |
| 3375 | Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation. Journal of Immunology Research, 2021, 2021, 1-18. | 0.9 | 21 |
| 3376 | First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis. Cost Effectiveness and Resource Allocation, 2021, 19, 77. | 0.6 | 15 |
| 3377 | Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. Nature Communications, 2021, 12, 7005. | 5.8 | 66 |
| 3378 | Future of PD-1/PD-L1 axis modulation for the treatment of triple-negative breast cancer. Pharmacological Research, 2022, 175, 106019. | 3.1 | 20 |
| 3379 | Immune System in Action. Advances in Experimental Medicine and Biology, 2021, 1342, 1-43. | 0.8 | 0 |
| 3380 | Using cfRNA as a tool to evaluate clinical treatment outcomes in patients with metastatic lung cancers and other tumors. Cancer Drug Resistance (Alhambra, Calif ), 2021, 4, 1061-1071. | 0.9 | 2 |
| 3381 | A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab. Journal of Investigative Medicine High Impact Case Reports, 2021, 9, 232470962110584. | 0.3 | 6 |
| 3382 | Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade. OncoImmunology, 2021, 10, . | 2.1 | 14 |
| 3383 | Tertiary lymphoid structures in cancer. Science, 2022, 375, eabf9419. | 6.0 | 303 |
| 3384 | Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise. Diagnostics, 2022, 12, 124. | 1.3 | 12 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 3385 | Immunotherapy toxicity: identification and management. Breast Cancer Research and Treatment, 2022, 192, 1-17. | 1.1 | 24 |
| 3386 | Accounting for B-cell Behavior and Sampling Bias Predicts Anti–PD-L1 Response in Bladder Cancer. Cancer Immunology Research, 2022, 10, 343-353. | 1.6 | 9 |
| 3387 | A Combined-Radiomics Approach of CT Images to Predict Response to Anti-PD-1 Immunotherapy in NSCLC: A Retrospective Multicenter Study. Frontiers in Oncology, 2021, 11, 688679. | 1.3 | 13 |
| 3388 | PTRF/Cavin-1 as a Novel RNA-Binding Protein Expedites the NF-κB/PD-L1 Axis by Stabilizing lncRNA NEAT1, Contributing to Tumorigenesis and Immune Evasion in Glioblastoma. Frontiers in Immunology, 2021, 12, 802795. | 2.2 | 14 |
| 3389 | Enhancing the HSV-1-mediated antitumor immune response by suppressing Bach1. Cellular and Molecular Immunology, 2022, 19, 516-526. | 4.8 | 4 |
| 3391 | Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma. Frontiers in Immunology, 2021, 12, 810388. | 2.2 | 9 |
| 3392 | Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nature Medicine, 2022, 28, 144-153. | 15.2 | 102 |
| 3394 | 802…Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkpoint blockade. , 2020, , . | | 0 |
| 3396 | Deep Proteomic Analysis on Biobanked Paraffine-Archived Melanoma with Prognostic/Predictive Biomarker Read-Out. Cancers, 2021, 13, 6105. | 1.7 | 3 |
| 3397 | Naringenin potentiates anti-tumor immunity against oral cancer by inducing lymph node CD169-positive macrophage activation and cytotoxic T cell infiltration. Cancer Immunology, Immunotherapy, 2022, 71, 2127-2139. | 2.0 | 11 |
| 3398 | Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects. Cells, 2022, 11, 320. | 1.8 | 43 |
| 3399 | Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, . | 3.3 | 33 |
| 3400 | Research progress of tumor targeted drug delivery based on PD-1/PD-L1. International Journal of Pharmaceutics, 2022, 616, 121527. | 2.6 | 16 |
| 3401 | Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?. Journal of Hematology and Oncology, 2022, 15, 6. | 6.9 | 17 |
| 3402 | Prostate cancer immunotherapy. Expert Opinion on Biological Therapy, 2022, 22, 577-590. | 1.4 | 17 |
| 3404 | Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity. Clinical Cancer Research, 2022, 28, 2038-2049. | 3.2 | 16 |
| 3405 | Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances. Cancers, 2022, 14, 621. | 1.7 | 34 |
| 3406 | High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study. Frontiers in Immunology, 2021, 12, 779248. | 2.2 | 3 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 3407 | Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer. Frontiers in Oncology, 2022, 12, 806963. | 1.3 | 14 |
| 3408 | <scp>PD‐L1</scp> and <scp>PD‐L2</scp> expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and <scp>DNA</scp> damage response molecules. Journal of Pathology: Clinical Research, 2022, 8, 257-267. | 1.3 | 9 |
| 3409 | IFN-Gamma Expression in the Tumor Microenvironment and CD8-Positive Tumor-Infiltrating Lymphocytes as Prognostic Markers in Urothelial Cancer Patients Receiving Pembrolizumab. Cancers, 2022, 14, 263. | 1.7 | 12 |
| 3410 | Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer. , 2022, 10, e003747. | | 23 |
| 3411 | Targeting NF-κB Signaling in Cancer Stem Cells: A Narrative Review. Biomedicines, 2022, 10, 261. | 1.4 | 11 |
| 3412 | Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. Genome Medicine, 2022, 14, 1. | 3.6 | 68 |
| 3413 | Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers. World Journal of Gastrointestinal Oncology, 2022, 14, 19-37. | 0.8 | 2 |
| 3414 | Recent advances in systemic therapy for hepatocellular carcinoma. Biomarker Research, 2022, 10, 3. | 2.8 | 94 |
| 3415 | DNA damage response inhibitor and anti-PD-L1 therapy for prostate cancer: Development of predictive biomarkers. Engineering, 2022, , . | 3.2 | 0 |
| 3416 | Insights into Modern Therapeutic Approaches in Pediatric Acute Leukemias. Cells, 2022, 11, 139. | 1.8 | 6 |
| 3417 | Cancer cell-expressed BTNL2 facilitates tumour immune escape via engagement with IL-17A-producing γδ T cells. Nature Communications, 2022, 13, 231. | 5.8 | 14 |
| 3418 | Comprehensive Analysis of Immune Implication and Prognostic Value of IFI44L in Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 798425. | 1.3 | 2 |
| 3419 | A combined biomarker panel shows improved sensitivity and specificity for detection of ovarian cancer. Journal of Clinical Laboratory Analysis, 2022, 36, e24232. | 0.9 | 3 |
| 3420 | Quantum dots for electrochemical cytosensing. TrAC - Trends in Analytical Chemistry, 2022, 148, 116531. | 5.8 | 21 |
| 3421 | Redox Metabolism-Associated Molecular Classification of Clear Cell Renal Cell Carcinoma. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-19. | 1.9 | 4 |
| 3422 | Molecular Mechanism of HIF-1α and CD31 Promoting Metastasis and Invasion of Advanced Hepatocellular Carcinoma. Advances in Clinical Medicine, 2022, 12, 236-245. | 0.0 | 0 |
| 3423 | Endoplasmic reticulum stress promotes the release of exosomal PD-L1 from head and neck cancer cells and facilitates M2 macrophage polarization. Cell Communication and Signaling, 2022, 20, 12. | 2.7 | 28 |
| 3424 | Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab. Journal of Immunotherapy, 2022, 45, 167-179. | 1.2 | 7 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 3425 | Irreversible Electroporation: An Emerging Immunomodulatory Therapy on Solid Tumors. Frontiers in Immunology, 2021, 12, 811726. | 2.2 | 24 |
| 3426 | <scp>PDâ€L1</scp> overexpression correlates with <scp><i>JAK2</i>â€V617F</scp> mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms. American Journal of Hematology, 2022, 97, 390-400. | 2.0 | 8 |
| 3427 | Co-delivery of dihydroartemisinin and pyropheophorbide-iron elicits ferroptosis to potentiate cancer immunotherapy. Biomaterials, 2022, 280, 121315. | 5.7 | 46 |
| 3428 | Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective. Journal of Personalized Medicine, 2022, 12, 149. | 1.1 | 14 |
| 3429 | Immunomagnetic microscopy of tumor tissues using quantum sensors in diamond. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, . | 3.3 | 17 |
| 3430 | Association of Peripheral Blood Biomarkers With Response to Anti-PD-1 Immunotherapy for Patients With Deficient Mismatch Repair Metastatic Colorectal Cancer: A Multicenter Cohort Study. Frontiers in Immunology, 2022, 13, 809971. | 2.2 | 6 |
| 3431 | PD-L1+CD8+ TÂcells enrichment in lung cancer exerted regulatory function and tumor-promoting tolerance. IScience, 2022, 25, 103785. | 1.9 | 19 |
| 3432 | Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis. Molecular Diagnosis and Therapy, 2022, , 1. | 1.6 | 2 |
| 3433 | Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defined imaging agents. Journal of Nanobiotechnology, 2022, 20, 64. | 4.2 | 5 |
| 3434 | PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted TÂcell clonotypes. Cell Reports, 2022, 38, 110331. | 2.9 | 45 |
| 3435 | Immune priming using DC- and TÂcell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition. Molecular Therapy - Oncolytics, 2022, 24, 429-442. | 2.0 | 9 |
| 3436 | Immunostimulation of tumor microenvironment by targeting tumor-associated macrophages with hypoxia-responsive nanocomplex for enhanced anti-tumor therapy. Journal of Controlled Release, 2022, 343, 78-88. | 4.8 | 6 |
| 3437 | Ferroptosis-associated molecular classification characterized by distinct tumor microenvironment profiles in colorectal cancer. International Journal of Biological Sciences, 2022, 18, 1773-1794. | 2.6 | 12 |
| 3438 | CD8<sup>+</sup>PD-1<sup>+</sup> to CD4<sup>+</sup>PD-1<sup>+</sup> ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers. , 2022, 10, e004012. | | 16 |
| 3439 | Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutationâ€"positive melanoma. Annals of Oncology, 2022, 33, 544-555. | 0.6 | 12 |
| 3440 | T Lymphocyte Infiltration in Association with IDO1 Expression in Resected Lung Adenocarcinoma and Normal Adjacent Lung Tissues. BioMed Research International, 2022, 2022, 1-9. | 0.9 | 1 |
| 3441 | Diagnostic Utility of the PD-L1 Immunostaining in Biopsy Specimens of Patients with Biliary Tract Neoplasms. Journal of Gastrointestinal Surgery, 2022, 26, 1213-1223. | 0.9 | 0 |
| 3442 | Mesenchymal stromal cells equipped by IFNÎ± empower T cells with potent anti-tumor immunity. Oncogene, 2022, 41, 1866-1881. | 2.6 | 9 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 3443 | Predictive Efficacy of Blood-Based Tumor Mutation Burden Assay for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2022, 12, 795933. | 1.3 | 4 |
| 3444 | Oncogenic Alterations in Histologically Negative Lymph Nodes Are Associated with Prognosis of Patients with Stage I Lung Adenocarcinoma. Cancers, 2022, 14, 824. | 1.7 | 2 |
| 3445 | Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 Therapy. International Journal of Radiation Oncology Biology Physics, 2022, 113, 415-425. | 0.4 | 9 |
| 3446 | Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy. Journal of Experimental and Clinical Cancer Research, 2022, 41, 56. | 3.5 | 20 |
| 3447 | Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. Nature Cancer, 2022, 3, 108-121. | 5.7 | 150 |
| 3448 | Camrelizumab: an investigational agent for hepatocellular carcinoma. Expert Opinion on Investigational Drugs, 2022, 31, 337-346. | 1.9 | 6 |
| 3449 | Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome. Blood Advances, 2022, 6, 1152-1161. | 2.5 | 13 |
| 3451 | Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 793808. | 1.3 | 2 |
| 3453 | The Relationship between Radiation Therapy and Immunotherapy. Advances in Clinical Medicine, 2022, 12, 1014-1021. | 0.0 | 0 |
| 3454 | Clinical Impact of &lt;i&gt;STK11&lt;/i&gt; Mutation in Advanced-Stage Non-Small-Cell Lung Cancer. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 3455 | Immunoexpression of PD-L1, CD4+ and CD8+ cell infiltrates and tumor-infiltrating lymphocytes (TILs) in the microenvironment of actinic cheilitis and lower lip squamous cell carcinoma. Journal of Applied Oral Science, 2022, 30, e20210344. | 0.7 | 1 |
| 3456 | Clinical Relevance of PD-L2 Expression in Surgically Resected Lung Adenocarcinoma. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 3457 | CD103+CD8+ tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer. British Journal of Cancer, 2022, 126, 1581-1588. | 2.9 | 16 |
| 3458 | Improving Cancer Immunotherapy: Exploring and Targeting Metabolism in Hypoxia Microenvironment. Frontiers in Immunology, 2022, 13, 845923. | 2.2 | 11 |
| 3459 | Biomarkers of response to PD-1 pathway blockade. British Journal of Cancer, 2022, 126, 1663-1675. | 2.9 | 52 |
| 3460 | Controlling Cell Trafficking: Addressing Failures in CAR T and NK Cell Therapy of Solid Tumours. Cancers, 2022, 14, 978. | 1.7 | 12 |
| 3461 | Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma. Cell Reports Medicine, 2022, 3, 100500. | 3.3 | 13 |
| 3462 | Recent pharmacological approaches for the treatment of renal cell carcinoma. Expert Review of Clinical Pharmacology, 2022, 15, 187-195. | 1.3 | 1 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 3463 | High farnesoid X receptor expression predicts favorable clinical outcomes in PD‑L1<sup>low/negative</sup> non‑small cell lung cancer patients receiving anti‑PD‑1‑based chemo‑immunotherapy. International Journal of Oncology, 2022, 60, . | 1.4 | 2 |
| 3464 | Discovery of Small-Molecule Inhibitors of the PD-1/PD-L1 Axis That Promote PD-L1 Internalization and Degradation. Journal of Medicinal Chemistry, 2022, 65, 3879-3893. | 2.9 | 55 |
| 3465 | Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Annals of Oncology, 2022, 33, 534-543. | 0.6 | 138 |
| 3466 | Cancer Vaccine in Cold Tumors: Clinical Landscape, Challenges, and Opportunities. Current Cancer Drug Targets, 2022, 22, 437-453. | 0.8 | 2 |
| 3467 | Nanoscale Drug Delivery Systems in Glioblastoma. Nanoscale Research Letters, 2022, 17, 27. | 3.1 | 19 |
| 3468 | Current WHO Guidelines and the Critical Role of Genetic Parameters in the Classification of Glioma: Opportunities for Immunotherapy. Current Treatment Options in Oncology, 2022, 23, 188-198. | 1.3 | 6 |
| 3469 | Stromal Characteristics and Impact on New Therapies for Metastatic Triple-Negative Breast Cancer. Cancers, 2022, 14, 1238. | 1.7 | 7 |
| 3470 | Immune Checkpoint FGL1 Expression of Circulating Tumor Cells Is Associated With Poor Survival in Curatively Resected Hepatocellular Carcinoma. Frontiers in Oncology, 2022, 12, 810269. | 1.3 | 14 |
| 3471 | Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in *KRAS-*mutated non-small cell lung cancer with *STK11*, *KEAP1,* or *TP53* comutations: subgroup results from the phase III IMpower150 trial. , 2022, 10, e003027. |  | 45 |
| 3472 | Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4. Pharmaceuticals, 2022, 15, 335. | 1.7 | 35 |
| 3473 | Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?. Cancers, 2022, 14, 1710. | 1.7 | 13 |
| 3474 | Fluence rate differences in photodynamic therapy efficacy and activation of immune checkpoints of murine colorectal cancer. , 2022, , . |  | 0 |
| 3475 | The New Treatment Methods for Non-Hodgkin Lymphoma in Pediatric Patients. Cancers, 2022, 14, 1569. | 1.7 | 4 |
| 3476 | Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia. Experimental Hematology and Oncology, 2022, 11, 11. | 2.0 | 35 |
| 3477 | FAT10 is a Prognostic Biomarker and Correlated With Immune Infiltrates in Skin Cutaneous Melanoma. Frontiers in Molecular Biosciences, 2022, 9, 805887. | 1.6 | 1 |
| 3478 | Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database. Frontiers in Pharmacology, 2022, 13, 803706. | 1.6 | 6 |
| 3479 | Comprehensive analysis of the correlations of S100B with hypoxia response and immune infiltration in hepatocellular carcinoma. PeerJ, 2022, 10, e13201. | 0.9 | 4 |
| 3480 | CD8+ T-cell exhaustion in the tumor microenvironment of head and neck squamous cell carcinoma determines poor prognosis. Annals of Translational Medicine, 2022, 10, 273-273. | 0.7 | 8 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 3481 | Predictive Simulations in Preclinical Oncology to Guide the Translation of Biologics. Frontiers in Pharmacology, 2022, 13, 836925. | 1.6 | 4 |
| 3482 | Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma. Blood Advances, 2022, 6, 5659-5667. | 2.5 | 3 |
| 3483 | Radiotherapy could increase the efficacy of immunotherapy in non-small cell lung cancer. Turkish Journal of Internal Medicine, 0, , . | 0.3 | 2 |
| 3484 | Identification of New m6A Methylation Modification Patterns and Tumor Microenvironment Infiltration Landscape that Predict Clinical Outcomes for Papillary Renal Cell Carcinoma Patients. Frontiers in Cell and Developmental Biology, 2022, 10, 818194. | 1.8 | 1 |
| 3485 | A novel peptide-based probe 99mTc-PEG6-RD-PDP2 for the molecular imaging of tumor PD-L2 expression. Chinese Chemical Letters, 2022, 33, 3497-3501. | 4.8 | 2 |
| 3486 | Harnessing the chemokine system to home CAR-T cells into solid tumors. Cell Reports Medicine, 2022, 3, 100543. | 3.3 | 24 |
| 3487 | Single-cell RNA sequencing reveals intrahepatic and peripheral immune characteristics related to disease phases in HBV-infected patients. Gut, 2023, 72, 153-167. | 6.1 | 42 |
| 3488 | CMTM6 as a master regulator of PD-L1. Cancer Immunology, Immunotherapy, 2022, 71, 2325-2340. | 2.0 | 7 |
| 3489 | Identification and Validation of N6-Methyladenosine-Related Biomarkers for Bladder Cancer: Implications for Immunotherapy. Frontiers in Oncology, 2022, 12, 820242. | 1.3 | 5 |
| 3490 | Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial. Lancet Oncology, The, 2022, 23, e105-e115. | 5.1 | 29 |
| 3491 | Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma. Nature Reviews Urology, 2022, 19, 305-320. | 1.9 | 9 |
| 3492 | Anti-tumor immunity and ferroptosis of hepatocellular carcinoma are enhanced by combined therapy of sorafenib and delivering modified GO-based PD-L1 siRNAs. , 2022, 136, 212761. | | 10 |
| 3493 | TcellInflamedDetector: an R package to distinguish T cell inflamed tumor types from non–T cell inflamed tumor types. Genomics and Informatics, 2022, 20, e13. | 0.4 | 0 |
| 3494 | Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments. Biomedicines, 2022, 10, 650. | 1.4 | 24 |
| 3495 | The real-world safety of atezolizumab as second-line or later treatment in Japanese patients with non-small-cell lung cancer: a post-marketing surveillance study. Japanese Journal of Clinical Oncology, 2022, , . | 0.6 | 3 |
| 3496 | PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy. Frontiers in Immunology, 2022, 13, 826045. | 2.2 | 13 |
| 3497 | DeepTI: A deep learning-based framework decoding tumor-immune interactions for precision immunotherapy in oncology. SLAS Discovery, 2022, 27, 121-127. | 1.4 | 3 |
| 3498 | N6-Methyladenine-Related Signature for Immune Microenvironment and Response to Immunotherapy in Hepatocellular Carcinoma. International Journal of General Medicine, 2022, Volume 15, 3525-3540. | 0.8 | 5 |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 3499 | Case Report: Outcome and Adverse Events of Anti-PD-1 Antibody Plus Chidamide for Relapsed/Refractory SÃ©zary Syndrome: Case Series and A Literature Review. Frontiers in Oncology, 2022, 12, 842123. | 1.3 | 1 |
| 3500 | eEF2K promotes PD-L1 stabilization through inactivating GSK3Î² in melanoma. , 2022, 10, e004026. | | 11 |
| 3501 | Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor. Cancer Discovery, 2022, 12, 1482-1499. | 7.7 | 48 |
| 3502 | Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy. Frontiers in Immunology, 2022, 13, 838966. | 2.2 | 3 |
| 3503 | Functionalized chitosan as a promising platform for cancer immunotherapy: A review. Carbohydrate Polymers, 2022, 290, 119452. | 5.1 | 30 |
| 3504 | Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients. Archives of Gynecology and Obstetrics, 2022, 306, 1689-1695. | 0.8 | 4 |
| 3505 | Different clinical significance of novel B7 family checkpoints VISTA and HHLA2 in human lung adenocarcinoma. Immunotherapy, 2022, 14, 419-431. | 1.0 | 5 |
| 3506 | Phosphorylation and Stabilization of PD-L1 by CK2 Suppresses Dendritic Cell Function. Cancer Research, 2022, 82, 2185-2195. | 0.4 | 15 |
| 3507 | KRAS: A Druggable Target in Colon Cancer Patients. International Journal of Molecular Sciences, 2022, 23, 4120. | 1.8 | 13 |
| 3508 | Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers. ESMO Open, 2022, 7, 100419. | 2.0 | 7 |
| 3509 | Suppression of RPL34 Inhibits Tumor Cell Proliferation and Promotes Apoptosis in Glioblastoma. Applied Biochemistry and Biotechnology, 2022, 194, 3494-3506. | 1.4 | 5 |
| 3510 | Immune Checkpoint Inhibitor Rechallenge and Resumption: a Systematic Review. Current Oncology Reports, 2022, 24, 1095-1106. | 1.8 | 14 |
| 3511 | Management of Regional Lymph Nodes in Head and Neck Melanoma. Oral and Maxillofacial Surgery Clinics of North America, 2022, , . | 0.4 | 0 |
| 3512 | Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. Nature Communications, 2022, 13, 1878. | 5.8 | 3 |
| 3513 | Imaging immunity in patients with cancer using positron emission tomography. Npj Precision Oncology, 2022, 6, 24. | 2.3 | 13 |
| 3514 | Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC. Clinical Cancer Research, 2022, 28, 2461-2473. | 3.2 | 9 |
| 3515 | Characterization of the immune cell infiltration landscape in lung adenocarcinoma. Archives of Biochemistry and Biophysics, 2022, 721, 109168. | 1.4 | 0 |
| 3516 | Towards a precision immune checkpoint blockade immunotherapy in patients with colorectal cancer: Strategies and perspectives. Biomedicine and Pharmacotherapy, 2022, 149, 112923. | 2.5 | 7 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 3517 | Novel insights into the SPOP E3 ubiquitin ligase: From the regulation of molecular mechanisms to tumorigenesis. Biomedicine and Pharmacotherapy, 2022, 149, 112882. | 2.5 | 13 |
| 3518 | CCL2-mediated monocytes regulate immune checkpoint blockade resistance in pancreatic cancer. International Immunopharmacology, 2022, 106, 108598. | 1.7 | 6 |
| 3519 | Multimodal predictors for precision immunotherapy. Immuno-Oncology Technology, 2022, 14, 100071. | 0.2 | 4 |
| 3520 | Current methods and emerging approaches for detection of programmed death ligand 1. Biosensors and Bioelectronics, 2022, 208, 114179. | 5.3 | 3 |
| 3521 | Differential Expression of PD-L1 during Cell Cycle Progression of Head and Neck Squamous Cell Carcinoma. International Journal of Molecular Sciences, 2021, 22, 13087. | 1.8 | 6 |
| 3522 | Cancer-immunotherapy biomarkers in the tumor microenvironment. Okayama Igakkai Zasshi, 2021, 133, 151-157. | 0.0 | 0 |
| 3523 | Cross-talk of pyroptosis and tumor immune landscape in lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 4423-4444. | 1.3 | 6 |
| 3524 | PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLCï¼š A Cost-Effectiveness Analysis in China. Frontiers in Oncology, 2021, 11, 745493. | 1.3 | 2 |
| 3525 | What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?. Frontiers in Immunology, 2021, 12, 773168. | 2.2 | 18 |
| 3526 | Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges. Cancers, 2022, 14, 109. | 1.7 | 21 |
| 3527 | Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production and immune response. Nature Communications, 2021, 12, 7297. | 5.8 | 25 |
| 3528 | Efficacy and safety of pembrolizumab for treating advanced non-small-cell lung cancer: a meta-analysis of phase II and III randomized controlled trials. Journal of Chemotherapy, 2021, , 1-9. | 0.7 | 0 |
| 3529 | Single-Cell Transcriptome Analysis Reveals RGS1 as a New Marker and Promoting Factor for T-Cell Exhaustion in Multiple Cancers. Frontiers in Immunology, 2021, 12, 767070. | 2.2 | 29 |
| 3530 | Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer. Journal of Advanced Research, 2022, 40, 109-124. | 4.4 | 10 |
| 3531 | The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nature Reviews Drug Discovery, 2022, 21, 509-528. | 21.5 | 201 |
| 3532 | Antiâ€VEGF antibody triggers the effect of antiâ€PDâ€L1 antibody in PDâ€L1low and immune desertâ€like mouse tumors. Oncology Reports, 2021, 47, . | 1.2 | 10 |
| 3533 | Prognostic value of programmed death ligand 1 (PD-L1) in glioblastoma: a systematic review, meta-analysis and validation based on dataset. Bioengineered, 2021, 12, 10366-10378. | 1.4 | 3 |
| 3535 | Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment. Pharmaceutics, 2022, 14, 41. | 2.0 | 27 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 3536 | Biological therapies in patients with liver disease: are they really lifesavers?. Expert Opinion on Biological Therapy, 2022, 22, 473-490. | 1.4 | 0 |
| 3537 | ENPEP as a potential predictor of immune checkpoint inhibitor efficacy. Cancer Medicine, 2022, 11, 880-887. | 1.3 | 5 |
| 3538 | Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab. Clinical Cancer Research, 2022, 28, 1363-1371. | 3.2 | 2 |
| 3539 | Galectins: An Ancient Family of Carbohydrate Binding Proteins with Modern Functions. Methods in Molecular Biology, 2022, 2442, 1-40. | 0.4 | 21 |
| 3540 | Nanobodies: from structure to applications in non-injectable and bispecific biotherapeutic development. Nanoscale, 2022, 14, 7110-7122. | 2.8 | 14 |
| 3541 | Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors. Clinical Cancer Research, 2022, 28, 2657-2668. | 3.2 | 4 |
| 3542 | Beyond the snapshot: optimizing prognostication and prediction by moving from fixed to functional multidimensional cancer pathology. Journal of Pathology, 2022, , . | 2.1 | 1 |
| 3543 | Robust delivery of RIGâ€‰ agonists using extracellular vesicles for antiâ€‰cancer immunotherapy. Journal of Extracellular Vesicles, 2022, 11, e12187. | 5.5 | 33 |
| 3545 | Investigating the Prognostic Relevance of Tumor Immune Microenvironment and Immune Gene Assembly in Breast Carcinoma Subtypes. Cancers, 2022, 14, 1942. | 1.7 | 2 |
| 3546 | Next-Generation CAR T-cell Therapies. Cancer Discovery, 2022, 12, 1625-1633. | 7.7 | 53 |
| 3547 | Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Cancers, 2022, 14, 2018. | 1.7 | 15 |
| 3611 | FN3 linked nanobubbles as a targeted contrast agent for US imaging of cancer-associated human PD-L1. Journal of Controlled Release, 2022, 346, 317-327. | 4.8 | 9 |
| 3612 | A variety of â€˜exhaustedâ€™ T cells in the tumor microenvironment. International Immunology, 2022, 34, 563-570. | 1.8 | 13 |
| 3614 | Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis. Immunotherapy, 2022, 14, 709-725. | 1.0 | 10 |
| 3624 | Deubiquitination and Stabilization of PD-L1 by USP21.. American Journal of Translational Research (discontinued), 2021, 13, 12763-12774. | 0.0 | 0 |
| 3625 | Melanoma: An immunotherapyÂjourney from bench to bedside. Cancer Treatment and Research, 2022, 183, 49-89. | 0.2 | 0 |
| 3626 | Murine Mammary Carcinoma Induces Chronic Systemic Inflammation and Immunosuppression in BALB/c Mice. Journal of Breast Cancer, 0, 25, . | 0.8 | 2 |
| 3627 | Monitoring of Circulating Exosomal Immuno Checkpoint in Tumor Microenvironment Through Ultrasensitive Aptamer-Functionalized Sers Probes. SSRN Electronic Journal, 0, , . | 0.4 | 0 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 3628 | Deep learning for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall survival risk. Translational Lung Cancer Research, 2022, 11, 670-685. | 1.3 | 13 |
| 3629 | Current Therapy for Metastatic Head and Neck Cancer: Evidence, Opportunities, and Challenges. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 527-540. | 1.8 | 9 |
| 3630 | A Machine Learning Model Based on PET/CT Radiomics and Clinical Characteristics Predicts Tumor Immune Profiles in Non-Small Cell Lung Cancer: A Retrospective Multicohort Study. Frontiers in Immunology, 2022, 13, 859323. | 2.2 | 25 |
| 3631 | Malignant pleural effusion cell blocks are reliable resources for PD-L1 analysis in advanced lung adenocarcinomas: a concordance study with matched histologic samples. Journal of the American Society of Cytopathology, 2022, 11, 253-263. | 0.2 | 0 |
| 3632 | In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue. Journal of Experimental Medicine, 2022, 219, . | 4.2 | 42 |
| 3633 | Companion Diagnostics: Lessons Learned and the Path Forward From the Programmed Death Ligand-1 Rollout. Archives of Pathology and Laboratory Medicine, 2023, 147, 62-70. | 1.2 | 2 |
| 3634 | Immune Checkpoint Inhibitors in Cancer Therapy. Current Oncology, 2022, 29, 3044-3060. | 0.9 | 239 |
| 3635 | Identification of Implications of Angiogenesis and m6A Modification on Immunosuppression and Therapeutic Sensitivity in Low-Grade Glioma by Network Computational Analysis of Subtypes and Signatures. Frontiers in Immunology, 2022, 13, 871564. | 2.2 | 4 |
| 3636 | Computational Investigations on the Natural Small Molecule as an Inhibitor of Programmed Death Ligand 1 for Cancer Immunotherapy. Life, 2022, 12, 659. | 1.1 | 4 |
| 3637 | Resistance Mechanisms to Anti-PD Cancer Immunotherapy. Annual Review of Immunology, 2022, 40, 45-74. | 9.5 | 122 |
| 3638 | The Cellular Tumor Immune Microenvironment of Childhood Solid Cancers: Informing More Effective Immunotherapies. Cancers, 2022, 14, 2177. | 1.7 | 2 |
| 3639 | The Use of Bacteriophages in Biotechnology and Recent Insights into Proteomics. Antibiotics, 2022, 11, 653. | 1.5 | 11 |
| 3640 | TIRSF: a web server for screening gene signatures to predict Tumor immunotherapy response. Nucleic Acids Research, 2022, 50, W761-W767. | 6.5 | 2 |
| 3641 | Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction. Clinical Cancer Research, 2022, 28, 3021-3031. | 3.2 | 32 |
| 3642 | Burgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1/PD-L1 Therapy. Frontiers in Immunology, 2022, 13, . | 2.2 | 5 |
| 3643 | Basket Trials: Review of Current Practice and Innovations for Future Trials. Journal of Clinical Oncology, 2022, 40, 3520-3528. | 0.8 | 10 |
| 3644 | Clinical relevance of PD-L2 expression in surgically resected lung adenocarcinoma. Lung Cancer, 2022, 168, 50-58. | 0.9 | 4 |
| 3646 | High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC. , 2022, 10, e004197. | | 5 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 3647 | Atezolizumab plus carboplatin and nab‐paclitaxel versus carboplatin and nab‐paclitaxel as treatments for Chinese, treatment‐naïve, stage IV, non‐squamous, non‐small‐cell lung cancer patients: A retrospective analysis. Pharmacology Research and Perspectives, 2022, 10, e00941. | 1.1 | 1 |
| 3648 | PD‐1 mediates decidual γδ T cells cytotoxicity during recurrent pregnancy loss. American Journal of Reproductive Immunology, 2022, 88, . | 1.2 | 4 |
| 3649 | Extension of the Alternative Intravenous Dosing Regimens of Atezolizumab into Combination Settings through Modeling and Simulation. Journal of Clinical Pharmacology, 2022, 62, 1393-1402. | 1.0 | 3 |
| 3650 | A novel four‐gene signature predicts immunotherapy response of patients with different cancers. Journal of Clinical Laboratory Analysis, 2022, , e24494. | 0.9 | 2 |
| 3651 | Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. Gut, 2023, 72, 736-748. | 6.1 | 42 |
| 3652 | Albendazole induces immunotherapy response by facilitating ubiquitin-mediated PD-L1 degradation. , 2022, 10, e003819. | | 13 |
| 3653 | CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy. , 2022, 10, e004022. | | 7 |
| 3654 | Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade. , 2022, 10, e004076. | | 30 |
| 3655 | Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome. , 2022, 10, e004329. | | 15 |
| 3656 | The role of biomarkers in personalized immunotherapy. Biomarker Research, 2022, 10, 32. | 2.8 | 27 |
| 3658 | Comprehensive Analysis of the Butyrate-Metabolism-Related Gene Signature in Tumor Microenvironment-Infiltrating Immune Cells in Clear Cell Renal Cell Carcinoma. Frontiers in Cell and Developmental Biology, 2022, 10, . | 1.8 | 4 |
| 3660 | Improvement of STING-mediated cancer immunotherapy using immune checkpoint inhibitors as a game-changer. Cancer Immunology, Immunotherapy, 2022, 71, 3029-3042. | 2.0 | 9 |
| 3662 | The Role of Cancer-Associated Fibroblasts in Ovarian Cancer. Cancers, 2022, 14, 2637. | 1.7 | 23 |
| 3663 | Immunoexpression of Programmed Death-1 Receptor (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Non-Small-Cell Lung Carcinoma and Its Correlation With Other Clinicopathological Parameters: A Cross-Sectional Study From North India. Cureus, 2022, , . | 0.2 | 0 |
| 3664 | Genomic and Transcriptomic Analysis of Microsatellite Instability-High Colorectal Cancer Patients with Targetable Alterations Identifies Clinical Implications for Immunotherapy. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 3665 | Clinically approved combination immunotherapy: Current status, limitations, and future perspective. Current Research in Immunology, 2022, 3, 118-127. | 1.2 | 20 |
| 3666 | Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review. Current Cardiology Reviews, 2023, 19, . | 0.6 | 3 |
| 3667 | Recent Applications of Artificial Intelligence from Histopathologic Image-Based Prediction of Microsatellite Instability in Solid Cancers: A Systematic Review. Cancers, 2022, 14, 2590. | 1.7 | 17 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 3668 | Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immuno-Profiling Melanoma. Frontiers in Molecular Biosciences, 2022, 9, . | 1.6 | 9 |
| 3669 | Indonesian consensus on systemic therapies for hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology, 2023, 19, 263-274. | 0.7 | 1 |
| 3670 | The paradox of immune checkpoint inhibition re-activating tuberculosis. European Respiratory Journal, 2022, 60, 2102512. | 3.1 | 8 |
| 3671 | Understanding Tricky Cellular and Molecular Interactions in Pancreatic Tumor Microenvironment: New Food for Thought. Frontiers in Immunology, 2022, 13, . | 2.2 | 7 |
| 3672 | Evaluation PD-L1, CD8 and CD20 as early predictor and tracking markers for breast cancer (BC) in Egypt. Heliyon, 2022, 8, e09474. | 1.4 | 1 |
| 3673 | Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy. Cells, 2022, 11, 1758. | 1.8 | 3 |
| 3674 | Smart hypoxia-responsive transformable and charge-reversible nanoparticles for the deep penetration and tumor microenvironment modulation of pancreatic cancer. Biomaterials, 2022, 287, 121599. | 5.7 | 28 |
| 3675 | Programmed Death Ligand 1 (PD-L1) Expression and CD8+ Tumor-infiltrating Lymphocyte-based Tumor Immune Microenvironment Classification in Gynecologic Carcinosarcoma: Prognostic Impact and Implications for Therapy. International Journal of Gynecological Pathology, 0, Publish Ahead of Print, . | 0.9 | 2 |
| 3676 | Genetic Variation of PD-L1 Gene Affects its Expression and Is Related to Clinical Outcome in Epithelial Ovarian Cancer. Frontiers in Oncology, 2022, 12, . | 1.3 | 1 |
| 3677 | Development and validation of a computed tomography–based immune ecosystem diversity index as an imaging biomarker in non-small cell lung cancer. European Radiology, 2022, 32, 8726-8736. | 2.3 | 2 |
| 3678 | Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer. , 2022, 10, e004440. |  | 49 |
| 3679 | Conscription of Immune Cells by Light–Activatable Silencing NK–Derived Exosome (LASNEO) for Synergetic Tumor Eradication. Advanced Science, 2022, 9, . | 5.6 | 30 |
| 3681 | Understanding the tumor microenvironment in head and neck squamous cell carcinoma. Clinical and Translational Immunology, 2022, 11, . | 1.7 | 10 |
| 3682 | Pathological Complete Response to Neoadjuvant Chemoimmunotherapy Correlates with Peripheral Blood Immune Cell Subsets and Metastatic Status of Mediastinal Lymph Nodes (N2 Lymph Nodes) in Non-Small Cell Lung Cancer. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 3683 | Programmed death 1 (PD–1) and ligand (PD–L1) inhibitors in head and neck squamous cell carcinoma: A meta–analysis. World Journal of Otorhinolaryngology - Head and Neck Surgery, 0, , . | 0.7 | 0 |
| 3684 | When Less May Be Enough: Dose Selection Strategies for Immune Checkpoint Inhibitors Focusing on AntiPD-(L)1 Agents. Targeted Oncology, 2022, 17, 253-270. | 1.7 | 5 |
| 3685 | Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with <i>nab</i>-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031). Japanese Journal of Clinical Oncology, 0, , . | 0.6 | 0 |
| 3686 | Real–world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive–disease small–cell lung cancer. Cancer Medicine, 2023, 12, 73-83. | 1.3 | 13 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 3687 | Pan-Cancer Pyroptosis Analyses Identified Novel Immunology and Chemotherapy-Related Prognostic Signatures in Cancer Subtypes. Journal of Oncology, 2022, 2022, 1-16. | 0.6 | 0 |
| 3688 | Role of Adenoviruses in Cancer Therapy. Frontiers in Oncology, 0, 12, . | 1.3 | 6 |
| 3689 | Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma. Molecular and Cellular Biochemistry, 2023, 478, 23-37. | 1.4 | 7 |
| 3690 | Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis. Pharmaceuticals, 2022, 15, 747. | 1.7 | 18 |
| 3691 | Metabolomic and Transcriptomic Profiling Identified Significant Genes in Thymic Epithelial Tumor. Metabolites, 2022, 12, 567. | 1.3 | 6 |
| 3692 | Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis. Frontiers in Immunology, 0, 13, . | 2.2 | 3 |
| 3693 | Monitoring of circulating exosomal immuno checkpoint in tumor microenvironment through ultrasensitive aptamer-functionalized SERS probes. Biosensors and Bioelectronics: X, 2022, 12, 100177. | 0.9 | 1 |
| 3694 | Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer. Investigational New Drugs, 2022, 40, 1066-1079. | 1.2 | 9 |
| 3695 | A digital assay for programmed death-ligand 1 (22C3) quantification combined with immune cell recognition algorithms in non-small cell lung cancer. Scientific Reports, 2022, 12, . | 1.6 | 1 |
| 3696 | Metabolism-Associated DNA Methylation Signature Stratifies Lower-Grade Glioma Patients and Predicts Response to Immunotherapy. Frontiers in Cell and Developmental Biology, 0, 10, . | 1.8 | 1 |
| 3697 | Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nature Reviews Drug Discovery, 2022, 21, 529-540. | 21.5 | 134 |
| 3698 | Differential Engraftment of Parental A20 PD-L1 WT and PD-L1 KO Leukemia Cells in Semiallogeneic Recipients in the Context of PD-L1/PD-1 Interaction and NK Cell-Mediated Hybrid Resistance. Frontiers in Immunology, 0, 13, . | 2.2 | 1 |
| 3699 | Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies. Frontiers in Oncology, 0, 12, . | 1.3 | 19 |
| 3700 | Cancer immunohistogram representing cancer-immunity cycle by immunohistochemistry predicts the efficacy of immune checkpoint inhibitors in urological cancer patients. Scientific Reports, 2022, 12, . | 1.6 | 3 |
| 3701 | Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacy. Journal of Clinical Investigation, 2022, 132, . | 3.9 | 9 |
| 3702 | Hypermutation as a potential predictive biomarker of immunotherapy efficacy in high-grade gliomas: a broken dream?. Immunotherapy, 0, , . | 1.0 | 3 |
| 3703 | Immune Checkpoint Proteins, Metabolism and Adhesion Molecules: Overlooked Determinants of CAR T-Cell Migration?. Cells, 2022, 11, 1854. | 1.8 | 7 |
| 3704 | Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nature Medicine, 2022, 28, 1599-1611. | 15.2 | 185 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 3705 | Ursodeoxycholic acid reduces antitumor immunosuppression by inducing CHIP-mediated TGF-Î² degradation. Nature Communications, 2022, 13, . | 5.8 | 26 |
| 3706 | EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment. International Journal of Molecular Sciences, 2022, 23, 6489. | 1.8 | 45 |
| 3707 | Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer. European Journal of Cancer, 2022, 172, 85-95. | 1.3 | 20 |
| 3708 | Sensitivity and specificity of amide proton transfer-weighted imaging for assessing programmed death-ligand 1 status in non-small cell lung cancer: a comparative study with intravoxel incoherent motion and 18F-FDG PET. Quantitative Imaging in Medicine and Surgery, 2022, 12, 4474-4487. | 1.1 | 5 |
| 3709 | Deconstructing T Cell Clonal Dynamics in Response to Immune-Checkpoint Blockade. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 3710 | Breast and Ovarian Carcinoma Overexpress HLA-G, a Neglected Cancer Immunosuppressive Protein. Advances in Breast Cancer Research, 2022, 11, 153-172. | 0.1 | 0 |
| 3711 | Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy. Cancer Treatment and Research Communications, 2022, 32, 100603. | 0.7 | 6 |
| 3712 | Atezolizumab With Neoadjuvant Antiâ€"Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2â€"Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial. Journal of Clinical Oncology, 2022, 40, 2946-2956. | 0.8 | 46 |
| 3713 | Comprehensive Analysis of Cuproptosis-Related Genes in Immune Infiltration and Prognosis in Melanoma. Frontiers in Pharmacology, 0, 13, . | 1.6 | 134 |
| 3714 | Comparative Characterization of Different Molecular Formats of Bispecific Antibodies Targeting EGFR and PD-L1. Pharmaceutics, 2022, 14, 1381. | 2.0 | 1 |
| 3715 | Oncolytic adenovirus <scp>H101</scp> ameliorate the efficacy of <scp>antiâ€PD</scp>â€1 monotherapy in colorectal cancer. Cancer Medicine, 2022, 11, 4575-4587. | 1.3 | 7 |
| 3716 | The second Mexican consensus on hepatocellular carcinoma. Part II: Treatment. Revista De GastroenterologÃa De MÃ©xico (English Edition), 2022, , . | 0.1 | 0 |
| 3718 | Prognostic attributes of immune signatures in soft tissue sarcomas show differential dependencies on tumor mutational burden. Cancer, 0, , . | 2.0 | 0 |
| 3719 | Molecular subtypes, prognostic and immunotherapeutic relevant gene signatures mediated by DNA methylation regulators in hepatocellular carcinoma. Aging, 2022, 14, 5271-5291. | 1.4 | 3 |
| 3720 | Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors. , 2022, 10, e004325. | | 4 |
| 3721 | HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8+ T-cell infiltration into tumors. Nature Communications, 2022, 13, . | 5.8 | 23 |
| 3722 | Pretreatment Modified Albuminâ€"Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma. Current Oncology, 2022, 29, 4799-4810. | 0.9 | 8 |
| 3723 | IGSF11 and VISTA: a pair of promising immune checkpoints in tumor immunotherapy. Biomarker Research, 2022, 10, . | 2.8 | 2 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 3724 | PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas. Biomedicines, 2022, 10, 1587. | 1.4 | 6 |
| 3725 | Personalized tumor vaccine for pancreatic cancer. Cancer Immunology, Immunotherapy, 2023, 72, 301-313. | 2.0 | 3 |
| 3726 | Clustering analysis and prognostic signature of lung adenocarcinoma based on the tumor microenvironment. Scientific Reports, 2022, 12, . | 1.6 | 0 |
| 3727 | Application of ATAC-seq in tumor-specific T cell exhaustion. Cancer Gene Therapy, 2023, 30, 1-10. | 2.2 | 4 |
| 3728 | Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy. Clinical Cancer Research, 2022, 28, 4370-4384. | 3.2 | 15 |
| 3729 | Retrospective Study of Clinical Outcomes and Toxicity Profile in Patients Treated with Immune Checkpoint Inhibitors. Asian Journal of Oncology, 0, , . | 0.2 | 0 |
| 3730 | Mechanisms of resistance to immune checkpoint inhibitors. Cancer Science, 2022, 113, 3303-3312. | 1.7 | 12 |
| 3731 | Changes of Immune Cell Fractions in Patients Treated with Immune Checkpoint Inhibitors. Cancers, 2022, 14, 3440. | 1.7 | 1 |
| 3733 | Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option. Frontiers in Immunology, 0, 13, . | 2.2 | 13 |
| 3734 | Generation, secretion and degradation of cancer immunotherapy target PD-L1. Cellular and Molecular Life Sciences, 2022, 79, . | 2.4 | 5 |
| 3735 | Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers. Journal of Experimental and Clinical Cancer Research, 2022, 41, . | 3.5 | 15 |
| 3736 | Additive Effect of CD73 Inhibitor in Colorectal Cancer Treatment With CDK4/6 Inhibitor Through Regulation of PD-L1. Cellular and Molecular Gastroenterology and Hepatology, 2022, 14, 769-788. | 2.3 | 6 |
| 3737 | Cyclin-dependent kinase inhibition and its intersection with immunotherapy in breast cancer: more than CDK4/6 inhibition. Expert Opinion on Investigational Drugs, 2022, 31, 933-944. | 1.9 | 0 |
| 3738 | Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration. Cancer Research Communications, 2022, 2, 739-753. | 0.7 | 2 |
| 3739 | Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer. Seminars in Oncology, 2022, 49, 306-318. | 0.8 | 8 |
| 3740 | A PD-L1 and VEGFR2 dual targeted peptide and its combination with irradiation for cancer immunotherapy. Pharmacological Research, 2022, 182, 106343. | 3.1 | 13 |
| 3741 | PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC. Clinical Cancer Research, 2022, 28, 4893-4906. | 3.2 | 18 |
| 3742 | Chokeberry (Aronia melanocarpa) fruit extract abrogates melanoma progression through boosting up IFN-γ-producing cells. Journal of Functional Foods, 2022, 95, 105185. | 1.6 | 1 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 3743 | Ubiquitin ligase RNF125 targets PD-L1 for ubiquitination and degradation. Frontiers in Oncology, 0, 12, . | 1.3 | 2 |
| 3744 | A novel immune checkpoints-based signature to predict prognosis and response to immunotherapy in lung adenocarcinoma. Journal of Translational Medicine, 2022, 20, . | 1.8 | 7 |
| 3745 | Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood. , 2022, 10, e004803. | | 15 |
| 3746 | Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduction and Targeted Therapy, 2022, 7, . | 7.1 | 142 |
| 3747 | N1-Methyladenosine-Related lncRNAs Are Potential Biomarkers for Predicting Prognosis and Immune Response in Uterine Corpus Endometrial Carcinoma. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-32. | 1.9 | 5 |
| 3748 | Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of IκBα. Cell Metabolism, 2022, 34, 1312-1324.e6. | 7.2 | 89 |
| 3749 | Clinical studies of Atezolizumab contributing to FDA approvals. , 0, 8, 390-395. | | 0 |
| 3750 | Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Frontiers in Immunology, 0, 13, . | 2.2 | 14 |
| 3751 | Advances in nuclear medicine-based molecular imaging in head and neck squamous cell carcinoma. Journal of Translational Medicine, 2022, 20, . | 1.8 | 5 |
| 3752 | The gamble between oncolytic virus therapy and IFN. Frontiers in Immunology, 0, 13, . | 2.2 | 10 |
| 3753 | Circular RNA circWWC3 augments breast cancer progression through promoting M2 macrophage polarization and tumor immune escape via regulating the expression and secretion of IL-4. Cancer Cell International, 2022, 22, . | 1.8 | 15 |
| 3754 | PD-L1 testing by immunohistochemistry in Immuno-Oncology. Bosnian Journal of Basic Medical Sciences, 0, , . | 0.6 | 6 |
| 3755 | Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer. JAMA Oncology, 2022, 8, 1456. | 3.4 | 60 |
| 3757 | From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades. Frontiers in Immunology, 0, 13, . | 2.2 | 20 |
| 3758 | Triple negative breast cancer: approved treatment options and their mechanisms of action. Journal of Cancer Research and Clinical Oncology, 2023, 149, 3701-3719. | 1.2 | 13 |
| 3759 | Phosphofructokinase 1 platelet isoform induces PD-L1 expression to promote glioblastoma immune evasion. Genes and Genomics, 2022, 44, 1509-1517. | 0.5 | 4 |
| 3760 | Fasting renders immunotherapy effective against low-immunogenic breast cancer while reducing side effects. Cell Reports, 2022, 40, 111256. | 2.9 | 25 |
| 3761 | The epiphany derived from T-cell–inflamed profiles: Pan-cancer characterization of CD8A as a biomarker spanning clinical relevance, cancer prognosis, immunosuppressive environment, and treatment responses. Frontiers in Genetics, 0, 13, . | 1.1 | 4 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 3763 | FN1 overexpression is correlated with unfavorable prognosis and immune infiltrates in breast cancer. Frontiers in Genetics, 0, 13, . | 1.1 | 16 |
| 3764 | <i>Escherichia coli</i>â€"Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer. Cancer Discovery, 2022, 12, 2280-2307. | 7.7 | 23 |
| 3765 | A 13-gene signature to predict the prognosis and immunotherapy responses of lung squamous cell carcinoma. Scientific Reports, 2022, 12, . | 1.6 | 3 |
| 3766 | STUB1 is an intracellular checkpoint for interferon gamma sensing. Scientific Reports, 2022, 12, . | 1.6 | 4 |
| 3767 | Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy. Cancer Research, 2022, 82, 3532-3548. | 0.4 | 14 |
| 3768 | The evolving role of checkpoint inhibitors in the treatment of urothelial carcinoma. British Journal of Clinical Pharmacology, 0, , . | 1.1 | 1 |
| 3769 | Immunotherapeutic targets in nonâ€small cell lung cancer. Immunology, 2023, 168, 256-272. | 2.0 | 5 |
| 3771 | Temporally restricted activation of IFNÎ² signaling underlies response to immune checkpoint therapy in mice. Nature Communications, 2022, 13, . | 5.8 | 12 |
| 3772 | Schlafen family is a prognostic biomarker and corresponds with immune infiltration in gastric cancer. Frontiers in Immunology, 0, 13, . | 2.2 | 9 |
| 3773 | Spatial Positioning and Matrix Programs of Cancer-Associated Fibroblasts Promote T-cell Exclusion in Human Lung Tumors. Cancer Discovery, 2022, 12, 2606-2625. | 7.7 | 69 |
| 3774 | Immune cellular components and signaling pathways in the tumor microenvironment. Seminars in Cancer Biology, 2022, 86, 187-201. | 4.3 | 18 |
| 3775 | Pathological complete response to neoadjuvant chemoimmunotherapy correlates with peripheral blood immune cell subsets and metastatic status of mediastinal lymph nodes (N2 lymph nodes) in non-small cell lung cancer. Lung Cancer, 2022, 172, 43-52. | 0.9 | 4 |
| 3776 | Atezolizumab plus bevacizumab versus nivolumab as firstâ€line treatment for advanced or unresectable hepatocellular carcinoma: A costâ€effectiveness analysis. Cancer, 2022, 128, 3995-4003. | 2.0 | 9 |
| 3777 | Finding the Right Heavy Chains for Immunostimulatory Antibodies. International Journal of Molecular Sciences, 2022, 23, 10367. | 1.8 | 3 |
| 3778 | Prediction of lung squamous cell carcinoma immune microenvironment and immunotherapy efficiency with pyroptosis-derived genes. Medicine (United States), 2022, 101, e30304. | 0.4 | 1 |
| 3779 | Nano-drug delivery systems for T cell-based immunotherapy. Nano Today, 2022, 46, 101621. | 6.2 | 13 |
| 3780 | Vedolizumab in the treatment of immune checkpoint inhibitor-induced colitis: Two case reports. World Journal of Clinical Cases, 0, 10, 10550-10558. | 0.3 | 1 |
| 3781 | A platinum@polymer-catechol nanobraker enables radio-immunotherapy for crippling melanoma tumorigenesis, angiogenesis, and radioresistance. Bioactive Materials, 2023, 22, 34-46. | 8.6 | 7 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 3782 | Spatial Immunophenotyping of the Tumor Microenvironment in Non-Small Cell Lung Cancer. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 3783 | Shaping of the Immune Landscape by Chemokine Receptors that Impacts the Clinical Outcome in Triple-Negative Breast Cancer. , 2022, , . | | 0 |
| 3784 | Checkpoint Inhibitors in Non-small Cell Lung Cancer: Potentials and Challenges. , 2022, , . | | 0 |
| 3785 | Duodenal Variceal Rupture during Atezolizumab and Bevacizumab Treatment for Hepatocellular Carcinoma. Internal Medicine, 2023, 62, 1467-1472. | 0.3 | 1 |
| 3786 | T-Cell Density at the Invasive Margin and Immune Phenotypes Predict Outcome in Vulvar Squamous Cell Cancer. Cancers, 2022, 14, 4246. | 1.7 | 4 |
| 3787 | Homodimerized cytoplasmic domain of PD-L1 regulates its complex glycosylation in living cells. Communications Biology, 2022, 5, . | 2.0 | 7 |
| 3788 | Neoadjuvant Immunotherapy Combined with Chemotherapy for Local Advanced Non-Small-Cell Lung Cancer in a Patient with a History of Breast Cancer: A Case Report. Current Oncology, 2022, 29, 6203-6210. | 0.9 | 1 |
| 3789 | Development of multivariable risk signature based on four immune-related RNA-binding proteins to predict survival and immune status in lung adenocarcinoma. Translational Cancer Research, 2022, 11, 2591-2606. | 0.4 | 1 |
| 3790 | Noninvasive imaging of the tumor immune microenvironment correlates with response to immunotherapy in gastric cancer. Nature Communications, 2022, 13, . | 5.8 | 25 |
| 3791 | The Tumor Microenvironment of Clear-Cell Ovarian Cancer. Cancer Immunology Research, 2022, 10, 1326-1339. | 1.6 | 12 |
| 3792 | Alpha radionuclide-chelated radioimmunotherapy promoters enable local radiotherapy/chemodynamic therapy to discourage cancer progression. Biomaterials Research, 2022, 26, . | 3.2 | 18 |
| 3793 | Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation. Frontiers in Immunology, 0, 13, . | 2.2 | 5 |
| 3794 | Th17, Th22, and Myeloid-Derived Suppressor Cell Population Dynamics and Response to IL-6 in 4T1 Mammary Carcinoma. International Journal of Molecular Sciences, 2022, 23, 10299. | 1.8 | 2 |
| 3795 | Envafolimab â€" first PD-1/PD-L1 antibody to be administered by subcutaneous injection for microsatellite instability-high or deficient mismatch repair advanced solid tumors. Expert Opinion on Biological Therapy, 2022, 22, 1227-1232. | 1.4 | 5 |
| 3796 | Multiparametric immune profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: an exploratory study of the CLAP trial. Clinical and Translational Oncology, 2023, 25, 256-268. | 1.2 | 3 |
| 3797 | Oral beclomethasone dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis. , 2022, 10, e005490. | | 4 |
| 3799 | Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma. , 2022, 10, e005052. | | 9 |
| 3800 | A Novel B7-H6â€"Targeted IgG-Like T Cellâ€"Engaging Antibody for the Treatment of Gastrointestinal Tumors. Clinical Cancer Research, 2022, 28, 5190-5201. | 3.2 | 7 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 3801 | Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition. Molecular Cancer, 2022, 21, . | 7.9 | 5 |
| 3802 | Dendritic Cells: The Long and Evolving Road towards Successful Targetability in Cancer. Cells, 2022, 11, 3028. | 1.8 | 7 |
| 3803 | A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study. Cancer Immunology, Immunotherapy, 2023, 72, 827-840. | 2.0 | 3 |
| 3804 | Identification of cuproptosis-related patterns and construction of a scoring system for predicting prognosis, tumor microenvironment-infiltration characteristics, and immunotherapy efficacy in breast cancer. Frontiers in Oncology, 0, 12, . | 1.3 | 7 |
| 3805 | Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). , 2022, 10, e005413. | | 6 |
| 3806 | Computational Biology Predicts the Efficacy of Tumor Immune Checkpoint Blockade. BioMed Research International, 2022, 2022, 1-9. | 0.9 | 1 |
| 3807 | A Review of Current and Emerging Therapies for Advanced Hepatocellular Carcinoma. Current Oncology, 2022, 29, 6445-6462. | 0.9 | 6 |
| 3808 | Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs. Cancers, 2022, 14, 4543. | 1.7 | 9 |
| 3809 | PD-L1-Mediated Immunosuppression in Hepatocellular Carcinoma: Relationship with Macrophages Infiltration and Inflammatory Response Activity. Biomolecules, 2022, 12, 1226. | 1.8 | 4 |
| 3810 | Combination of Tumor Mutational Burden and DNA Damage Repair Gene Mutations with Stromal/Immune Scores Improved Prognosis Stratification in Patients with Lung Adenocarcinoma. Journal of Oncology, 2022, 2022, 1-12. | 0.6 | 2 |
| 3811 | Adjuvant atezolizumab in Japanese patients with resected stage <scp>IB–IIIA</scp> non‐small cell lung cancer (<scp>IMpower010</scp>). Cancer Science, 2022, 113, 4327-4338. | 1.7 | 9 |
| 3812 | Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer. Clinical Cancer Research, 2022, 28, 5136-5148. | 3.2 | 8 |
| 3813 | An immunogold single extracellular vesicular RNA and protein (<sup>Au</sup>SERP) biochip to predict responses to immunotherapy in non‐small cell lung cancer patients. Journal of Extracellular Vesicles, 2022, 11, . | 5.5 | 16 |
| 3814 | Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. Nature Medicine, 2022, 28, 2155-2161. | 15.2 | 93 |
| 3815 | Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors. Frontiers in Pharmacology, 0, 13, . | 1.6 | 2 |
| 3816 | Site-Selective Lysine Acetylation of Human Immunoglobulin G for Immunoliposomes and Bispecific Antibody Complexes. Journal of the American Chemical Society, 2022, 144, 18494-18503. | 6.6 | 16 |
| 3817 | CD103 and periplakin are potential biomarkers for response of metastatic melanoma to pembrolizumab. Melanoma Research, 0, Publish Ahead of Print, . | 0.6 | 2 |
| 3818 | Dynamic monitoring of PD‐L1 and Ki67 in circulating tumor cells of metastatic non‐small cell lung cancer patients treated with pembrolizumab. Molecular Oncology, 2023, 17, 792-809. | 2.1 | 8 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 3819 | Fibrotic immune microenvironment remodeling mediates superior anti-tumor efficacy of a nano-PD-L1 trap in hepatocellular carcinoma. Molecular Therapy, 2023, 31, 119-133. | 3.7 | 13 |
| 3820 | Nanocarriers for cancer nano-immunotherapy. Drug Delivery and Translational Research, 2023, 13, 1936-1954. | 3.0 | 17 |
| 3821 | DNA methylation regulator-mediated modification pattern defines tumor microenvironment immune infiltration landscape in colon cancer. Frontiers in Genetics, 0, 13, . | 1.1 | 1 |
| 3822 | Delta radiomics model for the prediction of progression-free survival time in advanced non-small-cell lung cancer patients after immunotherapy. Frontiers in Oncology, 0, 12, . | 1.3 | 9 |
| 3823 | Platelet membrane camouflaged <scp>AIEgen</scp>â€mediated photodynamic therapy improves the effectiveness of <scp>antiâ€PDâ€L1</scp> immunotherapy in largeâ€burden tumors. Bioengineering and Translational Medicine, 2023, 8, . | 3.9 | 8 |
| 3824 | Technology meets TILs: Deciphering TÂcell function in the -omics era. Cancer Cell, 2023, 41, 41-57. | 7.7 | 17 |
| 3825 | The DNA damage induced immune response: Implications for cancer therapy. DNA Repair, 2022, 120, 103409. | 1.3 | 6 |
| 3826 | Anlotinib Benefits the Î±PDL1 Immunotherapy by Activating ROS/JNK/AP-1 Pathway to Upregulate PDL1 Expression in Colorectal Cancer. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-18. | 1.9 | 3 |
| 3827 | Characterizing the immune checkpoint marker profiles of cutaneous squamous cell carcinomas in patients with hidradenitis suppurativa. Journal of the European Academy of Dermatology and Venereology, 2023, 37, . | 1.3 | 1 |
| 3828 | Thyroid Dland Disorders Associated with Combination of Antiangiogenic Agents and Immune Checkpoint Inhibitors: A Pharmacovigilance Study. , 2022, , . | | 0 |
| 3829 | Inhibitory and Stimulatory Effects of IL-32 on HIV-1 Infection. Journal of Immunology, 2022, 209, 970-978. | 0.4 | 3 |
| 3830 | Tumor microenvironment-related gene selenium-binding protein 1 (SELENBP1) is associated with immunotherapy efficacy and survival in colorectal cancer. BMC Gastroenterology, 2022, 22, . | 0.8 | 7 |
| 3831 | SERS Multiplex Profiling of Melanoma Circulating Tumor Cells for Predicting the Response to Immune Checkpoint Blockade Therapy. Analytical Chemistry, 2022, 94, 14573-14582. | 3.2 | 9 |
| 3832 | Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis. Nature Communications, 2022, 13, . | 5.8 | 12 |
| 3833 | How Risk Factors Affect Head and Neck Squamous Cell Carcinoma (HNSCC) Tumor Immune Microenvironment (TIME): Their Influence on Immune Escape Mechanisms and Immunotherapy Strategy. Biomedicines, 2022, 10, 2498. | 1.4 | 6 |
| 3834 | Translational Research in Cancer Immunotherapies. Japanese Journal of Lung Cancer, 2022, 62, 363-370. | 0.0 | 0 |
| 3835 | Influence of chemoradiation on the immune microenvironment of cervical cancer patients. Strahlentherapie Und Onkologie, 2023, 199, 121-130. | 1.0 | 7 |
| 3836 | Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2023, 23, e59-e70. | 0.2 | 3 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 3837 | Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. Journal of Hematology and Oncology, 2022, 15, . | 6.9 | 59 |
| 3839 | Checkpoint Inhibitors in Cancer Therapy: Clinical Benefits for Head and Neck Cancers. Cancers, 2022, 14, 4985. | 1.7 | 5 |
| 3840 | Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types. , 2022, 10, e005573. | | 11 |
| 3841 | Single-cell transcriptomic profiling for inferring tumor origin and mechanisms of therapeutic resistance. Npj Precision Oncology, 2022, 6, . | 2.3 | 4 |
| 3842 | PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way. , 2022, 10, e004590. | | 12 |
| 3843 | Comprehensive analysis of the immunological implication and prognostic value of CXCR4 in non-small cell lung cancer. Cancer Immunology, Immunotherapy, 2023, 72, 1029-1045. | 2.0 | 2 |
| 3844 | The Association of Tumor Immune Microenvironment of the Primary Lesion with Time to Metastasis in Patients with Renal Cell Carcinoma: A Retrospective Analysis. Cancers, 2022, 14, 5258. | 1.7 | 1 |
| 3845 | Nanohydroxyapatite Stimulates PD-L1 Expression to Boost Melanoma Combination Immunotherapy. ACS Nano, 2022, 16, 18921-18935. | 7.3 | 3 |
| 3846 | Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement. Immunological Investigations, 2022, 51, 2176-2214. | 1.0 | 5 |
| 3847 | Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer. Cells, 2022, 11, 3226. | 1.8 | 0 |
| 3849 | Study of PD-L1 Expression with Association of Pathological Factors and Molecular Subtypes in Breast Carcinoma. Journal of Laboratory Physicians, 0, , . | 0.4 | 1 |
| 3850 | Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity. Scientific Reports, 2022, 12, . | 1.6 | 5 |
| 3851 | Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden. Frontiers in Immunology, 0, 13, . | 2.2 | 3 |
| 3852 | Prognostic stratification based on the levels of tumor-infiltrating myeloid-derived suppressor cells and PD-1/PD-L1 axis in locally advanced rectal cancer. Frontiers in Oncology, 0, 12, . | 1.3 | 2 |
| 3853 | Radioimmunotherapy study of 131I-labeled Atezolizumab in preclinical models of colorectal cancer. EJNMMI Research, 2022, 12, . | 1.1 | 4 |
| 3854 | Role of immuneâ€inflamed phenotype in the prognosis of hypopharyngeal carcinoma following primary surgery. Head and Neck, 2023, 45, 126-134. | 0.9 | 1 |
| 3855 | Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59. Cells, 2022, 11, 3365. | 1.8 | 4 |
| 3856 | Lung CAFs Show T Cells the Velvet Rope. Cancer Discovery, 2022, 12, 2501-2503. | 7.7 | 0 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 3857 | OncoTheradÂ® is an immunomodulator of biological response that downregulate RANK/RANKL signaling pathway and PD-1/PD-L1 immune checkpoint in non-muscle invasive bladder cancer. Journal of Cancer Research and Clinical Oncology, 2023, 149, 5025-5036. | 1.2 | 3 |
| 3858 | Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis. Science Translational Medicine, 2022, 14, . | 5.8 | 13 |
| 3859 | Identification of CKS1B as a prognostic indicator and a predictive marker for immunotherapy in pancreatic cancer. Frontiers in Immunology, 0, 13, . | 2.2 | 2 |
| 3860 | A photodynamically sensitized dendritic cell vaccine that promotes the anti-tumor effects of anti-PD-L1 monoclonal antibody in a murine model of head and neck squamous cell carcinoma. Journal of Translational Medicine, 2022, 20, . | 1.8 | 4 |
| 3861 | Nanomedicine for advanced cancer immunotherapy. Journal of Controlled Release, 2022, 351, 1017-1037. | 4.8 | 7 |
| 3862 | Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer. Medicina (Lithuania), 2022, 58, 1572. | 0.8 | 5 |
| 3863 | Cellular and molecular basis of therapeutic approaches to breast cancer. Cellular Signalling, 2023, 101, 110492. | 1.7 | 10 |
| 3864 | Photodynamic amplified immune checkpoint-blockade therapy of self-delivery bioregulator via epigenetic reprogramming. Chemical Engineering Journal, 2023, 453, 139729. | 6.6 | 2 |
| 3865 | A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice. BMC Cancer, 2022, 22, . | 1.1 | 1 |
| 3866 | Combined mitoxantrone and anti-TGFÎ² treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma. Journal of Experimental and Clinical Cancer Research, 2022, 41, . | 3.5 | 8 |
| 3867 | Low expression of INMT is associated with poor prognosis but favorable immunotherapy response in lung adenocarcinoma. Frontiers in Genetics, 0, 13, . | 1.1 | 0 |
| 3868 | Treatment beyond progression in non-small cell lung cancer: A systematic review and meta-analysis. Frontiers in Oncology, 0, 12, . | 1.3 | 1 |
| 3869 | Molecular subtypes identified by pyroptosis-related genes are associated with tumor microenvironment cell infiltration in colon cancer. Aging, 0, , . | 1.4 | 0 |
| 3870 | Overlapping pathogenic de novo CNVs in neurodevelopmental disorders and congenital anomalies impacting constraint genes regulating early development. Human Genetics, 2023, 142, 1201-1213. | 1.8 | 5 |
| 3872 | Once upon a prime: DCs shape cancer immunity. Trends in Cancer, 2023, 9, 172-184. | 3.8 | 6 |
| 3873 | Engineering metalâ€phenolic networks for enhancing cancer therapy by tumor microenvironment modulation. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2023, 15, . | 3.3 | 2 |
| 3874 | ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer. Future Oncology, 2022, 18, 3563-3572. | 1.1 | 6 |
| 3876 | WNK3 inhibition elicits antitumor immunity by suppressing PD-L1 expression on tumor cells and activating T-cell function. Experimental and Molecular Medicine, 2022, 54, 1913-1926. | 3.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 3878 | Spatial architecture of regulatory T-cells correlates with disease progression in patients with nasopharyngeal cancer. Frontiers in Immunology, 0, 13, . | 2.2 | 8 |
| 3879 | Long-term complete response in small cell bladder carcinoma treated with carboplatin, etoposide, and atezolizumab. BMC Urology, 2022, 22, . | 0.6 | 0 |
| 3880 | Intrinsic resistance and efficacy of immunotherapy in microsatellite instability-high colorectal cancer: A systematic review and meta-analysis. Bosnian Journal of Basic Medical Sciences, 2023, 23, . | 0.6 | 5 |
| 3881 | Effects of postoperative radiotherapy and docetaxel and PD-1 inhibitors on the survival and safety of glioblastoma patients: a systematic review and meta-analysis. Annals of Translational Medicine, 2022, 10, 1326-1326. | 0.7 | 1 |
| 3882 | Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabine for locally recurrent pancreatic cancer after surgical resection on survival outcomes: a secondary analysis of an open-label, randomised, controlled, phase 2 trial. EClinicalMedicine, 2023, 55, 101764. | 3.2 | 2 |
| 3883 | Recent progress in cancer immunotherapy: Overview of current status and challenges. Pathology Research and Practice, 2023, 241, 154241. | 1.0 | 8 |
| 3884 | Enhanced anti-tumor immunity of vaccine combined with anti-PD-1 antibody in a murine bladder cancer model. Investigative and Clinical Urology, 2023, 64, 74. | 1.0 | 3 |
| 3885 | Insights into the aberrant CDK4/6 signaling pathway as a therapeutic target in tumorigenesis. Advances in Protein Chemistry and Structural Biology, 2023, , 179-201. | 1.0 | 4 |
| 3886 | Immune biology of NSCLC revealed by single-cell technologies: implications for the development of biomarkers in patients treated with immunotherapy. Seminars in Immunopathology, 0, , . | 2.8 | 2 |
| 3887 | Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer. Cancer Immunology, Immunotherapy, 2023, 72, 1285-1300. | 2.0 | 8 |
| 3888 | Systemic therapies in hepatocellular carcinoma: Existing and emerging biomarkers for treatment response. Frontiers in Oncology, 0, 12, . | 1.3 | 3 |
| 3889 | Perspectives on the future of urothelial carcinoma therapy: chemotherapy and beyond. Expert Opinion on Pharmacotherapy, 2023, 24, 177-195. | 0.9 | 1 |
| 3890 | Combining dual-targeted liquid metal nanoparticles with autophagy activation and mild photothermal therapy to treat metastatic breast cancer and inhibit bone destruction. Acta Biomaterialia, 2023, 157, 578-592. | 4.1 | 14 |
| 3891 | Prognostic and Immunological Roles of Cell Cycle Regulator CDCA5 in Human Solid Tumors. International Journal of General Medicine, 0, Volume 15, 8257-8274. | 0.8 | 0 |
| 3892 | Prognostic value and immunological role of FOXM1 in human solid tumors. Aging, 2022, 14, 9128-9148. | 1.4 | 4 |
| 3893 | Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers. Clinical Cancer Research, 2023, 29, 921-929. | 3.2 | 2 |
| 3894 | Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy. Angiogenesis, 2023, 26, 279-293. | 3.7 | 12 |
| 3895 | Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates. International Journal of Molecular Sciences, 2023, 24, 41. | 1.8 | 6 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 3896 | Reversing the PAI-1-induced fibrotic immune exclusion of solid tumor by multivalent CXCR4 antagonistic nano-permeator. Acta Pharmaceutica Sinica B, 2023, 13, 3106-3120. | 5.7 | 1 |
| 3897 | CHI3L1 enhances melanoma lung metastasis via regulation of T cell co-stimulators and CTLA-4/B7 axis. Frontiers in Immunology, 0, 13, . | 2.2 | 7 |
| 3898 | Comprehensive analysis of alternative splicing signatures in pancreatic€„head cancer. IET Systems Biology, 0, , . | 0.8 | 1 |
| 3899 | Fecal Microbiota Transplant in Immunotherapy-Resistant Melanoma: What Can We Expect in the Near Future?. Cureus, 2022, , . | 0.2 | 2 |
| 3901 | Lung cancer patients with chronic obstructive pulmonary disease benefit from anti-PD-1/PD-L1 therapy. Frontiers in Immunology, 0, 13, . | 2.2 | 4 |
| 3902 | Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment. Frontiers in Immunology, 0, 13, . | 2.2 | 8 |
| 3903 | Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinoma. Acta Biomaterialia, 2023, 157, 337-351. | 4.1 | 3 |
| 3904 | A Dual€Responsive STAT3 Inhibitor Nanoprodrug Combined with Oncolytic Virus Elicits Synergistic Antitumor Immune Responses by Igniting Pyroptosis. Advanced Materials, 2023, 35, . | 11.1 | 28 |
| 3905 | Cerebrospinal fluid soluble programmed death€ligand 1 is a useful prognostic biomarker in primary central nervous system lymphoma. British Journal of Haematology, 0, , . | 1.2 | 0 |
| 3906 | Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines. Journal of Cancer Research and Clinical Oncology, 2023, 149, 5705-5715. | 1.2 | 1 |
| 3907 | Sensitive and quantitative in vivo analysis of PD-L1 using magnetic particle imaging and imaging-guided immunotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 1291-1305. | 3.3 | 5 |
| 3908 | Resistance to immune checkpoint inhibitors and the tumor microenvironment. Experimental Dermatology, 2023, 32, 240-249. | 1.4 | 5 |
| 3909 | Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial. Nature Medicine, 2022, 28, 2601-2610. | 15.2 | 34 |
| 3910 | Prognostic value of PD-L1 expression in recurrent renal cell carcinoma after nephrectomy: a secondary analysis of the ARCHERY study. International Journal of Clinical Oncology, 0, , . | 1.0 | 0 |
| 3911 | Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus€"Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2023, 29, 560-570. | 3.2 | 11 |
| 3912 | Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop. Cancer Cell, 2022, 40, 1600-1618.e10. | 7.7 | 40 |
| 3913 | Oncolytic Adenovirus, a New Treatment Strategy for Prostate Cancer. Biomedicines, 2022, 10, 3262. | 1.4 | 2 |
| 3915 | *P. gingivalis* Infection Upregulates PD-L1 Expression on Dendritic Cells, Suppresses CD8+ T-cell Responses, and Aggravates Oral Cancer. Cancer Immunology Research, 2023, 11, 290-305. | 1.6 | 3 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 3916 | Application of individualized multimodal radiotherapy combined with immunotherapy in metastatic tumors. Frontiers in Immunology, 0, 13, . | 2.2 | 4 |
| 3917 | Immunotherapy Assessment: A New Paradigm for Radiologists. Diagnostics, 2023, 13, 302. | 1.3 | 1 |
| 3918 | The stromal tumor-infiltrating lymphocytes, cancer stemness, epithelial-mesenchymal transition, and B7-H4 expression in ovarian serous carcinoma. Journal of Ovarian Research, 2023, 16, . | 1.3 | 1 |
| 3919 | CD8+ TÂcell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. Immunity, 2023, 56, 107-124.e5. | 6.6 | 75 |
| 3920 | The application basis of immuno-checkpoint inhibitors combined with chemotherapy in cancer treatment. Frontiers in Immunology, 0, 13, . | 2.2 | 1 |
| 3921 | Editorial: Impact of tumor microenvironment on lung cancer. Frontiers in Oncology, 0, 13, . | 1.3 | 0 |
| 3922 | Cannabinoid receptor 2 plays a pro-tumorigenic role in non-small cell lung cancer by limiting anti-tumor activity of CD8+ T and NK cells. Frontiers in Immunology, 0, 13, . | 2.2 | 13 |
| 3923 | At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC. Nature Reviews Clinical Oncology, 2023, 20, 143-159. | 12.5 | 29 |
| 3924 | DNA methylation-based patterns for early diagnostic prediction and prognostic evaluation in colorectal cancer patients with high tumor mutation burden. Frontiers in Oncology, 0, 12, . | 1.3 | 2 |
| 3925 | Atezolizumab induced new-onset type 1 diabetes mellitus. Journal of Oncology Pharmacy Practice, 0, , 107815522311516. | 0.5 | 1 |
| 3926 | CRISPR-mediated rapid arming of poxvirus vectors enables facile generation of the novel immunotherapeutic STINGPOX. Frontiers in Immunology, 0, 13, . | 2.2 | 2 |
| 3927 | Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer. Journal of Translational Medicine, 2023, 21, . | 1.8 | 8 |
| 3928 | Standardized Pathology Screening of Mature Tertiary Lymphoid Structures in Cancers. Laboratory Investigation, 2023, 103, 100063. | 1.7 | 9 |
| 3929 | Characterisation and outcome of RAC1 mutated melanoma. European Journal of Cancer, 2023, 183, 1-10. | 1.3 | 5 |
| 3930 | Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy. Frontiers in Immunology, 0, 13, . | 2.2 | 2 |
| 3931 | A Novel TrxR1 Inhibitor Regulates NK and CD8+ T Cell Infiltration and Cytotoxicity, Enhancing the Efficacy of Antiâ€"PD-1 Immunotherapy against Hepatocarcinoma. Journal of Immunology, 2023, 210, 681-695. | 0.4 | 2 |
| 3932 | Nicotinamide N-methyltransferase promotes M2 macrophage polarization by IL6 and MDSC conversion by GM-CSF in gallbladder carcinoma. Hepatology, 0, Publish Ahead of Print, . | 3.6 | 1 |
| 3933 | PDJ amplicon in triple negative breast cancer. Scientific Reports, 2023, 13, . | 1.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 3935 | Myeloid-derived suppressor cells in head and neck squamous cell carcinoma. International Review of Cell and Molecular Biology, 2023, , 33-92. | 1.6 | 2 |
| 3936 | Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer. Chinese Medical Journal, 2022, 135, 2436-2445. | 0.9 | 6 |
| 3937 | Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management. Targeted Oncology, 0, , . | 1.7 | 1 |
| 3938 | Advancements in Cancer Immunotherapies. Vaccines, 2023, 11, 59. | 2.1 | 8 |
| 3939 | Balancing the Risk of Adverse Events against the Efficacy of Immunotherapy in Advanced Thymic Epithelial Tumors. Cancers, 2023, 15, 289. | 1.7 | 2 |
| 3940 | A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. Npj Breast Cancer, 2022, 8, . | 2.3 | 8 |
| 3941 | Treatment Opportunities for Colorectal Liver Metastases. European Medical Journal (Chelmsford,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3.0 0 |  |  |
| 3942 | IFNÎ³ signaling in cytotoxic T cells restricts anti-tumor responses by inhibiting the maintenance and diversity ofÂintra-tumoral stem-like T cells. Nature Communications, 2023, 14, . | 5.8 | 12 |
| 3943 | Immunogenic Cell Death in Cancer. , 2023, , . |  | 0 |
| 3944 | YTHDF2 orchestrates tumor-associated macrophage reprogramming and controls antitumor immunity through CD8+ T cells. Nature Immunology, 2023, 24, 255-266. | 7.0 | 31 |
| 3945 | Impact of Precision Medicine in Oncology. Cancer Journal (Sudbury, Mass ), 2023, 29, 15-19. | 1.0 | 1 |
| 3946 | New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors. , 2023, 11, e005977. |  | 8 |
| 3947 | Identification of IRF-associated molecular subtypes in clear cell renal cell carcinoma to characterize immunological characteristics and guide therapy. Frontiers in Oncology, 0, 12, . | 1.3 | 1 |
| 3948 | Spatial Transcriptomic Approaches for Understanding the Tumor Microenvironment (TME). , 2023, , . |  | 0 |
| 3949 | Lenvatinib<i>Versus</i>Sorafenib in Advanced Hepatic Cell Carcinoma: A Double Center Retrospective Analysis. Anticancer Research, 2023, 43, 755-763. | 0.5 | 2 |
| 3950 | Real-world Efficacy and Safety of Atezolizumab Plus Bevacizumab, Paclitaxel and Carboplatin for First-line Treatment of Japanese Patients With Metastatic Non-squamous Non-small Cell Lung Cancer. Anticancer Research, 2023, 43, 713-724. | 0.5 | 4 |
| 3951 | Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer. Frontiers in Oncology, 0, 12, . | 1.3 | 0 |
| 3953 | A signature-based classification of lung adenocarcinoma that stratifies tumor immunity. Frontiers in Oncology, 0, 12, . | 1.3 | 0 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 3954 | Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Antiâ€"PD-1 Antibody. Molecular Cancer Therapeutics, 2023, 22, 499-510. | 1.9 | 3 |
| 3955 | The Utility of Radiomics in Predicting Response to Cancer Immunotherapy. , 2023, , 1-22. | | 0 |
| 3956 | High PD-L2 Predicts Early Recurrence of ER-Positive Breast Cancer. JCO Precision Oncology, 2023, , . | 1.5 | 6 |
| 3957 | Targeting the Tumor Immune Microenvironment Could Become a Potential Therapeutic Modality for Aggressive Pituitary Adenoma. Brain Sciences, 2023, 13, 164. | 1.1 | 2 |
| 3958 | The application of RNA sequencing in precision cancer medicine. , 2024, , 46-58. | | 0 |
| 3959 | Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages. Cancer Immunology, Immunotherapy, 2023, 72, 1789-1801. | 2.0 | 2 |
| 3960 | Migration of stem-like CD8 T cells between tissue microenvironments underpins successful anti-tumour immune responses. , 2023, 2, . | | 3 |
| 3961 | The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma. Nature Communications, 2023, 14, . | 5.8 | 17 |
| 3962 | Anticuerpos inmunomoduladores en el tratamiento del cÃ¡ncer. Repertorio De Medicina Y Cirugia, 2023, 32, 23-28. | 0.0 | 0 |
| 3963 | Application of radiomics in lung immunoâ€¢oncology. Precision Radiation Oncology, 2023, 7, 128-136. | 0.4 | 1 |
| 3964 | Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy. Frontiers in Genetics, 0, 14, . | 1.1 | 1 |
| 3965 | Higher Levels of Tumour-Infiltrating Lymphocytes (TILs) are Associated with a Better Prognosis, While CDK5 Plays a Different Role Between Nonmetastatic and Metastatic Colonic Carcinoma. Cancer Control, 2023, 30, 107327482311693. | 0.7 | 2 |
| 3966 | Lipid metabolism of hepatocellular carcinoma impacts targeted therapy and immunotherapy. World Journal of Gastrointestinal Oncology, 0, 15, 617-631. | 0.8 | 3 |
| 3968 | Highlights into historical and current immune interventions for cancer. International Immunopharmacology, 2023, 117, 109882. | 1.7 | 2 |
| 3969 | Moving Spatially Resolved Multiplexed Protein Profiling toward Clinical Oncology. Cancer Discovery, 2023, 13, 824-828. | 7.7 | 3 |
| 3970 | Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date. International Immunopharmacology, 2023, 117, 109881. | 1.7 | 8 |
| 3971 | Long noncoding RNA HITT coordinates with RGS2 to inhibit PD-L1 translation in T cell immunity. Journal of Clinical Investigation, 2023, 133, . | 3.9 | 7 |
| 3972 | Spatial immunophenotyping of the tumour microenvironment in nonâ€"small cell lung cancer. European Journal of Cancer, 2023, 185, 40-52. | 1.3 | 6 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 3973 | Considerations for individualized first-line systemic treatment in advanced hepatocellular carcinoma. Current Opinion in Pharmacology, 2023, 70, 102365. | 1.7 | 2 |
| 3974 | Ionizable polymeric nanocarriers for the codelivery of bi-adjuvant and neoantigens in combination tumor immunotherapy. Bioactive Materials, 2023, 26, 169-180. | 8.6 | 3 |
| 3975 | Immunotherapy for recurrent hepatocellular carcinoma. World Journal of Gastroenterology, 0, 29, 2261-2271. | 1.4 | 1 |
| 3976 | Single-cell transcriptome analysis revealed the immune profile of PD-1 blockade in gallbladder carcinoma liver metastasis. Hepatology Communications, 2023, 7, . | 2.0 | 1 |
| 3977 | Implications of Tumor Immune Microenvironment and Molecular Markers for Cancer Immunotherapy. , 2022, , 1-34. |  | 0 |
| 3978 | DKK1â€CKAP4 signal axis promotes hepatocellular carcinoma aggressiveness. Cancer Science, 2023, 114, 2063-2077. | 1.7 | 2 |
| 3979 | Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer. BMC Cancer, 2023, 23, . | 1.1 | 4 |
| 3980 | The Roles of Epigenetic Regulation and the Tumor Microenvironment in the Mechanism of Resistance to Systemic Therapy in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2023, 24, 2805. | 1.8 | 6 |
| 3981 | Immunotherapeutic Approaches in Ovarian Cancer. Current Issues in Molecular Biology, 2023, 45, 1233-1249. | 1.0 | 5 |
| 3982 | Efficacy and safety of first-line immune checkpoint inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: A network meta-analysis. Lung Cancer, 2023, 178, 47-56. | 0.9 | 4 |
| 3983 | Imageâ€based response assessment during immunotherapy in skin cancer. JDDG - Journal of the German Society of Dermatology, 2023, 21, 107-114. | 0.4 | 0 |
| 3984 | Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit. Communications Medicine, 2023, 3, . | 1.9 | 9 |
| 3985 | Concurrent immunotherapy and reâ€irradiation utilizing stereotactic body radiotherapy for recurrent highâ€grade gliomas. Cancer Reports, 0, , . | 0.6 | 2 |
| 3986 | Combination IFNÎ² and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity. Cancer Immunology Research, 2023, 11, 466-485. | 1.6 | 1 |
| 3987 | PD-1: A New Candidate Target for Analgesic Peptide Design. Journal of Pain, 2023, 24, 1142-1150. | 0.7 | 1 |
| 3988 | Post-Surgical Imaging Assessment in Rectal Cancer: Normal Findings and Complications. Journal of Clinical Medicine, 2023, 12, 1489. | 1.0 | 1 |
| 3990 | Unexpected curative effect of PD-1 inhibitor in gastric cancer with brain metastasis: A case report. Frontiers in Oncology, 0, 13, . | 1.3 | 0 |
| 3991 | Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer. Frontiers in Immunology, 0, 14, . | 2.2 | 2 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 3992 | Systems Biology Approaches for the Improvement of Oncolytic Virus-Based Immunotherapies. Cancers, 2023, 15, 1297. | 1.7 | 4 |
| 3993 | Prognostic significance of epidermal growth factor receptor and programmed cell death-ligand 1 co-expression in esophageal squamous cell carcinoma. Aging, 0, , . | 1.4 | 0 |
| 3994 | Bildgestützte Beurteilung des Ansprechens auf Immuntherapien bei Hauttumoren. JDDG - Journal of the German Society of Dermatology, 2023, 21, 107-115. | 0.4 | 0 |
| 3995 | Lung cancer immunotherapy: progress, pitfalls, and promises. Molecular Cancer, 2023, 22, . | 7.9 | 104 |
| 3996 | Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma. Cell Reports Medicine, 2023, 4, 100947. | 3.3 | 7 |
| 3997 | Developing an m5C regulator–mediated RNA methylation modification signature to predict prognosis and immunotherapy efficacy in rectal cancer. Frontiers in Immunology, 0, 14, . | 2.2 | 0 |
| 3998 | CMTM6 recruits T cells within the endocervical adenocarcinoma microenvironment and suppresses cell proliferation via the p53 pathway. Journal of Medical Virology, 2023, 95, . | 2.5 | 2 |
| 3999 | An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial. Frontiers in Immunology, 0, 14, . | 2.2 | 3 |
| 4001 | Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma. Cancer Immunology Research, 2023, 11, 558-569. | 1.6 | 2 |
| 4002 | High endothelial venules in cancer: Regulation, function, and therapeutic implication. Cancer Cell, 2023, 41, 527-545. | 7.7 | 5 |
| 4003 | Leveraging Tumor Microenvironment Infiltration in Pancreatic Cancer to Identify Gene Signatures Related to Prognosis and Immunotherapy Response. Cancers, 2023, 15, 1442. | 1.7 | 2 |
| 4004 | Molecular phenotypic linkage between N6-methyladenosine methylation and tumor immune microenvironment in hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 0, , . | 1.2 | 0 |
| 4005 | PD-L1/PD-1 blockage enhanced the cytotoxicity of natural killer cell on the non-small cell lung cancer (NSCLC) by granzyme B secretion. Clinical and Translational Oncology, 2023, 25, 2373-2383. | 1.2 | 3 |
| 4006 | Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer. ESMO Open, 2023, 8, 101160. | 2.0 | 3 |
| 4008 | Collectin-11 promotes cancer cell proliferation and tumor growth. JCI Insight, 2023, 8, . | 2.3 | 4 |
| 4009 | Status and prognostic value of immunological biomarkers of breast cancer. Oncology Letters, 2023, 25, . | 0.8 | 1 |
| 4010 | Characterisation of tumor microenvironment and prevalence of CD274/PD-L1 genetic alterations difference in colorectal Cancer. BMC Cancer, 2023, 23, . | 1.1 | 1 |
| 4011 | Turning a Tumor Microenvironment Pitfall into Opportunity: Discovery of Benzamidoxime as PD-L1 Ligand with pH-Dependent Potency. International Journal of Molecular Sciences, 2023, 24, 5535. | 1.8 | 3 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 4012 | Immune checkpoint inhibitors in metastatic NSCLC: challenges and future directions (CME article). International Journal of Cancer Care and Delivery, 2023, 3, . | 0.0 | 0 |
| 4013 | Pan-cancer analysis identifies PD-L2 as a tumor promotor in the tumor microenvironment. Frontiers in Immunology, 0, 14, . | 2.2 | 2 |
| 4014 | Nanomedicine in Lung Cancer Immunotherapy. Frontiers in Bioengineering and Biotechnology, 0, 11, . | 2.0 | 12 |
| 4015 | Vascular Normalization Was Associated with Colorectal Tumor Regression upon Anti-PD-L1 Combinational Therapy. Journal of Immunology Research, 2023, 2023, 1-13. | 0.9 | 2 |
| 4016 | Predictive Factors for Response and Resistance to Anti-PD-1 Immunotherapy in Melanoma. , 2023, , 1-19. | | 0 |
| 4017 | Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study. ESMO Open, 2023, 8, 100877. | 2.0 | 3 |
| 4018 | CX3CR1 deficiency-induced TIL tumor restriction as a novel addition for CAR-T design in solid malignancies. IScience, 2023, 26, 106443. | 1.9 | 2 |
| 4019 | Immunotherapy for hepatocellular carcinoma: Recent advances and future targets. , 2023, 244, 108387. | | 12 |
| 4020 | Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. Oncology and Therapy, 2023, 11, 185-198. | 1.0 | 2 |
| 4021 | Towards a consensus definition of immune exclusion in cancer. Frontiers in Immunology, 0, 14, . | 2.2 | 6 |
| 4023 | Immune Checkpoint Blockade Response Biomarkers. , 2023, , 1-34. | | 0 |
| 4024 | Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B-cell lymphomas. Frontiers in Immunology, 0, 14, . | 2.2 | 1 |
| 4025 | Emerging Targeted Therapies for HER2-Positive Breast Cancer. Cancers, 2023, 15, 1987. | 1.7 | 18 |
| 4027 | LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors. Translational Lung Cancer Research, 2023, 12, 510-529. | 1.3 | 2 |
| 4028 | Identifying novel biomarkers associated with bladder cancer treatment outcomes. Frontiers in Oncology, 0, 13, . | 1.3 | 5 |
| 4029 | Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy. Experimental Hematology and Oncology, 2023, 12, . | 2.0 | 8 |
| 4030 | Tumor Immunophenotyping‐Derived Signature Identifies Prognosis and Neoadjuvant Immunotherapeutic Responsiveness in Gastric Cancer. Advanced Science, 2023, 10, . | 5.6 | 3 |
| 4031 | A2AR as a Prognostic Marker and a Potential Immunotherapy Target in Human Glioma. International Journal of Molecular Sciences, 2023, 24, 6688. | 1.8 | 4 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 4032 | The peptide woods are lovely, dark and deep: Hunting for novel cancer antigens. Seminars in Immunology, 2023, 67, 101758. | 2.7 | 4 |
| 4033 | Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy. Nature Communications, 2023, 14, . | 5.8 | 7 |
| 4034 | Mechanism of inert inflammation in an immune checkpoint blockade-resistant tumor subtype bearing transcription elongation defects. Cell Reports, 2023, 42, 112364. | 2.9 | 0 |
| 4035 | Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status. Healthcare (Switzerland), 2023, 11, 1073. | 1.0 | 0 |
| 4036 | Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers. Advances in Anatomic Pathology, 2023, 30, 174-194. | 2.4 | 0 |
| 4037 | The novel putative methyltransferase METTL7A as one prognostic biomarker potentially associated with immune infiltration in human renal cancer. Heliyon, 2023, 9, e15371. | 1.4 | 1 |
| 4038 | Tumor immunosuppression relief via acidity modulation combined PD-L1 siRNA for enhanced immunotherapy. , 2023, 150, 213425. | | 2 |
| 4039 | Research Progress of Immunotherapy for Gastric Cancer. Technology in Cancer Research and Treatment, 2023, 22, 153303382211505. | 0.8 | 2 |
| 4040 | Distinct circulating cytokine/chemokine profiles correlate with clinical benefit of immune checkpoint inhibitor monotherapy and combination therapy in advanced nonâ€small cell lung cancer. Cancer Medicine, 2023, 12, 12234-12252. | 1.3 | 2 |
| 4041 | Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies. , 2023, 20, 694-713. | | 8 |
| 4042 | Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer. Nature Communications, 2023, 14, . | 5.8 | 8 |
| 4043 | Methods for assessment of the tumour microenvironment and immune interactions in non-small cell lung cancer. A narrative review. Frontiers in Oncology, 0, 13, . | 1.3 | 1 |
| 4044 | Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies: A rapidly evolving strategy. Pathology Research and Practice, 2023, 247, 154473. | 1.0 | 1 |
| 4045 | Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer. International Journal of Molecular Sciences, 2023, 24, 7577. | 1.8 | 2 |
| 4046 | Late-stage MC38 tumours recapitulate features of human colorectal cancer â€" implications for appropriate timepoint selection in preclinical studies. Frontiers in Immunology, 0, 14, . | 2.2 | 0 |
| 4047 | bITH, a blood-based metric of intratumor heterogeneity, is associated with clinical response to immune checkpoint blockade in non-small cell lung cancer. EBioMedicine, 2023, 91, 104564. | 2.7 | 1 |
| 4050 | Spatial Technologies: A Game Changer for Studying the Tumor Microenvironment. , 2023, , 1-34. | | 0 |
| 4063 | Flavonoids in the Treatment of Gastrointestinal Tract Cancer. , 2023, , 83-108. | | 0 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 4064 | Cancer immunotherapy. , 2023, , 681-741. | | 0 |
| 4069 | Spatial Technologies: A Game Changer for Studying the Tumor Microenvironment. , 2023, , 1-33. | | 0 |
| 4121 | Probiotics Based Anticancer Immunity In Stomach Cancer. , 2023, , 162-188. | | 0 |
| 4124 | To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations. Journal of Cancer Research and Clinical Oncology, 2023, 149, 10027-10040. | 1.2 | 2 |
| 4129 | Biomarkers in Precision Medicine with Special Reference to Oncology. , 2023, , 173-187. | | 0 |
| 4136 | Pragmatic solutions for optimizing oncology drug development trials. , 2024, , 293-303. | | 0 |
| 4142 | Immune Profiling of Meningiomas. Advances in Experimental Medicine and Biology, 2023, , 189-198. | 0.8 | 0 |
| 4150 | Case Report: Intervention of radiotherapy improves the prognosis of rectal squamous cell carcinoma with high PD-L1 expression and enable patients to obtain NED status. Frontiers in Immunology, 0, 14, . | 2.2 | 2 |
| 4193 | Cancer Immunotherapy. , 2023, , 121-154. | | 0 |
| 4198 | Current status and frontier tracking of clinical trials on Metformin for cancer treatment. Journal of Cancer Research and Clinical Oncology, 2023, 149, 16931-16946. | 1.2 | 1 |
| 4205 | Second-line therapy in advanced non–small cell lung cancer. , 2024, , 195-216. | | 0 |
| 4210 | Adoptive immunotherapy with cells from tumor-draining lymph nodes activated and expanded in vitro. Methods in Cell Biology, 2023, , . | 0.5 | 0 |
| 4231 | Molecular insight into renal cancer and latest therapeutic approaches to tackle it: an updated review. , 2023, 40, . | | 0 |
| 4235 | Development of nano-immunotherapy for cancer treatment: achievements and scopes. Journal of Pharmaceutical Investigation, 2023, 53, 827-844. | 2.7 | 0 |
| 4239 | FcÎ³ receptors and immunomodulatory antibodies in cancer. Nature Reviews Cancer, 2024, 24, 51-71. | 12.8 | 3 |
| 4245 | Plasmablastic Lymphoma. , 2023, , . | | 0 |
| 4265 | Immune Checkpoint Inhibitors and Systemic Side Effects: Overview for the Inpatient Dermatologist. Current Dermatology Reports, 2023, 12, 225-232. | 1.1 | 0 |
| 4273 | Recent Advances of RNA m6A Modifications in Cancer Immunoediting and Immunotherapy. Cancer Treatment and Research, 2023, , 49-94. | 0.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------| 
| 4300 | Inhaled delivery of immunotherapy for treatment of lung cancer. , 2024, , 403-439. | | 0 |
| 4330 | Immune-oncological drug atezolizumab. , 2024, , 89-101. | | 0 |
| 4335 | Important Biomarkers for Better Evaluation of Checkpoint Inhibitors and Other Immunotherapies in Lung Cancer. , 2024, , 331-351. | | 0 |